GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: October 19, 2004, 18:56:12 ; Search time 158 Seconds
(without alignments)
43.138 Million cell updates/sec

Title: US-10-799-005A-1
Perfect score: 97
Sequence: 1 EPNHLNSKIAFKIVSQEPA 19

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 249703

Minimum DB seq length: 19
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 500 summaries

Database : A_Geneseq_23Sep04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	38	39.2	22	2	AAR43461	Aar43461 Ro/SSA ep
2	35	36.1	46	3	AAB27169	Aab27169 Sendai vi
3	34	35.1	45	6	ABM72186	Abm72186 Staphyloc
4	34	35.1	46	3	AAB27167	Aab27167 HPIV3 par
5	34	35.1	49	4	AAU21220	Aau21220 Human nov
6	33	34.0	26	4	AAM33005	Aam33005 Peptide #
7	33	34.0	26	4	AAM72776	Aam72776 Human bon
8	33	34.0	26	4	AAM60161	Aam60161 Human bra
9	33	34.0	26	4	ABG54477	Abg54477 Human liv
10	33	34.0	26	5	ABG42601	Abg42601 Human pep
11	33	34.0	44	3	AAG27280	Aag27280 Zea mays
12	32.5	33.5	36	3	AAG59652	Aag59652 Arabidops
13	32.5	33.5	36	4	AAM16072	Aam16072 Peptide #
14	32.5	33.5	36	4	ABB35064	Abb35064 Peptide #
15	32.5	33.5	36	4	AAM28566	Aam28566 Peptide #
16	32.5	33.5	36	4	ABB20476	Abb20476 Protein #
17	32.5	33.5	36	4	AAM68248	Aam68248 Human bon
18	32.5	33.5	36	4	AAM55878	Aam55878 Human bra
19	32.5	33.5	36	4	ABG49902	Abg49902 Human liv
20	32.5	33.5	36	4	AAM03799	Aam03799 Peptide #
21	32.5	33.5	36	5	ABG37783	Abg37783 Human pep
22	32	33.0	24	6	ABO12904	Abo12904 Mouse zin
23	32	33.0	24	6	ABO11938	Abo11938 Human zin
24	32	33.0	24	6	ABU62168	Abu62168 Human zin
25	32	33.0	26	2	AAW60192	Aaw60192 Bacteriop
26	32	33.0	33	4	ABB17107	Abb17107 Human ner
27	32	33.0	38	4	ABB16071	Abb16071 Human ner
28	32	33.0	46	3	AAB27168	Aab27168 BPIV3 par
29	32	33.0	48	4	AAM13846	Aam13846 Peptide #
30	32	33.0	48	4	ABB32791	Abb32791 Peptide #
31	32	33.0	48	4	AAM26253	Aam26253 Peptide #
32	32	33.0	48	4	ABB27621	Abb27621 Human pep
33	32	33.0	48	4	ABB18273	Abb18273 Protein #
34	32	33.0	48	4	AAM65977	Aam65977 Human bon
35	32	33.0	48	4	AAM53598	Aam53598 Human bra
36	32	33.0	48	4	ABG47643	Abg47643 Human liv
37	32	33.0	48	4	AAM01589	Aam01589 Peptide #
38	32	33.0	48	5	ABG35625	Abg35625 Human pep
39	31	32.0	21	4	AAB89226	Aab89226 HIV gp120
40	31	32.0	21	4	AAB89227	Aab89227 HIV gp120
41	31	32.0	24	2	AAY27522	Aay27522 E. coli b
42	31	32.0	33	2	AAY02263	Aay02263 A F-box p
43	31	32.0	33	4	AAE08035	Aae08035 Mouse F-b
44	31	32.0	33	7	AAE39643	Aae39643 Mouse F-b
45	31	32.0	34	2	AAW73422	Aaw73422 Human sec
46	31	32.0	34	4	AAM95698	Aam95698 Human rep
47	31	32.0	34	4	ABB10877	Abb10877 Human ova
48	31	32.0	40	3	AAB20721	Aab20721 Polymeric
49	31	32.0	43	8	ABO60042	Abo60042 Human gen
50	31	32.0	44	4	AAM21342	Aam21342 Peptide #
51	31	32.0	44	4	ABB43679	Abb43679 Peptide #
52	31	32.0	44	4	AAM37572	Aam37572 Peptide #
53	31	32.0	44	4	ABB26626	Abb26626 Protein #
54	31	32.0	44	4	AAM77419	Aam77419 Human bon
55	31	32.0	44	4	AAM64636	Aam64636 Human bra
56	31	32.0	44	4	ABG59052	Abg59052 Human liv
57	31	32.0	44	4	AAU21016	Aau21016 Human nov
58	31	32.0	44	5	ABG46440	Abg46440 Human pep
59	31	32.0	44	7	ADF70009	Adf70009 AcmA-type
60	31	32.0	47	3	AAB16298	Aab16298 Eucalyptu
61	31	32.0	47	8	ADJ12233	Adj12233 Human sec
62	31	32.0	48	2	AAY14431	Aay14431 Human sec
63	31	32.0	49	7	ADE86990	Ade86990 Human pan
64	31	32.0	50	4	AAU17741	Aau17741 Novel hum
65	31	32.0	50	7	ADG41121	Adg41121 Human res
66	30.5	31.4	19	6	ABP71110	Abp71110 E10 prote
67	30.5	31.4	40	6	ABU43928	Abu43928 Protein e
68	30	30.9	20	2	AAR93211	Aar93211 Control p
69	30	30.9	24	5	ABG76721	Abg76721 Hepatitis
70	30	30.9	24	5	ABG76719	Abg76719 Hepatitis
71	30	30.9	26	4	AAM16525	Aam16525 Peptide #
72	30	30.9	26	4	AAM04245	Aam04245 Peptide #
73	30	30.9	27	2	AAW88880	Aaw88880 Polypepti
74	30	30.9	27	2	AAW88879	Aaw88879 Polypepti
75	30	30.9	27	4	ABB50945	Abb50945 Human sec
76	30	30.9	27	4	ABB50946	Abb50946 Human sec
77	30	30.9	27	6	ABO45202	Abo45202 Novel hum
78	30	30.9	27	6	ABO45203	Abo45203 Novel hum
79	30	30.9	27	7	ABO26682	Abo26682 Protein a
80	30	30.9	27	7	ABO26683	Abo26683 Protein a
81	30	30.9	30	5	ABP26325	Abp26325 Streptoco
82	30	30.9	30	5	AAU84722	Aau84722 HCV HepC1
83	30	30.9	30	5	AAU84721	Aau84721 HCV HepC1
84	30	30.9	30	5	ABG68718	Abg68718 Human pro
85	30	30.9	30	5	ABB79232	Abb79232 Human pro
86	30	30.9	31	3	AAB38429	Aab38429 Fragment
87	30	30.9	32	4	AAG75194	Aag75194 Human col
88	30	30.9	32	8	ADH96838	Adh96838 S. pneumo
89	30	30.9	33	2	AAW29908	Aaw29908 Porcine A
90	30	30.9	33	2	AAW35030	Aaw35030 Water sol
91	30	30.9	34	6	ABM73359	Abm73359 Staphyloc
92	30	30.9	34	7	ABM74126	Abm74126 DNA clone
93	30	30.9	37	8	ADL26414	Adl26414 Synthetic
94	30	30.9	37	8	ADL26416	Adl26416 Synthetic
95	30	30.9	39	2	AAW74948	Aaw74948 Human sec
96	30	30.9	39	4	AAG74232	Aag74232 Human col
97	30	30.9	39	5	ABG95405	Abg95405 Human nov
98	30	30.9	39	5	AAU88730	Aau88730 Insulin/i

99	30	30.9	39	6	ADA03571
100	30	30.9	39	6	ABO34599
101	30	30.9	39	7	ADH94784
102	30	30.9	39	7	ADI23260
103	30	30.9	39	8	ADH74262
104	30	30.9	39	8	ADL67475
105	30	30.9	39	8	ADM37320
106	30	30.9	40	2	AAW74791
107	30	30.9	40	5	ABG95241
108	30	30.9	40	6	ABO34435
109	30	30.9	40	7	ADB32063
110	30	30.9	40	7	ADI23096
111	30	30.9	40	8	ADH74098
112	30	30.9	41	4	AAM85472
113	30	30.9	42	5	ABP29414
114	30	30.9	46	4	ABB03481
115	30	30.9	46	6	ABU12775
116	30	30.9	46	8	ADJ28801
117	30	30.9	50	5	ABP33068
118	29.5	30.4	32	5	ABP30850
119	29.5	30.4	33	5	ABP28726
120	29.5	30.4	44	3	AAG56269
121	29.5	30.4	44	3	AAG60246
122	29.5	30.4	48	4	AAO11779
123	29	29.9	20	2	AAW42197
124	29	29.9	20	7	ADB75643
125	29	29.9	21	1	AAP71423
126	29	29.9	24	8	ADI40693
127	29	29.9	26	5	AAU87955
128	29	29.9	28	2	AAW72756
129	29	29.9	28	4	ABB41309
130	29	29.9	28	4	AAM35097
131	29	29.9	28	4	ABB25278
132	29	29.9	28	4	AAM74981
133	29	29.9	28	4	AAM62177
134	29	29.9	28	4	ABG56752
135	29	29.9	28	5	ABG44713
136	29	29.9	28	5	ABG93608
137	29	29.9	29	3	AAB27777
138	29	29.9	31	2	AAW19976
139	29	29.9	31	2	AAW82987
140	29	29.9	31	3	AAB39245
141	29	29.9	32	8	ABO55532
142	29	29.9	33	4	AAM42284
143	29	29.9	33	4	AAM96243
144	29	29.9	33	5	ADE01861
145	29	29.9	33	8	ADI40691
146	29	29.9	34	2	AAW30694
147	29	29.9	34	3	AAY89007
148	29	29.9	34	3	AAY89008
149	29	29.9	34	3	AAY89009
150	29	29.9	34	4	AAB54800
151	29	29.9	34	4	AAB92259
152	29	29.9	34	4	AAB77362
153	29	29.9	34	4	AAB77364
154	29	29.9	34	4	AAB77363
155	29	29.9	34	4	ABB00367
156	29	29.9	34	4	ABB00368
157	29	29.9	34	4	ABB00366
158	29	29.9	34	4	AAU12917
159	29	29.9	34	4	AAU12916
160	29	29.9	34	4	AAU12915
161	29	29.9	34	5	ADE01862
162	29	29.9	34	5	ADE01860
163	29	29.9	37	5	ABP29370
164	29	29.9	37	7	ADD90380
165	29	29.9	37	7	ADG90199
166	29	29.9	37	8	ADL26415
167	29	29.9	38	5	AAU87961
168	29	29.9	38	5	AAE22590
169	29	29.9	39	2	AAW20028
170	29	29.9	39	3	AAB53950
171	29	29.9	40	8	ABO55502

Ada03571 Insulin r
Abo34599 Region of
Adh94784 Insulin r
Adi23260 Novel hum
Adh74262 Human sec
Adl67475 IGF-1R/IR
Adm37320 Anti-IR f
Aaw74791 Human sec
Abg95241 Human nov
Abo34435 Region of
Adb32063 alphaA-in
Adi23096 Novel hum
Adh74098 Human sec
Aam85472 Human imm
Abp29414 Streptoco
Abb03481 Human mus
Abu12775 Novel hum
Adj28801 Human mus
Abp33068 Human ORF
Abp30850 Streptoco
Abp28726 Streptoco
Aag56269 Arabidops
Aag60246 Arabidops
Aao11779 Human pol
Aaw42197 T-cell ep
Adb75643 Human TM2
Aap71423 Immunomod
Adi40693 Nef/SH3 d
Aau87955 Human PDZ
Aaw72756 SpeI rest
Abb41309 Peptide #
Aam35097 Peptide #
Abb25278 Protein #
Aam74981 Human bon
Aam62177 Human bra
Abg56752 Human liv
Abg44713 Human pep
Abg93608 Human P-g
Aab27777 Sequence
Aaw19976 Fibronect
Aaw82987 Human fib
Aab39245 Gene 9 hu
Abo55532 Human gen
Aam42284 Human bre
Aam96243 Human rep
Ade01861 Hybrid po
Adi40691 Nef/SH3 d
Aaw30694 Repro-PC-
Aay89007 Core poly
Aay89008 Core poly
Aay89009 Core poly
Aab54800 RSV antiv
Aab92259 Virus rel
Aab77362 Core poly
Aab77364 Core poly
Aab77363 Core poly
Abb00367 RSV F2 pr
Abb00368 RSV F2 pr
Abb00366 RSV F2 pr
Aau12917 DP178-lik
Aau12916 DP178-lik
Aau12915 DP178-lik
Ade01862 Hybrid po
Ade01860 Hybrid po
Abp29370 Streptoco
Add90380 Novel hum
Adg90199 Human sec
Adl26415 Synthetic
Aau87961 Human WW
Aae22590 BS203 con
Aaw20028 Human aci
Aab53950 Human col
Abo55502 Human gen

172	29	29.9	41	8	ABO59597
173	29	29.9	42	4	AAB64605
174	29	29.9	43	3	AAG09091
175	29	29.9	44	5	ABG90950
176	29	29.9	44	5	ABJ04320
177	29	29.9	44	6	ABU61907
178	29	29.9	45	3	AAG59379
179	29	29.9	46	4	ABB50392
180	29	29.9	46	6	ABO44649
181	29	29.9	46	7	ABO26129
182	29	29.9	47	3	AAB44907
183	29	29.9	47	4	ABG02562
184	29	29.9	47	5	AAM47156
185	29	29.9	47	5	AAM47171
186	29	29.9	47	8	ABO54785
187	29	29.9	48	3	AAB34265
188	29	29.9	48	3	AAB58239
189	29	29.9	48	4	AAG73655
190	29	29.9	48	4	ABG01426
191	29	29.9	49	3	AAB32117
192	29	29.9	50	3	AAB45192
193	29	29.9	50	3	AAB29913
194	29	29.9	50	5	ABP29303
195	29	29.9	50	7	ADD90406
196	29	29.9	50	7	ADG90225
197	28.5	29.4	30	4	AAM33917
198	28.5	29.4	30	4	AAM73727
199	28.5	29.4	30	4	ABG55472
200	28.5	29.4	30	5	ABG43609
201	28.5	29.4	42	2	AAW27823
202	28	28.9	19	2	AAW78190
203	28	28.9	19	4	ABB40664
204	28	28.9	19	4	AAM34425
205	28	28.9	19	4	AAM74313
206	28	28.9	19	4	AAM61524
207	28	28.9	19	4	ABG56112
208	28	28.9	19	5	ABG44240
209	28	28.9	21	5	ABB09679
210	28	28.9	22	5	ABG93535
211	28	28.9	23	2	AAY36341
212	28	28.9	23	4	AAM15118
213	28	28.9	23	4	ABB34112
214	28	28.9	23	4	AAM27573
215	28	28.9	23	4	ABB28942
216	28	28.9	23	4	ABB19553
217	28	28.9	23	4	AAM67281
218	28	28.9	23	4	AAM54900
219	28	28.9	23	4	ABG48943
220	28	28.9	23	4	AAM02859
221	28	28.9	23	5	ABG36928
222	28	28.9	23	6	ADA11735
223	28	28.9	24	4	AAM19000
224	28	28.9	24	4	AAG76249
225	28	28.9	25	4	AAM70819
226	28	28.9	25	4	ABG52538
227	28	28.9	25	5	ABB09677
228	28	28.9	26	2	AAY12738
229	28	28.9	27	7	ADH17225
230	28	28.9	28	7	ADD35429
231	28	28.9	29	4	ABB43186
232	28	28.9	29	4	AAM37026
233	28	28.9	29	4	ABB26285
234	28	28.9	29	4	AAM76919
235	28	28.9	29	4	AAM64096
236	28	28.9	29	4	ABG58582
237	28	28.9	29	5	ABG46030
238	28	28.9	29	5	AAU97881
239	28	28.9	30	2	AAW30507
240	28	28.9	31	3	AAB28613
241	28	28.9	31	3	AAG08759
242	28	28.9	34	6	ABU02095
243	28	28.9	37	2	AAW30501
244	28	28.9	38	2	AAR58093

Abo59597 Human gen
Aab64605 Human sec
Aag09091 Arabidops
Abg90950 Human col
Abj04320 Human col
Abu61907 Mouse gly
Aag59379 Arabidops
Abb50392 Human sec
Abo44649 Novel hum
Abo26129 Human pro
Aab44907 Human sec
Abg02562 Novel hum
Aam47156 Modular e
Aam47171 Modular e
Abo54785 Human gen
Aab34265 Human sec
Aab58239 Lung canc
Aag73655 Human col
Abg01426 Novel hum
Aab32117 Human sec
Aab45192 Gene 26 h
Aab29913 Human sec
Abp29303 Streptoco
Add90406 Novel hum
Adg90225 Human sec
Aam33917 Peptide #
Aam73727 Human bon
Abg55472 Human liv
Abg43609 Human pep
Aaw27823 Amino aci
Aaw78190 Human sec
Abb40664 Peptide #
Aam34425 Peptide #
Aam74313 Human bon
Aam61524 Human bra
Abg56112 Human liv
Abg44240 Human pep
Abb09679 Synthetic
Abg93535 Human P-g
Aay36341 Fragment
Aam15118 Peptide #
Abb34112 Peptide #
Aam27573 Peptide #
Abb28942 Peptide #
Abb19553 Protein #
Aam67281 Human bon
Aam54900 Human bra
Abg48943 Human liv
Aam02859 Peptide #
Abg36928 Human pep
Ada11735 Human nov
Aam19000 Peptide #
Aag76249 Human col
Aam70819 Human bon
Abg52538 Human liv
Abb09677 Synthetic
Aay12738 Human 5'
Adh17225 Human D-A
Add35429 Pseudomon
Abb43186 Peptide #
Aam37026 Peptide #
Abb26285 Protein #
Aam76919 Human bon
Aam64096 Human bra
Abg58582 Human liv
Abg46030 Human pep
Aau97881 Mouse ang
Aaw30507 DP-1 tran
Aab28613 Human c-m
Aag08759 Arabidops
Abu02095 S. pneumo
Aaw30501 DP-1 tran
Aar58093 [Asn13]-h

245	28	28.9	38	2	AAY13001	Aay13001 Human sec
246	28	28.9	38	4	AAM15186	Aam15186 Peptide #
247	28	28.9	38	4	ABB34179	Abb34179 Peptide #
248	28	28.9	38	4	AAM27645	Aam27645 Peptide #
249	28	28.9	38	4	ABB29012	Abb29012 Peptide #
250	28	28.9	38	4	ABB19620	Abb19620 Protein #
251	28	28.9	38	4	AAM67353	Aam67353 Human bon
252	28	28.9	38	4	AAM54970	Aam54970 Human bra
253	28	28.9	38	4	ABG49016	Abg49016 Human liv
254	28	28.9	38	4	AAM02925	Aam02925 Peptide #
255	28	28.9	38	5	ABG36988	Abg36988 Human pep
256	28	28.9	39	4	AAM82762	Aam82762 Human imm
257	28	28.9	39	5	AAU88731	Aau88731 Insulin/i
258	28	28.9	39	5	AAU88749	Aau88749 Insulin/i
259	28	28.9	39	6	ADA03589	Ada03589 IGF-1R re
260	28	28.9	39	6	ADA03572	Ada03572 Insulin r
261	28	28.9	39	7	ADH94802	Adh94802 Insulin g
262	28	28.9	39	7	ADH94785	Adh94785 Insulin r
263	28	28.9	39	8	ADL67476	Adl67476 IGF-1R/IR
264	28	28.9	39	8	ADL67493	Adl67493 IGF-1R/IR
265	28	28.9	39	8	ADM37338	Adm37338 Anti-IGF-
266	28	28.9	39	8	ADM37321	Adm37321 Anti-IR f
267	28	28.9	40	6	AAE36707	Aae36707 Rat TI-VA
268	28	28.9	40	7	ABW01763	Abw01763 Rat T1-VA
269	28	28.9	40	8	ADM97081	Adm97081 Botulinum
270	28	28.9	41	4	AAU22274	Aau22274 Human car
271	28	28.9	41	7	ADE46242	Ade46242 Human car
272	28	28.9	42	2	AAW88776	Aaw88776 Polypepti
273	28	28.9	42	4	ABB50609	Abb50609 Human sec
274	28	28.9	42	6	ABO44866	Abo44866 Novel hum
275	28	28.9	42	7	ABO26346	Abo26346 Protein a
276	28	28.9	43	7	ADF70043	Adf70043 AcmA-type
277	28	28.9	44	4	ABB68452	Abb68452 Drosophil
278	28	28.9	45	3	AAG32980	Aag32980 Arabidops
279	28	28.9	45	4	AAM92489	Aam92489 Human dig
280	28	28.9	45	4	AAM86098	Aam86098 Human imm
281	28	28.9	45	4	AAU22534	Aau22534 Novel hum
282	28	28.9	45	7	ADB32374	Adb32374 Human nov
283	28	28.9	47	2	AAW78184	Aaw78184 Human sec
284	28	28.9	47	4	AAM13761	Aam13761 Peptide #
285	28	28.9	47	4	AAG74606	Aag74606 Human col
286	28	28.9	47	4	ABB32694	Abb32694 Peptide #
287	28	28.9	47	4	AAM26159	Aam26159 Peptide #
288	28	28.9	47	4	AAM83381	Aam83381 Human imm
289	28	28.9	47	4	ABB27535	Abb27535 Human pep
290	28	28.9	47	4	ABB18183	Abb18183 Protein #
291	28	28.9	47	4	AAM65894	Aam65894 Human bon
292	28	28.9	47	4	AAM53516	Aam53516 Human bra
293	28	28.9	47	4	ABG47549	Abg47549 Human liv
294	28	28.9	47	4	AAM01506	Aam01506 Peptide #
295	28	28.9	47	5	ABG35529	Abg35529 Human pep
296	28	28.9	48	4	AAM85100	Aam85100 Human imm
297	28	28.9	48	5	ABP28234	Abp28234 Streptoco
298	28	28.9	48	7	ADD44478	Add44478 Polypepti
299	28	28.9	50	3	AAG08758	Aag08758 Arabidops
300	28	28.9	50	5	ADH32512	Adh32512 Yeast smO
301	28	28.9	50	6	ABM71782	Abm71782 Staphyloc
302	27.5	28.4	30	2	AAR23781	Aar23781 N terminu
303	27.5	28.4	41	4	ABB16647	Abb16647 Human ner
304	27	27.8	19	2	AAY50599	Aay50599 Resin bou
305	27	27.8	19	7	ADF14612	Adf14612 Rheumatoi
306	27	27.8	20	2	AAW42169	Aaw42169 T-cell ep
307	27	27.8	21	2	AAW59015	Aaw59015 Lactococc
308	27	27.8	21	2	AAW94873	Aaw94873 N-termina
309	27	27.8	21	5	AAE20718	Aae20718 Human Mls
310	27	27.8	21	5	AAE21019	Aae21019 Human Icr
311	27	27.8	21	8	ADH89723	Adh89723 Cell pene
312	27	27.8	22	2	AAY04241	Aay04241 Human par
313	27	27.8	22	7	ADI24804	Adi24804 Parathyro
314	27	27.8	23	2	AAY04242	Aay04242 Human par
315	27	27.8	23	5	AAB71457	Aab71457 Cobra C3
316	27	27.8	23	5	AAB71459	Aab71459 Murine C3
317	27	27.8	23	7	ADI24805	Adi24805 Parathyro
318	27	27.8	23	8	ADQ35122	Adq35122 Novel pep
319	27	27.8	24	2	AAY04243	Aay04243 Human par
320	27	27.8	24	7	ADI24806	Adi24806 Parathyro
321	27	27.8	25	2	AAY04244	Aay04244 Human par
322	27	27.8	25	4	ABG09991	Abg09991 Novel hum
323	27	27.8	25	7	ADI24807	Adi24807 Parathyro
324	27	27.8	25	8	ABM79621	Abm79621 M tubercu
325	27	27.8	25	8	ADJ36098	Adj36098 Self-coal
326	27	27.8	26	2	AAW61646	Aaw61646 v-Src ATP
327	27	27.8	26	2	AAW64665	Aaw64665 Synthetic
328	27	27.8	26	2	AAY04245	Aay04245 Human par
329	27	27.8	26	3	AAB12831	Aab12831 V-Src ATP
330	27	27.8	26	7	ADI24808	Adi24808 Parathyro
331	27	27.8	26	8	ADQ14464	Adq14464 C2 H2 typ
332	27	27.8	27	2	AAW59014	Aaw59014 Lactococc
333	27	27.8	27	2	AAY06348	Aay06348 Mycelioph
334	27	27.8	27	2	AAW94872	Aaw94872 N-termina
335	27	27.8	27	2	AAY04227	Aay04227 Human par
336	27	27.8	27	2	AAY04246	Aay04246 Human par
337	27	27.8	27	2	AAY27328	Aay27328 Human C9
338	27	27.8	27	4	AAM14225	Aam14225 Peptide #
339	27	27.8	27	4	ABB33172	Abb33172 Peptide #
340	27	27.8	27	4	AAM26635	Aam26635 Peptide #
341	27	27.8	27	4	ABB28000	Abb28000 Human pep
342	27	27.8	27	4	ABB18637	Abb18637 Protein #
343	27	27.8	27	4	AAM66356	Aam66356 Human bon
344	27	27.8	27	4	AAM53968	Aam53968 Human bra
345	27	27.8	27	4	ABG48022	Abg48022 Human liv
346	27	27.8	27	4	AAM01957	Aam01957 Peptide #
347	27	27.8	27	5	ABG36004	Abg36004 Human pep
348	27	27.8	27	7	ADI24809	Adi24809 Parathyro
349	27	27.8	27	7	ADI24803	Adi24803 Parathyro
350	27	27.8	28	2	AAY04226	Aay04226 Human par
351	27	27.8	28	2	AAY04248	Aay04248 Human par
352	27	27.8	28	2	AAY04247	Aay04247 Human par
353	27	27.8	28	2	AAY04240	Aay04240 Human par
354	27	27.8	28	2	AAY50589	Aay50589 Resin bou
355	27	27.8	28	2	AAY50592	Aay50592 Resin bou
356	27	27.8	28	7	ADI24810	Adi24810 Parathyro
357	27	27.8	28	7	ADI24802	Adi24802 Parathyro
358	27	27.8	28	7	ADI24827	Adi24827 Parathyro
359	27	27.8	28	7	ADI24813	Adi24813 Parathyro
360	27	27.8	29	2	AAY04225	Aay04225 Human par
361	27	27.8	29	2	AAY04228	Aay04228 Human par
362	27	27.8	29	7	ADI24801	Adi24801 Parathyro
363	27	27.8	29	7	ADI24811	Adi24811 Parathyro
364	27	27.8	30	2	AAY04224	Aay04224 Human par
365	27	27.8	30	2	AAY04229	Aay04229 Human par
366	27	27.8	30	2	AAY50601	Aay50601 Resin bou
367	27	27.8	30	4	ABB38725	Abb38725 Peptide #
368	27	27.8	30	4	AAM32194	Aam32194 Peptide #
369	27	27.8	30	4	AAM71913	Aam71913 Human bon
370	27	27.8	30	4	AAM59358	Aam59358 Human bra
371	27	27.8	30	4	ABG53596	Abg53596 Human liv
372	27	27.8	30	5	ABG41727	Abg41727 Human pep
373	27	27.8	30	5	AAU84870	Aau84870 Human MAR
374	27	27.8	30	7	ADI24812	Adi24812 Parathyro
375	27	27.8	30	7	ADI24800	Adi24800 Parathyro
376	27	27.8	31	2	AAY04179	Aay04179 Human par
377	27	27.8	31	2	AAY04209	Aay04209 Human par
378	27	27.8	31	2	AAY04254	Aay04254 Human par
379	27	27.8	31	2	AAY04192	Aay04192 Human par
380	27	27.8	31	2	AAY04208	Aay04208 Human par
381	27	27.8	31	2	AAY04238	Aay04238 Human par
382	27	27.8	31	2	AAY04255	Aay04255 Human par
383	27	27.8	31	2	AAY04186	Aay04186 Human par
384	27	27.8	31	2	AAY04187	Aay04187 Human par
385	27	27.8	31	2	AAY04250	Aay04250 Human par
386	27	27.8	31	2	AAY04178	Aay04178 Human par
387	27	27.8	31	2	AAY04184	Aay04184 Human par
388	27	27.8	31	2	AAY04199	Aay04199 Human par
389	27	27.8	31	2	AAY04202	Aay04202 Human par
390	27	27.8	31	2	AAY04210	Aay04210 Human par

391	27	27.8	31	2	AAY04256	Aay04256 Human par
392	27	27.8	31	2	AAY04258	Aay04258 Human par
393	27	27.8	31	2	AAY04185	Aay04185 Human par
394	27	27.8	31	2	AAY04198	Aay04198 Human par
395	27	27.8	31	2	AAY04213	Aay04213 Human par
396	27	27.8	31	2	AAY04260	Aay04260 Human par
397	27	27.8	31	2	AAY04183	Aay04183 Human par
398	27	27.8	31	2	AAY04211	Aay04211 Human par
399	27	27.8	31	2	AAY04259	Aay04259 Human par
400	27	27.8	31	2	AAY04195	Aay04195 Human par
401	27	27.8	31	2	AAY04261	Aay04261 Human par
402	27	27.8	31	2	AAY04176	Aay04176 Human par
403	27	27.8	31	2	AAY04182	Aay04182 Human par
404	27	27.8	31	2	AAY04194	Aay04194 Human par
405	27	27.8	31	2	AAY04222	Aay04222 Human par
406	27	27.8	31	2	AAY04180	Aay04180 Human par
407	27	27.8	31	2	AAY04193	Aay04193 Human par
408	27	27.8	31	2	AAY04203	Aay04203 Human par
409	27	27.8	31	2	AAY04257	Aay04257 Human par
410	27	27.8	31	2	AAY04197	Aay04197 Human par
411	27	27.8	31	2	AAY04200	Aay04200 Human par
412	27	27.8	31	2	AAY04177	Aay04177 Human par
413	27	27.8	31	2	AAY04181	Aay04181 Human par
414	27	27.8	31	2	AAY04196	Aay04196 Human par
415	27	27.8	31	2	AAY04201	Aay04201 Human par
416	27	27.8	31	2	AAY04212	Aay04212 Human par
417	27	27.8	31	2	AAY50575	Aay50575 Resin bou
418	27	27.8	31	2	AAY50571	Aay50571 Resin bou
419	27	27.8	31	2	AAY50579	Aay50579 Resin bou
420	27	27.8	31	2	AAY50570	Aay50570 Resin bou
421	27	27.8	31	2	AAY50584	Aay50584 Resin bou
422	27	27.8	31	2	AAY50569	Aay50569 Resin bou
423	27	27.8	31	2	AAY50574	Aay50574 Resin bou
424	27	27.8	31	2	AAY50577	Aay50577 Resin bou
425	27	27.8	31	2	AAY50576	Aay50576 Resin bou
426	27	27.8	31	2	AAY50578	Aay50578 Resin bou
427	27	27.8	31	2	AAY50573	Aay50573 Resin bou
428	27	27.8	31	2	AAY50568	Aay50568 Resin bou
429	27	27.8	31	2	AAY50572	Aay50572 Resin bou
430	27	27.8	31	7	ADI24768	Adi24768 Parathyro
431	27	27.8	31	7	ADI24763	Adi24763 Parathyro
432	27	27.8	31	7	ADI24751	Adi24751 Parathyro
433	27	27.8	31	7	ADI24757	Adi24757 Parathyro
434	27	27.8	31	7	ADI24761	Adi24761 Parathyro
435	27	27.8	31	7	ADI24772	Adi24772 Parathyro
436	27	27.8	31	7	ADI24787	Adi24787 Parathyro
437	27	27.8	31	7	ADI24831	Adi24831 Parathyro
438	27	27.8	31	7	ADI24774	Adi24774 Parathyro
439	27	27.8	31	7	ADI24758	Adi24758 Parathyro
440	27	27.8	31	7	ADI24770	Adi24770 Parathyro
441	27	27.8	31	7	ADI24832	Adi24832 Parathyro
442	27	27.8	31	7	ADI24834	Adi24834 Parathyro
443	27	27.8	31	7	ADI24753	Adi24753 Parathyro
444	27	27.8	31	7	ADI24759	Adi24759 Parathyro
445	27	27.8	31	7	ADI24775	Adi24775 Parathyro
446	27	27.8	31	7	ADI24752	Adi24752 Parathyro
447	27	27.8	31	7	ADI24760	Adi24760 Parathyro
448	27	27.8	31	7	ADI24776	Adi24776 Parathyro
449	27	27.8	31	7	ADI24762	Adi24762 Parathyro
450	27	27.8	31	7	ADI24778	Adi24778 Parathyro
451	27	27.8	31	7	ADI24829	Adi24829 Parathyro
452	27	27.8	31	7	ADI24773	Adi24773 Parathyro
453	27	27.8	31	7	ADI24798	Adi24798 Parathyro
454	27	27.8	31	7	ADI24756	Adi24756 Parathyro
455	27	27.8	31	7	ADI24779	Adi24779 Parathyro
456	27	27.8	31	7	ADI24830	Adi24830 Parathyro
457	27	27.8	31	7	ADI24755	Adi24755 Parathyro
458	27	27.8	31	7	ADI24771	Adi24771 Parathyro
459	27	27.8	31	7	ADI24786	Adi24786 Parathyro
460	27	27.8	31	7	ADI24835	Adi24835 Parathyro
461	27	27.8	31	7	ADI24769	Adi24769 Parathyro
462	27	27.8	31	7	ADI24777	Adi24777 Parathyro
463	27	27.8	31	7	ADI24784	Adi24784 Parathyro
464	27	27.8	31	7	ADI24785	Adi24785 Parathyro
465	27	27.8	31	7	ADI24789	Adi24789 Parathyro
466	27	27.8	31	7	ADI24754	Adi24754 Parathyro
467	27	27.8	31	7	ADI24822	Adi24822 Parathyro
468	27	27.8	31	7	ADI24833	Adi24833 Parathyro
469	27	27.8	31	7	ADI24836	Adi24836 Parathyro
470	27	27.8	31	7	ADI24788	Adi24788 Parathyro
471	27	27.8	32	4	AAG62184	Aag62184 Human gen
472	27	27.8	32	5	ABG63583	Abg63583 Human alb
473	27	27.8	32	8	ADL76848	Adl76848 Albumin f
474	27	27.8	33	4	AAG77644	Aag77644 Human col
475	27	27.8	34	1	AAP92220	Aap92220 Peptide s
476	27	27.8	34	2	AAY04218	Aay04218 Human par
477	27	27.8	34	2	AAY50585	Aay50585 Resin bou
478	27	27.8	34	3	AAB53927	Aab53927 Human col
479	27	27.8	34	4	AAU18637	Aau18637 Human lun
480	27	27.8	34	7	ADB33261	Adb33261 Human nov
481	27	27.8	34	7	ADI24794	Adi24794 Parathyro
482	27	27.8	35	3	AAY89302	Aay89302 Core poly
483	27	27.8	35	4	AAB77704	Aab77704 Core poly
484	27	27.8	35	4	ABB00710	Abb00710 RSV F1 pr
485	27	27.8	35	4	ABB02187	Abb02187 Viral cor
486	27	27.8	35	4	AAU13257	Aau13257 DP178-lik
487	27	27.8	35	4	AAU20775	Aau20775 Human nov
488	27	27.8	35	5	ADH32768	Adh32768 Yeast smO
489	27	27.8	36	2	AAR58185	Aar58185 [Lys18]-h
490	27	27.8	36	4	AAE03915	Aae03915 Human gen
491	27	27.8	36	4	ABB16686	Abb16686 Human ner
492	27	27.8	36	8	ABO55022	Abo55022 Human gen
493	27	27.8	37	3	AAB16673	Aab16673 Bacteriop
494	27	27.8	37	3	AAB45168	Aab45168 Human sec
495	27	27.8	37	4	AAB64430	Aab64430 Human sec
496	27	27.8	37	8	ADF45218	Adf45218 Human INP
497	27	27.8	38	3	AAB10619	Aab10619 Human SAP
498	27	27.8	38	7	ABO23537	Abo23537 Borrelia
499	27	27.8	38	7	ADF76747	Adf76747 Novel hum
500	27	27.8	39	8	ADM37301	Adm37301 Anti-IR f

ALIGNMENTS

RESULT 1
AAR43461
ID AAR43461 standard; peptide; 22 AA.
XX
AC AAR43461;
XX
DT 25-MAR-2003 (revised)
DT 12-MAY-1994 (first entry)
XX
DE Ro/SSA epitope 257.
XX
KW Linear; epitope; 60 kD; Ro/SSA; La/SSB; autoantigen; E/F; G; 70 kD;
KW nuclear ribonucleoprotein; nRNP; Sm B/B'; polypeptide; antigen; D;
KW systemic lupus erythematosus; SLE; autoantibody; U4/U6; U5; B; B';
KW RNA polymerase III; U1; U2; Sjogrens syndrome; SS; human; vaccine; ss.
XX
OS Homo sapiens.
XX
PN WO9321223-A1.
XX
PD 28-OCT-1993.
XX
PF 13-APR-1993; 93WO-US003484.
XX
PR 13-APR-1992; 92US-00867819.
XX
PA (OKLA) UNIV OKLAHOMA STATE.
XX
PI Harley JB;
XX
DR WPI; 1993-351658/44.

XX
PT New linear epitope(s) for human auto-antibodies - from the Ro/SSA, La/SSB
PT and Sm B/B' antigens and ribo:nucleoprotein, used for diagnosing and
PT treating auto-immune disorders e.g. systemic lupus erythematosus.
XX
PS Claim 1; Page 31; 43pp; English.
XX
CC The sequences given in AAR43391-562 are linear epitopes which are derived
CC from the 60 kD Ro/SSA peptide, the La/SSB autoantigen, the 70 kD nuclear
CC ribonucleoprotein (nRNP) and the Sm B/B' polypeptide. These antigens are
CC common in systemic lupus erythematosus (SLE) and closely related
CC disorders. The Ro/SSA family of proteins has been shown to have several
CC molecular forms which are defined by the molecular weight of the antigen
CC identified. The major form has a molecular weight of 60 kD and two
CC additional forms have molecular weights of 52 and 54 kD. La/SSB is also a
CC member of this group of autoantibodies and binds small RNAs with a
CC polyuridine terminus. La/SSB is bound by a third of the anti-Ro/SSA
CC precipitin positive sera. La/SSB has been shown to be a 46-50 kD
CC monomeric phosphoprotein which associates with RNA polymerase III
CC transcripts. Anti-Sm antibodies precipitate snRNPs containing the U1, U2,
CC U4/U6 and U5 RNA. Anti-Sm antibodies may be directed against one or a
CC combination of the polypeptides: B (26 kD), B' (27 kD), D (13 kD), E/F
CC (11 kD doublet) and G (less than 10 kD). These epitopes may be used for
CC preventing, treating or screening autoimmune disorders, especially SLE or
CC Sjogrens syndrome (SS). They bind to a human autoantibody and may
CC therefore be used as vaccines. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 22 AA;

Query Match 39.2%; Score 38; DB 2; Length 22;
Best Local Similarity 53.3%; Pred. No. 21;
Matches 8; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
||| || :| : ||
Db 5 NHLKSKEVWKALLQE 19

RESULT 2
AAB27169
ID AAB27169 standard; protein; 46 AA.
XX
AC AAB27169;
XX
DT 27-FEB-2001 (first entry)
XX
DE Sendai virus partial protein sequence SEQ ID NO: 17.
XX
KW Negative stranded RNA virus; vaccine; attenuated virus; RSV; PIV;
KW measles; respiratory syncytial virus; parainfluenza virus.
XX
OS Sendai virus.
XX
PN WO200061737-A2.
XX
PD 19-OCT-2000.
XX
PF 12-APR-2000; 2000WO-US009695.
XX
PR 13-APR-1999; 99US-0129006P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Murphy BR, Collins PL, Durbin AP, Skiadopoulos MH;
XX
DR WPI; 2000-687044/67.
XX
PT Producing attenuated negative stranded RNA virus vaccines from cloned
PT sequences, useful for immunizing against e.g. respiratory syncytial
PT virus, human parainfluenza virus, Sendai virus Newcastle disease virus,
PT mumps virus and measles virus.
XX
PS Example 1; Page 62; 137pp; English.
XX
CC The present invention is concerned with producing vaccines against
CC negative stranded RNA viruses. These viruses include measles, respiratory
CC syncytial virus (RSV) and parainfluenza virus (PIV) in particular. The
CC method of the invention comprises the production of a mutated form of the
CC virus which attenuates the strain and enables it to be used as a vaccine.
CC The present sequence comprises a partial viral protein sequence
XX
SQ Sequence 46 AA;

Query Match 36.1%; Score 35; DB 3; Length 46;
Best Local Similarity 28.6%; Pred. No. 1.7e+02;
Matches 4; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVSQEP 18
|: :: :::::|||
Db 1 LDKQVLYRVMNQEP 14

RESULT 3
ABM72186
ID ABM72186 standard; protein; 45 AA.
XX
AC ABM72186;
XX
DT 20-NOV-2003 (first entry)
XX
DE Staphylococcus aureus protein #1426.
XX
KW Antibacterial; vaccine; gene therapy; infection; sepsis; diagnosis;
KW enzymatic assay; antibiotic target.
XX
OS Staphylococcus aureus.
XX
PN WO200294868-A2.
XX
PD 28-NOV-2002.
XX
PF 27-MAR-2002; 2002WO-IB002637.
XX
PR 27-MAR-2001; 2001GB-00007661.
XX
PA (CHIR-) CHIRON SPA.
XX
PI Masignani V, Mora M, Scarselli M;
XX
DR WPI; 2003-120786/11.
DR N-PSDB; ACF73746.
XX
PT New Staphylococcus aureus protein, useful as a vaccine for treating or
PT preventing Staphylococcal infection, specifically an infection caused by
PT S. aureus, e.g. sepsis.
XX
PS Claim 1; SEQ ID NO 2852; 49pp; English.
XX
CC The invention relates to novel genes and encoded proteins from
CC Staphylococcus aureus. A composition comprising the S. aureus protein, a
CC nucleic acid encoding the protein, or an antibody to the protein, is
CC useful as a pharmaceutical, particularly as a vaccine for treating or
CC preventing infection due to Staphylococcus bacteria, specifically an
CC infection caused by S. aureus. The composition is particularly useful for
CC treating or preventing sepsis in a patient. The composition can also be
CC used for diagnostics. The protein is also used in an assay for enzymatic
CC studies and as a target for antibiotics. This sequence represents one of
CC the novel S. aureus proteins of the invention
XX
SQ Sequence 45 AA;

Query Match 35.1%; Score 34; DB 6; Length 45;
Best Local Similarity 62.5%; Pred. No. 2.6e+02;
Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```
Qy          2 PNHLNSKI 9
              |||||: :
Db         16 PNHLNTDV 23
```

RESULT 4
AAB27167
ID AAB27167 standard; protein; 46 AA.
XX
AC AAB27167;
XX
DT 27-FEB-2001 (first entry)
XX
DE HPIV3 partial protein sequence SEQ ID NO: 15.
XX
KW Negative stranded RNA virus; vaccine; attenuated virus; RSV; PIV;
KW measles; respiratory syncytial virus; parainfluenza virus.
XX
OS Human parainfluenza virus.
XX
PN WO200061737-A2.
XX
PD 19-OCT-2000.
XX
PF 12-APR-2000; 2000WO-US009695.
XX
PR 13-APR-1999; 99US-0129006P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Murphy BR, Collins PL, Durbin AP, Skiadopoulos MH;
XX
DR WPI; 2000-687044/67.
XX
PT Producing attenuated negative stranded RNA virus vaccines from cloned
PT sequences, useful for immunizing against e.g. respiratory syncytial
PT virus, human parainfluenza virus, Sendai virus Newcastle disease virus,
PT mumps virus and measles virus.
XX
PS Example 1; Page 62; 137pp; English.
XX
CC The present invention is concerned with producing vaccines against
CC negative stranded RNA viruses. These viruses include measles, respiratory
CC syncytial virus (RSV) and parainfluenza virus (PIV) in particular. The
CC method of the invention comprises the production of a mutated form of the
CC virus which attenuates the strain and enables it to be used as a vaccine.
CC The present sequence comprises a partial viral protein sequence
XX
SQ Sequence 46 AA;

  Query Match   35.1%; Score 34; DB 3; Length 46;
  Best Local Similarity   35.7%; Pred. No. 2.6e+02;
  Matches   5; Conservative   6; Mismatches   3; Indels   0; Gaps   0;

```
Qy          5 LNSKIAFKIVSQEP 18
              |:  : ::|::|||
Db          1 LDRSVLYRIMNQEP 14
```

RESULT 5
AAU21220
ID AAU21220 standard; protein; 49 AA.
XX
AC AAU21220;
XX
DT 17-DEC-2001 (first entry)
XX
DE Human novel foetal antigen, SEQ ID NO 1464.
XX
KW Human; foetal tissue antigen; antiinflammatory; neuroprotective;
KW immunomodulator; cardiovascular; cytostatic; nephrothropic;
KW cardiovascular; autoimmune disease; rheumatoid arthritis;
KW hyperproliferative disorder; breast neoplasm; cancer;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; food additive.
XX
OS Homo sapiens.
XX
PN WO200155312-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001321.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.

PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488782/53.
DR N-PSDB; AAS34040.
XX
PT New polynucleotides and polypeptides for diagnosing, treating, preventing
PT or prognosing e.g. diseases or disorders of the nervous, musculoskeletal,
PT excretory, gastrointestinal, reproductive, and respiratory systems.
XX
PS Claim 11; SEQ ID NO 1464; 642pp; English.
XX
CC The invention relates to novel nucleic acids encoding novel human foetal
CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g.
CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. The antibodies to the antigens can also be used
CC in alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection.
CC The polypeptides can also be used to aid wound healing and epithelial
CC cell proliferation, to prevent skin aging due to sunburn, to maintain
CC organs before transplantation, for supporting cell culture of primary
CC tissues, to regenerate tissues and in chemotaxis. The polypeptides can
CC also be used as a food additive or preservative to increase or decrease
CC storage capabilities, fat content, lipid, protein, carbohydrate,
CC vitamins, minerals, cofactors and other nutritional components. Numerous
CC examples of diseases and disorders treated by the nucleic acids and
CC proteins are given in the specification. The present sequence represents
CC a foetal antigen of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained

Query Match 35.1%; Score 34; DB 4; Length 49;
Best Local Similarity 70.0%; Pred. No. 2.8e+02;
Matches 7; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAF 11
| | |||| |
Db 3 PFHRNSKIKF 12

RESULT 6
AAM33005
ID AAM33005 standard; protein; 26 AA.
XX
AC AAM33005;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #7042 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
KW genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX

PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 27; SEQ ID NO 33274; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders
XX
SQ Sequence 26 AA;

Query Match 34.0%; Score 33; DB 4; Length 26;
Best Local Similarity 43.8%; Pred. No. 2e+02;
Matches 7; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQEP 18
Db 2 NTLERKTPIQILGQEP 17

RESULT 7
AAM72776
ID AAM72776 standard; protein; 26 AA.
XX
AC AAM72776;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 33082.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 33082; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention
XX
SQ Sequence 26 AA;

Query Match 34.0%; Score 33; DB 4; Length 26;
Best Local Similarity 43.8%; Pred. No. 2e+02;
Matches 7; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQEP 18
Db 2 NTLERKTPIQILGQEP 17

RESULT 8
AAM60161
ID AAM60161 standard; protein; 26 AA.
XX
AC AAM60161;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 32266.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX
PS Example 4; SEQ ID NO 32266; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention
XX
SQ Sequence 26 AA;

Query Match 34.0%; Score 33; DB 4; Length 26;

```
  Best Local Similarity   43.8%;  Pred. No. 2e+02;
  Matches    7;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              | |  |   :|: |||
Db          2 NTLERKTPIQILGQEP 17


RESULT 9
ABG54477
ID   ABG54477 standard; peptide; 26 AA.
XX
AC   ABG54477;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 33125.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 33125; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 26 AA;

  Query Match             34.0%;  Score 33;  DB 4;  Length 26;
  Best Local Similarity   43.8%;  Pred. No. 2e+02;
  Matches    7;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              | |  |   :|: |||
Db          2 NTLERKTPIQILGQEP 17


RESULT 10
ABG42601
ID   ABG42601 standard; peptide; 26 AA.
XX
AC   ABG42601;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 32266.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US000665.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples.
XX
PS   Claim 27; SEQ ID NO 32266; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of probes
CC   ; the novel set of probes which hybridise at high stringency to a nucleic
CC   acid expressed in the human lung; measuring gene expression in a sample
CC   derived from human lung, comprising (a) contacting the array with a
CC   collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of the
CC   array; identifying exons in a eukaryotic genome, comprising (a)
CC   algorithmically predicting at least one exon from genomic sequences of
CC   the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene expression
```

```
CC   analysis, and for identifying exons in a gene, particularly using human
CC   lung derived mRNA and for the study of lung diseases such as asthma, lung
CC   cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC   disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC   tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC   Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC   histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC   Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC   dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC   present sequence is a peptide/protein encoded by a single exon probe of
CC   the invention. Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 26 AA;

  Query Match             34.0%;  Score 33;  DB 5;  Length 26;
  Best Local Similarity   43.8%;  Pred. No. 2e+02;
  Matches    7;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              | |  |   :|: |||
Db          2 NTLERKTPIQILGQEP 17


RESULT 11
AAG27280
ID   AAG27280 standard; protein; 44 AA.
XX
AC   AAG27280;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Zea mays protein fragment SEQ ID NO: 32054.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence; corn.
XX
OS   Zea mays subsp. mays.
XX
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-00301439.
XX
PR   25-FEB-1999;   99US-0121825P.
PR   05-MAR-1999;   99US-0123180P.
PR   09-MAR-1999;   99US-0123548P.
PR   23-MAR-1999;   99US-0125788P.
PR   25-MAR-1999;   99US-0126264P.
PR   29-MAR-1999;   99US-0126785P.
PR   01-APR-1999;   99US-0127462P.
PR   06-APR-1999;   99US-0128234P.
PR   08-APR-1999;   99US-0128714P.
PR   16-APR-1999;   99US-0129845P.
PR   19-APR-1999;   99US-0130077P.
PR   21-APR-1999;   99US-0130449P.
PR   23-APR-1999;   99US-0130510P.
PR   23-APR-1999;   99US-0130891P.
PR   28-APR-1999;   99US-0131449P.
PR   30-APR-1999;   99US-0132048P.
PR   30-APR-1999;   99US-0132407P.
PR   04-MAY-1999;   99US-0132484P.
PR   05-MAY-1999;   99US-0132485P.
PR   06-MAY-1999;   99US-0132486P.
PR   06-MAY-1999;   99US-0132487P.
PR   07-MAY-1999;   99US-0132863P.
PR   11-MAY-1999;   99US-0134256P.
PR   14-MAY-1999;   99US-0134218P.
PR   14-MAY-1999;   99US-0134219P.
PR   14-MAY-1999;   99US-0134221P.
PR   14-MAY-1999;   99US-0134370P.
PR   18-MAY-1999;   99US-0134768P.
PR   19-MAY-1999;   99US-0134941P.
PR   20-MAY-1999;   99US-0135124P.
PR   21-MAY-1999;   99US-0135353P.
PR   24-MAY-1999;   99US-0135629P.
PR   25-MAY-1999;   99US-0136021P.
PR   27-MAY-1999;   99US-0136392P.
PR   28-MAY-1999;   99US-0136782P.
PR   01-JUN-1999;   99US-0137222P.
PR   03-JUN-1999;   99US-0137528P.
PR   04-JUN-1999;   99US-0137502P.
PR   07-JUN-1999;   99US-0137724P.
PR   08-JUN-1999;   99US-0138094P.
PR   10-JUN-1999;   99US-0138540P.
PR   10-JUN-1999;   99US-0138847P.
PR   14-JUN-1999;   99US-0139119P.
PR   16-JUN-1999;   99US-0139452P.
PR   16-JUN-1999;   99US-0139453P.
PR   17-JUN-1999;   99US-0139492P.
PR   18-JUN-1999;   99US-0139454P.
PR   18-JUN-1999;   99US-0139455P.
PR   18-JUN-1999;   99US-0139456P.
PR   18-JUN-1999;   99US-0139457P.
PR   18-JUN-1999;   99US-0139458P.
PR   18-JUN-1999;   99US-0139459P.
PR   18-JUN-1999;   99US-0139460P.
PR   18-JUN-1999;   99US-0139461P.
PR   18-JUN-1999;   99US-0139462P.
PR   18-JUN-1999;   99US-0139463P.
PR   18-JUN-1999;   99US-0139750P.
PR   18-JUN-1999;   99US-0139763P.
PR   21-JUN-1999;   99US-0139817P.
PR   22-JUN-1999;   99US-0139899P.
PR   23-JUN-1999;   99US-0140353P.
PR   23-JUN-1999;   99US-0140354P.
PR   24-JUN-1999;   99US-0140695P.
PR   28-JUN-1999;   99US-0140823P.
PR   29-JUN-1999;   99US-0140991P.
PR   30-JUN-1999;   99US-0141287P.
PR   01-JUL-1999;   99US-0141842P.
PR   01-JUL-1999;   99US-0142154P.
PR   02-JUL-1999;   99US-0142055P.
PR   06-JUL-1999;   99US-0142390P.
PR   08-JUL-1999;   99US-0142803P.
PR   09-JUL-1999;   99US-0142920P.
PR   12-JUL-1999;   99US-0142977P.
PR   13-JUL-1999;   99US-0143542P.
PR   14-JUL-1999;   99US-0143624P.
PR   15-JUL-1999;   99US-0144005P.
PR   16-JUL-1999;   99US-0144085P.
PR   16-JUL-1999;   99US-0144086P.
PR   19-JUL-1999;   99US-0144325P.
PR   19-JUL-1999;   99US-0144331P.
PR   19-JUL-1999;   99US-0144332P.
PR   19-JUL-1999;   99US-0144333P.
PR   19-JUL-1999;   99US-0144334P.
PR   19-JUL-1999;   99US-0144335P.
PR   20-JUL-1999;   99US-0144352P.
PR   20-JUL-1999;   99US-0144632P.
PR   20-JUL-1999;   99US-0144884P.
PR   21-JUL-1999;   99US-0144814P.
PR   21-JUL-1999;   99US-0145086P.
PR   21-JUL-1999;   99US-0145088P.
PR   22-JUL-1999;   99US-0145085P.
PR   22-JUL-1999;   99US-0145087P.
PR   22-JUL-1999;   99US-0145089P.
PR   22-JUL-1999;   99US-0145192P.
PR   23-JUL-1999;   99US-0145145P.
PR   23-JUL-1999;   99US-0145218P.
PR   23-JUL-1999;   99US-0145224P.
PR   26-JUL-1999;   99US-0145276P.
PR   27-JUL-1999;   99US-0145913P.
```

PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 34.0%; Score 33; DB 3; Length 44;
Best Local Similarity 46.2%; Pred. No. 3.7e+02;
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

```
Qy          1 EPNHLNSKIAFKI 13
              :||||:|  :| :
Db         10 QPNHLDSWGSFAL 22
```

RESULT 12
AAG59652
ID AAG59652 standard; protein; 36 AA.
XX
AC AAG59652;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 77180.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.

PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.

```
PR   29-OCT-1999;   99US-0162142P.

  Query Match             33.5%;  Score 32.5;  DB 3;  Length 36;
  Best Local Similarity   57.1%;  Pred. No. 3.6e+02;
  Matches    8;  Conservative    3;  Mismatches    2;  Indels    1;  Gaps    1;

Qy          3 NHLNSKIA-FKIVS 15
              :||: ||  ||:||
Db         14 HHLSLKITPFKVVS 27


RESULT 13
AAM16072
ID   AAM16072 standard; protein; 36 AA.
XX
AC   AAM16072;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #2506 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000670.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human cervical epithelial cells.
XX
PS   Claim 27; SEQ ID NO 20898; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 36 AA;

  Query Match             33.5%;  Score 32.5;  DB 4;  Length 36;
  Best Local Similarity   53.8%;  Pred. No. 3.6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKI 13
              |||| || : | :
Db         19 EPNH-NSLLVFPL 30


RESULT 14
ABB35064
ID   ABB35064 standard; peptide; 36 AA.
XX
AC   ABB35064;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #2570 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 27699; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 36 AA;

  Query Match             33.5%;  Score 32.5;  DB 4;  Length 36;
  Best Local Similarity   53.8%;  Pred. No. 3.6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKI 13
              |||| || : | :
Db         19 EPNH-NSLLVFPL 30


RESULT 15
AAM28566
ID   AAM28566 standard; protein; 36 AA.
XX
AC   AAM28566;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #2603 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
```

XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 27; SEQ ID NO 28835; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders
XX
SQ Sequence 36 AA;

Query Match 33.5%; Score 32.5; DB 4; Length 36;
Best Local Similarity 53.8%; Pred. No. 3.6e+02;
Matches 7; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

Qy 1 EPNHLNSKIAFKI 13
|||| || : | :
Db 19 EPNH-NSLLVFPL 30

RESULT 16
ABB20476
ID ABB20476 standard; protein; 36 AA.
XX
AC ABB20476;
XX
DT 23-JAN-2002 (first entry)
XX
DE Protein #2475 encoded by probe for measuring heart cell gene expression.
XX
KW Human; gene expression; heart; microarray; vascular system;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease.
XX
OS Homo sapiens.
XX
PN WO200157274-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000666.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488899/53.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX
PS Claim 15; SEQ ID NO 22246; 530pp; English.
XX
CC The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart (see
CC ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC probe. The probes may be used for predicting, measuring and displaying
CC gene expression in samples derived from the human heart via microarrays.
CC By measuring gene expression, the probes are useful for predicting,
CC diagnosing, grading, staging, monitoring and prognosing diseases of the
CC human heart and vascular system e.g. cardiovascular disease,
CC hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 36 AA;

Query Match 33.5%; Score 32.5; DB 4; Length 36;
Best Local Similarity 53.8%; Pred. No. 3.6e+02;
Matches 7; Conservative 2; Mismatches 3; Indels 1; Gaps 1;

Qy 1 EPNHLNSKIAFKI 13
|||| || : | :
Db 19 EPNH-NSLLVFPL 30

RESULT 17
AAM68248
ID AAM68248 standard; protein; 36 AA.
XX
AC AAM68248;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 28554.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.

```
XX
PS   Example 4; SEQ ID NO 28554; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention
XX
SQ   Sequence 36 AA;

  Query Match             33.5%;  Score 32.5;  DB 4;  Length 36;
  Best Local Similarity   53.8%;  Pred. No. 3.6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKI 13
              |||| || : | :
Db         19 EPNH-NSLLVFPL 30


RESULT 18
AAM55878
ID   AAM55878 standard; protein; 36 AA.
XX
AC   AAM55878;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 27983.
XX
KW   Human; brain expressed exon; gene expression analysis; probe; microarray;
KW   Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000667.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains.
XX
PS   Example 4; SEQ ID NO 27983; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 36 AA;

  Query Match             33.5%;  Score 32.5;  DB 4;  Length 36;
  Best Local Similarity   53.8%;  Pred. No. 3.6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKI 13
              |||| || : | :
Db         19 EPNH-NSLLVFPL 30


RESULT 19
ABG49902
ID   ABG49902 standard; peptide; 36 AA.
XX
AC   ABG49902;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 28550.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 28550; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 36 AA;

  Query Match             33.5%;  Score 32.5;  DB 4;  Length 36;
  Best Local Similarity   53.8%;  Pred. No. 3.6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKI 13
              |||| || : | :
Db         19 EPNH-NSLLVFPL 30
```

```
RESULT 20
AAM03799
ID   AAM03799 standard; protein; 36 AA.
XX
AC   AAM03799;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Peptide #2481 encoded by probe for measuring breast gene expression.
XX
KW   Probe; human; breast disease; breast cancer; development disorder;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US000661.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression in
PT   a human breast.
XX
PS   Claim 27; SEQ ID NO 12539; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes
CC   (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for measuring human gene expression in
CC   a human breast sample, where the probe hybridises at high stringency to a
CC   nucleic acid expressed in the human breast. The probes are useful for
CC   predicting, diagnosing, grading, staging, monitoring and prognosing
CC   diseases of the human breast, particularly those diseases with polygenic
CC   aetiology. The diseases include: breast cancer, disorders of development,
CC   inflammatory diseases of the breast, fibrocystic changes, proliferative
CC   breast disease and non-carcinoma tumours. Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 36 AA;

  Query Match             33.5%;  Score 32.5;  DB 4;  Length 36;
  Best Local Similarity   53.8%;  Pred. No. 3.6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKI 13
              |||| || : | :
Db         19 EPNH-NSLLVFPL 30


RESULT 21
ABG37783
ID   ABG37783 standard; peptide; 36 AA.
XX
AC   ABG37783;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 27448.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US000665.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples.
XX
PS   Claim 27; SEQ ID NO 27448; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of probes
CC   ; the novel set of probes which hybridise at high stringency to a nucleic
CC   acid expressed in the human lung; measuring gene expression in a sample
CC   derived from human lung, comprising (a) contacting the array with a
CC   collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of the
CC   array; identifying exons in a eukaryotic genome, comprising (a)
CC   algorithmically predicting at least one exon from genomic sequences of
CC   the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene expression
CC   analysis, and for identifying exons in a gene, particularly using human
CC   lung derived mRNA and for the study of lung diseases such as asthma, lung
CC   cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC   disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC   tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC   Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC   histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC   Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC   dyskinesis, pulmonary hypertension and hyaline membrane disease. The
```

```
CC   present sequence is a peptide/protein encoded by a single exon probe of
CC   the invention. Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 36 AA;

  Query Match             33.5%;  Score 32.5;  DB 5;  Length 36;
  Best Local Similarity   53.8%;  Pred. No. 3.6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKI 13
              |||| || : | :
Db         19 EPNH-NSLLVFPL 30


RESULT 22
ABO12904
ID   ABO12904 standard; peptide; 24 AA.
XX
AC   ABO12904;
XX
DT   25-AUG-2003  (first entry)
XX
DE   Mouse zinc finger DNA binding domain #10.
XX
KW   Composite binding polypeptide; zinc finger nucleic acid binding domain;
KW   autoimmune disorder; immunosuppressive; zinc finger DNA binding domain;
KW   mouse.
XX
OS   Mus sp.
XX
PN   WO200299084-A2.
XX
PD   12-DEC-2002.
XX
PF   04-APR-2002; 2002WO-US022272.
XX
PR   04-APR-2001; 2001GB-00008491.
XX
PA   (SANG-) SANGAMO BIOSCIENCES INC.
XX
PI   Moore M,  Sepp A,  Isalan M,  Choo Y;
XX
DR   WPI; 2003-278214/27.
XX
PT   New composite binding zinc finger polypeptide, useful for designing
PT   sequence-specific binding proteins regulating gene expression in the
PT   fields of molecular biology, and for the diagnosis and treatment of
PT   autoimmune disorders.
XX
PS   Example 3; Page 97; 157pp; English.
XX
CC   The invention relates to a composite binding polypeptide comprising a
CC   first natural binding domain derived from a first natural binding
CC   polypeptide and a second natural binding domain derived from a second
CC   natural binding polypeptide, where the first and second natural binding
CC   polypeptides may be the same or different and where the polypeptide binds
CC   to a target differing from the natural target of both the first and
CC   second binding polypeptides. The invention also relates to a chimeric
CC   polypeptide comprising a binding polypeptide cited above and a biological
CC   effector domain, a library of natural binding domains, a library of
CC   natural zinc finger nucleic acid binding domains comprising a linker
CC   attached to it, a method for selecting a binding polypeptide capable of
CC   binding to a target site and a method for designing a composite binding
CC   polypeptide. The methods and compositions of the present invention are
CC   useful for designing sequence-specific binding proteins for regulation of
CC   gene expression in the fields of molecular biology. They can also be used
CC   for the diagnosis and treatment of autoimmune disorders, and as research
CC   tools and in transgenic animals. This sequence represents a mouse zinc
CC   finger DNA binding domain used in the scope of the invention
XX
SQ   Sequence 24 AA;

  Query Match             33.0%;  Score 32;  DB 6;  Length 24;
  Best Local Similarity   62.5%;  Pred. No. 2.7e+02;
  Matches    5;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKI 9
              |:|||| :
Db         13 PDHLNSHV 20


RESULT 23
ABO11938
ID   ABO11938 standard; peptide; 24 AA.
XX
AC   ABO11938;
XX
DT   25-AUG-2003  (first entry)
XX
DE   Human zinc finger DNA binding domain #238.
XX
KW   Composite binding polypeptide; zinc finger nucleic acid binding domain;
KW   autoimmune disorder; immunosuppressive; zinc finger DNA binding domain;
KW   human.
XX
OS   Homo sapiens.
XX
PN   WO200299084-A2.
XX
PD   12-DEC-2002.
XX
PF   04-APR-2002; 2002WO-US022272.
XX
PR   04-APR-2001; 2001GB-00008491.
XX
PA   (SANG-) SANGAMO BIOSCIENCES INC.
XX
PI   Moore M,  Sepp A,  Isalan M,  Choo Y;
XX
DR   WPI; 2003-278214/27.
XX
PT   New composite binding zinc finger polypeptide, useful for designing
PT   sequence-specific binding proteins regulating gene expression in the
PT   fields of molecular biology, and for the diagnosis and treatment of
PT   autoimmune disorders.
XX
PS   Example 2; Page 76; 157pp; English.
XX
CC   The invention relates to a composite binding polypeptide comprising a
CC   first natural binding domain derived from a first natural binding
CC   polypeptide and a second natural binding domain derived from a second
CC   natural binding polypeptide, where the first and second natural binding
CC   polypeptides may be the same or different and where the polypeptide binds
CC   to a target differing from the natural target of both the first and
CC   second binding polypeptides. The invention also relates to a chimeric
CC   polypeptide comprising a binding polypeptide cited above and a biological
CC   effector domain, a library of natural binding domains, a library of
CC   natural zinc finger nucleic acid binding domains comprising a linker
CC   attached to it, a method for selecting a binding polypeptide capable of
CC   binding to a target site and a method for designing a composite binding
CC   polypeptide. The methods and compositions of the present invention are
CC   useful for designing sequence-specific binding proteins for regulation of
CC   gene expression in the fields of molecular biology. They can also be used
CC   for the diagnosis and treatment of autoimmune disorders, and as research
CC   tools and in transgenic animals. This sequence represents a human zinc
CC   finger DNA binding domain used in the scope of the invention
XX
SQ   Sequence 24 AA;

  Query Match             33.0%;  Score 32;  DB 6;  Length 24;
  Best Local Similarity   62.5%;  Pred. No. 2.7e+02;
  Matches    5;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKI 9
```

```
              |:|||| :
Db          13 PDHLNSHV 20


RESULT 24
ABU62168
ID   ABU62168 standard; peptide; 24 AA.
XX
AC   ABU62168;
XX
DT   25-AUG-2003  (first entry)
XX
DE   Human zinc finger DNA binding domain #6.
XX
KW   Composite binding polypeptide; zinc finger nucleic acid binding domain;
KW   autoimmune disorder; immunosuppressive; zinc finger DNA binding domain;
KW   human.
XX
OS   Homo sapiens.
XX
PN   WO200299084-A2.
XX
PD   12-DEC-2002.
XX
PF   04-APR-2002; 2002WO-US022272.
XX
PR   04-APR-2001; 2001GB-00008491.
XX
PA   (SANG-) SANGAMO BIOSCIENCES INC.
XX
PI   Moore M,  Sepp A,  Isalan M,  Choo Y;
XX
DR   WPI; 2003-278214/27.
XX
PT   New composite binding zinc finger polypeptide, useful for designing
PT   sequence-specific binding proteins regulating gene expression in the
PT   fields of molecular biology, and for the diagnosis and treatment of
PT   autoimmune disorders.
XX
PS   Example 1; Page 70; 157pp; English.
XX
CC   The invention relates to a composite binding polypeptide comprising a
CC   first natural binding domain derived from a first natural binding
CC   polypeptide and a second natural binding domain derived from a second
CC   natural binding polypeptide, where the first and second natural binding
CC   polypeptides may be the same or different and where the polypeptide binds
CC   to a target differing from the natural target of both the first and
CC   second binding polypeptides. The invention also relates to a chimeric
CC   polypeptide comprising a binding polypeptide cited above and a biological
CC   effector domain, a library of natural binding domains, a library of
CC   natural zinc finger nucleic acid binding domains comprising a linker
CC   attached to it, a method for selecting a binding polypeptide capable of
CC   binding to a target site and a method for designing a composite binding
CC   polypeptide. The methods and compositions of the present invention are
CC   useful for designing sequence-specific binding proteins for regulation of
CC   gene expression in the fields of molecular biology. They can also be used
CC   for the diagnosis and treatment of autoimmune disorders, and as research
CC   tools and in transgenic animals. This sequence represents a human zinc
CC   finger DNA binding domain used in the scope of the invention
XX
SQ   Sequence 24 AA;

  Query Match             33.0%;  Score 32;  DB 6;  Length 24;
  Best Local Similarity   62.5%;  Pred. No. 2.7e+02;
  Matches    5;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKI 9
              |:|||| :
Db         13 PDHLNSHV 20


RESULT 25
AAW60192
ID   AAW60192 standard; protein; 26 AA.
XX
AC   AAW60192;
XX
DT   27-AUG-2003  (revised)
DT   03-SEP-1998  (first entry)
XX
DE   Bacteriophage spo1 Pol I-type DNA polymerase helix O region sequence.
XX
KW   Pol I-type; non-discriminating DNA polymerase; leprosy; tuberculosis;
KW   mycobacteria; Bacteriophage spo1.
XX
OS   Bacteriophage SPO1.
XX
PN   US5776673-A.
XX
PD   07-JUL-1998.
XX
PF   21-APR-1995;   95US-00427072.
XX
PR   21-APR-1995;   95US-00427072.
XX
PA   (HARD ) HARVARD COLLEGE.
XX
PI   Tabor S,  Richardson CC;
XX
DR   WPI; 1998-398014/34.
XX
PT   Detecting mycobacteria for diagnosing tuberculosis and/or leprosy -
PT   comprises detecting the presence of a DNA polymerase that does not
PT   discriminate between deoxy- and di:deoxy-nucleoside tri:phosphate(s).
XX
PS   Disclosure; Col 5; 21pp; English.
XX
CC   This sequence represents the helix O region of Bacteriophage spo1 Pol I-
CC   type DNA polymerase. This can be used in the method of invention of
CC   diagnosing the presence of a mycobacterial organism. The method comprises
CC   providing a sample from a patient, detecting the presence of a non-
CC   discriminating DNA polymerase, not normally present by determining the
CC   ability of the non-discriminating DNA polymerase to incorporate
CC   dideoxynucleotides (ddNTP) relative to deoxynucleotides (dNTP). The
CC   presence of non-discriminating DNA polymerase is indicative of presence
CC   of a mycobacterial organism. The method is used to diagnose tuberculosis
CC   and leprosy. (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ   Sequence 26 AA;

  Query Match             33.0%;  Score 32;  DB 2;  Length 26;
  Best Local Similarity   57.1%;  Pred. No. 3e+02;
  Matches    8;  Conservative    1;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQEPA 19
              : || | || || |
Db          6 SKKIQFGIVYQESA 19


RESULT 26
ABB17107
ID   ABB17107 standard; protein; 33 AA.
XX
AC   ABB17107;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Human nervous system related polypeptide SEQ ID NO 5764.
XX
KW   Human; nootropic; neuroprotective; cytostatic; dermatological; virucide;
KW   immunosuppressive; antiinflammatory; anti-HIV; antibacterial; vulnerary;
KW   antiparkinsonian; antisickling; antianaemic; antiarthritic; cancer;
KW   antirheumatic; hepatotropic; cerebroprotective; antiinflammatory;
KW   antiallergic; antidiabetic; antiulcer; anticonvulsant; antifungal;
KW   antiparasitic; cardiant; immune disorder; cardiovascular disorder;
KW   neurological disease; infection; nephrotropic; gene therapy; vaccine.
```

XX
OS Homo sapiens.
XX
PN WO200159063-A2.
XX
PD 16-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001334.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 20-OCT-2000; 2000US-0242221P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250391P.
PR 01-DEC-2000; 2000US-0251160P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX

PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-541565/60.
DR N-PSDB; ABA13433.
XX
PT Nucleic acids encoding 3224 human nervous system antigen polypeptides,
PT useful for preventing, diagnosing and/or treating nervous system cancers
PT and metastases.
XX
PS Claim 11; SEQ ID NO 5764; 1701pp + Sequence Listing; English.
XX
CC The invention relates to novel genes (ABA11004-ABA21534) and proteins
CC (ABB14678-ABB18001) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 33 AA;

Query Match 33.0%; Score 32; DB 4; Length 33;
Best Local Similarity 66.7%; Pred. No. 4e+02;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy          3 NHLNSKIAF 11
              |||  | |
Db         22 NHLNVSITF 30
```

RESULT 27
ABB16071
ID ABB16071 standard; protein; 38 AA.
XX
AC ABB16071;
XX
DT 23-JAN-2002 (first entry)
XX
DE Human nervous system related polypeptide SEQ ID NO 4728.
XX
KW Human; nootropic; neuroprotective; cytostatic; dermatological; virucide;
KW immunosuppressive; antiinflammatory; anti-HIV; antibacterial; vulnerary;
KW antiparkinsonian; antisickling; antianaemic; antiarthritic; cancer;
KW antirheumatic; hepatotropic; cerebroprotective; antiinflammatory;
KW antiallergic; antidiabetic; antiulcer; anticonvulsant; antifungal;
KW antiparasitic; cardiant; immune disorder; cardiovascular disorder;
KW neurological disease; infection; nephrotropic; gene therapy; vaccine.
XX
OS Homo sapiens.
XX
PN WO200159063-A2.
XX
PD 16-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001334.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.

PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 20-OCT-2000; 2000US-0242221P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250391P.
PR 01-DEC-2000; 2000US-0251160P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-541565/60.
DR N-PSDB; ABA12397.
XX
PT Nucleic acids encoding 3224 human nervous system antigen polypeptides,
PT useful for preventing, diagnosing and/or treating nervous system cancers
PT and metastases.
XX
PS Claim 11; SEQ ID NO 4728; 1701pp + Sequence Listing; English.
XX
CC The invention relates to novel genes (ABA11004-ABA21534) and proteins
CC (ABB14678-ABB18001) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 38 AA;

Query Match 33.0%; Score 32; DB 4; Length 38;
Best Local Similarity 40.0%; Pred. No. 4.7e+02;
Matches 6; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

```
Qy          2 PNHLNSKIAFKIVSQ 16
              | | ||::    :||
Db          8 PAHCNSRLRATSISQ 22
```

RESULT 28
AAB27168
ID AAB27168 standard; protein; 46 AA.
XX
AC AAB27168;
XX
DT 27-FEB-2001 (first entry)
XX
DE BPIV3 partial protein sequence SEQ ID NO: 16.
XX
KW Negative stranded RNA virus; vaccine; attenuated virus; RSV; PIV;
KW measles; respiratory syncytial virus; parainfluenza virus.
XX
OS Bovine parainfluenza virus.
XX
PN WO200061737-A2.
XX
PD 19-OCT-2000.
XX
PF 12-APR-2000; 2000WO-US009695.
XX
PR 13-APR-1999; 99US-0129006P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Murphy BR, Collins PL, Durbin AP, Skiadopoulos MH;
XX
DR WPI; 2000-687044/67.
XX
PT Producing attenuated negative stranded RNA virus vaccines from cloned
PT sequences, useful for immunizing against e.g. respiratory syncytial
PT virus, human parainfluenza virus, Sendai virus Newcastle disease virus,
PT mumps virus and measles virus.
XX
PS Example 1; Page 62; 137pp; English.
XX
CC The present invention is concerned with producing vaccines against
CC negative stranded RNA viruses. These viruses include measles, respiratory
CC syncytial virus (RSV) and parainfluenza virus (PIV) in particular. The
CC method of the invention comprises the production of a mutated form of the
CC virus which attenuates the strain and enables it to be used as a vaccine.
CC The present sequence comprises a partial viral protein sequence
XX
SQ Sequence 46 AA;

```
  Query Match             33.0%;  Score 32;  DB 3;  Length 46;
  Best Local Similarity   35.7%;  Pred. No. 6e+02;
  Matches    5;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              |:  : ::|::|||
Db          1 LDRGVLYRIMNQEP 14


RESULT 29
AAM13846
ID   AAM13846 standard; protein; 48 AA.
XX
AC   AAM13846;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #280 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000670.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human cervical epithelial cells.
XX
PS   Claim 27; SEQ ID NO 18672; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 30
ABB32791
ID   ABB32791 standard; peptide; 48 AA.
XX
AC   ABB32791;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #297 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 25426; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 31
AAM26253
ID   AAM26253 standard; protein; 48 AA.
XX
AC   AAM26253;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #290 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
```

```
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 26522; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 32
ABB27621
ID   ABB27621 standard; peptide; 48 AA.
XX
AC   ABB27621;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Human peptide #272 encoded by breast cell single exon nucleic acid probe.
XX
KW   Human; microarray; single exon probe; gene expression; breast; disease;
KW   cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157271-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000662.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-496933/54.
XX
PT   New spatially-addressable set of single exon nucleic acid probes, useful
PT   for measuring gene expression in sample derived from human breast,
PT   comprises number of single exon nucleic acid probes.
XX
PS   Claim 27; SEQ ID NO 10589; 327pp + Sequence Listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting the
CC   probes with a collection of detectably labelled nucleic acids derived
CC   from mRNA of human breast, and then measuring the label bound to each
CC   probe of the microarray. The probes are useful for verifying the
CC   expression of regions of genomic DNA predicted to encode proteins. They
CC   are useful for gene discovery, and for determining predisposition and/or
CC   prognosing breast disease. Gene expression analysis is useful for
CC   assessing the toxicity of chemical agents on cells. The microarray of
CC   this invention presents a far greater diversity of probes for measuring
CC   gene expression, with far less bias than expressed sequence tag
CC   microarrays. The method is suitable for rapid production of functional
CC   information from genomic sequence. The present sequence is a peptide
CC   encoded by a single exon nucleic acid probe of the invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 33
ABB18273
ID   ABB18273 standard; protein; 48 AA.
XX
AC   ABB18273;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #272 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000666.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
```

```
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts.
XX
PS   Claim 15; SEQ ID NO 20043; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart (see
CC   ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC   probe. The probes may be used for predicting, measuring and displaying
CC   gene expression in samples derived from the human heart via microarrays.
CC   By measuring gene expression, the probes are useful for predicting,
CC   diagnosing, grading, staging, monitoring and prognosing diseases of the
CC   human heart and vascular system e.g. cardiovascular disease,
CC   hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 34
AAM65977
ID   AAM65977 standard; protein; 48 AA.
XX
AC   AAM65977;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human bone marrow expressed probe encoded protein SEQ ID NO: 26283.
XX
KW   Human; bone marrow expressed exon; gene expression analysis; probe;
KW   microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS   Homo sapiens.
XX
PN   WO200157276-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000668.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488900/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human bone marrow.
XX
PS   Example 4; SEQ ID NO 26283; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 35
AAM53598
ID   AAM53598 standard; protein; 48 AA.
XX
AC   AAM53598;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 25703.
XX
KW   Human; brain expressed exon; gene expression analysis; probe; microarray;
KW   Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000667.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains.
XX
PS   Example 4; SEQ ID NO 25703; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
```

```
Db         14 NHINVMVKFPSIVEE 28


RESULT 36
ABG47643
ID   ABG47643 standard; peptide; 48 AA.
XX
AC   ABG47643;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 26291.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 26291; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 37
AAM01589
ID   AAM01589 standard; protein; 48 AA.
XX
AC   AAM01589;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Peptide #271 encoded by probe for measuring human breast gene expression.
XX
KW   Probe; human; breast disease; breast cancer; development disorder;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US000661.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression in
PT   a human breast.
XX
PS   Claim 27; SEQ ID NO 10329; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes
CC   (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for measuring human gene expression in
CC   a human breast sample, where the probe hybridises at high stringency to a
CC   nucleic acid expressed in the human breast. The probes are useful for
CC   predicting, diagnosing, grading, staging, monitoring and prognosing
CC   diseases of the human breast, particularly those diseases with polygenic
CC   aetiology. The diseases include: breast cancer, disorders of development,
CC   inflammatory diseases of the breast, fibrocystic changes, proliferative
CC   breast disease and non-carcinoma tumours. Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 48 AA;

  Query Match             33.0%;  Score 32;  DB 4;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.3e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 38
ABG35625
ID   ABG35625 standard; peptide; 48 AA.
XX
AC   ABG35625;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 25290.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
```

KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesis; pulmonary hypertension;
KW hyaline membrane disease.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US000665.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.
XX
PS Claim 27; SEQ ID NO 25290; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of probes
CC ; the novel set of probes which hybridise at high stringency to a nucleic
CC acid expressed in the human lung; measuring gene expression in a sample
CC derived from human lung, comprising (a) contacting the array with a
CC collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of the
CC array; identifying exons in a eukaryotic genome, comprising (a)
CC algorithmically predicting at least one exon from genomic sequences of
CC the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene expression
CC analysis, and for identifying exons in a gene, particularly using human
CC lung derived mRNA and for the study of lung diseases such as asthma, lung
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC present sequence is a peptide/protein encoded by a single exon probe of
CC the invention. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 48 AA;

Query Match 33.0%; Score 32; DB 5; Length 48;
Best Local Similarity 33.3%; Pred. No. 6.3e+02;
Matches 5; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
||:| : | : :|
Db 14 NHINVMVKFPSIVEE 28

RESULT 39
AAB89226
ID AAB89226 standard; peptide; 21 AA.
XX
AC AAB89226;
XX
DT 23-MAY-2001 (first entry)
XX
DE HIV gp120 protein binding peptide #319.
XX
KW Human chemokine receptor; CD4; HIV; glycoprotein 120; gp120; antagonist;
KW replication; CCR5; CXCR4; CD4; STRL33.
XX
OS Homo sapiens.
XX
PN WO200116182-A2.
XX
PD 08-MAR-2001.
XX
PF 25-AUG-2000; 2000WO-US023505.
XX
PR 27-AUG-1999; 99US-0151270P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Saxinger C;
XX
DR WPI; 2001-244398/25.
XX
PT Novel polypeptides useful for treating HIV infection, have homology to
PT regions of domains of human chemokine receptors CCR5, CXCR4 and STRL33,
PT and binds to HIV gp120 under physiological conditions.
XX
PS Example 4; Page 46; 114pp; English.
XX
CC The present invention describes a number of peptides which are able to
CC bind to HIV glycoprotein 120 (gp120). These are similar to the human
CC chemokine receptors CCR5, CXCR4 and STRL33, as well as CD4. These are
CC useful in the treatment of HIV, as they prevent replication of the virus.
CC The present sequence is an example of a peptide of the invention
XX
SQ Sequence 21 AA;

Query Match 32.0%; Score 31; DB 4; Length 21;
Best Local Similarity 38.5%; Pred. No. 3.5e+02;
Matches 5; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy 6 NSKIAFKIVSQEP 18
| ::: | |:|:|
Db 8 NKEVSVKRVTQDP 20

RESULT 40
AAB89227
ID AAB89227 standard; peptide; 21 AA.
XX
AC AAB89227;
XX
DT 23-MAY-2001 (first entry)
XX
DE HIV gp120 protein binding peptide #320.

```
XX
KW   Human chemokine receptor; CD4; HIV; glycoprotein 120; gp120; antagonist;
KW   replication; CCR5; CXCR4; CD4; STRL33.
XX
OS   Homo sapiens.
XX
PN   WO200116182-A2.
XX
PD   08-MAR-2001.
XX
PF   25-AUG-2000; 2000WO-US023505.
XX
PR   27-AUG-1999;   99US-0151270P.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Saxinger C;
XX
DR   WPI; 2001-244398/25.
XX
PT   Novel polypeptides useful for treating HIV infection, have homology to
PT   regions of domains of human chemokine receptors CCR5, CXCR4 and STRL33,
PT   and binds to HIV gp120 under physiological conditions.
XX
PS   Example 4; Page 46; 114pp; English.
XX
CC   The present invention describes a number of peptides which are able to
CC   bind to HIV glycoprotein 120 (gp120). These are similar to the human
CC   chemokine receptors CCR5, CXCR4 and STRL33, as well as CD4. These are
CC   useful in the treatment of HIV, as they prevent replication of the virus.
CC   The present sequence is an example of a peptide of the invention
XX
SQ   Sequence 21 AA;

  Query Match             32.0%;  Score 31;  DB 4;  Length 21;
  Best Local Similarity   38.5%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQEP 18
              |  :::  |  |:|:|
Db          3 NKEVSVKRVTQDP 15


RESULT 41
AAY27522
ID   AAY27522 standard; peptide; 24 AA.
XX
AC   AAY27522;
XX
DT   29-NOV-1999  (first entry)
XX
DE   E. coli beta'-subunit conserved regions B and I derived peptide 55.
XX
KW   Bacterial life cycle; protein subunit; ribonucleic acid polymerase; RNAP;
KW   enzyme function; anti-bacterial; E. coli.
XX
OS   Synthetic.
OS   Escherichia coli.
XX
PN   WO9943338-A1.
XX
PD   02-SEP-1999.
XX
PF   26-FEB-1999;   99WO-US004351.
XX
PR   26-FEB-1998;   98US-00031122.
XX
PA   (GLIN/) GLINSKII G V.
XX
PI   Glinskii GV;
XX
DR   WPI; 1999-550829/46.
XX
PT   Identifying antibacterial drugs, by identifying compounds that block the
PT   binding of protein subunits of ribonucleic acid polymerase.
XX
PS   Claim 31; Page 64; 106pp; English.
XX
CC   The invention relates to methods of interfering with bacterial life cycle
CC   by bringing bacterial cells into contact with a compound that blocks the
CC   binding of at least one protein subunit of ribonucleic acid polymerase
CC   (RNAP) to a second protein subunit of RNAP. The methods can be used for
CC   obtaining compounds which inhibit subunit-subunit interactions and
CC   assembly necessary for enzyme function in bacteria. The compounds inhibit
CC   the binding of (a) at least one protein subunit of RNAP to a second
CC   protein subunit of RNAP; (b) the sigma-subunit of RNAP to the RNAP core;
CC   and blocks a nucleic acid binding to the beta-subunit or the beta'-
CC   subunit of RNAP. The compounds obtained can be used as anti-bacterial
CC   drugs. Sequences AAY27509-523 represent peptides derived from the
CC   putative nucleic acid binding sequences of the conserved regions B and I
CC   of E. coli beta'-subunit. The antibacterial compounds that block nucleic
CC   acid binding to the beta-subunit of the RNAP bind to the sequences
CC   indicated above
XX
SQ   Sequence 24 AA;

  Query Match             32.0%;  Score 31;  DB 2;  Length 24;
  Best Local Similarity   33.3%;  Pred. No. 4.1e+02;
  Matches    5;  Conservative    5;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIVSQEP 18
              |  |  :: :|:|:|
Db          2 HARSTGSYSLVTQQP 16


RESULT 42
AAY02263
ID   AAY02263 standard; protein; 33 AA.
XX
AC   AAY02263;
XX
DT   08-JUL-1999  (first entry)
XX
DE   A F-box protein sequence.
XX
KW   F-box protein; targeted ubiquitination; cellular protein;
KW   cell cycle regulator; transcription regulator; DNA replication;
KW   inflammatory response; infectious disease; protein degradation; cancer;
KW   virus infection.
XX
OS   Mus sp.
XX
PN   WO9918989-A1.
XX
PD   22-APR-1999.
XX
PF   15-OCT-1998;   98WO-US021763.
XX
PR   16-OCT-1997;   97US-00951621.
XX
PA   (BAYU ) BAYLOR COLLEGE MEDICINE.
XX
PI   Harper JW,  Elledge SJ;
XX
DR   WPI; 1999-277441/23.
DR   N-PSDB; AAX35537.
XX
PT   New isolated F-box proteins and genes for development of therapeutics,
PT   e.g. for cancer treatment.
XX
PS   Claim 4; Page 109; 170pp; English.
XX
CC   AAX35523-51 encode F-box proteins (AAY02249-77) which are involved in the
CC   targeted ubiquitination of cellular proteins. The F-box proteins are
CC   involved in targeted ubiquitination of cellular proteins, including cell
CC   cycle regulators. The products and methods can be used for determining
```

```
CC   the interaction of these proteins with other proteins, e.g. to identify
CC   and/or investigate cell cycle regulators, transcription regulators,
CC   proteins involved in DNA replication, and other cellular regulatory
CC   proteins. They can be used in elucidating inflammatory response and
CC   infectious disease processes involving protein degradation as well as
CC   development of compounds that control (i.e. either enhance or retard)
CC   protein degradation, as appropriate to ameliorate the effects of the
CC   inflammatory response or disease process. They can be used for
CC   identifying and developing compounds effective against cancers or virus
CC   infection, e.g. immunodeficiency viruses such as HIV, feline
CC   immunodeficiency virus, bovine immunodeficiency virus, and simian
CC   immunodeficiency virus
XX
SQ   Sequence 33 AA;

  Query Match             32.0%;  Score 31;  DB 2;  Length 33;
  Best Local Similarity   58.3%;  Pred. No. 6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              | ::| ||| ||
Db          1 LPAEITFKIFSQ 12


RESULT 43
AAE08035
ID   AAE08035 standard; peptide; 33 AA.
XX
AC   AAE08035;
XX
DT   01-NOV-2001  (first entry)
XX
DE   Mouse F-box protein, F10 Lambda.
XX
KW   Mouse; nuclear factor-kappaB; NF-kB; regulatory factor; slimb protein;
KW   targetted ubiquitination; F-box protein; F10 Lambda.
XX
OS   Mus musculus.
XX
PN   US6232081-B1.
XX
PD   15-MAY-2001.
XX
PF   15-OCT-1998;   98US-00172841.
XX
PR   16-OCT-1997;   97US-00951621.
XX
PA   (BAYU ) BAYLOR COLLEGE MEDICINE.
XX
PI   Harper JW,  Elledge SJ,  Winston JT;
XX
DR   WPI; 2001-342771/36.
DR   N-PSDB; AAD14872.
XX
PT   Detecting nuclear factor-kappaB regulatory factors, such as F-box
PT   proteins involved in targeted ubiquitination, by contacting the
PT   regulatory factors with slimb protein to form a complex and detecting the
PT   complex.
XX
PS   Example 6; Fig 7; 69pp; English.
XX
CC   The present invention relates to a method for detection of one or more
CC   nuclear factor (NF)-kappaB (kB) regulatory factors. The method comprises
CC   exposing a slimb protein to a sample suspected of containing one or more
CC   NF-kB regulatory factors, so that the slimb protein binds to one or more
CC   NF-kB regulatory factors to form a slimb/regulatory factor complex and
CC   detecting the slimb/regulatory factor complex. The method is useful for
CC   detecting NF-kB regulatory factors such as F-box proteins, IkBs, IKKs and
CC   agonists, antagonists and cofactors that interact with these factors. F-
CC   box proteins are involved in targetted ubiquitination of cellular
CC   proteins. The present sequence is mouse F-box protein, F10 Lambda
XX
SQ   Sequence 33 AA;

  Query Match             32.0%;  Score 31;  DB 4;  Length 33;
  Best Local Similarity   58.3%;  Pred. No. 6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              | ::| ||| ||
Db          1 LPAEITFKIFSQ 12


RESULT 44
AAE39643
ID   AAE39643 standard; peptide; 33 AA.
XX
AC   AAE39643;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Mouse F-box protein, F10 (lambda).
XX
KW   Mouse; F-Box domain; E3 complex; ubiquitination; cell cycle regulator;
KW   inflammatory disease.
XX
OS   Mus sp.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 30. .33
FT                   /note= "Encoded by GAC"
XX
PN   US6573094-B1.
XX
PD   03-JUN-2003.
XX
PF   16-OCT-1997;   97US-00951621.
XX
PR   16-OCT-1997;   97US-00951621.
XX
PA   (BAYU ) BAYLOR COLLEGE MEDICINE.
XX
PI   Harper JW,  Elledge SJ;
XX
DR   WPI; 2003-776006/73.
DR   N-PSDB; AAD60312.
XX
PT   New isolated nucleic acid segment encoding a protein with at least one
PT   functionally active F-box domain, useful for identifying related genes,
PT   and for developing compounds for treating infectious or inflammatory
PT   disease.
XX
PS   Example 6; Col 57-58; 0pp; English.
XX
CC   The invention relates to an isolated nucleic acid segment comprising or
CC   consisting essentially of a nucleic acid sequence encoding a protein
CC   comprising at least one functionally active F-Box domain sequence. The
CC   polypeptide encoded by the nucleic acid segment is part of an E3 complex
CC   involved in ubiquitination of cell cycle regulators and may be useful in
CC   investigating mechanisms of infectious and inflammatory diseases and in
CC   developing therapeutic agents for treating such diseases. The invention
CC   is useful for detecting related polynucleotides encoding F-box proteins
CC   and in the determination of the function of proteins such as elongin C,
CC   SkpI-related protein, elongin B and elongin A. The present sequence is
CC   mouse F-box protein
XX
SQ   Sequence 33 AA;

  Query Match             32.0%;  Score 31;  DB 7;  Length 33;
  Best Local Similarity   58.3%;  Pred. No. 6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              | ::| ||| ||
Db          1 LPAEITFKIFSQ 12
```

```
RESULT 45
AAW73422
ID   AAW73422 standard; protein; 34 AA.
XX
AC   AAW73422;
XX
DT   19-FEB-1999  (first entry)
XX
DE   Human secreted protein encoded by Gene No. 26.
XX
KW   Secreted protein; human; protein therapy; gene therapy; blood disorder;
KW   pathological condition; diagnosis; cancer; neurological disorder;
KW   developmental abnormality; foetal deficiency; leukaemia; hepatic disease;
KW   immune system disorder; Alzheimer's disease; cognitive disorder;
KW   schizophrenia; prostate disease; autoimmune disorder; AIDS.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 34
FT                   /note= "unspecified amino acid"
XX
PN   WO9854206-A1.
XX
PD   03-DEC-1998.
XX
PF   28-MAY-1998;   98WO-US010868.
XX
PR   30-MAY-1997;   97US-0044039P.
PR   30-MAY-1997;   97US-0048093P.
PR   30-MAY-1997;   97US-0048101P.
PR   30-MAY-1997;   97US-0048190P.
PR   30-MAY-1997;   97US-0048356P.
PR   30-MAY-1997;   97US-0050935P.
PR   29-AUG-1997;   97US-0056250P.
PR   29-AUG-1997;   97US-0056293P.
PR   29-AUG-1997;   97US-0056296P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Rosen CA,  Carter KC,  Dillon PJ,  Endress GA,  Yu G;
PI   Ni J,  Feng P;
XX
DR   WPI; 1999-070209/06.
DR   N-PSDB; AAV08836.
XX
PT   New isolated human genes - useful for diagnosis and treatment of, e.g.
PT   cancers, neurological disorders, immune diseases, developmental disorders
PT   or blood disorders.
XX
PS   Claim 11; Page 160; 188pp; English.
XX
CC   This sequence is encoded by a cDNA of the invention, designated Gene No.
CC   26. This sequence represents a human secreted protein, and is expressed
CC   in a variety of tissues including colon cancer, breast cancer,
CC   neutrophils, T-cells, spinal fluid, fibroblasts and vascular endothelial
CC   cells. The DNA sequences of the invention and their corresponding
CC   secreted polypeptides are useful for preventing, treating or ameliorating
CC   medical conditions, e.g. by protein or gene therapy. Also pathological
CC   conditions can be diagnosed by determining the amount of the new
CC   polypeptides in a sample or by determining the presence of mutations in
CC   the DNA sequences. Specific uses are described for each of the DNA
CC   sequences and the encoded proteins, based on which tissues they are most
CC   highly expressed in, and include developing products for the diagnosis or
CC   treatment of cancer, tumours, neurological disorders, developmental
CC   abnormalities and foetal deficiencies, blood disorders, leukaemias,
CC   diseases of the immune system (including allergies or asthma), hepatic
CC   disease, Alzheimer's and cognitive disorders, schizophrenia, prostate
CC   diseases, autoimmune disorders and AIDS. The polypeptides are also useful
CC   for identifying their binding partners
XX
SQ   Sequence 34 AA;

  Query Match             32.0%;  Score 31;  DB 2;  Length 34;
  Best Local Similarity   47.4%;  Pred. No. 6.2e+02;
  Matches    9;  Conservative    2;  Mismatches    4;  Indels    4;  Gaps    1;

Qy          5 LNSKIAFKIV----SQEPA 19
              ||||:   :|    || ||
Db         11 LNSKLVAAVVNLKASQMPA 29


RESULT 46
AAM95698
ID   AAM95698 standard; protein; 34 AA.
XX
AC   AAM95698;
XX
DT   21-NOV-2001  (first entry)
XX
DE   Human reproductive system related antigen SEQ ID NO: 4356.
XX
KW   Human; reproductive system related antigen; reproductive system disorder;
KW   cancer; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200155320-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001339.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
```

PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
DR N-PSDB; AAL01668.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen is
PT used in preventing, treating or ameliorating a medical condition.
XX
PS Claim 11; SEQ ID NO 4356; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a protein of the invention
XX
SQ Sequence 34 AA;

Query Match 32.0%; Score 31; DB 4; Length 34;
Best Local Similarity 40.0%; Pred. No. 6.2e+02;
Matches 6; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

```
Qy          3 NHLNSKIAFKIVSQE 17
              :||| |   |:| :
Db         12 HHLNQVIKXNIISNK 26
```

RESULT 47
ABB10877
ID ABB10877 standard; protein; 34 AA.
XX
AC ABB10877;
XX
DT 11-JAN-2002 (first entry)
XX
DE Human ovarian and/or breast cancer associated polypeptide SEQ ID NO 383.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
OS Homo sapiens.
XX
PN WO200155325-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001345.

XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488786/53.
DR N-PSDB; ABA07588.
XX
PT New isolated ovarian and/or breast cancer related nucleic acids and

```
PT   polypeptides, useful for diagnosing, treating and/or preventing human
PT   diseases and disorders, particularly ovarian and/or breast cancer.
XX
PS   Claim 11; SEQ ID NO 383; 577pp + Sequence Listing; English.
XX
CC   The invention relates to novel genes (ABA07454-ABA08224) and proteins
CC   (ABB10743-ABB10980) useful for preventing, treating or ameliorating
CC   medical conditions e.g. by protein or gene therapy. The genes are
CC   isolated from a range of human tissues disclosed in the specification.
CC   The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC   the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC   ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC   breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC   disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC   anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC   multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC   cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC   ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC   infectious diseases such as viral, bacterial, fungal and parasitic
CC   infections. Note: The sequence data for this patent did not form part of
CC   the printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 34 AA;

  Query Match             32.0%;  Score 31;  DB 4;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 6.2e+02;
  Matches    6;  Conservative    3;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              :|||  |    |:| :
Db         12 HHLNQVIKXNIISNK 26


RESULT 48
AAB20721
ID   AAB20721 standard; peptide; 40 AA.
XX
AC   AAB20721;
XX
DT   20-DEC-2000  (first entry)
XX
DE   Polymeric immunoglobulin receptor binding domain peptide SEQ ID NO:37.
XX
KW   Polymeric immunoglobulin receptor; pIgR; binding domain; diagnosis;
KW   identification; infection; cancer; asthma; antiasthmatic; cytostatic;
KW   antiinflammatory; antiinfectious; antidiarrhoeal; hepatotropic; virucide;
KW   vasotropic; anti-human immunodeficiency virus; antibacterial;
KW   mucosal epithelia; bronchitis; emphysema; cystic fibrosis; dysphagia;
KW   bronchiectasis; bronchiolitis; pulmonary oedema; viral tracheobronchitis;
KW   sleep apnea syndrome; infectious disease; neoplastic condition;
KW   Loffler's syndrome; kyphocliosis; peptic ulcer; diarrhoeal disease;
KW   ulcerative colitis; Crohn's disease; hepatitis; cirrhosis; haemorrhoid;
KW   systemic vasculitis; acquired immunodeficiency syndrome; gonorrhea;
KW   syphilis; chlamydia; antiulcer.
XX
OS   Synthetic.
XX
PN   WO200047611-A2.
XX
PD   17-AUG-2000.
XX
PF   11-FEB-2000; 2000WO-US003650.
XX
PR   12-FEB-1999;   99US-0119932P.
XX
PA   (OKLA-) OKLAHOMA MEDICAL RES FOUND.
PA   (TEXA ) UNIV TEXAS SYSTEM.
PA   (DGIB-) DGI BIOTECHNOLOGIES.
XX
PI   Capra JD,  White K,  Hexham JM,  Mandecki W;
XX
DR   WPI; 2000-549134/50.
XX
PT   Novel polypeptides containing pIgR-binding domains used for targeting and
PT   transport to the mucosal epithelia, in the treatment of disorders
PT   accessible to the mucosal epithelia, e.g. asthma.
XX
PS   Claim 13; Page 101; 139pp; English.
XX
CC   The present invention describes a 10-50 residue peptide (I) comprising a
CC   polymeric immunoglobulin receptor (pIgR)-binding domain. (I) can have
CC   antiasthmatic, antiinflammatory, antiinfectious, cytostatic, antiulcer,
CC   antidiarrhoeal, hepatotropic, virucide, vasotropic, anti-human
CC   immunodeficiency virus and antibacterial activities. (I) can be used for
CC   targeting and transport to the mucosal epithelium, for the prevention or
CC   treatment of diseases, ailments or conditions that are accessible to
CC   mucosal epithelia, including asthma, bronchitis, emphysema, cystic
CC   fibrosis, bronchiectasis, bronchiolitis, pulmonary oedema, viral
CC   tracheobronchitis, sleep apnea syndrome, infectious diseases, neoplastic
CC   conditions, Loffler's syndrome, kyphocliosis, dysphagia, peptic ulcers,
CC   diarrhoeal diseases, ulcerative colitis, Crohn's disease, hepatitis,
CC   cirrhosis, haemorrhoids, systemic vasculitis, acquired immunodeficiency
CC   syndrome, gonorrhea, syphilis and chlamydia. (I) can be attached to a
CC   detectable label for use in diagnostics. The present sequence represents
CC   a specifically claimed example of (I)
XX
SQ   Sequence 40 AA;

  Query Match             32.0%;  Score 31;  DB 3;  Length 40;
  Best Local Similarity   37.5%;  Pred. No. 7.6e+02;
  Matches    6;  Conservative    2;  Mismatches    8;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |||  |:  :   | |
Db         22 NHLRGKVRRESADQVP 37


RESULT 49
ABO60042
ID   ABO60042 standard; protein; 43 AA.
XX
AC   ABO60042;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human genome derived single exon protein #6276.
XX
KW   Human; gene expression; single exon probe; microarray;
KW   alternative splicing event; genomic alteration.
XX
OS   Homo sapiens.
XX
PN   US2003194704-A1.
XX
PD   16-OCT-2003.
XX
PF   03-APR-2002; 2002US-00029386.
XX
PR   03-APR-2002; 2002US-00029386.
XX
PA   (PENN/) PENN S G.
PA   (RANK/) RANK D R.
PA   (HANZ/) HANZEL D K.
XX
PI   Penn SG,  Rank DR,  Hanzel DK;
XX
DR   WPI; 2004-119264/12.
XX
PT   New human genome-derived single exon nucleic acid probes useful for human
PT   gene expression analysis, for identifying or characterizing alternative
PT   splicing events, for assessing genomic alterations or as tools for
PT   surveying tissues.
XX
PS   Claim 45; SEQ ID NO 33676; 80pp; English.
XX
```

```
CC   The invention relates to a nucleic acid probe for measuring human gene
CC   expression, comprising any of the 27,400 fully defined nucleotide
CC   sequences in the specification, or their complements or fragments, and
CC   encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC   fully defined in the specification. The probe is a single exon probe that
CC   hybridises under high stringency conditions to a nucleic acid molecule
CC   expressed in human cells or tissues. Also included are a spatially-
CC   addressable set of single exon nucleic acid probes for measuring human
CC   gene expression (comprising a plurality of single exon nucleic acid
CC   probes cited above, where each of the plurality of probes is separately
CC   and addressably isolatable or amplifiable from the plurality), a single
CC   exon microarray for measuring human gene expression, a method of
CC   measuring human gene expression, a vector comprising the single exon
CC   probe cited above, an ORF-encoded peptide comprising at least 8
CC   contiguous amino acids of any of the above- mentioned amino acid
CC   sequences (optionally with conservative amino acid substitutions), an
CC   isolated antibody that binds specifically to a peptide cited above,
CC   methods of selling and/or licensing single exon probes or microarrays to
CC   a customer desiring to measure gene expression, a method of providing
CC   human gene expression data by subscription, and a computer-readable
CC   storage medium which contains a database having a plurality of records
CC   (each record including data on the expression of a single exon probe
CC   cited above. The probe, methods and apparatus are useful in gene
CC   expression analysis. The probes may be used as tools for surveying
CC   tissues to detect the presence of expressed messages that contain their
CC   specific exon, or in constructing genome-derived single exon microarrays.
CC   In addition, the probes are used in identifying and characterising
CC   alternative splicing events, in detecting and characterising gross
CC   alterations in the genomic locus that includes their exon, in assessing
CC   smaller genomic alterations, in priming the synthesis of nucleic acids,
CC   or in expressing the ORF-encoded peptide. The present sequence is a human
CC   single exon probe protein of the invention. Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from USPTO at
CC   seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ   Sequence 43 AA;

  Query Match             32.0%;  Score 31;  DB 8;  Length 43;
  Best Local Similarity   41.7%;  Pred. No. 8.3e+02;
  Matches    5;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKI 13
              | ||:| :|: :
Db         15 PIHLHSNVAWTV 26


RESULT 50
AAM21342
ID   AAM21342 standard; protein; 44 AA.
XX
AC   AAM21342;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #7776 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000670.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human cervical epithelial cells.
XX
PS   Claim 27; SEQ ID NO 26168; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 44 AA;

  Query Match             32.0%;  Score 31;  DB 4;  Length 44;
  Best Local Similarity   33.3%;  Pred. No. 8.5e+02;
  Matches    8;  Conservative    3;  Mismatches    5;  Indels    8;  Gaps    1;

Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32


RESULT 51
ABB43679
ID   ABB43679 standard; peptide; 44 AA.
XX
AC   ABB43679;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #11185 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
```

```
PS   Claim 27; SEQ ID NO 36314; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 44 AA;

  Query Match             32.0%;  Score 31;  DB 4;  Length 44;
  Best Local Similarity   33.3%;  Pred. No. 8.5e+02;
  Matches    8;  Conservative    3;  Mismatches    5;  Indels    8;  Gaps    1;

Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32


RESULT 52
AAM37572
ID   AAM37572 standard; protein; 44 AA.
XX
AC   AAM37572;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #11609 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 37841; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 44 AA;

  Query Match             32.0%;  Score 31;  DB 4;  Length 44;
  Best Local Similarity   33.3%;  Pred. No. 8.5e+02;
  Matches    8;  Conservative    3;  Mismatches    5;  Indels    8;  Gaps    1;

Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32


RESULT 53
ABB26626
ID   ABB26626 standard; protein; 44 AA.
XX
AC   ABB26626;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #8625 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000666.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts.
XX
PS   Claim 15; SEQ ID NO 28396; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart (see
CC   ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC   probe. The probes may be used for predicting, measuring and displaying
CC   gene expression in samples derived from the human heart via microarrays.
CC   By measuring gene expression, the probes are useful for predicting,
CC   diagnosing, grading, staging, monitoring and prognosing diseases of the
CC   human heart and vascular system e.g. cardiovascular disease,
CC   hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 44 AA;

  Query Match             32.0%;  Score 31;  DB 4;  Length 44;
  Best Local Similarity   33.3%;  Pred. No. 8.5e+02;
  Matches    8;  Conservative    3;  Mismatches    5;  Indels    8;  Gaps    1;

Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32


RESULT 54
```

AAM77419
ID AAM77419 standard; protein; 44 AA.
XX
AC AAM77419;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 37725.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 37725; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention
XX
SQ Sequence 44 AA;

Query Match 32.0%; Score 31; DB 4; Length 44;
Best Local Similarity 33.3%; Pred. No. 8.5e+02;
Matches 8; Conservative 3; Mismatches 5; Indels 8; Gaps 1;

```
Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32
```

RESULT 55
AAM64636
ID AAM64636 standard; protein; 44 AA.
XX
AC AAM64636;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 36741.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX
PS Example 4; SEQ ID NO 36741; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention
XX
SQ Sequence 44 AA;

Query Match 32.0%; Score 31; DB 4; Length 44;
Best Local Similarity 33.3%; Pred. No. 8.5e+02;
Matches 8; Conservative 3; Mismatches 5; Indels 8; Gaps 1;

```
Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32
```

RESULT 56
ABG59052
ID ABG59052 standard; peptide; 44 AA.
XX
AC ABG59052;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID No 37700.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.

```
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 37700; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 44 AA;

  Query Match             32.0%;  Score 31;  DB 4;  Length 44;
  Best Local Similarity   33.3%;  Pred. No. 8.5e+02;
  Matches    8;  Conservative    3;  Mismatches    5;  Indels    8;  Gaps    1;

Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32


RESULT 57
AAU21016
ID   AAU21016 standard; protein; 44 AA.
XX
AC   AAU21016;
XX
DT   17-DEC-2001  (first entry)
XX
DE   Human novel foetal antigen, SEQ ID NO 1260.
XX
KW   Human; foetal tissue antigen; antiinflammatory; neuroprotective;
KW   immunomodulator; cardiovascular; cytostatic; nephrothropic;
KW   cardiovascular; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; breast neoplasm; cancer;
KW   cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW   cerebral ischaemia; angiogenesis; nervous system disorder;
KW   Alzheimer's disease; infection; ocular disorder; corneal infection;
KW   wound healing; epithelial cell proliferation; food additive.
XX
OS   Homo sapiens.
XX
PN   WO200155312-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001321.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   06-SEP-2000; 2000US-0230437P.
PR   06-SEP-2000; 2000US-0230438P.
PR   08-SEP-2000; 2000US-0231242P.
PR   08-SEP-2000; 2000US-0231243P.
PR   08-SEP-2000; 2000US-0231244P.
PR   08-SEP-2000; 2000US-0231413P.
PR   08-SEP-2000; 2000US-0231414P.
PR   08-SEP-2000; 2000US-0232080P.
PR   08-SEP-2000; 2000US-0232081P.
PR   12-SEP-2000; 2000US-0231968P.
PR   14-SEP-2000; 2000US-0232397P.
PR   14-SEP-2000; 2000US-0232398P.
PR   14-SEP-2000; 2000US-0232399P.
PR   14-SEP-2000; 2000US-0232400P.
PR   14-SEP-2000; 2000US-0232401P.
PR   14-SEP-2000; 2000US-0233063P.
PR   14-SEP-2000; 2000US-0233064P.
PR   14-SEP-2000; 2000US-0233065P.
PR   21-SEP-2000; 2000US-0234223P.
PR   21-SEP-2000; 2000US-0234274P.
PR   25-SEP-2000; 2000US-0234997P.
PR   25-SEP-2000; 2000US-0234998P.
PR   26-SEP-2000; 2000US-0235484P.
PR   27-SEP-2000; 2000US-0235834P.
PR   27-SEP-2000; 2000US-0235836P.
PR   29-SEP-2000; 2000US-0236327P.
PR   29-SEP-2000; 2000US-0236367P.
PR   29-SEP-2000; 2000US-0236368P.
PR   29-SEP-2000; 2000US-0236369P.
PR   29-SEP-2000; 2000US-0236370P.
PR   02-OCT-2000; 2000US-0236802P.
PR   02-OCT-2000; 2000US-0237037P.
PR   02-OCT-2000; 2000US-0237038P.
PR   02-OCT-2000; 2000US-0237039P.
PR   02-OCT-2000; 2000US-0237040P.
PR   13-OCT-2000; 2000US-0239935P.
PR   13-OCT-2000; 2000US-0239937P.
PR   20-OCT-2000; 2000US-0240960P.
PR   20-OCT-2000; 2000US-0241221P.
PR   20-OCT-2000; 2000US-0241785P.
PR   20-OCT-2000; 2000US-0241786P.
```

PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488782/53.
DR N-PSDB; AAS33836.
XX
PT New polynucleotides and polypeptides for diagnosing, treating, preventing
PT or prognosing e.g. diseases or disorders of the nervous, musculoskeletal,
PT excretory, gastrointestinal, reproductive, and respiratory systems.
XX
PS Claim 11; SEQ ID NO 1260; 642pp; English.
XX
CC The invention relates to novel nucleic acids encoding novel human foetal
CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g.
CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. The antibodies to the antigens can also be used
CC in alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection.
CC The polypeptides can also be used to aid wound healing and epithelial
CC cell proliferation, to prevent skin aging due to sunburn, to maintain
CC organs before transplantation, for supporting cell culture of primary
CC tissues, to regenerate tissues and in chemotaxis. The polypeptides can
CC also be used as a food additive or preservative to increase or decrease
CC storage capabilities, fat content, lipid, protein, carbohydrate,
CC vitamins, minerals, cofactors and other nutritional components. Numerous
CC examples of diseases and disorders treated by the nucleic acids and
CC proteins are given in the specification. The present sequence represents
CC a foetal antigen of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained

Query Match 32.0%; Score 31; DB 4; Length 44;
Best Local Similarity 75.0%; Pred. No. 8.5e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy          5 LNSKIAFK 12
              |||| : ||
Db         24 LNSKLLFK 31
```

RESULT 58
ABG46440
ID ABG46440 standard; peptide; 44 AA.
XX
AC ABG46440;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 36105.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesis; pulmonary hypertension;
KW hyaline membrane disease.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US000665.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.

```
XX
PS   Claim 27; SEQ ID NO 36105; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of probes
CC   ; the novel set of probes which hybridise at high stringency to a nucleic
CC   acid expressed in the human lung; measuring gene expression in a sample
CC   derived from human lung, comprising (a) contacting the array with a
CC   collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of the
CC   array; identifying exons in a eukaryotic genome, comprising (a)
CC   algorithmically predicting at least one exon from genomic sequences of
CC   the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene expression
CC   analysis, and for identifying exons in a gene, particularly using human
CC   lung derived mRNA and for the study of lung diseases such as asthma, lung
CC   cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC   disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC   tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC   Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC   histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC   Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC   dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC   present sequence is a peptide/protein encoded by a single exon probe of
CC   the invention. Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 44 AA;

  Query Match             32.0%;  Score 31;  DB 5;  Length 44;
  Best Local Similarity   33.3%;  Pred. No. 8.5e+02;
  Matches    8;  Conservative    3;  Mismatches    5;  Indels    8;  Gaps    1;

Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32


RESULT 59
ADF70009
ID   ADF70009 standard; protein; 44 AA.
XX
AC   ADF70009;
XX
DT   12-FEB-2004  (first entry)
XX
DE   AcmA-type homologue amino acid sequence.
XX
KW   delivery; targeting system; AcmA-type anchor protein; solid tumour;
KW   health; medical; agricultural; cosmetic; controlled release.
XX
OS   Lactococcus lactis.
XX
PN   WO2003084508-A1.
XX
PD   16-OCT-2003.
XX
PF   04-APR-2003; 2003WO-NL000256.
XX
PR   04-APR-2002; 2002EP-00076316.
PR   04-APR-2002; 2002US-0369927P.
PR   05-APR-2002; 2002US-0370485P.
PR   20-DEC-2002; 2002EP-00080481.
XX
PA   (NANO-) APPLIED NANOSYSTEMS BV.
XX
PI   Friesen RHE,  Leenhouts CJ,  Hektor HJ,  Van Esch JH,  Heeres A;
PI   Robillard GT;
XX
DR   WPI; 2003-877005/81.
XX
PT   Vehicle for targeted delivery of therapeutic or diagnostic agents,
PT   includes protein anchor and system for inducing availability of the
PT   agent.
XX
PS   Example 3; Page 191; 303pp; English.
XX
CC   The present invention describes a vehicle (A) for delivering a substance
CC   (I) to a predetermined site, which comprises (I); a system for inducing
CC   availability of at least one compartment of (A) towards the exterior;
CC   and, as targeting system for directing (A) to the site, an AcmA-type
CC   anchor protein (II). (A) are used for delivery of diagnostic and
CC   therapeutic agents to predetermined sites in the body, particularly
CC   joints or solid tumours but can be used more generally for health,
CC   medical, agricultural and cosmetic applications. (A) significantly
CC   increases the half-life of peptides in the circulation and, by providing
CC   controlled release, ensures relatively high bioavailability, allowing
CC   therapeutic use of agents that would otherwise be too toxic for systemic
CC   administration. The native AcmA peptide targets Gram-positive bacteria
CC   but its homologues can be engineered to have different selectivity. The
CC   present sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 44 AA;

  Query Match             32.0%;  Score 31;  DB 7;  Length 44;
  Best Local Similarity   66.7%;  Pred. No. 8.5e+02;
  Matches    6;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAF 11
              |||||   |
Db         28 NHLNSDTIF 36


RESULT 60
AAB16298
ID   AAB16298 standard; protein; 47 AA.
XX
AC   AAB16298;
XX
DT   31-OCT-2000  (first entry)
XX
DE   Eucalyptus grandis AGP protein sequence SEQ ID NO:84.
XX
KW   Eucalyptus grandis; pinus radiata; Monterey pine; modification;
KW   plant cell wall; polysaccharide; polysaccharide biosynthetic pathway;
KW   transgenic plant.
XX
OS   Eucalyptus grandis.
XX
PN   WO200022092-A2.
XX
PD   20-APR-2000.
XX
PF   08-OCT-1999;   99WO-NZ000169.
XX
PR   13-OCT-1998;   98US-00170862.
PR   11-AUG-1999;   99US-0148426P.
XX
PA   (GENE-) GENESIS RES & DEV CORP LTD.
PA   (FLET-) FLETCHER CHALLENGE FORESTS LTD.
XX
```

PI Bloksberg LN;
XX
DR WPI; 2000-339328/29.
DR N-PSDB; AAA67105.
XX
PT New genes encoding proteins involved in a plant polysaccharide
PT biosynthetic pathway, useful for modulating or altering the
PT polysaccharide content, composition or structure of the plant.
XX
PS Claim 17; Page 78; 301pp; English.
XX
CC The present invention describes isolated polynucleotides (PN) comprising
CC a sequence selected from one of 835 nucleotide sequences given in
CC AAA67073 to AAA67907, their (reverse) complements, sequences producing an
CC Expectation (E) value of 0.01 or less compared to the 835 sequences,
CC sequences at least 50% identical to them, 200, 100, 40 or 20-mers of the
CC 835 sequences or sequences that are degenerately equivalent or allelic to
CC the 835 sequences. The polynucleotides are used to modify the activity of
CC a polypeptide involved in a polysaccharide biosynthetic pathway in the
CC plant. They are especially used to modulate or alter the polysaccharide
CC content, composition or structure of the plant. AAB16268 to AAB16340 are
CC proteins encoded by some of the polynucleotide sequence given in the
CC present invention
XX
SQ Sequence 47 AA;

Query Match 32.0%; Score 31; DB 3; Length 47;
Best Local Similarity 50.0%; Pred. No. 9.2e+02;
Matches 7; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVSQEP 18
|:| ||| | ::|
Db 4 LDSADAFKSVRRDP 17

RESULT 61
ADJ12233
ID ADJ12233 standard; protein; 47 AA.
XX
AC ADJ12233;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human secreted protein SeqID 87.
XX
KW human; secreted; cancer; haematopoietic disease; anaemia;
KW multiple myeloma; reproductive system disorder; prostatitis;
KW inguinal hernia; musculoskeletal disease; systemic lupus erythematosus;
KW gout; cardiovascular disease; arrhythmia; hypernatraemia; fetal disease;
KW fetal alcohol syndrome; Down's syndrome; excretory disease;
KW urinary incontinence; renal disorder; neural; sensory disease;
KW Alzheimer's disease; meningitis; respiratory disease; emphysema;
KW occupational lung disease; endocrine disease; diabetes;
KW glomerulonephritis; digestive disease; portal hypertension;
KW irritable bowel syndrome; epithelial disease; scleroderma;
KW epidermolysis bullosa; cytostatic; antianemic; antiarthritic;
KW antiasthmatic; anti-HIV; immunosuppressive; antiinflammatory;
KW antipsoriatic; antibacterial; osteopathic; dermatological; antigout;
KW immunomodulator; antiarrhythmic; cardiant; nootropic; antilipemic;
KW nephrotropic; uropathic; neuroprotective; antiparkinsonian; tranquilizer;
KW antidiabetic; anabolic; hypertensive; vulnerary.
XX
OS Homo sapiens.
XX
PN US2004010132-A1.
XX
PD 15-JAN-2004.
XX
PF 30-OCT-2001; 2001US-00984429.
XX
PR 09-OCT-1997; 97US-0061463P.
PR 09-OCT-1997; 97US-0061527P.
PR 09-OCT-1997; 97US-0061529P.
PR 09-OCT-1997; 97US-0061532P.
PR 09-OCT-1997; 97US-0061536P.
PR 09-OCT-1997; 97US-0071498P.
PR 08-OCT-1998; 98WO-US021142.
PR 08-APR-1999; 99US-00288143.
PR 01-NOV-2000; 2000US-0244591P.
XX
PA (ROSE/) ROSEN C A.
PA (BREW/) BREWER L A.
PA (DUAN/) DUAN R D.
PA (RUBE/) RUBEN S M.
PA (FLOR/) FLORENCE K A.
PA (GREE/) GREENE J M.
PA (YOUN/) YOUNG P E.
PA (FERR/) FERRIE A M.
PA (YUGG/) YU G.
PA (FLOR/) FLORENCE C.
PA (EBNE/) EBNER R.
PA (OLSE/) OLSEN H.
XX
PI Rosen CA, Brewer LA, Duan RD, Ruben SM, Florence KA, Greene JM;
PI Young PE, Ferrie AM, Yu G, Florence C, Ebner R, Olsen H;
XX
DR WPI; 2004-090518/09.
DR N-PSDB; ADJ12177.
XX
PT New isolated nucleic acids and polypeptides, useful for diagnosing,
PT treating, preventing or ameliorating diseases or disorders e.g. cancer,
PT anemia, arthritis, asthma, inflammatory bowel disease or Alzheimer's
PT disease.
XX
PS Claim 11; SEQ ID NO 87; 286pp; English.
XX
CC This invention relates to novel polynucleotides encoding human secreted
CC proteins. Specifically, it refers to the vectors, host cells, recombinant
CC and synthetic methods for producing human polynucleotides, polypeptides
CC and antibodies. Furthermore, it relates to screening methods to identify
CC agonists and antagonists that can be used to inhibit or enhance the
CC production and function of the secreted proteins. The present invention
CC describes these compositions as useful for diagnosing, treating or
CC preventing disorders such as cancer, haematopoietic diseases including
CC anaemia and multiple myeloma, reproductive system disorders including
CC prostatitis and inguinal hernia, musculoskeletal diseases including
CC systemic lupus erythematosus and gout, cardiovascular disease including
CC arrhythmia and hypernatraemia, mixed fetal diseases including fetal
CC alcohol syndrome and Down's syndrome, excretory diseases including
CC urinary incontinence and renal disorders, neural or sensory disease
CC including Alzheimer's disease and meningitis, respiratory disease
CC including emphysema and occupational lung disease, endocrine diseases
CC including diabetes and glomerulonephritis, digestive diseases including
CC portal hypertension and irritable bowel syndrome and connective tissue or
CC epithelial diseases including scleroderma and epidermolysis bullosa. As
CC such, there are various activites such as cytostatic, antianemic,
CC antiarthritic, antiasthmatic, anti-HIV, immunosuppressive,
CC antiinflammatory, antipsoriatic, antibacterial, osteopathic,
CC dermatological, antigout, immunomodulator, antiarrhythmic, cardiant,
CC nootropic, antilipemic, nephrotropic, uropathic, neuroprotective,
CC antiparkinsonian, tranquilizer, antidiabetic, anabolic, hypertensive and
CC vulnerary. This polypeptide is a human secreted protein of the invention.
CC NOTE: This sequence does not appear in the printed specification but has
CC been obtained in electronic format from the US patent office at the
CC following web site www.seqdata.uspto.gov/sequence.html; Document ID:
CC 20040010132.
XX
SQ Sequence 47 AA;

Query Match 32.0%; Score 31; DB 8; Length 47;
Best Local Similarity 45.5%; Pred. No. 9.2e+02;
Matches 5; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 9 IAFKIVSQEPA 19
:||:: :| ||
Db 19 VAFRLTNQIPA 29

```
RESULT 62
AAY14431
ID   AAY14431 standard; protein; 48 AA.
XX
AC   AAY14431;
XX
DT   17-AUG-1999  (first entry)
XX
DE   Human secreted protein encoded by gene 21 clone HRDED19.
XX
KW   Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW   diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW   developmental abnormality; foetal deficiency; blood; allergy; renal;
KW   immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW   inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW   cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW   osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW   endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS   Homo sapiens.
XX
PN   WO9919339-A1.
XX
PD   22-APR-1999.
XX
PF   08-OCT-1998;   98WO-US021142.
XX
PR   09-OCT-1997;   97US-0061463P.
PR   09-OCT-1997;   97US-0061527P.
PR   09-OCT-1997;   97US-0061529P.
PR   09-OCT-1997;   97US-0061532P.
PR   09-OCT-1997;   97US-0061536P.
PR   09-OCT-1997;   97US-0071498P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Brewer LA,  Olsen HS,  Duan R,  Ebner R,  Rosen CA,  Ruben SM;
PI   Florence KA,  Young PE,  Greene JM,  Yu G,  Ferrie AM,  Florence C;
XX
DR   WPI; 1999-277587/23.
DR   N-PSDB; AAX79031.
XX
PT   New isolated human genes and the secreted polypeptides they encode.
XX
PS   Claim 11; Page 192; 226pp; English.
XX
CC   This sequence represents a secreted human protein encoded by the gene
CC   clone detailed in the descriptor line. The gene can be used to generate
CC   fusion proteins by linking to the gene to a human immunoglobulin Fc
CC   portion (e.g. AAX79002) for increasing the stability of the fused protein
CC   as compared to the human protein only. The invention relates to 53 novel
CC   genes and their fragments (nucleic acid sequences: AAX79011-X79064; amino
CC   acid sequences AAY14411-Y14464) which are useful for preventing, treating
CC   or ameliorating medical conditions e.g. by protein or gene therapy. Also,
CC   pathological conditions can be diagnosed by determining the amount of the
CC   new polypeptides in a sample or by determining the presence of mutations
CC   in the new polynucleotides. Specific uses are described for each of the
CC   53 polynucleotides, based on which tissues they are most highly expressed
CC   in (see AAX79011 for described uses)
XX
SQ   Sequence 48 AA;

  Query Match             32.0%;  Score 31;  DB 2;  Length 48;
  Best Local Similarity   45.5%;  Pred. No. 9.4e+02;
  Matches    5;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          9 IAFKIVSQEPA 19
              :||:: :| ||
Db         19 VAFRLTNQIPA 29
```

```
RESULT 63
ADE86990
ID   ADE86990 standard; protein; 49 AA.
XX
AC   ADE86990;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human pancreatic cell protein sequence SeqID450.
XX
KW   neoplastic pancreatic cell; pancreatic cell; pancreatic cancer;
KW   cancer death; cytostatic; vaccine; gene therapy;
KW   non-cancerous pancreas disease; human.
XX
OS   Homo sapiens.
XX
PN   WO2003060145-A2.
XX
PD   24-JUL-2003.
XX
PF   19-DEC-2002; 2002WO-US040655.
XX
PR   21-DEC-2001; 2001US-0342768P.
XX
PA   (DIAD-) DIADEXUS INC.
XX
PI   Sun Y,  Liu C;
XX
DR   WPI; 2003-587286/55.
DR   N-PSDB; ADE87263.
XX
PT   New pancreatic specific nucleic acid molecule or protein for diagnosing,
PT   staging, imaging, monitoring, preventing or treating pancreatic cancer or
PT   non-cancerous disease states of the pancreas.
XX
PS   Claim 12; SEQ ID NO 450; 635pp; English.
XX
CC   This invention relates to novel nucleic acids and proteins present in
CC   normal and neoplastic pancreatic cells. Pancreatic cancer is a common
CC   cause of cancer death worldwide, therefore accurate methods of diagnosis
CC   and treatment are required. Compounds which modulate the proteins of the
CC   invention may have cytostatic activity and the protein and DNA sequences
CC   of the invention may be useful for the development of a vaccine or in
CC   gene therapy. The composition and methods are useful in diagnosing,
CC   staging, imaging, monitoring, preventing or treating pancreatic cancer
CC   and non-cancerous disease states of the pancreas. The present sequence is
CC   that of a human pancreatic protein of the invention.
XX
SQ   Sequence 49 AA;

  Query Match             32.0%;  Score 31;  DB 7;  Length 49;
  Best Local Similarity   50.0%;  Pred. No. 9.7e+02;
  Matches    5;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              ||:|:| : |
Db          2 PNYLHSSLPF 11
```

```
RESULT 64
AAU17741
ID   AAU17741 standard; protein; 50 AA.
XX
AC   AAU17741;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Novel human respiratory antigen #57.
XX
KW   Human; respiratory antigen; respiratory disorder; throat disorder;
KW   lung disorder; nose disorder; lung cancer; gene therapy; cytostatic;
KW   anti allergic; anti asthmatic; anti inflammatory; olfactory;
KW   respiratory active.
```

XX
OS Homo sapiens.
XX
PN WO200155448-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001333.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX

PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476224/51.
DR N-PSDB; AAS27925.
XX
PT Isolated polypeptide for treating, preventing and/ or prognosing
PT disorders related to the respiratory system including respiratory cancers
PT and also for testing and detection e.g. diagnosis.
XX
PS Claim 11; SED ID No 359; 546pp; English.
XX
CC The present invention relates to the isolation of novel human respiratory
CC antigens, and cDNA (AAS27869-AAS28159) and genomic sequences encoding for
CC these polypeptides. The sequences of the invention are useful for
CC preventing, treating and/or prognosing disorders related to the
CC respiratory system including throat disorders (e.g. vocal cord paralysis,
CC tonsillitis, and laryngitis), lung disorders e.g. pneumonia, allergic
CC disorders e.g. asthma, pleurisy, cystic fibrosis, emphysema, nose
CC disorders and cancers of the respiratory tissues e.g. lung cancer. The
CC polynucleotide sequences of the invention are useful in gene therapy and
CC antisense therapy. AAU17685-AAU17975 represent novel human respiratory
CC antigens. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 50 AA;

Query Match 32.0%; Score 31; DB 4; Length 50;
Best Local Similarity 60.0%; Pred. No. 9.9e+02;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

```
Qy          2 PNHLNSKIAF 11
              | |:| | ||
Db         36 PPHVNWKTAF 45
```

RESULT 65
ADG41121
ID ADG41121 standard; protein; 50 AA.
XX
AC ADG41121;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human respiratory system associated protein seq id 359.
XX
KW antiinflammatory; antiallergic; antiasthmatic; cytostatic; gene therapy;
KW respiratory system antigen;
KW human respiratory system associated polynucleotide;
KW respiratory system disorder; throat disorder; vocal cord paralysis;
KW tonsillitis; laryngitis; lung disorder; pneumonia; allergic disorder;
KW asthma; eosinophilic pneumonia; pleurisy; cystic fibrosis; emphysema;
KW histiocytosis; sarcoidosis; nose disorder; rhinitis; sinusitis; neoplasm;
KW cancer; respiratory tissue cancer; throat cancer; lung cancer;
KW cancer of the nose; gene therapy; chromosome identification; forensic;
KW human respiratory system associated protein; human.
XX
OS Homo sapiens.
XX
PN US2003215893-A1.
XX
PD 20-NOV-2003.
XX
PF 07-AUG-2002; 2002US-00212872.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 28-SEP-2000; 2000US-0235935P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239937P.

PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
PR 17-JAN-2001; 2001US-00764860.
PR 14-FEB-2002; 2002US-00074095.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
DR WPI; 2003-902033/82.
DR N-PSDB; ADG40829.
XX
PT Novel respiratory system antigen and polynucleotides encoding the
PT polypeptides, useful for treating diagnosing, treating or preventing
PT tonsillitis, pneumonia, asthma and cystic fibrosis, emphysema, throat
PT cancer.
XX
PS Claim 11; SEQ ID NO 359; 236pp; English.
XX
CC The invention describes an isolated polypeptide (I) comprising an amino
CC acid sequence that is at least 90% identical to polypeptide fragment of
CC any one of 299 respiratory system antigen sequences (PS) and having
CC biological activity, polypeptide domain or epitope of PS, full-length
CC protein of PS, or variant, allelic variant or species homolog of PS. (I)
CC or a polynucleotide (II) encoding (I) is also useful for diagnosing a
CC pathological condition or a susceptibility to a pathological condition in
CC a subject which involves determining the presence or absence of mutation
CC in (II) or determining the presence or amount of expression of (I) in a
CC biological sample and diagnosing a pathological condition based on the
CC result. The human respiratory system associated polynucleotides, the
CC polypeptides encoded by them, and antibodies that immunospecifically bind
CC these polypeptides are useful in diagnosis, treatment, prevention and/or
CC prognosis of disorders of respiratory system such as throat disorders
CC (e.g., vocal cord paralysis, tonsillitis, and laryngitis), lung disorders
CC (e.g., pneumonia), allergic disorders, (e.g., asthma and eosinophilic
CC pneumonia), pleurisy, cystic fibrosis, emphysema, histiocytosis,
CC sarcoidosis, nose disorders (rhinitis and sinusitis), neoplasms and/or
CC cancers of respiratory tissues (e.g., throat cancer, lung cancer, and
CC cancer of the nose). The polynucleotides are useful in gene therapy

Query Match 32.0%; Score 31; DB 7; Length 50;
Best Local Similarity 60.0%; Pred. No. 9.9e+02;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

```
Qy          2 PNHLNSKIAF 11
              | |:| | ||
Db         36 PPHVNWKTAF 45
```

RESULT 66
ABP71110
ID ABP71110 standard; peptide; 19 AA.
XX
AC ABP71110;
XX
DT 14-APR-2003 (first entry)
XX
DE E10 protein CARD region fragment.
XX
KW BTF3; cell death; apoptosis; basic transcription factor; cytostatic;
KW nootropic; neuroprotective; antiparkinsonian; antiarteriosclerotic;
KW antirheumatic; antiarthritic; gene therapy; CARD; E10.
XX
OS Unidentified.
XX
PN WO200295001-A2.
XX
PD 28-NOV-2002.
XX
PF 21-MAY-2002; 2002WO-US016230.
XX
PR 21-MAY-2001; 2001US-0292559P.
XX
PA (REGC) UNIV CALIFORNIA.
XX
PI Rothman JH, Bloss T, Witze E;
XX
DR WPI; 2003-167228/16.
XX
PT Inhibiting or increasing programmed cell death of a cell, for treating
PT e.g. cancer, comprises upregulating or inhibiting, respectively, the
PT expression or activity of basic transcription factor (BTF)3 or its
PT homolog in the cell.
XX
PS Example; Fig 2A; 84pp; English.
XX
CC The invention relates to inhibiting or increasing programmed cell death
CC of a cell. The method involves upregulating or inhibiting, respectively,
CC the expression or activity of basic transcription factor (BTF)3 or its
CC homologue in the cell. The BTF3 polypeptides and nucleic acids are useful
CC for inhibiting or increasing programmed cell death. They are used for

CC screening for an agent that increases or inhibits programmed cell death
CC or pre-screening for an agent that modulates programmed cell death. The
CC screened agent that increases or inhibits programmed cell death, is used
CC for diagnosing or treating cancer or neurodegenerative diseases (e.g.
CC amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease
CC or multiple sclerosis), atherosclerosis, or rheumatoid arthritis.
CC Sequences ABP71106-123 represent CARD regions of various CARD proteins
XX
SQ Sequence 19 AA;

Query Match 31.4%; Score 30.5; DB 6; Length 19;
Best Local Similarity 47.1%; Pred. No. 3.8e+02;
Matches 8; Conservative 4; Mismatches 2; Indels 3; Gaps 1;

Qy 3 NHLNSKIAFKIVSQEPA 19
:|| :| ||:|:| |
Db 2 DHLRAK---KILSREDA 15

RESULT 67
ABU43928
ID ABU43928 standard; protein; 40 AA.
XX
AC ABU43928;
XX
DT 19-JUN-2003 (first entry)
XX
DE Protein encoded by Prokaryotic essential gene #29455.
XX
KW Antisense; prokaryotic essential gene; cell proliferation; drug design.
XX
OS Staphylococcus haemolyticus.
XX
PN WO200277183-A2.
XX
PD 03-OCT-2002.
XX
PF 21-MAR-2002; 2002WO-US009107.
XX
PR 21-MAR-2001; 2001US-00815242.
PR 06-SEP-2001; 2001US-00948993.
PR 25-OCT-2001; 2001US-0342923P.
PR 08-FEB-2002; 2002US-00072851.
PR 06-MAR-2002; 2002US-0362699P.
XX
PA (ELIT-) ELITRA PHARM INC.
XX
PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;
PI Wall D, Trawick JD, Carr GJ, Yamamoto R, Forsyth RA, Xu HH;
XX
DR WPI; 2003-029926/02.
DR N-PSDB; ACA47798.
XX
PT New antisense nucleic acids, useful for identifying proteins or screening
PT for homologous nucleic acids required for cellular proliferation to
PT isolate candidate molecules for rational drug discovery programs.
XX
PS Claim 25; SEQ ID NO 71852; 1766pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising any one of
CC the 6213 antisense sequences given in the specification where expression
CC of the nucleic acid inhibits proliferation of a cell. Also included are:
CC (1) a vector comprising a promoter operably linked to the nucleic acid
CC encoding a polypeptide whose expression is inhibited by the antisense
CC nucleic acid; (2) a host cell containing the vector; (3) an isolated
CC polypeptide or its fragment whose expression is inhibited by the
CC antisense nucleic acid; (4) an antibody capable of specifically binding
CC the polypeptide;(5) producing the polypeptide; (6) inhibiting cellular
CC proliferation or the activity of a gene in an operon required for
CC proliferation; (7) identifying a compound that influences the activity of
CC the gene product or that has an activity against a biological pathway
CC required for proliferation, or that inhibits cellular proliferation; (8)
CC identifying a gene required for cellular proliferation or the biological
CC pathway in which a proliferation-required gene or its gene product lies
CC or a gene on which the test compound that inhibits proliferation of an
CC organism acts; (9) manufacturing an antibiotic; (10) profiling a
CC compound's activity; (11) a culture comprising strains in which the gene
CC product is overexpressed or underexpressed; (12) determining the extent
CC to which each of the strains is present in a culture or collection of
CC strains; or (13) identifying the target of a compound that inhibits the
CC proliferation of an organism. The antisense nucleic acids are useful for
CC identifying proteins or screening for homologous nucleic acids required
CC for cellular proliferation to isolate candidate molecules for rational
CC drug discovery programs, or for screening homologous nucleic acids
CC required for proliferation in cells other than S. aureus, S. typhimurium,
CC K. pneumoniae or P. aeruginosa. The present sequence is encoded by one of
CC the target prokaryotic essential genes. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 40 AA;

Query Match 31.4%; Score 30.5; DB 6; Length 40;
Best Local Similarity 37.5%; Pred. No. 9.3e+02;
Matches 6; Conservative 6; Mismatches 3; Indels 1; Gaps 1;

Qy 1 EPNHLNSKIAFKIVSQ 16
:| | |||: |:::
Db 15 DPIH-NSKLVTKLINK 29

RESULT 68
AAR93211
ID AAR93211 standard; peptide; 20 AA.
XX
AC AAR93211;
XX
DT 04-OCT-1996 (first entry)
XX
DE Control peptide #1 for assay for anti-ZP3 protein antibodies.
XX
KW Zona pellucida; ZP3; vaccine; humoral response; contraception; epitope;
KW pathogenic T cell response; ovary; assay; autoimmune; antibody;
KW passive immunisation.
XX
OS Synthetic.
XX
PN WO9606113-A1.
XX
PD 29-FEB-1996.
XX
PF 18-AUG-1995; 95WO-EP003311.
XX
PR 22-AUG-1994; 94EP-00202392.
XX
PA (ALKU) AKZO NOBEL NV.
XX
PI Van Duin M, Grootenhuis AJ, Bunschoten EJ;
XX
DR WPI; 1996-151331/15.
XX
PT Immuno:contraceptive peptide(s) derived from Zona Pellucida protein ZP3 -
PT used to prepare contraceptive vaccine and in assays to measure autoimmune
PT antibodies.
XX
PS Example 1; Page 29; 43pp; English.
XX
CC The peptides AAR93211-3 are control peptides used in an assay for
CC detecting the reactivity of an antibody, pref. the monoclonal antibody
CC produced by the hybridoma ECACC 94032402, to peptide epitopes derived
CC from the Zona Pellucida protein ZP3 esp. peptide AAR93205-9. The epitopes
CC are esp. based on amino acids 23-30 of the ZP3 protein. The novel
CC peptides can be used in vaccines to induce a humoral response against the
CC ZP3 protein e.g. for contraception, esp. as they do not raise a
CC pathogenic T cell response since they do not contain T cell epitopes. The

```
CC   novel peptides thus avoid potential ovarian damage caused by some
CC   peptides used as vaccines. The peptides are also useful in assays for
CC   detecting autoimmune antibodies or for generating antibodies for passive
CC   immunisation
XX
SQ   Sequence 20 AA;

  Query Match             30.9%;  Score 30;  DB 2;  Length 20;
  Best Local Similarity   45.5%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAF 11
              :|| ||   :|
Db          8 DPNELNKACSF 18


RESULT 69
ABG76721
ID   ABG76721 standard; peptide; 24 AA.
XX
AC   ABG76721;
XX
DT   05-NOV-2002  (first entry)
XX
DE   Hepatitis C virus (HCV)-specific ligand #52.
XX
KW   Binding specificity; anti-antigen antibody; serum; ADAM;
KW   antigen detection by antigen mimic; Hepatitis C virus infection; HCV;
KW   HCV-specific ligand; human.
XX
OS   Homo sapiens.
XX
PN   WO200237115-A1.
XX
PD   10-MAY-2002.
XX
PF   03-NOV-2000; 2000WO-IT000442.
XX
PR   03-NOV-2000; 2000WO-IT000442.
XX
PA   (KENT-) KENTON SRL.
XX
PI   Felici F,  Gargano N,  Minenkova O,  Monaci P;
XX
DR   WPI; 2002-599299/64.
XX
PT   Making diagnosis of antigen, by identifying binding specificity of anti-
PT   antigen antibody molecules in serum by antibody detection by antigen
PT   mimics methodology, and identifying antibodies associated with antigen.
XX
PS   Claim 26; Page 43; 86pp; English.
XX
CC   The present invention relates to a method for making a diagnosis of an
CC   antigen. The method involves identifying the binding specificity of the
CC   anti-antigen antibody molecules in serum by the antibody detection by
CC   antigen mimics (ADAM) methodology. The method comprises screening phage
CC   libraries using sera from antigen-infected and non-infected individuals,
CC   and identifying peptides binding antibodies (ligands) specifically
CC   associated with the antigen. The method of the invention can be used for
CC   the detection of infectious agents, particularly Hepatitis C virus (HCV).
CC   The invention provides HCV-specific ligands which are useful for the
CC   preparation of a diagnostic assay for detecting HCV infection in a
CC   subject. The HCV-specific ligands are also useful for the preparation of
CC   vaccines against HCV. ABG76670-ABG76743 represent HCV-specific ligands
CC   identified from human sera
XX
SQ   Sequence 24 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 24;
  Best Local Similarity   53.8%;  Pred. No. 6.1e+02;
  Matches    7;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          7 SKIAFKIVSQEPA 19
                |  || | :|:||
Db         11 SNKAFGIETQDPA 23


RESULT 70
ABG76719
ID   ABG76719 standard; peptide; 24 AA.
XX
AC   ABG76719;
XX
DT   05-NOV-2002  (first entry)
XX
DE   Hepatitis C virus (HCV)-specific ligand #50.
XX
KW   Binding specificity; anti-antigen antibody; serum; ADAM;
KW   antigen detection by antigen mimic; Hepatitis C virus infection; HCV;
KW   HCV-specific ligand; human.
XX
OS   Homo sapiens.
XX
PN   WO200237115-A1.
XX
PD   10-MAY-2002.
XX
PF   03-NOV-2000; 2000WO-IT000442.
XX
PR   03-NOV-2000; 2000WO-IT000442.
XX
PA   (KENT-) KENTON SRL.
XX
PI   Felici F,  Gargano N,  Minenkova O,  Monaci P;
XX
DR   WPI; 2002-599299/64.
XX
PT   Making diagnosis of antigen, by identifying binding specificity of anti-
PT   antigen antibody molecules in serum by antibody detection by antigen
PT   mimics methodology, and identifying antibodies associated with antigen.
XX
PS   Claim 26; Page 43; 86pp; English.
XX
CC   The present invention relates to a method for making a diagnosis of an
CC   antigen. The method involves identifying the binding specificity of the
CC   anti-antigen antibody molecules in serum by the antibody detection by
CC   antigen mimics (ADAM) methodology. The method comprises screening phage
CC   libraries using sera from antigen-infected and non-infected individuals,
CC   and identifying peptides binding antibodies (ligands) specifically
CC   associated with the antigen. The method of the invention can be used for
CC   the detection of infectious agents, particularly Hepatitis C virus (HCV).
CC   The invention provides HCV-specific ligands which are useful for the
CC   preparation of a diagnostic assay for detecting HCV infection in a
CC   subject. The HCV-specific ligands are also useful for the preparation of
CC   vaccines against HCV. ABG76670-ABG76743 represent HCV-specific ligands
CC   identified from human sera
XX
SQ   Sequence 24 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 24;
  Best Local Similarity   47.1%;  Pred. No. 6.1e+02;
  Matches    8;  Conservative    2;  Mismatches    5;  Indels    2;  Gaps    1;

Qy          3 NHLNSKIAFKIVSQEPA 19
              |:||   || |   :||
Db          9 NYLNK--AFGIEGMDPA 23


RESULT 71
AAM16525
ID   AAM16525 standard; protein; 26 AA.
XX
AC   AAM16525;
XX
DT   12-OCT-2001  (first entry)
XX
```

```
DE   Peptide #2959 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000670.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human cervical epithelial cells.
XX
PS   Claim 27; SEQ ID NO 21351; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 26 AA;

  Query Match             30.9%;  Score 30;  DB 4;  Length 26;
  Best Local Similarity   46.2%;  Pred. No. 6.7e+02;
  Matches    6;  Conservative    2;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKI 13
              | :||:  | | |
Db          1 EKHHLDQMIKFSI 13


RESULT 72
AAM04245
ID   AAM04245 standard; protein; 26 AA.
XX
AC   AAM04245;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Peptide #2927 encoded by probe for measuring breast gene expression.
XX
KW   Probe; human; breast disease; breast cancer; development disorder;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US000661.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression in
PT   a human breast.
XX
PS   Claim 27; SEQ ID NO 12985; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes
CC   (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for measuring human gene expression in
CC   a human breast sample, where the probe hybridises at high stringency to a
CC   nucleic acid expressed in the human breast. The probes are useful for
CC   predicting, diagnosing, grading, staging, monitoring and prognosing
CC   diseases of the human breast, particularly those diseases with polygenic
CC   aetiology. The diseases include: breast cancer, disorders of development,
CC   inflammatory diseases of the breast, fibrocystic changes, proliferative
CC   breast disease and non-carcinoma tumours. Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 26 AA;

  Query Match             30.9%;  Score 30;  DB 4;  Length 26;
  Best Local Similarity   46.2%;  Pred. No. 6.7e+02;
  Matches    6;  Conservative    2;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKI 13
              | :||:  | | |
Db          1 EKHHLDQMIKFSI 13


RESULT 73
AAW88880
ID   AAW88880 standard; protein; 27 AA.
XX
AC   AAW88880;
XX
DT   01-MAR-1999  (first entry)
XX
DE   Polypeptide fragment encoded by gene 100.
XX
KW   Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW   diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW   developmental abnormality; foetal deficiency; blood; allergy; renal;
KW   immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW   inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW   cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW   osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW   endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS   Homo sapiens.
XX
PN   WO9854963-A2.
XX
PD   10-DEC-1998.
XX
PF   04-JUN-1998;  98WO-US011422.
XX
```

PR 06-JUN-1997; 97US-0048875P.
PR 06-JUN-1997; 97US-0048876P.
PR 06-JUN-1997; 97US-0048877P.
PR 06-JUN-1997; 97US-0048878P.
PR 06-JUN-1997; 97US-0048880P.
PR 06-JUN-1997; 97US-0048881P.
PR 06-JUN-1997; 97US-0048882P.
PR 06-JUN-1997; 97US-0048883P.
PR 06-JUN-1997; 97US-0048884P.
PR 06-JUN-1997; 97US-0048885P.
PR 06-JUN-1997; 97US-0048892P.
PR 06-JUN-1997; 97US-0048893P.
PR 06-JUN-1997; 97US-0048894P.
PR 06-JUN-1997; 97US-0048895P.
PR 06-JUN-1997; 97US-0048896P.
PR 06-JUN-1997; 97US-0048897P.
PR 06-JUN-1997; 97US-0048898P.
PR 06-JUN-1997; 97US-0048899P.
PR 06-JUN-1997; 97US-0048900P.
PR 06-JUN-1997; 97US-0048901P.
PR 06-JUN-1997; 97US-0048915P.
PR 06-JUN-1997; 97US-0048916P.
PR 06-JUN-1997; 97US-0048917P.
PR 06-JUN-1997; 97US-0048949P.
PR 06-JUN-1997; 97US-0048962P.
PR 06-JUN-1997; 97US-0048963P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048970P.
PR 06-JUN-1997; 97US-0048971P.
PR 06-JUN-1997; 97US-0048972P.
PR 06-JUN-1997; 97US-0048974P.
PR 06-JUN-1997; 97US-0049019P.
PR 06-JUN-1997; 97US-0049020P.
PR 06-JUN-1997; 97US-0049373P.
PR 06-JUN-1997; 97US-0049374P.
PR 06-JUN-1997; 97US-0049375P.
PR 05-SEP-1997; 97US-0057584P.
PR 05-SEP-1997; 97US-0057627P.
PR 05-SEP-1997; 97US-0057628P.
PR 05-SEP-1997; 97US-0057629P.
PR 05-SEP-1997; 97US-0057634P.
PR 05-SEP-1997; 97US-0057635P.
PR 05-SEP-1997; 97US-0057642P.
PR 05-SEP-1997; 97US-0057643P.
PR 05-SEP-1997; 97US-0057644P.
PR 05-SEP-1997; 97US-0057645P.
PR 05-SEP-1997; 97US-0057646P.
PR 05-SEP-1997; 97US-0057647P.
PR 05-SEP-1997; 97US-0057648P.
PR 05-SEP-1997; 97US-0057649P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057651P.
PR 05-SEP-1997; 97US-0057654P.
PR 05-SEP-1997; 97US-0057661P.
PR 05-SEP-1997; 97US-0057662P.
PR 05-SEP-1997; 97US-0057666P.
PR 05-SEP-1997; 97US-0057667P.
PR 05-SEP-1997; 97US-0057668P.
PR 05-SEP-1997; 97US-0057760P.
PR 05-SEP-1997; 97US-0057761P.
PR 05-SEP-1997; 97US-0057762P.
PR 05-SEP-1997; 97US-0057763P.
PR 05-SEP-1997; 97US-0057764P.
PR 05-SEP-1997; 97US-0057765P.
PR 05-SEP-1997; 97US-0057769P.
PR 05-SEP-1997; 97US-0057770P.
PR 05-SEP-1997; 97US-0057771P.
PR 05-SEP-1997; 97US-0057774P.
PR 05-SEP-1997; 97US-0057775P.
PR 05-SEP-1997; 97US-0057776P.
PR 05-SEP-1997; 97US-0057777P.
PR 05-SEP-1997; 97US-0057778P.
PR 18-DEC-1997; 97US-0070923P.

XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Young P, Greene JM, Ferrie AM, Ruben SM, Rosen CA, Hu J;
PI Olsen HS, Ebner R, Brewer LA, Moore PA, Shi Y, Florence C;
PI Florence K, Lafleur DW, Ni J, Fan P, Wei Y, Fischer CL, Soppet DR;
PI Li Y, Zeng Z, Kyaw H, Yu G, Feng P, Dillon PJ, Endress GA;
PI Carter KC;
XX
DR WPI; 1999-059865/05.
DR N-PSDB; AAV84510.
XX
PT New isolated human genes and the secreted polypeptides they encode -
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX
PS Disclosure; Page 77; 772pp; English.
XX
CC The invention relates to nucleic acid sequences (AAV84411 to AAV84633)
CC encoding human secreted proteins (AAW88534 to AAW88756). The secreted
CC protein gene sequences are deposited with the ATCC under deposit numbers
CC ATCC 97979, 97974, 97975, 97976, 97977, 209007, 209008, 209009, 209010,
CC 209011, 209080, 209081, 209082, 209083, 209084, 209085, 209511. Host
CC cells comprising recombinant vectors containing the nucleic acid
CC sequences are used for the recombinant production of the secreted
CC proteins. The polynucleotide and amino acid sequences are useful for are
CC useful for preventing, treating or ameliorating medical conditions e.g.
CC by protein or gene therapy. Pathological conditions can be also diagnosed
CC by determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the polynucleotides, based on
CC which tissues they are most highly expressed in, and include developing
CC products for the diagnosis or treatment of cancer, neurodegenerative
CC disorders, developmental abnormalities and foetal deficiencies, blood
CC disorders, tumours, leukemias, diseases of the immune system, autoimmune
CC diseases, hepatic and renal disease, lymphomas, inflammation, allergies,
CC ischemic shock, Alzheimer's and cognitive disorders, schizophrenia,
CC restenosis, prostate diseases, obesity, disorders involving osteoclasts
CC such as osteoporosis, arthritis or malignancies, diseases of testes, lung
CC or thymus, digestive/endocrine disorders, infections and AIDS. The
CC polypeptides are also useful for identifying their binding partners. The
CC present sequence represents a polypeptide fragment encoded by a gene of
CC the invention (see descriptor line for gene number)
XX
SQ Sequence 27 AA;

Query Match 30.9%; Score 30; DB 2; Length 27;
Best Local Similarity 37.5%; Pred. No. 7.1e+02;
Matches 6; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAFKIVSQE 17
|: | : || :|:|
Db 6 PSANNQRFAFSPLSEE 21

RESULT 74
AAW88879
ID AAW88879 standard; protein; 27 AA.
XX
AC AAW88879;
XX
DT 01-MAR-1999 (first entry)
XX
DE Polypeptide fragment encoded by gene 100.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.

XX
OS Homo sapiens.
XX
PN WO9854963-A2.
XX
PD 10-DEC-1998.
XX
PF 04-JUN-1998; 98WO-US011422.
XX
PR 06-JUN-1997; 97US-0048875P.
PR 06-JUN-1997; 97US-0048876P.
PR 06-JUN-1997; 97US-0048877P.
PR 06-JUN-1997; 97US-0048878P.
PR 06-JUN-1997; 97US-0048880P.
PR 06-JUN-1997; 97US-0048881P.
PR 06-JUN-1997; 97US-0048882P.
PR 06-JUN-1997; 97US-0048883P.
PR 06-JUN-1997; 97US-0048884P.
PR 06-JUN-1997; 97US-0048885P.
PR 06-JUN-1997; 97US-0048892P.
PR 06-JUN-1997; 97US-0048893P.
PR 06-JUN-1997; 97US-0048894P.
PR 06-JUN-1997; 97US-0048895P.
PR 06-JUN-1997; 97US-0048896P.
PR 06-JUN-1997; 97US-0048897P.
PR 06-JUN-1997; 97US-0048898P.
PR 06-JUN-1997; 97US-0048899P.
PR 06-JUN-1997; 97US-0048900P.
PR 06-JUN-1997; 97US-0048901P.
PR 06-JUN-1997; 97US-0048915P.
PR 06-JUN-1997; 97US-0048916P.
PR 06-JUN-1997; 97US-0048917P.
PR 06-JUN-1997; 97US-0048949P.
PR 06-JUN-1997; 97US-0048962P.
PR 06-JUN-1997; 97US-0048963P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048970P.
PR 06-JUN-1997; 97US-0048971P.
PR 06-JUN-1997; 97US-0048972P.
PR 06-JUN-1997; 97US-0048974P.
PR 06-JUN-1997; 97US-0049019P.
PR 06-JUN-1997; 97US-0049020P.
PR 06-JUN-1997; 97US-0049373P.
PR 06-JUN-1997; 97US-0049374P.
PR 06-JUN-1997; 97US-0049375P.
PR 05-SEP-1997; 97US-0057584P.
PR 05-SEP-1997; 97US-0057627P.
PR 05-SEP-1997; 97US-0057628P.
PR 05-SEP-1997; 97US-0057629P.
PR 05-SEP-1997; 97US-0057634P.
PR 05-SEP-1997; 97US-0057635P.
PR 05-SEP-1997; 97US-0057642P.
PR 05-SEP-1997; 97US-0057643P.
PR 05-SEP-1997; 97US-0057644P.
PR 05-SEP-1997; 97US-0057645P.
PR 05-SEP-1997; 97US-0057646P.
PR 05-SEP-1997; 97US-0057647P.
PR 05-SEP-1997; 97US-0057648P.
PR 05-SEP-1997; 97US-0057649P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057651P.
PR 05-SEP-1997; 97US-0057654P.
PR 05-SEP-1997; 97US-0057661P.
PR 05-SEP-1997; 97US-0057662P.
PR 05-SEP-1997; 97US-0057666P.
PR 05-SEP-1997; 97US-0057667P.
PR 05-SEP-1997; 97US-0057668P.
PR 05-SEP-1997; 97US-0057760P.
PR 05-SEP-1997; 97US-0057761P.
PR 05-SEP-1997; 97US-0057762P.
PR 05-SEP-1997; 97US-0057763P.
PR 05-SEP-1997; 97US-0057764P.
PR 05-SEP-1997; 97US-0057765P.
PR 05-SEP-1997; 97US-0057769P.
PR 05-SEP-1997; 97US-0057770P.
PR 05-SEP-1997; 97US-0057771P.
PR 05-SEP-1997; 97US-0057774P.
PR 05-SEP-1997; 97US-0057775P.
PR 05-SEP-1997; 97US-0057776P.
PR 05-SEP-1997; 97US-0057777P.
PR 05-SEP-1997; 97US-0057778P.
PR 18-DEC-1997; 97US-0070923P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Young P, Greene JM, Ferrie AM, Ruben SM, Rosen CA, Hu J;
PI Olsen HS, Ebner R, Brewer LA, Moore PA, Shi Y, Florence C;
PI Florence K, Lafleur DW, Ni J, Fan P, Wei Y, Fischer CL, Soppet DR;
PI Li Y, Zeng Z, Kyaw H, Yu G, Feng P, Dillon PJ, Endress GA;
PI Carter KC;
XX
DR WPI; 1999-059865/05.
DR N-PSDB; AAV84510.
XX
PT New isolated human genes and the secreted polypeptides they encode -
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX
PS Disclosure; Page 77; 772pp; English.
XX
CC The invention relates to nucleic acid sequences (AAV84411 to AAV84633)
CC encoding human secreted proteins (AAW88534 to AAW88756). The secreted
CC protein gene sequences are deposited with the ATCC under deposit numbers
CC ATCC 97979, 97974, 97975, 97976, 97977, 209007, 209008, 209009, 209010,
CC 209011, 209080, 209081, 209082, 209083, 209084, 209085, 209511. Host
CC cells comprising recombinant vectors containing the nucleic acid
CC sequences are used for the recombinant production of the secreted
CC proteins. The polynucleotide and amino acid sequences are useful for are
CC useful for preventing, treating or ameliorating medical conditions e.g.
CC by protein or gene therapy. Pathological conditions can be also diagnosed
CC by determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the polynucleotides, based on
CC which tissues they are most highly expressed in, and include developing
CC products for the diagnosis or treatment of cancer, neurodegenerative
CC disorders, developmental abnormalities and foetal deficiencies, blood
CC disorders, tumours, leukemias, diseases of the immune system, autoimmune
CC diseases, hepatic and renal disease, lymphomas, inflammation, allergies,
CC ischemic shock, Alzheimer's and cognitive disorders, schizophrenia,
CC restenosis, prostate diseases, obesity, disorders involving osteoclasts
CC such as osteoporosis, arthritis or malignancies, diseases of testes, lung
CC or thymus, digestive/endocrine disorders, infections and AIDS. The
CC polypeptides are also useful for identifying their binding partners. The
CC present sequence represents a polypeptide fragment encoded by a gene of
CC the invention (see descriptor line for gene number)
XX
SQ Sequence 27 AA;

Query Match 30.9%; Score 30; DB 2; Length 27;
Best Local Similarity 37.5%; Pred. No. 7.1e+02;
Matches 6; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAFKIVSQE 17
|: | : || :|:|
Db 6 PSANNQRFAFSPLSEE 21

RESULT 75
ABB50945
ID ABB50945 standard; protein; 27 AA.
XX
AC ABB50945;
XX
DT 07-FEB-2002 (first entry)
XX
DE Human secreted protein encoded by gene 100 SEQ ID NO:898.

```
XX
KW   Human; secreted protein; immunomodulatory; antisclerotic; anti-HIV;
KW   dermatological; immunosuppressive; antiinflammatory; immunostimulant;
KW   cytostatic; cardiant; vascular; anti-angiogenic; ophthalmological;
KW   neuroprotective; nootropic; anticonvulsant; antialzheimers; vulnerary;
KW   antiparkinsonian; antimicrobial; gene therapy; vaccine; immune disorder;
KW   multiple sclerosis; systemic lupus erythematosus; HIV infection; cancer;
KW   human immunodeficiency virus; hyperproliferative disorder; wound healing;
KW   Gaucher's disease; cardiovascular disease; Scimitar syndrome; chemotaxis;
KW   Chaga's cardiomyopathy; coronary arteriosclerosis; angiogenic disorder;
KW   corneal graft neovascularisation; diabetic retinopathy; regeneration;
KW   neurological disorder; Huntington's chorea; Alzheimer's disease;
KW   Parkinson's disease; infectious disease; chromosome 15.
XX
OS   Homo sapiens.
XX
PN   WO200162891-A2.
XX
PD   30-AUG-2001.
XX
PF   21-FEB-2001; 2001WO-US005614.
XX
PR   24-FEB-2000; 2000US-0184836P.
PR   29-MAR-2000; 2000US-0193170P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ni J,  Ebner R,  Lafleur DW,  Moore PA,  Olsen HS,  Rosen CA;
PI   Ruben SM,  Soppet DR,  Young PE,  Shi Y,  Florence KA,  Wei Y;
PI   Florence C,  Hu J,  Li Y,  Kyaw H,  Fischer CL,  Ferrie AM,  Fan P;
PI   Feng P,  Endress GA,  Dillon PJ,  Carter KC,  Brewer LA,  Yu G,  Zeng Z;
PI   Greene JM;
XX
DR   WPI; 2001-625724/72.
XX
PT   Nucleic acids encoding 207 human secreted polypeptides, useful for
PT   preventing, diagnosing and/or treating, e.g. cancers, Parkinson's disease
PT   and diabetic retinopathy.
XX
PS   Disclosure; Page 229; 1533pp; English.
XX
CC   ABB50301 to ABB51287 and ABA83194 to ABA83441 represent human secreted
CC   proteins (I) and polynucleotide (II) sequences. (I) and (II) have various
CC   activities based on the tissues and cells the genes are expressed in.
CC   Example of these activities include: immunomodulatory; antisclerotic;
CC   dermatological; immunosuppressive; antiinflammatory; immunostimulant;
CC   anti-HIV; cytostatic; cardiant; anti-angiogenic; ophthalmological;
CC   neuroprotective; nootropic; anticonvulsant; antialzheimers; vascular;
CC   antiparkinsonian; antimicrobial; and vulnerary. (I) and (II) can be used
CC   in gene therapy and vaccine production. (I) and (II) can be used in the
CC   prevention, diagnosis and treatment of immune disorders (e.g. multiple
CC   sclerosis, systemic lupus erythematosus and human immunodeficiency virus
CC   (HIV) infections), hyperproliferative disorders (e.g. cancers and
CC   Gaucher's disease), cardiovascular diseases (e.g. Scimitar syndrome,
CC   Chaga's cardiomyopathy and coronary arteriosclerosis), angiogenic
CC   disorders (e.g. corneal graft neovascularisation and diabetic
CC   retinopathy), neurological disorders (e.g. Huntington's chorea,
CC   Alzheimer's disease and Parkinson's disease), infectious diseases and/or
CC   for promoting wound healing, regeneration and/or chemotaxis. ABA83185 to
CC   ABA83193 and ABB50300 represent sequences used in the exemplification of
CC   the present invention
XX
SQ   Sequence 27 AA;

  Query Match             30.9%;  Score 30;  DB 4;  Length 27;
  Best Local Similarity   37.5%;  Pred. No. 7.1e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21
```

```
RESULT 76
ABB50946
ID   ABB50946 standard; protein; 27 AA.
XX
AC   ABB50946;
XX
DT   07-FEB-2002  (first entry)
XX
DE   Human secreted protein encoded by gene 100 SEQ ID NO:899.
XX
KW   Human; secreted protein; immunomodulatory; antisclerotic; anti-HIV;
KW   dermatological; immunosuppressive; antiinflammatory; immunostimulant;
KW   cytostatic; cardiant; vascular; anti-angiogenic; ophthalmological;
KW   neuroprotective; nootropic; anticonvulsant; antialzheimers; vulnerary;
KW   antiparkinsonian; antimicrobial; gene therapy; vaccine; immune disorder;
KW   multiple sclerosis; systemic lupus erythematosus; HIV infection; cancer;
KW   human immunodeficiency virus; hyperproliferative disorder; wound healing;
KW   Gaucher's disease; cardiovascular disease; Scimitar syndrome; chemotaxis;
KW   Chaga's cardiomyopathy; coronary arteriosclerosis; angiogenic disorder;
KW   corneal graft neovascularisation; diabetic retinopathy; regeneration;
KW   neurological disorder; Huntington's chorea; Alzheimer's disease;
KW   Parkinson's disease; infectious disease; chromosome 15.
XX
OS   Homo sapiens.
XX
PN   WO200162891-A2.
XX
PD   30-AUG-2001.
XX
PF   21-FEB-2001; 2001WO-US005614.
XX
PR   24-FEB-2000; 2000US-0184836P.
PR   29-MAR-2000; 2000US-0193170P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ni J,  Ebner R,  Lafleur DW,  Moore PA,  Olsen HS,  Rosen CA;
PI   Ruben SM,  Soppet DR,  Young PE,  Shi Y,  Florence KA,  Wei Y;
PI   Florence C,  Hu J,  Li Y,  Kyaw H,  Fischer CL,  Ferrie AM,  Fan P;
PI   Feng P,  Endress GA,  Dillon PJ,  Carter KC,  Brewer LA,  Yu G,  Zeng Z;
PI   Greene JM;
XX
DR   WPI; 2001-625724/72.
XX
PT   Nucleic acids encoding 207 human secreted polypeptides, useful for
PT   preventing, diagnosing and/or treating, e.g. cancers, Parkinson's disease
PT   and diabetic retinopathy.
XX
PS   Disclosure; Page 229; 1533pp; English.
XX
CC   ABB50301 to ABB51287 and ABA83194 to ABA83441 represent human secreted
CC   proteins (I) and polynucleotide (II) sequences. (I) and (II) have various
CC   activities based on the tissues and cells the genes are expressed in.
CC   Example of these activities include: immunomodulatory; antisclerotic;
CC   dermatological; immunosuppressive; antiinflammatory; immunostimulant;
CC   anti-HIV; cytostatic; cardiant; anti-angiogenic; ophthalmological;
CC   neuroprotective; nootropic; anticonvulsant; antialzheimers; vascular;
CC   antiparkinsonian; antimicrobial; and vulnerary. (I) and (II) can be used
CC   in gene therapy and vaccine production. (I) and (II) can be used in the
CC   prevention, diagnosis and treatment of immune disorders (e.g. multiple
CC   sclerosis, systemic lupus erythematosus and human immunodeficiency virus
CC   (HIV) infections), hyperproliferative disorders (e.g. cancers and
CC   Gaucher's disease), cardiovascular diseases (e.g. Scimitar syndrome,
CC   Chaga's cardiomyopathy and coronary arteriosclerosis), angiogenic
CC   disorders (e.g. corneal graft neovascularisation and diabetic
CC   retinopathy), neurological disorders (e.g. Huntington's chorea,
CC   Alzheimer's disease and Parkinson's disease), infectious diseases and/or
CC   for promoting wound healing, regeneration and/or chemotaxis. ABA83185 to
CC   ABA83193 and ABB50300 represent sequences used in the exemplification of
CC   the present invention
XX
SQ   Sequence 27 AA;
```

```
  Query Match             30.9%;  Score 30;  DB 4;  Length 27;
  Best Local Similarity   37.5%;  Pred. No. 7.1e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  |  : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 77
ABO45202
ID   ABO45202 standard; protein; 27 AA.
XX
AC   ABO45202;
XX
DT   02-OCT-2003  (first entry)
XX
DE   Novel human secreted protein #100 fragment #4.
XX
KW   Human; gene therapy; autoimmune disorder; multiple sclerosis; cancer;
KW   systemic lupus erythematosus; haematopoietic cell disorder; allergy;
KW   agammaglobulinaemia; ataxia telangiectasia; blood coagulation disorder;
KW   afibrinogenaemia; thrombocytopenia; graft-versus-host disease; arthritis;
KW   inflammatory condition; ischaemia-reperfusion injury; infectious disease;
KW   hyperproliferative disorder; purpura; viral infection; regeneration;
KW   bacterial infection; ulcer; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   US2003065160-A1.
XX
PD   03-APR-2003.
XX
PF   07-DEC-2001; 2001US-00004860.
XX
PR   06-JUN-1997;   97US-0048875P.
PR   06-JUN-1997;   97US-0048876P.
PR   06-JUN-1997;   97US-0048877P.
PR   06-JUN-1997;   97US-0048878P.
PR   06-JUN-1997;   97US-0048880P.
PR   06-JUN-1997;   97US-0048881P.
PR   06-JUN-1997;   97US-0048882P.
PR   06-JUN-1997;   97US-0048883P.
PR   06-JUN-1997;   97US-0048884P.
PR   06-JUN-1997;   97US-0048885P.
PR   06-JUN-1997;   97US-0048892P.
PR   06-JUN-1997;   97US-0048893P.
PR   06-JUN-1997;   97US-0048894P.
PR   06-JUN-1997;   97US-0048895P.
PR   06-JUN-1997;   97US-0048896P.
PR   06-JUN-1997;   97US-0048897P.
PR   06-JUN-1997;   97US-0048898P.
PR   06-JUN-1997;   97US-0048899P.
PR   06-JUN-1997;   97US-0048900P.
PR   06-JUN-1997;   97US-0048901P.
PR   06-JUN-1997;   97US-0048915P.
PR   06-JUN-1997;   97US-0048916P.
PR   06-JUN-1997;   97US-0048917P.
PR   06-JUN-1997;   97US-0048949P.
PR   06-JUN-1997;   97US-0048962P.
PR   06-JUN-1997;   97US-0048963P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048970P.
PR   06-JUN-1997;   97US-0048971P.
PR   06-JUN-1997;   97US-0048972P.
PR   06-JUN-1997;   97US-0048974P.
PR   06-JUN-1997;   97US-0049019P.
PR   06-JUN-1997;   97US-0049020P.
PR   06-JUN-1997;   97US-0049373P.
PR   06-JUN-1997;   97US-0049374P.
PR   06-JUN-1997;   97US-0049375P.
PR   05-SEP-1997;   97US-0057584P.
PR   05-SEP-1997;   97US-0057627P.
PR   05-SEP-1997;   97US-0057628P.
PR   05-SEP-1997;   97US-0057629P.
PR   05-SEP-1997;   97US-0057634P.
PR   05-SEP-1997;   97US-0057635P.
PR   05-SEP-1997;   97US-0057642P.
PR   05-SEP-1997;   97US-0057643P.
PR   05-SEP-1997;   97US-0057644P.
PR   05-SEP-1997;   97US-0057645P.
PR   05-SEP-1997;   97US-0057646P.
PR   05-SEP-1997;   97US-0057647P.
PR   05-SEP-1997;   97US-0057648P.
PR   05-SEP-1997;   97US-0057649P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057651P.
PR   05-SEP-1997;   97US-0057654P.
PR   05-SEP-1997;   97US-0057661P.
PR   05-SEP-1997;   97US-0057662P.
PR   05-SEP-1997;   97US-0057666P.
PR   05-SEP-1997;   97US-0057667P.
PR   05-SEP-1997;   97US-0057668P.
PR   05-SEP-1997;   97US-0057760P.
PR   05-SEP-1997;   97US-0057761P.
PR   05-SEP-1997;   97US-0057762P.
PR   05-SEP-1997;   97US-0057763P.
PR   05-SEP-1997;   97US-0057764P.
PR   05-SEP-1997;   97US-0057765P.
PR   05-SEP-1997;   97US-0057769P.
PR   05-SEP-1997;   97US-0057770P.
PR   05-SEP-1997;   97US-0057771P.
PR   05-SEP-1997;   97US-0057774P.
PR   05-SEP-1997;   97US-0057775P.
PR   05-SEP-1997;   97US-0057776P.
PR   05-SEP-1997;   97US-0057777P.
PR   05-SEP-1997;   97US-0057778P.
PR   18-DEC-1997;   97US-0070923P.
PR   04-JUN-1998;   98WO-US011422.
PR   15-JUL-1998;   98US-0092921P.
PR   30-JUL-1998;   98US-0094657P.
PR   04-DEC-1998;   98US-00205258.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Young P,  Greene JM,  Ferrie AM,  Ruben SM,  Rosen CA,  Hu J;
PI   Olsen HS,  Ebner R,  Brewer LA,  Moore PA,  Shi Y,  Florence C;
PI   Florence K,  Lafleur DW,  Ni J,  Fan P,  Wei Y,  Fischer CL,  Soppet DR;
PI   Li Y,  Zeng Z,  Kyaw H,  Yu G,  Feng P,  Dillon PJ,  Endress GA;
PI   Carter KC;
XX
DR   WPI; 2003-540804/51.
XX
PT   New isolated protein, useful for preparing a composition for diagnosing
PT   or treating cancer, inflammatory, immune or infectious diseases.
XX
PS   Disclosure; Page 63; 172pp; English.
XX
CC   The invention relates to an isolated HEMAE80 protein. The protein is
CC   useful for preparing a composition for diagnosing or treating autoimmune
CC   disorders e.g. multiple sclerosis and systemic lupus erythematosus;
CC   haematopoietic cell disorders e.g. agammaglobulinaemia and ataxia
CC   telangiectasia; blood coagulation disorders e.g. afibrinogenaemia and
CC   thrombocytopenia; allergy; graft-versus-host disease; inflammatory
CC   conditions e.g. ischaemia-reperfusion injury and arthritis;
CC   hyperproliferative disorders e.g. cancer and purpura; infectious disease
CC   e.g. viral infection and bacterial infection. The polynucleotide or
CC   protein can be used to regenerate damaged tissue e.g. ulcers and
CC   Alzheimer's disease. The present sequence represents the amino acid
CC   sequence of a novel human secreted protein fragment. Note: The sequence
CC   data for this patent did not form part of the printed specification but
CC   was obtained in electronic format directly from USPTO at
CC   seqdata.uspto.gov/sequence.html?DocID=20030065160
XX
SQ   Sequence 27 AA;
```

```
  Query Match             30.9%;  Score 30;  DB 6;  Length 27;
  Best Local Similarity   37.5%;  Pred. No. 7.1e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 78
ABO45203
ID   ABO45203 standard; protein; 27 AA.
XX
AC   ABO45203;
XX
DT   02-OCT-2003  (first entry)
XX
DE   Novel human secreted protein #100 fragment #5.
XX
KW   Human; gene therapy; autoimmune disorder; multiple sclerosis; cancer;
KW   systemic lupus erythematosus; haematopoietic cell disorder; allergy;
KW   agammaglobulinaemia; ataxia telangiectasia; blood coagulation disorder;
KW   afibrinogenaemia; thrombocytopenia; graft-versus-host disease; arthritis;
KW   inflammatory condition; ischaemia-reperfusion injury; infectious disease;
KW   hyperproliferative disorder; purpura; viral infection; regeneration;
KW   bacterial infection; ulcer; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   US2003065160-A1.
XX
PD   03-APR-2003.
XX
PF   07-DEC-2001; 2001US-00004860.
XX
PR   06-JUN-1997;   97US-0048875P.
PR   06-JUN-1997;   97US-0048876P.
PR   06-JUN-1997;   97US-0048877P.
PR   06-JUN-1997;   97US-0048878P.
PR   06-JUN-1997;   97US-0048880P.
PR   06-JUN-1997;   97US-0048881P.
PR   06-JUN-1997;   97US-0048882P.
PR   06-JUN-1997;   97US-0048883P.
PR   06-JUN-1997;   97US-0048884P.
PR   06-JUN-1997;   97US-0048885P.
PR   06-JUN-1997;   97US-0048892P.
PR   06-JUN-1997;   97US-0048893P.
PR   06-JUN-1997;   97US-0048894P.
PR   06-JUN-1997;   97US-0048895P.
PR   06-JUN-1997;   97US-0048896P.
PR   06-JUN-1997;   97US-0048897P.
PR   06-JUN-1997;   97US-0048898P.
PR   06-JUN-1997;   97US-0048899P.
PR   06-JUN-1997;   97US-0048900P.
PR   06-JUN-1997;   97US-0048901P.
PR   06-JUN-1997;   97US-0048915P.
PR   06-JUN-1997;   97US-0048916P.
PR   06-JUN-1997;   97US-0048917P.
PR   06-JUN-1997;   97US-0048949P.
PR   06-JUN-1997;   97US-0048962P.
PR   06-JUN-1997;   97US-0048963P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048970P.
PR   06-JUN-1997;   97US-0048971P.
PR   06-JUN-1997;   97US-0048972P.
PR   06-JUN-1997;   97US-0048974P.
PR   06-JUN-1997;   97US-0049019P.
PR   06-JUN-1997;   97US-0049020P.
PR   06-JUN-1997;   97US-0049373P.
PR   06-JUN-1997;   97US-0049374P.
PR   06-JUN-1997;   97US-0049375P.
PR   05-SEP-1997;   97US-0057584P.
PR   05-SEP-1997;   97US-0057627P.
PR   05-SEP-1997;   97US-0057628P.
PR   05-SEP-1997;   97US-0057629P.
PR   05-SEP-1997;   97US-0057634P.
PR   05-SEP-1997;   97US-0057635P.
PR   05-SEP-1997;   97US-0057642P.
PR   05-SEP-1997;   97US-0057643P.
PR   05-SEP-1997;   97US-0057644P.
PR   05-SEP-1997;   97US-0057645P.
PR   05-SEP-1997;   97US-0057646P.
PR   05-SEP-1997;   97US-0057647P.
PR   05-SEP-1997;   97US-0057648P.
PR   05-SEP-1997;   97US-0057649P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057651P.
PR   05-SEP-1997;   97US-0057654P.
PR   05-SEP-1997;   97US-0057661P.
PR   05-SEP-1997;   97US-0057662P.
PR   05-SEP-1997;   97US-0057666P.
PR   05-SEP-1997;   97US-0057667P.
PR   05-SEP-1997;   97US-0057668P.
PR   05-SEP-1997;   97US-0057760P.
PR   05-SEP-1997;   97US-0057761P.
PR   05-SEP-1997;   97US-0057762P.
PR   05-SEP-1997;   97US-0057763P.
PR   05-SEP-1997;   97US-0057764P.
PR   05-SEP-1997;   97US-0057765P.
PR   05-SEP-1997;   97US-0057769P.
PR   05-SEP-1997;   97US-0057770P.
PR   05-SEP-1997;   97US-0057771P.
PR   05-SEP-1997;   97US-0057774P.
PR   05-SEP-1997;   97US-0057775P.
PR   05-SEP-1997;   97US-0057776P.
PR   05-SEP-1997;   97US-0057777P.
PR   05-SEP-1997;   97US-0057778P.
PR   18-DEC-1997;   97US-0070923P.
PR   04-JUN-1998;   98WO-US011422.
PR   15-JUL-1998;   98US-0092921P.
PR   30-JUL-1998;   98US-0094657P.
PR   04-DEC-1998;   98US-00205258.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Young P,  Greene JM,  Ferrie AM,  Ruben SM,  Rosen CA,  Hu J;
PI   Olsen HS,  Ebner R,  Brewer LA,  Moore PA,  Shi Y,  Florence C;
PI   Florence K,  Lafleur DW,  Ni J,  Fan P,  Wei Y,  Fischer CL,  Soppet DR;
PI   Li Y,  Zeng Z,  Kyaw H,  Yu G,  Feng P,  Dillon PJ,  Endress GA;
PI   Carter KC;
XX
DR   WPI; 2003-540804/51.
XX
PT   New isolated protein, useful for preparing a composition for diagnosing
PT   or treating cancer, inflammatory, immune or infectious diseases.
XX
PS   Disclosure; Page 63; 172pp; English.
XX
CC   The invention relates to an isolated HEMAE80 protein. The protein is
CC   useful for preparing a composition for diagnosing or treating autoimmune
CC   disorders e.g. multiple sclerosis and systemic lupus erythematosus;
CC   haematopoietic cell disorders e.g. agammaglobulinaemia and ataxia
CC   telangiectasia; blood coagulation disorders e.g. afibrinogenaemia and
CC   thrombocytopenia; allergy; graft-versus-host disease; inflammatory
CC   conditions e.g. ischaemia-reperfusion injury and arthritis;
CC   hyperproliferative disorders e.g. cancer and purpura; infectious disease
CC   e.g. viral infection and bacterial infection. The polynucleotide or
CC   protein can be used to regenerate damaged tissue e.g. ulcers and
CC   Alzheimer's disease. The present sequence represents the amino acid
CC   sequence of a novel human secreted protein fragment. Note: The sequence
CC   data for this patent did not form part of the printed specification but
CC   was obtained in electronic format directly from USPTO at
CC   seqdata.uspto.gov/sequence.html?DocID=20030065160
XX
SQ   Sequence 27 AA;
```

```
  Query Match             30.9%;  Score 30;  DB 6;  Length 27;
  Best Local Similarity   37.5%;  Pred. No. 7.1e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 79
ABO26682
ID   ABO26682 standard; protein; 27 AA.
XX
AC   ABO26682;
XX
DT   10-SEP-2003  (first entry)
XX
DE   Protein associated with novel secreted protein gene 100 #4.
XX
KW   Secreted protein; precerebellin-like protein; sepsis; acne; psoriasis;
KW   neurodegenerative disorder; behavioural disorder; Alzheimer's disease;
KW   Parkinson's disease; Huntington's disease; schizophrenia; mania;
KW   dementia; paranoia; psychosis; autism; immune disorder; infection;
KW   inflammation; allergy; liver disorder; hepatoblastoma; jaundice;
KW   hepatitis; immunological disorder; AIDS; leukaemia; rheumatoid arthritis;
KW   cancer.
XX
OS   Unidentified.
XX
PN   US6525174-B1.
XX
PD   25-FEB-2003.
XX
PF   04-DEC-1998;   98US-00205258.
XX
PR   06-JUN-1997;   97US-0048875P.
PR   06-JUN-1997;   97US-0048876P.
PR   06-JUN-1997;   97US-0048877P.
PR   06-JUN-1997;   97US-0048878P.
PR   06-JUN-1997;   97US-0048880P.
PR   06-JUN-1997;   97US-0048881P.
PR   06-JUN-1997;   97US-0048882P.
PR   06-JUN-1997;   97US-0048883P.
PR   06-JUN-1997;   97US-0048884P.
PR   06-JUN-1997;   97US-0048885P.
PR   06-JUN-1997;   97US-0048892P.
PR   06-JUN-1997;   97US-0048893P.
PR   06-JUN-1997;   97US-0048894P.
PR   06-JUN-1997;   97US-0048895P.
PR   06-JUN-1997;   97US-0048896P.
PR   06-JUN-1997;   97US-0048897P.
PR   06-JUN-1997;   97US-0048898P.
PR   06-JUN-1997;   97US-0048899P.
PR   06-JUN-1997;   97US-0048900P.
PR   06-JUN-1997;   97US-0048901P.
PR   06-JUN-1997;   97US-0048915P.
PR   06-JUN-1997;   97US-0048916P.
PR   06-JUN-1997;   97US-0048917P.
PR   06-JUN-1997;   97US-0048949P.
PR   06-JUN-1997;   97US-0048962P.
PR   06-JUN-1997;   97US-0048963P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048970P.
PR   06-JUN-1997;   97US-0048971P.
PR   06-JUN-1997;   97US-0048972P.
PR   06-JUN-1997;   97US-0048974P.
PR   06-JUN-1997;   97US-0049019P.
PR   06-JUN-1997;   97US-0049020P.
PR   06-JUN-1997;   97US-0049373P.
PR   06-JUN-1997;   97US-0049374P.
PR   06-JUN-1997;   97US-0049375P.
PR   05-SEP-1997;   97US-0057584P.
PR   05-SEP-1997;   97US-0057627P.
PR   05-SEP-1997;   97US-0057628P.
PR   05-SEP-1997;   97US-0057629P.
PR   05-SEP-1997;   97US-0057634P.
PR   05-SEP-1997;   97US-0057635P.
PR   05-SEP-1997;   97US-0057642P.
PR   05-SEP-1997;   97US-0057643P.
PR   05-SEP-1997;   97US-0057644P.
PR   05-SEP-1997;   97US-0057645P.
PR   05-SEP-1997;   97US-0057646P.
PR   05-SEP-1997;   97US-0057647P.
PR   05-SEP-1997;   97US-0057648P.
PR   05-SEP-1997;   97US-0057649P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057651P.
PR   05-SEP-1997;   97US-0057654P.
PR   05-SEP-1997;   97US-0057661P.
PR   05-SEP-1997;   97US-0057662P.
PR   05-SEP-1997;   97US-0057666P.
PR   05-SEP-1997;   97US-0057667P.
PR   05-SEP-1997;   97US-0057668P.
PR   05-SEP-1997;   97US-0057760P.
PR   05-SEP-1997;   97US-0057761P.
PR   05-SEP-1997;   97US-0057762P.
PR   05-SEP-1997;   97US-0057763P.
PR   05-SEP-1997;   97US-0057764P.
PR   05-SEP-1997;   97US-0057765P.
PR   05-SEP-1997;   97US-0057769P.
PR   05-SEP-1997;   97US-0057770P.
PR   05-SEP-1997;   97US-0057771P.
PR   05-SEP-1997;   97US-0057774P.
PR   05-SEP-1997;   97US-0057775P.
PR   05-SEP-1997;   97US-0057776P.
PR   05-SEP-1997;   97US-0057777P.
PR   05-SEP-1997;   97US-0057778P.
PR   18-DEC-1997;   97US-0070923P.
PR   04-JUN-1998;   98WO-US011422.
PR   15-JUL-1998;   98US-0092921P.
PR   30-JUL-1998;   98US-0094657P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Young P,  Greene JM,  Ferrie AM,  Ruben SM,  Rosen CA,  Hu J;
PI   Olsen HS,  Ebner R,  Brewer LA,  Moore PA,  Shi Y,  Florence C;
PI   Florence K,  Lafleur DW,  Ni J,  Fan P,  Wei Y,  Fischer CL,  Soppet DR;
PI   Li Y,  Zeng Z,  Kyaw H,  Yu G,  Feng P,  Dillon PJ,  Endress GA;
PI   Carter KC;
XX
DR   WPI; 2003-511926/48.
XX
PT   New precerebellin-like protein, useful for diagnosing or treating
PT   neurodegenerative and behavioral disorders, immune disorders, liver
PT   disorders, and cancer.
XX
PS   Disclosure; Col 115; 156pp; English.
XX
CC   The invention relates to an isolated protein comprising amino acid
CC   residues 33-205 or 1-205 of a a novel human secreted protein appearing as
CC   ABO26252. The protein is encoded by one of 238 disclosed cDNA sequences
CC   encoding 238 secreted proteins. ABO26252 is a precerebellin-like protein.
CC   Also included are a composition comprising the protein and a carrier and
CC   an isolated protein produced by expressing the protein cited above by a
CC   cell, and recovering the protein. The proteins are useful for diagnosing
CC   or treating neurodegenerative and behavioural disorders (e.g. Alzheimer's
CC   disease, Parkinson's disease, Huntington's disease, schizophrenia, mania,
CC   dementia, paranoia, psychoses or autism), immune disorders (e.g.
CC   infection, inflammation, allergy), liver disorders (e.g. hepatoblastoma,
CC   jaundice, hepatitis), immunological disorders (e.g. AIDS, leukaemia,
CC   rheumatoid arthritis, sepsis, acne, psoriasis) and cancer. The present
CC   sequence is a protein associated with one of the 238 disclosed novel
CC   secreted proteins
XX
SQ   Sequence 27 AA;
```

```
  Query Match             30.9%;  Score 30;  DB 7;  Length 27;
  Best Local Similarity   37.5%;  Pred. No. 7.1e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 80
ABO26683
ID   ABO26683 standard; protein; 27 AA.
XX
AC   ABO26683;
XX
DT   10-SEP-2003  (first entry)
XX
DE   Protein associated with novel secreted protein gene 100 #5.
XX
KW   Secreted protein; precerebellin-like protein; sepsis; acne; psoriasis;
KW   neurodegenerative disorder; behavioural disorder; Alzheimer's disease;
KW   Parkinson's disease; Huntington's disease; schizophrenia; mania;
KW   dementia; paranoia; psychosis; autism; immune disorder; infection;
KW   inflammation; allergy; liver disorder; hepatoblastoma; jaundice;
KW   hepatitis; immunological disorder; AIDS; leukaemia; rheumatoid arthritis;
KW   cancer.
XX
OS   Unidentified.
XX
PN   US6525174-B1.
XX
PD   25-FEB-2003.
XX
PF   04-DEC-1998;   98US-00205258.
XX
PR   06-JUN-1997;   97US-0048875P.
PR   06-JUN-1997;   97US-0048876P.
PR   06-JUN-1997;   97US-0048877P.
PR   06-JUN-1997;   97US-0048878P.
PR   06-JUN-1997;   97US-0048880P.
PR   06-JUN-1997;   97US-0048881P.
PR   06-JUN-1997;   97US-0048882P.
PR   06-JUN-1997;   97US-0048883P.
PR   06-JUN-1997;   97US-0048884P.
PR   06-JUN-1997;   97US-0048885P.
PR   06-JUN-1997;   97US-0048892P.
PR   06-JUN-1997;   97US-0048893P.
PR   06-JUN-1997;   97US-0048894P.
PR   06-JUN-1997;   97US-0048895P.
PR   06-JUN-1997;   97US-0048896P.
PR   06-JUN-1997;   97US-0048897P.
PR   06-JUN-1997;   97US-0048898P.
PR   06-JUN-1997;   97US-0048899P.
PR   06-JUN-1997;   97US-0048900P.
PR   06-JUN-1997;   97US-0048901P.
PR   06-JUN-1997;   97US-0048915P.
PR   06-JUN-1997;   97US-0048916P.
PR   06-JUN-1997;   97US-0048917P.
PR   06-JUN-1997;   97US-0048949P.
PR   06-JUN-1997;   97US-0048962P.
PR   06-JUN-1997;   97US-0048963P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048970P.
PR   06-JUN-1997;   97US-0048971P.
PR   06-JUN-1997;   97US-0048972P.
PR   06-JUN-1997;   97US-0048974P.
PR   06-JUN-1997;   97US-0049019P.
PR   06-JUN-1997;   97US-0049020P.
PR   06-JUN-1997;   97US-0049373P.
PR   06-JUN-1997;   97US-0049374P.
PR   06-JUN-1997;   97US-0049375P.
PR   05-SEP-1997;   97US-0057584P.
PR   05-SEP-1997;   97US-0057627P.
PR   05-SEP-1997;   97US-0057628P.
PR   05-SEP-1997;   97US-0057629P.
PR   05-SEP-1997;   97US-0057634P.
PR   05-SEP-1997;   97US-0057635P.
PR   05-SEP-1997;   97US-0057642P.
PR   05-SEP-1997;   97US-0057643P.
PR   05-SEP-1997;   97US-0057644P.
PR   05-SEP-1997;   97US-0057645P.
PR   05-SEP-1997;   97US-0057646P.
PR   05-SEP-1997;   97US-0057647P.
PR   05-SEP-1997;   97US-0057648P.
PR   05-SEP-1997;   97US-0057649P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057651P.
PR   05-SEP-1997;   97US-0057654P.
PR   05-SEP-1997;   97US-0057661P.
PR   05-SEP-1997;   97US-0057662P.
PR   05-SEP-1997;   97US-0057666P.
PR   05-SEP-1997;   97US-0057667P.
PR   05-SEP-1997;   97US-0057668P.
PR   05-SEP-1997;   97US-0057760P.
PR   05-SEP-1997;   97US-0057761P.
PR   05-SEP-1997;   97US-0057762P.
PR   05-SEP-1997;   97US-0057763P.
PR   05-SEP-1997;   97US-0057764P.
PR   05-SEP-1997;   97US-0057765P.
PR   05-SEP-1997;   97US-0057769P.
PR   05-SEP-1997;   97US-0057770P.
PR   05-SEP-1997;   97US-0057771P.
PR   05-SEP-1997;   97US-0057774P.
PR   05-SEP-1997;   97US-0057775P.
PR   05-SEP-1997;   97US-0057776P.
PR   05-SEP-1997;   97US-0057777P.
PR   05-SEP-1997;   97US-0057778P.
PR   18-DEC-1997;   97US-0070923P.
PR   04-JUN-1998;   98WO-US011422.
PR   15-JUL-1998;   98US-0092921P.
PR   30-JUL-1998;   98US-0094657P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Young P,  Greene JM,  Ferrie AM,  Ruben SM,  Rosen CA,  Hu J;
PI   Olsen HS,  Ebner R,  Brewer LA,  Moore PA,  Shi Y,  Florence C;
PI   Florence K,  Lafleur DW,  Ni J,  Fan P,  Wei Y,  Fischer CL,  Soppet DR;
PI   Li Y,  Zeng Z,  Kyaw H,  Yu G,  Feng P,  Dillon PJ,  Endress GA;
PI   Carter KC;
XX
DR   WPI; 2003-511926/48.
XX
PT   New precerebellin-like protein, useful for diagnosing or treating
PT   neurodegenerative and behavioral disorders, immune disorders, liver
PT   disorders, and cancer.
XX
PS   Disclosure; Col 115; 156pp; English.
XX
CC   The invention relates to an isolated protein comprising amino acid
CC   residues 33-205 or 1-205 of a a novel human secreted protein appearing as
CC   ABO26252. The protein is encoded by one of 238 disclosed cDNA sequences
CC   encoding 238 secreted proteins. ABO26252 is a precerebellin-like protein.
CC   Also included are a composition comprising the protein and a carrier and
CC   an isolated protein produced by expressing the protein cited above by a
CC   cell, and recovering the protein. The proteins are useful for diagnosing
CC   or treating neurodegenerative and behavioural disorders (e.g. Alzheimer's
CC   disease, Parkinson's disease, Huntington's disease, schizophrenia, mania,
CC   dementia, paranoia, psychoses or autism), immune disorders (e.g.
CC   infection, inflammation, allergy), liver disorders (e.g. hepatoblastoma,
CC   jaundice, hepatitis), immunological disorders (e.g. AIDS, leukaemia,
CC   rheumatoid arthritis, sepsis, acne, psoriasis) and cancer. The present
CC   sequence is a protein associated with one of the 238 disclosed novel
CC   secreted proteins
XX
SQ   Sequence 27 AA;
```

```
  Query Match             30.9%;  Score 30;  DB 7;  Length 27;
  Best Local Similarity   37.5%;  Pred. No. 7.1e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 81
ABP26325
ID   ABP26325 standard; protein; 30 AA.
XX
AC   ABP26325;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Streptococcus polypeptide SEQ ID NO 1826.
XX
KW   Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
KW   group A streptococcus; Streptococcus pyogenes; antibacterial;
KW   antiinflammatory; infection; vaccine; meningitis; gene therapy.
XX
OS   Streptococcus agalactiae.
XX
PN   WO200234771-A2.
XX
PD   02-MAY-2002.
XX
PF   29-OCT-2001; 2001WO-GB004789.
XX
PR   27-OCT-2000; 2000GB-00026333.
PR   24-NOV-2000; 2000GB-00028727.
PR   07-MAR-2001; 2001GB-00005640.
XX
PA   (CHIR-) CHIRON SPA.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Telford J,  Masignani V,  Margarit Y RosI,  Grandi G,  Fraser C;
PI   Tettelin H;
XX
DR   WPI; 2002-352536/38.
DR   N-PSDB; ABN66956.
XX
PT   New Streptococcus protein for the treatment or prevention of infection or
PT   disease caused by Streptococcus bacteria, such as meningitis, and for
PT   detecting a compound that binds to the protein.
XX
PS   Claim 1; Page 3332; 4525pp; English.
XX
CC   The invention relates to a protein (ABP25413-ABP30895) from group B
CC   streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
CC   (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
CC   the specification. The proteins have antibacterial and antiinflammatory
CC   activity. (I), nucleic acids encoding (I), ABN66044-ABN71526 and
CC   antibodies that bind (I) are used in the manufacture of medicaments for
CC   the treatment or prevention of infection or disease caused by
CC   Streptococcus bacteria, particularly S. agalactiae and S. pyrogenes.
CC   Nucleic acids encoding (I) are used to detect Streptococcus in a
CC   biological sample. (I) is used to determine whether a compound binds to
CC   (I). A composition comprising (I) or a nucleic acid encoding (I), may be
CC   used as a vaccine or diagnostic composition. The disease caused by
CC   Streptococcus that is prevented or treated may be meningitis. Nucleic
CC   acid encoding (I) may be used to recombinantly produce (I) and may be
CC   used in gene therapy. Antibodies to (I) are used for affinity
CC   chromatography, immunoassays, and distinguishing/identifying
CC   Streptococcus proteins
XX
SQ   Sequence 30 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 30;
  Best Local Similarity   66.7%;  Pred. No. 8e+02;
  Matches    6;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          7 SKIAFKIVS 15
              |||:|||  :
Db          4 SKISFKIAT 12


RESULT 82
AAU84722
ID   AAU84722 standard; peptide; 30 AA.
XX
AC   AAU84722;
XX
DT   08-MAY-2002  (first entry)
XX
DE   HCV HepC1a segment 125.
XX
KW   Savine; vaccine; cancer; viral infection; HIV; hepatitis C virus;
KW   viral infection; human immunodeficieny virus; melanoma;
KW   bacterial infection; Salmonella; Legionella; parasitic infection;
KW   Trypanosoma; Toxoplasma; Giardia.
XX
OS   Hepatitis C virus.
XX
PN   WO200190197-A1.
XX
PD   29-NOV-2001.
XX
PF   25-MAY-2001; 2001WO-AU000622.
XX
PR   26-MAY-2000; 2000AU-00007761.
XX
PA   (AUSU ) UNIV AUSTRALIAN NAT.
XX
PI   Thomson SA,  Ramshaw IA;
XX
DR   WPI; 2002-147575/19.
DR   N-PSDB; ABK36560.
XX
PT   New synthetic polypeptides having several different segments of at least
PT   one parent polypeptide linked together differently compared to the
PT   linkage in the parent polypeptide, for inducing immune response against a
PT   pathogen or cancer.
XX
PS   Example 2; Fig 26; 364pp; English.
XX
CC   The invention relates to a new synthetic polypeptide (I) comprising
CC   several different segments of at least one parent polypeptide linked
CC   together in a different relationship relative to their linkage in the
CC   parent polypeptide to impede, abrogate or otherwise alter at least one
CC   function associated with the parent polypeptide and for inducing an
CC   immune response against a pathogen or cancer. Also included are a
CC   synthetic polynucleotide encoding and a computer system for designing the
CC   synthetic polypeptides. The synthetic polypeptides and polynucleotides
CC   are referred to as a Savine. The synthetic polypeptide is useful for
CC   modulating immune responses preferably directed against a pathogen or a
CC   cancer, (e.g., cancers of the lung, breast, ovary, cervix, colon, head
CC   and neck, pancreas, prostate, stomach, bladder, kidney, bone liver,
CC   oesophagus, brain, testicle, uterus), as potentiating agents.
CC   Compositions comprising the polypeptide may be used in the treatment or
CC   prophylaxis against viral (such as infections caused by HIV (human
CC   immunodeficiency virus), hepatitis, influenza, Japanese encephalitis
CC   virus, Epstein-Barr virus and respiratory syncytial virus), bacterial
CC   (e.g., infections caused by Neisseria, Meningococcal, Haemophilus,
CC   Salmonella, Streptococcal, Legionella and Mycobacterium or parasitic
CC   (e.g., infections caused by Plasmodium, Schistosoma, Leishmania,
CC   Trypanosoma, Toxoplasma and Giardia) infections. The present sequence is
CC   a peptide derived from a parent protein used to construct a savine of the
CC   invention
XX
SQ   Sequence 30 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 30;
  Best Local Similarity   66.7%;  Pred. No. 8e+02;
```

Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```
Qy          9 IAFKIVSQE 17
              :||||:| |
Db          6 VAFKIMSGE 14
```

RESULT 83
AAU84721
ID AAU84721 standard; peptide; 30 AA.
XX
AC AAU84721;
XX
DT 08-MAY-2002 (first entry)
XX
DE HCV HepC1a segment 124.
XX
KW Savine; vaccine; cancer; viral infection; HIV; hepatitis C virus;
KW viral infection; human immunodeficieny virus; melanoma;
KW bacterial infection; Salmonella; Legionella; parasitic infection;
KW Trypanosoma; Toxoplasma; Giardia.
XX
OS Hepatitis C virus.
XX
PN WO200190197-A1.
XX
PD 29-NOV-2001.
XX
PF 25-MAY-2001; 2001WO-AU000622.
XX
PR 26-MAY-2000; 2000AU-00007761.
XX
PA (AUSU) UNIV AUSTRALIAN NAT.
XX
PI Thomson SA, Ramshaw IA;
XX
DR WPI; 2002-147575/19.
DR N-PSDB; ABK36559.
XX
PT New synthetic polypeptides having several different segments of at least
PT one parent polypeptide linked together differently compared to the
PT linkage in the parent polypeptide, for inducing immune response against a
PT pathogen or cancer.
XX
PS Example 2; Fig 26; 364pp; English.
XX
CC The invention relates to a new synthetic polypeptide (I) comprising
CC several different segments of at least one parent polypeptide linked
CC together in a different relationship relative to their linkage in the
CC parent polypeptide to impede, abrogate or otherwise alter at least one
CC function associated with the parent polypeptide and for inducing an
CC immune response against a pathogen or cancer. Also included are a
CC synthetic polynucleotide encoding and a computer system for designing the
CC synthetic polypeptides. The synthetic polypeptides and polynucleotides
CC are referred to as a Savine. The synthetic polypeptide is useful for
CC modulating immune responses preferably directed against a pathogen or a
CC cancer, (e.g., cancers of the lung, breast, ovary, cervix, colon, head
CC and neck, pancreas, prostate, stomach, bladder, kidney, bone liver,
CC oesophagus, brain, testicle, uterus), as potentiating agents.
CC Compositions comprising the polypeptide may be used in the treatment or
CC prophylaxis against viral (such as infections caused by HIV (human
CC immunodeficiency virus), hepatitis, influenza, Japanese encephalitis
CC virus, Epstein-Barr virus and respiratory syncytial virus), bacterial
CC (e.g., infections caused by Neisseria, Meningococcal, Haemophilus,
CC Salmonella, Streptococcal, Legionella and Mycobacterium or parasitic
CC (e.g., infections caused by Plasmodium, Schistosoma, Leishmania,
CC Trypanosoma, Toxoplasma and Giardia) infections. The present sequence is
CC a peptide derived from a parent protein used to construct a savine of the
CC invention
XX
SQ Sequence 30 AA;

Query Match 30.9%; Score 30; DB 5; Length 30;
Best Local Similarity 66.7%; Pred. No. 8e+02;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```
Qy          9 IAFKIVSQE 17
              :||||:| |
Db         21 VAFKIMSGE 29
```

RESULT 84
ABG68718
ID ABG68718 standard; protein; 30 AA.
XX
AC ABG68718;
XX
DT 07-OCT-2002 (first entry)
XX
DE Human prostate specific protein DEX0293_87.
XX
KW Human; prostate specific nucleic acid; PSNA; prostate cancer; PSP;
KW prostate specific protein; cytostatic; non-cancerous prostate disease;
KW gene therapy; cancer; immunostimulant; vaccine.
XX
OS Homo sapiens.
XX
PN WO200255735-A2.
XX
PD 18-JUL-2002.
XX
PF 27-NOV-2001; 2001WO-US044363.
XX
PR 27-NOV-2000; 2000US-0253176P.
XX
PA (DIAD-) DIADEXUS INC.
XX
PI Salceda S, Macina RA, Recipon H, Cafferkey R, Ali S, Sun Y;
PI Liu C, Chen S;
XX
DR WPI; 2002-557831/59.
DR N-PSDB; ABK97600.
XX
PT New prostate specific genes, useful for treating or diagnosing cancer, or
PT useful as vaccines for treating cancer, particularly prostate cancer, in
PT a patient.
XX
PS Claim 11; Page 196-197; 212pp; English.
XX
CC The invention relates to a new isolated prostate-specific nucleic acid
CC (PSNA) molecule comprising the cDNA sequences appearing as ABK97574-
CC ABK97642 which encode prostate specific proteins appearing as ABG68701-
CC ABG68746, or a sequence hybridising to a PSNA or which has 60% sequence
CC homology with a PSNA. Also included are a method of determining the
CC presence of a PSNA in a sample, a vector comprising the PSNA, a host cell
CC comprising the vector, producing the polypeptide encoded by the PSNA, a
CC method of determining the presence of a PSP in a sample, diagnosing and
CC monitoring the presence and metastases of prostate cancer in a patient, a
CC kit for detecting a risk of cancer or presence of cancer in a patient
CC (the kit comprising a means for determining the presence of the PSNA or
CC PSP in a sample of a patient) and a vaccine comprising the polypeptide or
CC the nucleic acid encoding the polypeptide. The PSNA, PSP and anti-PSP
CC antibody are useful for diagnosing and treating cancer in a patient (e.g.
CC by gene therapy). The nucleic acid molecule and polypeptide are also
CC useful as vaccines for treating cancer, particularly prostate cancer and
CC non-cancerous prostate diseases. The present sequence is a PSP of the
CC invention
XX
SQ Sequence 30 AA;

Query Match 30.9%; Score 30; DB 5; Length 30;
Best Local Similarity 45.5%; Pred. No. 8e+02;
Matches 5; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

```
Qy          7 SKIAFKIVSQE 17
              ||| |::::|:
```

```
Db         10 SKIVFQLLNQK 20


RESULT 85
ABB79232
ID   ABB79232 standard; protein; 30 AA.
XX
AC   ABB79232;
XX
DT   08-AUG-2002  (first entry)
XX
DE   Human prostate specific protein sequence SEQ ID NO:181.
XX
KW   Human; prostate specific gene; prostate specific protein; PSG; PSP;
KW   prostate cancer.
XX
OS   Homo sapiens.
XX
PN   WO200236808-A2.
XX
PD   10-MAY-2002.
XX
PF   05-NOV-2001; 2001WO-US047283.
XX
PR   03-NOV-2000; 2000US-0245740P.
XX
PA   (DIAD-) DIADEXUS INC.
XX
PI   Sun Y,  Recipon H,  Chen S,  Liu C;
XX
DR   WPI; 2002-471506/50.
XX
PT   New prostate-specific nucleic acids and polypeptides, useful for
PT   identifying, diagnosing, monitoring, staging, imaging, and treating
PT   prostate cancer and non-cancerous disease states in prostate tissue.
XX
PS   Claim 11; Page 231; 254pp; English.
XX
CC   ABN87650 to ABN87789 represent human prostate-specific nucleic acids (I),
CC   and ABB79192 to ABB79295 represent human prostate-specific proteins (II)
CC   from the present invention. (I) and (II) have cytostatic activity. (I)
CC   can be used in gene therapy. The prostate-specific nucleic acids,
CC   polypeptides and compositions from the present invention can be used for
CC   identifying, diagnosing, monitoring, staging, imaging, and treating
CC   prostate cancer and non-cancerous disease states in prostate tissue; for
CC   identifying prostate tissue; for monitoring, identifying and/or designing
CC   agonists and antagonists of the polypeptides; in gene therapy; in
CC   producing transgenic animals and cells; for producing engineered prostate
CC   tissue for treatment and research; and as elements in an array or
CC   computer program for pattern recognition of prostate disorders. The
CC   nucleic acids may be used as hybridisation probes to detect, characterise
CC   and quantify hybridising nucleic acids in, and isolate hybridising
CC   nucleic acids from, both genomic and transcript-derived nucleic acid
CC   samples
XX
SQ   Sequence 30 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 30;
  Best Local Similarity   46.2%;  Pred. No. 8e+02;
  Matches    6;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIVSQ 16
              |||    ||:  |
Db         13 HLNINFIFKLDQQ 25


RESULT 86
AAB38429
ID   AAB38429 standard; peptide; 31 AA.
XX
AC   AAB38429;
XX
DT   31-JAN-2001  (first entry)
XX
DE   Fragment of human secreted protein encoded by gene 10 clone HTEBV72.
XX
KW   Immunosuppressive; antiarthritic; antirheumatic; antiproliferative;
KW   cytostatic; cardiant; vasotropic; cerebroprotective; neuroprotective;
KW   nootropic; antibacterial; virucide; fungicide; opthalmalogical; human;
KW   vulnerary; gene therapy; infection; secreted protein.
XX
OS   Homo sapiens.
XX
PN   WO200061623-A1.
XX
PD   19-OCT-2000.
XX
PF   06-APR-2000; 2000WO-US008979.
XX
PR   09-APR-1999;   99US-0128693P.
PR   26-APR-1999;   99US-0130991P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ni J,  Komatsoulis GA,  Rosen CA,  Soppet DR,  Shi Y;
PI   Lafleur DW,  Olsen HS,  Ebner R,  Florence KA,  Moore PA,  Birse CE;
PI   Young PE;
XX
DR   WPI; 2000-647418/62.
XX
PT   New nucleic acid molecules encoding 62 human secreted proteins for
PT   diagnosing, preventing, treating or ameliorating medical conditions and
PT   used as food additives or preservatives.
XX
PS   Disclosure; Page 32; 716pp; English.
XX
CC   Sequences AAB38321-B38396 represent the amino acid sequences of 62 human
CC   secreted proteins encoded by the genes AAC69512-C69587. The genes and
CC   proteins are useful for preventing, ameliorating or treating medical
CC   conditions, e.g. by protein or gene therapy. The genes are isolated from
CC   a range of human tissues disclosed in the specification. The nucleic
CC   acids, proteins, antibodies and (ant)agonists are useful in the
CC   diagnosis, treatment and prevention of: (a) autoimmune diseases e.g.
CC   rheumatoid arthritis; (b) hyperproliferative disorders e.g. neoplasms of
CC   the breast or liver; (c) cardiovascular disorders e.g. cardiac arrest;
CC   (d) cerebrovascular disorders e.g. cerebral ischemia; (e) angiogenesis;
CC   (f) nervous system disorders e.g. Alzheimer's disease; (g) infections
CC   caused by bacteria, viruses and fungi; and (h) ocular disorders e.g.
CC   corneal infection. The polypeptides can also be used to aid wound healing
CC   and epithelial cell proliferation, to prevent skin aging due to sunburn,
CC   to maintain organs before transplantation, for supporting cell culture of
CC   primary tissues, to regenerate tissues and in chemotaxis
XX
SQ   Sequence 31 AA;

  Query Match             30.9%;  Score 30;  DB 3;  Length 31;
  Best Local Similarity   33.3%;  Pred. No. 8.4e+02;
  Matches    5;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQ 16
              ||::  |    :| |
Db          5 PNNIRHKFGSNVVDQ 19


RESULT 87
AAG75194
ID   AAG75194 standard; protein; 32 AA.
XX
AC   AAG75194;
XX
DT   03-SEP-2001  (first entry)
XX
DE   Human colon cancer antigen protein SEQ ID NO:5958.
XX
KW   Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW   colorectal carcinoma.
```

XX
OS Homo sapiens.
XX
PN WO200122920-A2.
XX
PD 05-APR-2001.
XX
PF 28-SEP-2000; 2000WO-US026524.
XX
PR 29-SEP-1999; 99US-0157137P.
PR 03-NOV-1999; 99US-0163280P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Birse CE, Rosen CA;
XX
DR WPI; 2001-235357/24.
DR N-PSDB; AAH34599.
XX
PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT useful for preventing, diagnosing and/or treating colorectal cancers.
XX
PS Claim 11; Page 7465; 9803pp; English.
XX
CC AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC cancer-associated nucleic acid molecules (N) and proteins (P), where the
CC proteins are collectively known as colon cancer antigens. The colon
CC cancer antigens have cytostatic activity and can be used in gene therapy
CC and vaccine production. N and P may be used in the prevention, diagnosis
CC and treatment of diseases associated with inappropriate P expression. For
CC example, N and P may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of P by expressing inactive proteins or to
CC supplement the patients own production of P. Additionally, N may be used
CC to produce the colon cancer-associated Ps, by inserting the nucleic acids
CC into a host cell and culturing the cell to express the proteins. N and P
CC can be used in the prevention, diagnosis and treatment of colorectal
CC carcinomas and cancers. AAH37196 to AAH37204 and AAB77789 represent
CC sequences used in the exemplification of the present invention. N.B.
CC Pages 666 to 682 and page 7053 of the sequence listing were missing at
CC time of publication, meaning no sequences are present for SEQ ID NO:1027
CC to 1052, 7921 and 7922
XX
SQ Sequence 32 AA;

Query Match 30.9%; Score 30; DB 4; Length 32;
Best Local Similarity 77.8%; Pred. No. 8.7e+02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 8 KIAFKIVSQ 16
||:|||.|
Db 5 KIAWKIVIQ 13

RESULT 88
ADH96838
ID ADH96838 standard; protein; 32 AA.
XX
AC ADH96838;
XX
DT 06-MAY-2004 (first entry)
XX
DE S. pneumoniae DNA polymerase III beta-subunit epitope #2.
XX
KW antibacterial; antiinflammatory; gastrointestinal; antiulcer;
KW antidiarrhoeic; ophthalmological; enzyme inhibitor; antisense therapy;
KW vaccine; microbial target; modulator; furuncle; pneumonia; gastritis;
KW peptic ulcer disease; diarrhoea; meningitis; bacteraemia; conjunctivitis;
KW toxic shock syndrome; epitope.
XX
OS Streptococcus pneumoniae.
XX
PN WO2003102190-A2.
XX
PD 11-DEC-2003.
XX
PF 02-JUN-2003; 2003WO-CA000786.
XX
PR 31-MAY-2002; 2002US-0384634P.
PR 31-MAY-2002; 2002US-0385157P.
PR 04-JUN-2002; 2002US-0385542P.
PR 04-JUN-2002; 2002US-0385611P.
PR 04-JUN-2002; 2002US-0385747P.
PR 04-JUN-2002; 2002US-0385750P.
PR 04-JUN-2002; 2002US-0385752P.
PR 04-JUN-2002; 2002US-0385773P.
PR 04-JUN-2002; 2002US-0385780P.
PR 04-JUN-2002; 2002US-0385785P.
PR 04-JUN-2002; 2002US-0385797P.
PR 05-JUN-2002; 2002US-0385962P.
PR 05-JUN-2002; 2002US-0386022P.
PR 05-JUN-2002; 2002US-0386024P.
PR 05-JUN-2002; 2002US-0386087P.
PR 05-JUN-2002; 2002US-0386141P.
PR 05-JUN-2002; 2002US-0386350P.
PR 05-JUN-2002; 2002US-0386586P.
PR 06-JUN-2002; 2002US-0386368P.
PR 06-JUN-2002; 2002US-0386369P.
PR 06-JUN-2002; 2002US-0386436P.
PR 06-JUN-2002; 2002US-0386441P.
PR 06-JUN-2002; 2002US-0386528P.
PR 06-JUN-2002; 2002US-0386573P.
PR 06-JUN-2002; 2002US-0386834P.
PR 31-JUL-2002; 2002US-0399839P.
PR 31-JUL-2002; 2002US-0399861P.
PR 31-JUL-2002; 2002US-0399969P.
PR 31-JUL-2002; 2002US-0399970P.
PR 31-JUL-2002; 2002US-0399983P.
PR 31-JUL-2002; 2002US-0399984P.
PR 31-JUL-2002; 2002US-0399985P.
PR 01-AUG-2002; 2002US-0400154P.
PR 01-AUG-2002; 2002US-0400230P.
PR 01-AUG-2002; 2002US-0400268P.
PR 01-AUG-2002; 2002US-0400363P.
PR 01-AUG-2002; 2002US-0400365P.
PR 01-AUG-2002; 2002US-0400374P.
PR 01-AUG-2002; 2002US-0400380P.
PR 01-AUG-2002; 2002US-0400433P.
PR 01-AUG-2002; 2002US-0400434P.
PR 01-AUG-2002; 2002US-0400436P.
PR 01-AUG-2002; 2002US-0400442P.
PR 01-AUG-2002; 2002US-0400463P.
XX
PA (AFFI-) AFFINIUM PHARM INC.
XX
PI Edwards A, Dharamsi A, Vedadi M, Vallee F, Awrey D, Beattie B;
PI Richards D, Domagala M, Mansoury K, Virag C, Buzadzija K;
PI Mcdonald M, Houston S, Arrowsmith C, Ouyang H, Nethery K, Ng I;
PI Kanagarajah D;
XX
DR WPI; 2004-071165/07.
XX
PT Compositions comprising recombinant polypeptide targets for pathogenic
PT bacteria, useful for designing modulators for preventing or treating a
PT disease or disorder associated with the species of origin for the
PT polypeptide.
XX
PS Disclosure; SEQ ID NO 29; 606pp; English.
XX
CC The invention relates to novel compositions (I) comprising isolated,
CC recombinant polypeptides, amino acid sequences having at least about 95%
CC identity with these or an amino acid sequence encoded by a polynucleotide
CC that hybridizes under stringent conditions to the complementary strand of
CC the polynucleotide encoding these polypeptides. The compositions and
CC polypeptides are useful as microbial targets for designing modulators for
CC the prevention or treatment of a disease or disorder associated with the

CC species of origin for the polypeptide, e.g. furuncle, pneumonia,
CC gastritis, peptic ulcer disease, diarrhoea, meningitis, bacteraemia,
CC conjunctivitis or toxic shock syndrome. The polypeptides are also useful
CC for diagnosing a patient suffering from a disease or disorder of a
CC pathogenic species, or for monitoring the effectiveness of an anti-
CC pathogenic treatment. This sequence corresponds to an epitope of one of
CC the protein sequences of the invention.
XX
SQ Sequence 32 AA;

Query Match 30.9%; Score 30; DB 8; Length 32;
Best Local Similarity 45.5%; Pred. No. 8.7e+02;
Matches 5; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 9 IAFKIVSQEPA 19
: ||: |: ||
Db 14 VDFKVFSEAPA 24

RESULT 89
AAW29908
ID AAW29908 standard; peptide; 33 AA.
XX
AC AAW29908;
XX
DT 16-MAR-1998 (first entry)
XX
DE Porcine AMPK-alpha1 active peptide fragment 3.
XX
KW 5'-AMP activated protein kinase; AMPK; catalytic subunit;
KW protein phosphorylation; cholesterol; fatty acid; pig;
KW hormone sensitive lipase; HSL; alpha1 subunit.
XX
OS Sus scrofa.
XX
PN WO9725341-A1.
XX
PD 17-JUL-1997.
XX
PF 07-JAN-1997; 97WO-US000270.
XX
PR 08-JAN-1996; 96AU-00007450.
XX
PA (SVIN-) ST VINCENTS INST MEDICAL RES.
PA (DART-) DARTMOUTH COLLEGE.
XX
PI Kemp BE, Stapleton DI, Mitchelhill KI, Witters LA;
XX
DR WPI; 1997-372811/34.
XX
PT New isolated 5'-AMP-activated protein kinase subunit(s) - used to develop
PT products for treating e.g. hyper-cholesterolaemia, obesity, hypoxia,
PT ischaemia, nutrition disorders or diabetes mellitus.
XX
PS Disclosure; Page 36; 63pp; English.
XX
CC This sequence represent a biologically active peptide derived from the 5'
CC -AMP-activated protein kinase (AMPK) catalytic alpha1 subunit from pig
CC liver. This fragment retains at least one of the activities of native
CC AMPk-alpha1 i.e the ability to stimulate phosphorylation of protein
CC molecules and the ability to mimic the binding of native AMPK-alpha1 to
CC at least one antibody or ligand molecule. AMPK polypeptides can be used
CC to identify compounds which regulate the action of kinases. Such
CC fragments can be used to reduce biosynthesis of cholesterol and fatty
CC acids. They may also be used to inhibit the release of these molecules
CC from intracellular stores by hormone sensitive lipase (HSL). They may
CC also be used to reduce cellular malonyl CoA levels and promote the beta-
CC oxidation of fatty acids by mitochondria. AMPK-alpha1 fragments could be
CC used in the treatment of e.g. hypercholesterolaemia, hyperlipidaemia,
CC obesity, clinical syndromes associated with hypoxia or ischaemia (e.g.
CC myocardial infarction) disorders of nutrition and diabetes mellitus
XX
SQ Sequence 33 AA;

Query Match 30.9%; Score 30; DB 2; Length 33;
Best Local Similarity 71.4%; Pred. No. 9e+02;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 4 HLNSKIA 10
|:|:|||
Db 12 HMNAKIA 18

RESULT 90
AAW35030
ID AAW35030 standard; peptide; 33 AA.
XX
AC AAW35030;
XX
DT 22-MAY-1998 (first entry)
XX
DE Water soluble beta-sheet forming peptide beta pep-13.
XX
KW Water soluble; beta-sheet; treatment; acute peritonitis; fever; shock;
KW bacterial infection; tumour.
XX
OS Synthetic.
XX
PN WO9744354-A2.
XX
PD 27-NOV-1997.
XX
PF 23-MAY-1997; 97WO-US008944.
XX
PR 24-MAY-1996; 96US-00653632.
PR 27-JUN-1996; 96US-00671487.
XX
PA (MINU) UNIV MINNESOTA.
XX
PI Gray BH, Haseman JR, Mayo K, Griffioen AW;
XX
DR WPI; 1998-018429/02.
XX
PT Synthesis of water soluble beta-sheet peptide - which neutralises
PT endotoxin, acts as bactericidal agent and inhibits TNF-alpha levels and
PT endothelial cell proliferation.
XX
PS Claim 21; Page 22; 60pp; English.
XX
CC Synthesising a water soluble peptide, e.g. the present peptide, where at
CC least 35% of its amino acids have hydrophobic side chains, comprises
CC combining amino acids with non-charged polar and charged side chains,
CC where the ratio of positively to negatively charged side chains is at
CC least about 2:1, with amino acids having hydrophobic side chains. A
CC peptide prepared using the above process is capable of neutralising
CC endotoxin, and is active as bactericidal agent. It may also be used to
CC inhibit tumour necrosis factor-alpha (TNF-alpha) levels and endothelial
CC cell proliferation and promote intercellular adhesion molecule (ICAM)
CC expression. The peptide may therefore be used to treat acute peritonitis,
CC fever, shock and bacterial infections. It may also be used to inhibit
CC angiogenesis, e.g. in treatment of tumours. The peptide is water soluble,
CC soluble under physiological conditions, forms beta-sheets and can self
CC associate
XX
SQ Sequence 33 AA;

Query Match 30.9%; Score 30; DB 2; Length 33;
Best Local Similarity 60.0%; Pred. No. 9e+02;
Matches 6; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 4 HLNSKIAFKI 13
|| || ||:
Db 15 HLKWKIIFKL 24

RESULT 91

```
ABM73359
ID   ABM73359 standard; protein; 34 AA.
XX
AC   ABM73359;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Staphylococcus aureus protein #2599.
XX
KW   Antibacterial; vaccine; gene therapy; infection; sepsis; diagnosis;
KW   enzymatic assay; antibiotic target.
XX
OS   Staphylococcus aureus.
XX
PN   WO200294868-A2.
XX
PD   28-NOV-2002.
XX
PF   27-MAR-2002; 2002WO-IB002637.
XX
PR   27-MAR-2001; 2001GB-00007661.
XX
PA   (CHIR-) CHIRON SPA.
XX
PI   Masignani V,  Mora M,  Scarselli M;
XX
DR   WPI; 2003-120786/11.
DR   N-PSDB; ACF74919.
XX
PT   New Staphylococcus aureus protein, useful as a vaccine for treating or
PT   preventing Staphylococcal infection, specifically an infection caused by
PT   S. aureus, e.g. sepsis.
XX
PS   Claim 1; SEQ ID NO 5198; 49pp; English.
XX
CC   The invention relates to novel genes and encoded proteins from
CC   Staphylococcus aureus. A composition comprising the S. aureus protein, a
CC   nucleic acid encoding the protein, or an antibody to the protein, is
CC   useful as a pharmaceutical, particularly as a vaccine for treating or
CC   preventing infection due to Staphylococcus bacteria, specifically an
CC   infection caused by S. aureus. The composition is particularly useful for
CC   treating or preventing sepsis in a patient. The composition can also be
CC   used for diagnostics. The protein is also used in an assay for enzymatic
CC   studies and as a target for antibiotics. This sequence represents one of
CC   the novel S. aureus proteins of the invention
XX
SQ   Sequence 34 AA;

  Query Match             30.9%;  Score 30;  DB 6;  Length 34;
  Best Local Similarity   46.7%;  Pred. No. 9.4e+02;
  Matches    7;  Conservative    1;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQ 16
              ||    | | ||: |
Db         15 PNIKTRKRALKIIKQ 29


RESULT 92
ABM74126
ID   ABM74126 standard; protein; 34 AA.
XX
AC   ABM74126;
XX
DT   17-OCT-2003  (first entry)
XX
DE   DNA clone originating in barley containing SNP sequence #536.
XX
KW   Barley; single nucleotide polymorphism; SNP; genotype-phenotype analysis.
XX
OS   Hordeum vulgare.
XX
PN   WO2003057877-A1.
XX
PD   17-JUL-2003.
XX
PF   16-DEC-2002; 2002WO-IB005403.
XX
PR   20-DEC-2001; 2001JP-00387059.
PR   20-DEC-2001; 2001JP-00387131.
PR   20-DEC-2001; 2001JP-00403299.
PR   20-DEC-2001; 2001JP-00403300.
PR   27-SEP-2002; 2002JP-00327515.
XX
PA   (UYNI-) UNIV JAPAN OKAYAMA.
XX
PI   Sato K,  Takeda K,  Kohara Y;
XX
DR   WPI; 2003-587127/55.
XX
PT   Single nucleotide polymorphism sites in barley varieties and DNA
PT   sequences containing them for analysis and identification of barley
PT   varieties and production of barley transformants with desired
PT   characteristics.
XX
PS   Disclosure; SEQ ID XX; 284pp; Japanese.
XX
CC   The present invention relates to oligonucleotide clones originating in
CC   barley (Hordeum vulgare) which contain single nucleotide polymorphisms
CC   (SNP). The oligonucleotides may be used for analysis of SNPs among barley
CC   varieties, identification of particular varieties and genotype-phenotype
CC   analysis, isolation of specific genes and creation of new varieties by
CC   transformation of barley varieties with them and production of new barley
CC   varieties with desired properties. The present sequence represents an
CC   oligonucleotide clone sequence featured in the specification. The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published-pct-sequences
XX
SQ   Sequence 34 AA;

  Query Match             30.9%;  Score 30;  DB 7;  Length 34;
  Best Local Similarity   45.5%;  Pred. No. 9.4e+02;
  Matches    5;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          7 SKIAFKIVSQE 17
              ||: | :| :|
Db          7 SKVLFSLVQEE 17


RESULT 93
ADL26414
ID   ADL26414 standard; peptide; 37 AA.
XX
AC   ADL26414;
XX
DT   17-JUN-2004  (first entry)
XX
DE   Synthetic peptide 1553 derived from a conserved region of HCV.
XX
KW   HCV; hepatitis C virus; virucide; vaccine; MHC; HLA;
KW   major histocompatibility complex; human leukocyte antigen.
XX
OS   Synthetic.
XX
PN   WO2004024182-A2.
XX
PD   25-MAR-2004.
XX
PF   27-AUG-2003; 2003WO-EP009482.
XX
PR   13-SEP-2002; 2002AT-00001376.
PR   27-FEB-2003; 2003WO-EP002005.
PR   11-JUL-2003; 2003EP-00450171.
XX
PA   (INTE-) INTERCELL AG.
XX
```

PI Buschle M, Habel A, Klade C, Mattner F, Otava O, Vytvytska O;
PI Zauner W, Zinke S, Kirlappos H;
XX
DR WPI; 2004-269899/25.
XX
PT Isolating Hepatitis C Virus peptides (HPs) which have a binding capacity
PT to a MHC/HLA molecule or a complex comprising the HCV-peptide and the
PT molecule by separating the complex from the HCV-peptides which do not
PT bind to the molecule.
XX
PS Example 1; Page 32; 73pp; English.
XX
CC The invention relates to a novel method for isolating Hepatitis C Virus
CC (HCV) peptides (HPs). The method of the invention has virucide activity,
CC and may be useful in producing a vaccine. The method is useful for
CC isolating Hepatitis C Virus peptides (HPs) which have a binding capacity
CC to a MHC/HLA molecule or a complex comprising the HCV-peptide and the
CC MHC/HLA molecule for preparing a vaccine against HCV infection. The T
CC cells, a T cell clone or a T cell population or preparation is useful for
CC identifying heteroclitic epitopes or for preparing a composition for
CC treating HCV infection. The present sequence represents a synthetic
CC peptide derived from a conserved region of HCV.
XX
SQ Sequence 37 AA;

Query Match 30.9%; Score 30; DB 8; Length 37;
Best Local Similarity 66.7%; Pred. No. 1e+03;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 9 IAFKIVSQE 17
:||||:| |
Db 29 VAFKIMSGE 37

RESULT 94
ADL26416
ID ADL26416 standard; peptide; 37 AA.
XX
AC ADL26416;
XX
DT 17-JUN-2004 (first entry)
XX
DE Synthetic peptide 1555 derived from a conserved region of HCV.
XX
KW HCV; hepatitis C virus; virucide; vaccine; MHC; HLA;
KW major histocompatibility complex; human leukocyte antigen.
XX
OS Synthetic.
XX
PN WO2004024182-A2.
XX
PD 25-MAR-2004.
XX
PF 27-AUG-2003; 2003WO-EP009482.
XX
PR 13-SEP-2002; 2002AT-00001376.
PR 27-FEB-2003; 2003WO-EP002005.
PR 11-JUL-2003; 2003EP-00450171.
XX
PA (INTE-) INTERCELL AG.
XX
PI Buschle M, Habel A, Klade C, Mattner F, Otava O, Vytvytska O;
PI Zauner W, Zinke S, Kirlappos H;
XX
DR WPI; 2004-269899/25.
XX
PT Isolating Hepatitis C Virus peptides (HPs) which have a binding capacity
PT to a MHC/HLA molecule or a complex comprising the HCV-peptide and the
PT molecule by separating the complex from the HCV-peptides which do not
PT bind to the molecule.
XX
PS Example 1; Page 32; 73pp; English.
XX
CC The invention relates to a novel method for isolating Hepatitis C Virus
CC (HCV) peptides (HPs). The method of the invention has virucide activity,
CC and may be useful in producing a vaccine. The method is useful for
CC isolating Hepatitis C Virus peptides (HPs) which have a binding capacity
CC to a MHC/HLA molecule or a complex comprising the HCV-peptide and the
CC MHC/HLA molecule for preparing a vaccine against HCV infection. The T
CC cells, a T cell clone or a T cell population or preparation is useful for
CC identifying heteroclitic epitopes or for preparing a composition for
CC treating HCV infection. The present sequence represents a synthetic
CC peptide derived from a conserved region of HCV.
XX
SQ Sequence 37 AA;

Query Match 30.9%; Score 30; DB 8; Length 37;
Best Local Similarity 66.7%; Pred. No. 1e+03;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 9 IAFKIVSQE 17
:||||:| |
Db 29 VAFKIMSGE 37

RESULT 95
AAW74948
ID AAW74948 standard; protein; 39 AA.
XX
AC AAW74948;
XX
DT 19-JAN-1999 (first entry)
XX
DE Human secreted protein encoded by gene 62 clone HATDT67.
XX
KW Human; secreted protein; testis; tumour; foetal brain tissue;
KW fusion protein; cancer; central nervous system; seizure; diagnosis;
KW neurodegenerative disease.
XX
OS Homo sapiens.
XX
PN WO9839448-A2.
XX
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98WO-US004493.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.

PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;
PI Bednarik DP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 1998-506364/43.
DR N-PSDB; AAV59732.
XX
PT New isolated human genes and the secreted polypeptide(s) they encode -
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX
PS Claim 1; Page 669; 721pp; English.
XX
CC This sequence represents a secreted human protein encoded by the nucleic
CC acid molecule designated Gene 62 from the human cDNA clone HATDT67
CC (deposited as clone ATCC 97900 and ATCC 209046). The gene can be used to
CC generate fusion proteins by linking to the gene to a human immunoglobulin
CC Fc portion (e.g. AAV59502) for increasing the stability of the fused
CC protein as compared to the human protein only. The invention relates to
CC 186 novel genes and their fragments (nucleic acid sequences: AAV59511-
CC V59812; amino acid sequences AAW74731-W75026) which are useful for
CC preventing, treating or ameliorating medical conditions e.g. by protein
CC or gene therapy. Also, pathological conditions can be diagnosed by
CC determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the 186 polynucleotides, based on
CC which tissues they are most highly expressed in (see AAV59511 for
CC described uses)
XX
SQ Sequence 39 AA;

Query Match 30.9%; Score 30; DB 2; Length 39;
Best Local Similarity 58.3%; Pred. No. 1.1e+03;
Matches 7; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

```
Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38
```

RESULT 96
AAG74232
ID AAG74232 standard; protein; 39 AA.
XX
AC AAG74232;
XX
DT 03-SEP-2001 (first entry)
XX
DE Human colon cancer antigen protein SEQ ID NO:4996.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW colorectal carcinoma.
XX
OS Homo sapiens.
XX
PN WO200122920-A2.
XX
PD 05-APR-2001.
XX
PF 28-SEP-2000; 2000WO-US026524.
XX
PR 29-SEP-1999; 99US-0157137P.
PR 03-NOV-1999; 99US-0163280P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Birse CE, Rosen CA;
XX
DR WPI; 2001-235357/24.
DR N-PSDB; AAH33663.
XX

PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT useful for preventing, diagnosing and/or treating colorectal cancers.
XX
PS Claim 11; Page 6739-6740; 9803pp; English.
XX
CC AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC cancer-associated nucleic acid molecules (N) and proteins (P), where the
CC proteins are collectively known as colon cancer antigens. The colon
CC cancer antigens have cytostatic activity and can be used in gene therapy
CC and vaccine production. N and P may be used in the prevention, diagnosis
CC and treatment of diseases associated with inappropriate P expression. For
CC example, N and P may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of P by expressing inactive proteins or to
CC supplement the patients own production of P. Additionally, N may be used
CC to produce the colon cancer-associated Ps, by inserting the nucleic acids
CC into a host cell and culturing the cell to express the proteins. N and P
CC can be used in the prevention, diagnosis and treatment of colorectal
CC carcinomas and cancers. AAH37196 to AAH37204 and AAB77789 represent
CC sequences used in the exemplification of the present invention. N.B.
CC Pages 666 to 682 and page 7053 of the sequence listing were missing at
CC time of publication, meaning no sequences are present for SEQ ID NO:1027
CC to 1052, 7921 and 7922
XX
SQ Sequence 39 AA;

Query Match 30.9%; Score 30; DB 4; Length 39;
Best Local Similarity 42.9%; Pred. No. 1.1e+03;
Matches 6; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

```
Qy          1 EPNHLNSKIAFKIV 14
              :|::|| |:   ||
Db         19 KPHYLNIKLPNNIV 32
```

RESULT 97
ABG95405
ID ABG95405 standard; protein; 39 AA.
XX
AC ABG95405;
XX
DT 15-JAN-2003 (first entry)
XX
DE Human novel secreted protein #226.
XX
KW Human; secreted protein; autoimmune disease; chemotaxis;
KW rheumatoid arthritis; hyperproliferative disorder; breast neoplasm;
KW liver neoplasm cardiovascular disorder; cardiac arrest; skin aging;
KW cerebrovascular disorder; cerebral ischaemia; angiogenesis; sunburn;
KW nervous system disorders; Alzheimer's disease; infection;
KW ocular disorder; corneal infection; wound healing; tissue regeneration;
KW epithelial cell proliferation; organ transplantation; food additive;
KW preservative; nutritional.
XX
OS Homo sapiens.
XX
PN US6420526-B1.
XX
PD 16-JUL-2002.
XX
PF 08-SEP-1998; 98US-00149476.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.

```
PR   22-AUG-1997;   97US-0056887P.
PR   22-AUG-1997;   97US-0056888P.
PR   22-AUG-1997;   97US-0056889P.
PR   22-AUG-1997;   97US-0056892P.
PR   22-AUG-1997;   97US-0056893P.
PR   22-AUG-1997;   97US-0056894P.
PR   22-AUG-1997;   97US-0056903P.
PR   22-AUG-1997;   97US-0056908P.
PR   22-AUG-1997;   97US-0056909P.
PR   22-AUG-1997;   97US-0056910P.
PR   22-AUG-1997;   97US-0056911P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057669P.
PR   05-SEP-1997;   97US-0057761P.
PR   12-SEP-1997;   97US-0058785P.
PR   02-OCT-1997;   97US-0061060P.
PR   06-MAR-1998;   98WO-US004493.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Rosen CA,  Fischer CL,  Soppet DP,  Carter KC;
PI   Bednarik DR,  Endress GA,  Yu G,  Ni J,  Feng P,  Young PE,  Greene JM;
PI   Ferrie AM,  Duan R,  Hu J,  Florence KA,  Olsen HS,  Ebner R,  Brewer LA;
PI   Moore PA,  Shi Y,  Lafleur DW,  Li Y,  Zeng Z,  Kyaw H;
XX
DR   WPI; 2002-634796/68.
DR   N-PSDB; ABS73723.
XX
PT   New isolated human secreted protein for diagnosing, preventing, treating
PT   or ameliorating medical conditions and used as a food additive or
PT   preservative.
XX
PS   Example 1; SEQ ID NO 545; 129pp; English.
XX
CC   The invention relates to an isolated protein that is one of 186 human
CC   secreted proteins, given in the specification, encoded by one of 309 cDNA
CC   sequences also given in the specification. The protein is used in a
CC   pharmaceutical composition used to prevent, treat or ameliorate a medical
CC   condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs,
CC   chickens or sheep. Disorders which are diagnosed or treated include
CC   autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC   disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC   e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC   angiogenesis, nervous system disorders e.g. Alzheimer's disease,
CC   infections caused by bacteria, viruses and fungi and ocular disorders
CC   e.g. corneal infection. The polypeptides can also be used to aid wound
CC   healing and epithelial cell proliferation, to prevent skin aging due to
CC   sunburn, to maintain organs before transplantation, for supporting cell
CC   culture of primary tissues, to regenerate tissues and in chemotaxis. The
CC   polypeptides can also be used as a food additive or preservative to
CC   increase or decrease storage capabilities, fat content, lipid, protein,
CC   carbohydrate, vitamins, minerals, cofactors and other nutritional
CC   components. The present sequence represents one of the novel human
CC   secreted proteins of the invention. Note: This sequence did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from USPTO at seqdata.uspto.gov/sequence.html?DocID=6420526B1
XX
SQ   Sequence 39 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 39;
  Best Local Similarity   58.3%;  Pred. No. 1.1e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38


RESULT 98
AAU88730
ID   AAU88730 standard; peptide; 39 AA.
XX
AC   AAU88730;
XX
DT   18-JUN-2002  (first entry)
XX
DE   Insulin/insulin-like growth factor receptor-binding peptide #686.
XX
KW   Cytostatic; antidiabetic; neuroprotective; cerebroprotective;
KW   ophthalmological; insulin; receptor; gene therapy; diabetes;
KW   insulin-like growth factor-1; IGF-1; tumour; prostate; breast;
KW   diabetic retinopathy; neurological diseases; stroke; diabetic neuropathy.
XX
OS   Synthetic.
XX
PN   WO200172771-A2.
XX
PD   04-OCT-2001.
XX
PF   29-MAR-2000; 2000WO-US008528.
XX
PR   29-MAR-2000; 2000WO-US008528.
XX
PA   (DGIB-) DGI BIOTECHNOLOGIES LLC.
PA   (NOVO ) NOVO NORDISK AS.
XX
PI   Beasley J,  Blume AJ,  Schaeffer L,  Pillutla R,  Brandt J;
PI   Brissette R,  Spetzler J,  Cheng W,  Ostergaard S,  Mandecki WS;
PI   Hansen PH,  Ravera M,  Hsiao K;
XX
DR   WPI; 2002-025774/03.
XX
PT   Modulating insulin activity in mammalian cells, for treating e.g.
PT   diabetes and tumors, comprises using peptides that bind to insulin or
PT   insulin-like growth factor receptors.
XX
PS   Disclosure; Fig 1G-2; 390pp; English.
XX
CC   The invention relates to a method of modulating insulin activity in
CC   mammalian cells by administering a peptide that binds the insulin
CC   receptor (IR). A composition containing a peptide, optionally expressed
CC   from gene therapy vectors, that binds to Site 1 of IR and an insulin
CC   agonist are useful for treating diabetes. Also, peptides that are
CC   antagonists of the insulin-like growth factor-1 (IGF-1) receptor are
CC   useful for treating insulin-like growth factor (IGF)-sensitive tumours
CC   (e.g. of prostate and breast) and diabetic retinopathy, while IGF-1
CC   receptor agonists are useful for treating neurological diseases,
CC   including stroke and diabetic neuropathy. The peptides are also useful in
CC   screening for compounds that bind to IR or IGF-1 receptor, potential
CC   therapeutics and research reagents. AAU88034-AAU90957 represent IR and/or
CC   IGF-1 receptor-binding peptides and related amino acid sequences of the
CC   invention
XX
SQ   Sequence 39 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 39;
  Best Local Similarity   60.0%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         10 AFKIVSQEPA 19
              | |:||: ||
Db         14 ASKVVSEPPA 23


RESULT 99
ADA03571
ID   ADA03571 standard; peptide; 39 AA.
XX
AC   ADA03571;
XX
DT   06-NOV-2003  (first entry)
XX
DE   Insulin receptor (IR) related Formula 1 motif peptide SEQ ID NO:202.
XX
KW   insulin-like growth factor receptor; IGFR; modulate; insulin receptor;
KW   IR; insulin; cytostatic; IGFR agonist; IGFR antagonist; cancer;
```

```
KW   leukaemia; sarcoma; lymphoma; carcinoma.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003027246-A2.
XX
PD   03-APR-2003.
XX
PF   24-SEP-2002; 2002WO-US030412.
XX
PR   24-SEP-2001; 2001US-00962756.
XX
PA   (NOVO ) NOVO NORDISK AS.
PA   (DGIB-) DGI BIOTECHNOLOGIES.
XX
PI   Pillutla R, Dedova O, Blume AJ, Goldstein NI, Brissette R;
PI   Wang P, Liu H, Hsiao K, Lennick M, Fletcher P;
XX
DR   WPI; 2003-363211/34.
XX
PT   Modulating insulin-like growth factor receptor (IGFR) activity in IGF-
PT   responsive mammalian cells, useful for treating cancer comprises
PT   contacting the cells with an amino acid sequence to modulate the activity
PT   of IGFR.
XX
PS   Disclosure; Fig 1G; 372pp; English.
XX
CC   The present invention describes a method for modulating insulin-like
CC   growth factor receptor (IGFR) activity in insulin-like growth factor-
CC   responsive mammalian cells comprising contacting the cells with an amino
CC   acid sequence to modulate the activity of IGFR. In modulating IGFR
CC   activity, the amino acid sequence comprises X1X2X3X4X5 (I), where X1, X2
CC   and X5 = phenylalanine or tyrosine; X3 = aspartic acid, glutamic acid,
CC   glycine or serine; and X4 = tryptophan, tyrosine or phenylalanine. The
CC   amino acid sequence is not insulin, insulin-like growth factor, an anti-
CC   insulin receptor antibody, an anti-insulin-like growth receptor antibody,
CC   or its fragment. Also described: (1) decreasing or increasing IGFR
CC   activity in IGF-responsive mammalian cells by contacting the cells with
CC   an amino acid sequence to decrease or increase the activity of IGFR; (2)
CC   an IGFR modulator, agonist or antagonist; (3) identifying IGFR modulator;
CC   and (4) enhancing survival of an IGF-responsive mammalian cell by
CC   contacting the cell with (I) to enhance the survival of the cell. IGFR
CC   modulators have cytostatic activity, and can be used as IGFR agonists or
CC   IGFR antagonists. The methods, modulators, agonists and antagonists are
CC   useful for treating cancer, e.g. leukaemia, sarcoma, lymphoma or
CC   carcinoma. The methods are useful for identifying molecular structures
CC   that are capable of acting as an IGFR agonist or antagonist. The present
CC   sequence represents a peptide given in the exemplification of the present
CC   invention.
XX
SQ   Sequence 39 AA;

  Query Match             30.9%;  Score 30;  DB 6;  Length 39;
  Best Local Similarity   60.0%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         10 AFKIVSQEPA 19
              | |:||: ||
Db         14 ASKVVSEPPA 23


RESULT 100
ABO34599
ID   ABO34599 standard; protein; 39 AA.
XX
AC   ABO34599;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Region of human secreted protein encoded by cDNA sequence #226.
XX
KW   Human; secreted protein; hyperproliferative disorder; leukaemia;
KW   breast cancer; wound; reproductive disorder; blood-related disorder;
KW   haemophilia; thrombocytopaenia; immunodeficiency; thymic hypoplasia;
KW   Wiskott-Aldrich syndrome; autoimmune disorder; multiple sclerosis;
KW   graft-versus-host disease; Hashimoto's thyroiditis; allergy; asthma;
KW   viral infection; bacterial infection; fungal infection; AIDS; sepsis;
KW   renal disorder; kidney failure; cardiovascular disorder; cytostatic;
KW   angina pectoris; cerebral ischaemia; congenital heart defect;
KW   respiratory disorder; neurological disorder; Alzheimer's disease;
KW   Parkinson's disease; inflammation; Crohn's disease; vulnerary;
KW   immunosuppressive; antibacterial; haemostatic; thrombolytic;
KW   anticoagulant; neuroprotective; thyromimetic; antiallergic;
KW   antiasthmatic; virucide; fungicide; anti-HIV; nephrotropic; antianginal;
KW   cerebroprotective; cardiant; nootropic; antiparkinsonian;
KW   antiinflammatory.
XX
OS   Homo sapiens.
XX
PN   US2003049618-A1.
XX
PD   13-MAR-2003.
XX
PF   16-MAR-2001; 2001US-00809391.
XX
PR   07-MAR-1997;   97US-0038621P.
PR   07-MAR-1997;   97US-0040162P.
PR   07-MAR-1997;   97US-0040163P.
PR   07-MAR-1997;   97US-0040333P.
PR   07-MAR-1997;   97US-0040334P.
PR   07-MAR-1997;   97US-0040336P.
PR   07-MAR-1997;   97US-0040626P.
PR   11-APR-1997;   97US-0043311P.
PR   11-APR-1997;   97US-0043312P.
PR   11-APR-1997;   97US-0043313P.
PR   11-APR-1997;   97US-0043314P.
PR   11-APR-1997;   97US-0043315P.
PR   11-APR-1997;   97US-0043568P.
PR   11-APR-1997;   97US-0043569P.
PR   11-APR-1997;   97US-0043576P.
PR   11-APR-1997;   97US-0043578P.
PR   11-APR-1997;   97US-0043580P.
PR   11-APR-1997;   97US-0043669P.
PR   11-APR-1997;   97US-0043670P.
PR   11-APR-1997;   97US-0043671P.
PR   11-APR-1997;   97US-0043672P.
PR   11-APR-1997;   97US-0043674P.
PR   23-MAY-1997;   97US-0047492P.
PR   23-MAY-1997;   97US-0047500P.
PR   23-MAY-1997;   97US-0047501P.
PR   23-MAY-1997;   97US-0047502P.
PR   23-MAY-1997;   97US-0047503P.
PR   23-MAY-1997;   97US-0047581P.
PR   23-MAY-1997;   97US-0047582P.
PR   23-MAY-1997;   97US-0047583P.
PR   23-MAY-1997;   97US-0047584P.
PR   23-MAY-1997;   97US-0047585P.
PR   23-MAY-1997;   97US-0047586P.
PR   23-MAY-1997;   97US-0047587P.
PR   23-MAY-1997;   97US-0047588P.
PR   23-MAY-1997;   97US-0047589P.
PR   23-MAY-1997;   97US-0047590P.
PR   23-MAY-1997;   97US-0047592P.
PR   23-MAY-1997;   97US-0047593P.
PR   23-MAY-1997;   97US-0047594P.
PR   23-MAY-1997;   97US-0047595P.
PR   23-MAY-1997;   97US-0047596P.
PR   23-MAY-1997;   97US-0047597P.
PR   23-MAY-1997;   97US-0047598P.
PR   23-MAY-1997;   97US-0047599P.
PR   23-MAY-1997;   97US-0047600P.
PR   23-MAY-1997;   97US-0047601P.
PR   23-MAY-1997;   97US-0047612P.
PR   23-MAY-1997;   97US-0047613P.
PR   23-MAY-1997;   97US-0047614P.
```

```
PR   23-MAY-1997;   97US-0047615P.
PR   23-MAY-1997;   97US-0047617P.
PR   23-MAY-1997;   97US-0047618P.
PR   23-MAY-1997;   97US-0047632P.
PR   23-MAY-1997;   97US-0047633P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048974P.
PR   13-JUN-1997;   97US-0049610P.
PR   08-JUL-1997;   97US-0051926P.
PR   16-JUL-1997;   97US-0052874P.
PR   18-AUG-1997;   97US-0055724P.
PR   22-AUG-1997;   97US-0056630P.
PR   22-AUG-1997;   97US-0056631P.
PR   22-AUG-1997;   97US-0056632P.
PR   22-AUG-1997;   97US-0056636P.
PR   22-AUG-1997;   97US-0056637P.
PR   22-AUG-1997;   97US-0056662P.
PR   22-AUG-1997;   97US-0056664P.
PR   22-AUG-1997;   97US-0056845P.
PR   22-AUG-1997;   97US-0056862P.
PR   22-AUG-1997;   97US-0056864P.
PR   22-AUG-1997;   97US-0056872P.
PR   22-AUG-1997;   97US-0056874P.
PR   22-AUG-1997;   97US-0056875P.
PR   22-AUG-1997;   97US-0056876P.
PR   22-AUG-1997;   97US-0056877P.
PR   22-AUG-1997;   97US-0056878P.
PR   22-AUG-1997;   97US-0056879P.
PR   22-AUG-1997;   97US-0056880P.
PR   22-AUG-1997;   97US-0056881P.
PR   22-AUG-1997;   97US-0056882P.
PR   22-AUG-1997;   97US-0056884P.
PR   22-AUG-1997;   97US-0056886P.
PR   22-AUG-1997;   97US-0056887P.
PR   22-AUG-1997;   97US-0056888P.
PR   22-AUG-1997;   97US-0056889P.
PR   22-AUG-1997;   97US-0056892P.
PR   22-AUG-1997;   97US-0056893P.
PR   22-AUG-1997;   97US-0056894P.
PR   22-AUG-1997;   97US-0056903P.
PR   22-AUG-1997;   97US-0056908P.
PR   22-AUG-1997;   97US-0056909P.
PR   22-AUG-1997;   97US-0056910P.
PR   22-AUG-1997;   97US-0056911P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057669P.
PR   05-SEP-1997;   97US-0057761P.
PR   12-SEP-1997;   97US-0058785P.
PR   09-OCT-1997;   97US-0061660P.
PR   06-MAR-1998;   98WO-US004493.
PR   08-SEP-1998;   98US-00149476.
PR   17-MAR-2000; 2000US-0190068P.
XX
PA   (RUBE/) RUBEN S M.
PA   (ROSE/) ROSEN C A.
PA   (SOPP/) SOPPET D R.
PA   (CART/) CARTER K C.
PA   (BEDN/) BEDNARIK D P.
PA   (ENDR/) ENDRESS G A.
PA   (YUGG/) YU G.
PA   (NIJJ/) NI J.
PA   (FENG/) FENG P.
PA   (YOUN/) YOUNG P E.
PA   (GREE/) GREENE J M.
PA   (FERR/) FERRIE A M.
PA   (DUAN/) DUAN D R.
PA   (HUJJ/) HU J.
PA   (FLOR/) FLORENCE K A.
PA   (OLSE/) OLSEN H S.
PA   (FISC/) FISCHER C L.
PA   (EBNE/) EBNER R.
PA   (BREW/) BREWER L A.
PA   (MOOR/) MOORE P A.
PA   (SHIY/) SHI Y.
PA   (LAFL/) LAFLEUR D W.
PA   (LIYY/) LI Y.
PA   (ZENG/) ZENG Z.
PA   (KYAW/) KYAW H.
XX
PI   Ruben SM,  Rosen CA,  Soppet DR,  Carter KC,  Bednarik DP;
PI   Endress GA,  Yu G,  Ni J,  Feng P,  Young PE,  Greene JM,  Ferrie AM;
PI   Duan DR,  Hu J,  Florence KA,  Olsen HS,  Fischer CL,  Ebner R;
PI   Brewer LA,  Moore PA,  Shi Y,  Lafleur DW,  Li Y,  Zeng Z,  Kyaw H;
XX
DR   WPI; 2003-521800/49.
DR   N-PSDB; ACD82866.
XX
PT   New genes and its encoded prostate cancer antigen proteins, useful for
PT   preventing, treating, ameliorating or diagnosing e.g. prostate cancers,
PT   thymic hypoplasia, multiple sclerosis, AIDS, angina pectoris or cerebral
PT   ischemia.
XX
PS   Claim 3; SEQ ID NO 545; 260pp; English.
XX
CC   The present invention relates to the isolation of novel human secreted
CC   proteins and the polynucleotide sequences encoding them. The invention
CC   also discloses vectors, host cells, antibodies, and recombinant methods
CC   for producing human secreted proteins. The polypeptide and polynucleotide
CC   sequences for the secreted proteins are useful for preventing, treating,
CC   ameliorating or diagnosing medical conditions such as hyperproliferative
CC   disorders (e.g. leukaemia or breast cancers), wounds, reproductive
CC   disorders, blood-related disorders (e.g. haemophilia or
CC   thrombocytopaenia), immunodeficiencies (e.g. Wiskott-Aldrich syndrome or
CC   thymic hypoplasia), autoimmune disorders (e.g. graft-versus-host disease,
CC   multiple sclerosis or Hashimoto's thyroiditis), allergies (e.g. asthma),
CC   viral or bacterial or fungal infections (e.g. AIDS or sepsis), renal
CC   disorders (e.g. kidney failure), cardiovascular disorders (e.g. angina
CC   pectoris, cerebral ischaemia or congenital heart defects), respiratory
CC   disorders, neurological disorders (e.g. Alzheimer's disease or
CC   Parkinson's disease), and inflammations (e.g. Crohn's disease). The
CC   polynucleotide or polypeptide may also be used as vaccine adjuvants.
CC   ABO34374-ABO34815 represent human secreted proteins or their fragments.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from the
CC   USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ   Sequence 39 AA;

  Query Match             30.9%;  Score 30;  DB 6;  Length 39;
  Best Local Similarity   58.3%;  Pred. No. 1.1e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38


RESULT 101
ADH94784
ID   ADH94784 standard; protein; 39 AA.
XX
AC   ADH94784;
XX
DT   22-APR-2004  (first entry)
XX
DE   Insulin receptor motif polypeptide, SEQ ID No 202.
XX
KW   insulin receptor; insulin; insulin-like growth factor receptor; agonist;
KW   antagonist; antidiabetic; diabetes; insulin shock.
XX
OS   Unidentified.
XX
PN   WO2003070747-A2.
XX
PD   28-AUG-2003.
XX
```

PF 24-SEP-2002; 2002WO-US030312.
XX
PR 24-SEP-2001; 2001US-00962756.
XX
PA (NOVO) NOVO NORDISK AS.
PA (DGIB-) DGI BIOTECHNOLOGIES.
XX
PI Pillutla R, Brissette R, Blume AJ, Schaeffer L, Brandt J;
PI Goldstein NI, Spetzler J, Ostergaard S;
XX
DR WPI; 2003-833235/77.
XX
PT Modulating insulin-like growth factor receptor (IGFR) activity in IGF-
PT responsive mammalian cells, useful for treating diabetes comprises
PT contacting the cells with an amino acid sequence to modulate the activity
PT of IGFR.
XX
PS Claim 7; SEQ ID NO 202; 328pp; English.
XX
CC The invention relates to a novel method for decreasing or increasing
CC insulin receptor activity in mammalian cells. The invention further
CC relates to peptide sequences capable of binding to insulin and/or insulin
CC -like growth factor receptors with either agonist or antagonist activity.
CC The peptide sequences are identified from various peptide libraries. The
CC novel method comprises administering to the mammalian cells an amino acid
CC having subsequences that binds to site 1 and site 2 of an insulin
CC receptor. The subsequences are joined C-terminus to N-terminus and
CC oriented site 1 to site 2. The sequence is not insulin or insulin-like
CC growth factor. The peptide sequences of the invention have antidiabetic
CC activity. The peptides are useful for treating diabetes or insulin shock.
CC This sequence represents an insulin receptor/ insulin growth factor
CC receptor binding polypeptide relating to the invention.
XX
SQ Sequence 39 AA;

Query Match 30.9%; Score 30; DB 7; Length 39;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 6; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 10 AFKIVSQEPA 19
| |:||: ||
Db 14 ASKVVSEPPA 23

RESULT 102
ADI23260
ID ADI23260 standard; protein; 39 AA.
XX
AC ADI23260;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted protein seq id 545.
XX
KW cytostatic; gene therapy; cancer; human; secreted protein.
XX
OS Homo sapiens.
XX
PN US2003175858-A1.
XX
PD 18-SEP-2003.
XX
PF 18-JUN-2001; 2001US-00882171.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.

PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 09-OCT-1997; 97US-0061660P.
PR 06-MAR-1998; 98WO-US004493.
PR 08-SEP-1998; 98US-00149476.
PR 17-MAR-2000; 2000US-0190068P.
PR 16-MAR-2001; 2001US-00809391.
XX
PA (RUBE/) RUBEN S M.
PA (ROSE/) ROSEN C A.
PA (SOPP/) SOPPET D R.
PA (CART/) CARTER K C.
PA (BEDN/) BEDNARIK D P.
PA (ENDR/) ENDRESS G A.
PA (YUGG/) YU G.
PA (NIJJ/) NI J.
PA (FENG/) FENG P.
PA (YOUN/) YOUNG P E.
PA (GREE/) GREENE J M.
PA (FERR/) FERRIE A M.
PA (DUAN/) DUAN D R.
PA (HUJJ/) HU J.
PA (FLOR/) FLORENCE K A.
PA (OLSE/) OLSEN H S.
PA (FISC/) FISCHER C L.
PA (EBNE/) EBNER R.
PA (BREW/) BREWER L A.
PA (MOOR/) MOORE P A.
PA (SHIY/) SHI Y.
PA (LAFL/) LAFLEUR D W.
PA (LIYY/) LI Y.
PA (ZENG/) ZENG Z.
PA (KYAW/) KYAW H.
XX
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 2003-898535/82.
DR N-PSDB; ADI22951.
XX
PT New nucleic acid molecule, useful for preparing a medicament for
PT diagnosing, preventing, treating or ameliorating a medical condition
PT e.g., cancer.
XX
PS Claim 11; SEQ ID NO 545; 256pp; English.
XX
CC The invention describes an isolated nucleic acid comprising a sequence
CC having 95 % identity with: a polynucleotide fragment of a sequence not
CC given in the specification, or its allelic variant; a polynucleotide
CC fragment of the cDNA sequence; a polynucleotide sequence encoding a
CC polypeptide, or its fragment, domain, epitope or species homologue; or a
CC polynucleotide that hybridises under stringent conditions to any one of
CC the sequences of (a)-(c). The nucleic acid is useful for preparing a
CC medicament for diagnosing, preventing, treating or ameliorating a medical
CC condition e.g., cancer. The is the amino acid sequence of a novel human
CC secreted protein of the invention.
XX

SQ Sequence 39 AA;

Query Match 30.9%; Score 30; DB 7; Length 39;
Best Local Similarity 58.3%; Pred. No. 1.1e+03;
Matches 7; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIV 14
||| :| | ||
Db 27 NHLAFRILFFIV 38

RESULT 103
ADH74262
ID ADH74262 standard; protein; 39 AA.
XX
AC ADH74262;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human secreted protein #226.
XX
KW human; secreted protein; cancer; haematopoietic disorder;
KW endocrine disorder; immune system disease; inflammatory disorder.
XX
OS Homo sapiens.
XX
PN US2003225248-A1.
XX
PD 04-DEC-2003.
XX
PF 10-JUN-2002; 2002US-00164861.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.

PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
PR 06-MAR-1998; 98WO-US004493.
PR 08-SEP-1998; 98US-00149476.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
PI Duan R, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 2004-131264/13.
DR N-PSDB; ADH73953.
XX
PT Isolated nucleic acid molecules encoding human secreted proteins, useful
PT for preventing, diagnosing and treating disorders associated with
PT aberrant expression and activity.
XX
PS Claim 11; SEQ ID NO 545; 142pp; English.
XX
CC The invention relates to isolated nucleic acid molecules and the human
CC secreted proteins (SPs) they encode. The proteins and nucleic acids may
CC be used in the prevention, diagnosis and treatment of diseases associated
CC with inappropriate SP expression e.g. cancer, haematopoietic disorders,
CC endocrine disorders, diseases of the immune system, inflammatory
CC disorders and many others. Full details of disorders that may be
CC prevented, diagnosed and/or treated by the above methods are given in the
CC specification. The nucleic acid molecules may be used to produce their
CC proteins. The nucleic acid and it's complementary sequences may also be
CC used as DNA probes in diagnostic assays to detect and quantitate the
CC presence of similar nucleic acids in samples, and therefore which
CC patients may be in need of restorative therapy. The SPs may also be used
CC as antigens in the production of antibodies against the proteins and in
CC assays to identify modulators of SP expression and activity. The anti-SP
CC antibodies and antagonists may also be used to down regulate expression
CC and activity. The anti-SP antibodies may also be used as diagnostic
CC agents for detecting the presence of the proteins in samples (e.g. by
CC enzyme linked immunosorbant assay (ELISA)). The present sequence
CC represents the amino acid sequence of a human secreted protein.
XX
SQ Sequence 39 AA;

Query Match 30.9%; Score 30; DB 8; Length 39;
Best Local Similarity 58.3%; Pred. No. 1.1e+03;
Matches 7; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIV 14
||| :| | ||
Db 27 NHLAFRILFFIV 38

RESULT 104
ADL67475
ID ADL67475 standard; peptide; 39 AA.
XX
AC ADL67475;
XX
DT 20-MAY-2004 (first entry)
XX
DE IGF-1R/IR binding peptide seq id 202.
XX
KW cytostatic; insulin-like growth factor receptor activity;
KW insulin-like growth factor-responsive mammalian cell;
KW insulin-like growth factor receptor modulator;
KW insulin-like growth factor receptor antagonist;
KW insulin-like growth factor receptor agonist; insulin receptor;
KW insulin-like growth factor receptor; therapeutic; peptide hormone;
KW cancer; breast cancer; prostate cancer; colorectal cancer;
KW ovarian cancer; peptide library; IGF-1R; IR.
XX
OS Unidentified.
XX
PN US2004023887-A1.
XX
PD 05-FEB-2004.
XX
PF 24-SEP-2002; 2002US-00253493.
XX
PR 02-SEP-1998; 98US-00146127.
PR 29-MAR-2000; 2000US-00538038.
PR 24-SEP-2001; 2001US-00962756.
XX
PA (PILL/) PILLUTLA R.
PA (DEDO/) DEDOVA O.
PA (BLUM/) BLUME A J.
PA (GOLD/) GOLDSTEIN N I.
PA (BRIS/) BRISSETTE R.
PA (WANG/) WANG P.

PA (LIUH/) LIU H.
PA (HSIA/) HSIAO K.
PA (LENN/) LENNICK M.
PA (FLET/) FLETCHER P.
XX
PI Pillutla R, Dedova O, Blume AJ, Goldstein NI, Brissette R;
PI Wang P, Liu H, Hsiao K, Lennick M, Fletcher P;
XX
DR WPI; 2004-132606/13.
XX
PS Disclosure; SEQ ID NO 202; 242pp; English.
XX
CC The invention describes the use of molecular structures, preferably
CC peptides for modulating, increasing or decreasing insulin-like growth
CC factor receptor activity in insulin-like growth factor-responsive
CC mammalian cells. Also described are: modulating, decreasing or increasing
CC insulin-like growth factor receptor activity in insulin-like growth
CC factor-responsive mammalian cells; an insulin-like growth factor receptor
CC modulator; an insulin-like growth factor receptor antagonist; an insulin-
CC like growth factor receptor agonist; identifying an insulin-like growth
CC factor receptor modulator; and enhancing survival of an insulin-like
CC growth factor-responsive mammalian cell. The molecular structures of the
CC peptides are useful for modulating, increasing or decreasing insulin-like
CC growth factor receptor activity in insulin-like growth factor-responsive
CC mammalian cells. The peptide sequences are useful for binding to insulin
CC and/or insulin-like growth factor receptors with either agonist or
CC antagonist activity. As agonists, the peptides are useful for development
CC of therapeutics to supplement or replace endogenous peptide hormones. The
CC antagonist peptides can also be developed as therapeutics. The IR and IGF
CC -1R agonist and antagonist peptides are useful as lead compounds for
CC identifying other more potent or selective therapeutics, assay reagents
CC for identifying other useful ligands, as research tools for further
CC analysis of IR and IGF-1R. The IGF-1R antagonists are useful as treatment
CC for cancer, e.g. breast, prostate, colorectal or ovarian cancer. This is
CC the amino acid sequence of a IGF-1R/IR binding peptide obtained by
CC panning a peptide library against the insulin-like growth factor 1
CC receptor (IGF-1R) and insulin receptor (IR). Note: This sequence is also
CC available in electronic format from the US patent office at
CC ftp.seqdata.uspto.gov/sequence.html?DocID=20040023887.
XX
SQ Sequence 39 AA;

Query Match 30.9%; Score 30; DB 8; Length 39;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 6; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 10 AFKIVSQEPA 19
| |:||: ||
Db 14 ASKVVSEPPA 23

RESULT 105
ADM37320
ID ADM37320 standard; peptide; 39 AA.
XX
AC ADM37320;
XX
DT 03-JUN-2004 (first entry)
XX
DE Anti-IR formula 1 motif peptide #125.
XX
KW insulin receptor activity; insulin-related disease;
KW insulin-like growth factor-related disease; diabetes; insulin shock.
XX
OS Synthetic.
XX
PN US2003236190-A1.
XX
PD 25-DEC-2003.
XX
PF 24-SEP-2002; 2002US-00253471.
XX
PR 02-SEP-1998; 98US-00146127.
PR 29-MAR-2000; 2000US-00538038.
PR 24-SEP-2001; 2001US-00962756.
XX
PA (PILL/) PILLUTLA R.
PA (BRIS/) BRISSETTE R.
PA (BLUM/) BLUME A J.
PA (SCHA/) SCHAFFER L.
PA (BRAN/) BRANDT J.
PA (GOLD/) GOLDSTEIN N I.
PA (SPET/) SPETZLER J.
PA (OSTE/) OSTERGAARD S.
PA (HANS/) HANSEN P H.
XX
PI Pillutla R, Brissette R, Blume AJ, Schaffer L, Brandt J;
PI Goldstein NI, Spetzler J, Ostergaard S, Hansen PH;
XX
DR WPI; 2004-081583/08.
XX
PT Decreasing or increasing insulin receptor activity in mammalian cells
PT using peptide sequences that bind insulin and/or insulin-like growth
PT factor receptors, useful for treating diabetes and insulin shock.
XX
PS Claim 7; SEQ ID NO 202; 203pp; English.
XX
CC The invention relates to a method of decreasing insulin receptor activity
CC in mammalian cells which comprises administering an amino acid sequence
CC having a subsequence comprising a sequence that binds to Site 1 and Site
CC 2 of insulin receptor, where the subsequences are linked C-terminus to N-
CC terminus and oriented Site 1 to Site 2, where the amino acid sequence is
CC not insulin, insulin-like growth factor or their fragments. The methods
CC and compositions of the present invention are useful for treating insulin
CC - or insulin-like growth factor-related diseases or conditions, such as
CC diabetes and insulin shock. The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 39 AA;

Query Match 30.9%; Score 30; DB 8; Length 39;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 6; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 10 AFKIVSQEPA 19
| |:||: ||
Db 14 ASKVVSEPPA 23

RESULT 106
AAW74791
ID AAW74791 standard; protein; 40 AA.
XX
AC AAW74791;
XX
DT 25-JAN-1999 (first entry)
XX
DE Human secreted protein encoded by gene 62 clone HATDT67.
XX
KW Human; secreted protein; testis; tumour; foetal brain tissue;
KW fusion protein; cancer; central nervous system; seizure; diagnosis;
KW neurodegenerative disease.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 40
FT /label= unknown
XX
PN WO9839448-A2.
XX
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98WO-US004493.
XX
PR 07-MAR-1997; 97US-0038621P.

PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;
PI Bednarik DP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 1998-506364/43.
DR N-PSDB; AAV59572.
XX
PT New isolated human genes and the secreted polypeptide(s) they encode -
PT useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders.
XX
PS Claim 1; Page 577; 721pp; English.
XX
CC This sequence represents a secreted human protein encoded by the nucleic
CC acid molecule designated Gene 62 from the human cDNA clone HATDT67
CC (deposited as clone ATCC 97900 and ATCC 209046). The gene can be used to
CC generate fusion proteins by linking to the gene to a human immunoglobulin
CC Fc portion (e.g. AAV59502) for increasing the stability of the fused
CC protein as compared to the human protein only. The invention relates to
CC 186 novel genes and their fragments (nucleic acid sequences: AAV59511-
CC V59812; amino acid sequences AAW74731-W75026) which are useful for
CC preventing, treating or ameliorating medical conditions e.g. by protein
CC or gene therapy. Also, pathological conditions can be diagnosed by
CC determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new polynucleotides.
CC Specific uses are described for each of the 186 polynucleotides, based on
CC which tissues they are most highly expressed in (see AAV59511 for
CC described uses)
XX
SQ Sequence 40 AA;

Query Match 30.9%; Score 30; DB 2; Length 40;
Best Local Similarity 58.3%; Pred. No. 1.1e+03;
Matches 7; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIV 14
||| :| | ||
Db 27 NHLAFRILFFIV 38

RESULT 107
ABG95241
ID ABG95241 standard; protein; 40 AA.

XX
AC ABG95241;
XX
DT 15-JAN-2003 (first entry)
XX
DE Human novel secreted protein #62.
XX
KW Human; secreted protein; autoimmune disease; chemotaxis;
KW rheumatoid arthritis; hyperproliferative disorder; breast neoplasm;
KW liver neoplasm cardiovascular disorder; cardiac arrest; skin aging;
KW cerebrovascular disorder; cerebral ischaemia; angiogenesis; sunburn;
KW nervous system disorders; Alzheimer's disease; infection;
KW ocular disorder; corneal infection; wound healing; tissue regeneration;
KW epithelial cell proliferation; organ transplantation; food additive;
KW preservative; nutritional.
XX
OS Homo sapiens.
XX
PN US6420526-B1.
XX
PD 16-JUL-2002.
XX
PF 08-SEP-1998; 98US-00149476.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.
PR 22-AUG-1997; 97US-0056876P.
PR 22-AUG-1997; 97US-0056877P.
PR 22-AUG-1997; 97US-0056878P.
PR 22-AUG-1997; 97US-0056879P.
PR 22-AUG-1997; 97US-0056880P.
PR 22-AUG-1997; 97US-0056881P.
PR 22-AUG-1997; 97US-0056882P.
PR 22-AUG-1997; 97US-0056884P.
PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 02-OCT-1997; 97US-0061060P.
PR 06-MAR-1998; 98WO-US004493.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Rosen CA, Fischer CL, Soppet DP, Carter KC;
PI Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 2002-634796/68.
DR N-PSDB; ABS73559.
XX
PT New isolated human secreted protein for diagnosing, preventing, treating
PT or ameliorating medical conditions and used as a food additive or
PT preservative.
XX
PS Example 1; SEQ ID NO 381; 129pp; English.
XX
CC The invention relates to an isolated protein that is one of 186 human
CC secreted proteins, given in the specification, encoded by one of 309 cDNA
CC sequences also given in the specification. The protein is used in a
CC pharmaceutical composition used to prevent, treat or ameliorate a medical

```
CC   condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs,
CC   chickens or sheep. Disorders which are diagnosed or treated include
CC   autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC   disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC   e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC   angiogenesis, nervous system disorders e.g. Alzheimer's disease,
CC   infections caused by bacteria, viruses and fungi and ocular disorders
CC   e.g. corneal infection. The polypeptides can also be used to aid wound
CC   healing and epithelial cell proliferation, to prevent skin aging due to
CC   sunburn, to maintain organs before transplantation, for supporting cell
CC   culture of primary tissues, to regenerate tissues and in chemotaxis. The
CC   polypeptides can also be used as a food additive or preservative to
CC   increase or decrease storage capabilities, fat content, lipid, protein,
CC   carbohydrate, vitamins, minerals, cofactors and other nutritional
CC   components. The present sequence represents one of the novel human
CC   secreted proteins of the invention. Note: This sequence did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from USPTO at seqdata.uspto.gov/sequence.html?DocID=6420526B1
XX
SQ   Sequence 40 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 40;
  Best Local Similarity   58.3%;  Pred. No. 1.1e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38


RESULT 108
ABO34435
ID   ABO34435 standard; protein; 40 AA.
XX
AC   ABO34435;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Region of human secreted protein encoded by cDNA sequence #62.
XX
KW   Human; secreted protein; hyperproliferative disorder; leukaemia;
KW   breast cancer; wound; reproductive disorder; blood-related disorder;
KW   haemophilia; thrombocytopaenia; immunodeficiency; thymic hypoplasia;
KW   Wiskott-Aldrich syndrome; autoimmune disorder; multiple sclerosis;
KW   graft-versus-host disease; Hashimoto's thyroiditis; allergy; asthma;
KW   viral infection; bacterial infection; fungal infection; AIDS; sepsis;
KW   renal disorder; kidney failure; cardiovascular disorder; cytostatic;
KW   angina pectoris; cerebral ischaemia; congenital heart defect;
KW   respiratory disorder; neurological disorder; Alzheimer's disease;
KW   Parkinson's disease; inflammation; Crohn's disease; vulnerary;
KW   immunosuppressive; antibacterial; haemostatic; thrombolytic;
KW   anticoagulant; neuroprotective; thyromimetic; antiallergic;
KW   antiasthmatic; virucide; fungicide; anti-HIV; nephrotropic; antianginal;
KW   cerebroprotective; cardiant; nootropic; antiparkinsonian;
KW   antiinflammatory.
XX
OS   Homo sapiens.
XX
PN   US2003049618-A1.
XX
PD   13-MAR-2003.
XX
PF   16-MAR-2001; 2001US-00809391.
XX
PR   07-MAR-1997;   97US-0038621P.
PR   07-MAR-1997;   97US-0040162P.
PR   07-MAR-1997;   97US-0040163P.
PR   07-MAR-1997;   97US-0040333P.
PR   07-MAR-1997;   97US-0040334P.
PR   07-MAR-1997;   97US-0040336P.
PR   07-MAR-1997;   97US-0040626P.
PR   11-APR-1997;   97US-0043311P.
PR   11-APR-1997;   97US-0043312P.
PR   11-APR-1997;   97US-0043313P.
PR   11-APR-1997;   97US-0043314P.
PR   11-APR-1997;   97US-0043315P.
PR   11-APR-1997;   97US-0043568P.
PR   11-APR-1997;   97US-0043569P.
PR   11-APR-1997;   97US-0043576P.
PR   11-APR-1997;   97US-0043578P.
PR   11-APR-1997;   97US-0043580P.
PR   11-APR-1997;   97US-0043669P.
PR   11-APR-1997;   97US-0043670P.
PR   11-APR-1997;   97US-0043671P.
PR   11-APR-1997;   97US-0043672P.
PR   11-APR-1997;   97US-0043674P.
PR   23-MAY-1997;   97US-0047492P.
PR   23-MAY-1997;   97US-0047500P.
PR   23-MAY-1997;   97US-0047501P.
PR   23-MAY-1997;   97US-0047502P.
PR   23-MAY-1997;   97US-0047503P.
PR   23-MAY-1997;   97US-0047581P.
PR   23-MAY-1997;   97US-0047582P.
PR   23-MAY-1997;   97US-0047583P.
PR   23-MAY-1997;   97US-0047584P.
PR   23-MAY-1997;   97US-0047585P.
PR   23-MAY-1997;   97US-0047586P.
PR   23-MAY-1997;   97US-0047587P.
PR   23-MAY-1997;   97US-0047588P.
PR   23-MAY-1997;   97US-0047589P.
PR   23-MAY-1997;   97US-0047590P.
PR   23-MAY-1997;   97US-0047592P.
PR   23-MAY-1997;   97US-0047593P.
PR   23-MAY-1997;   97US-0047594P.
PR   23-MAY-1997;   97US-0047595P.
PR   23-MAY-1997;   97US-0047596P.
PR   23-MAY-1997;   97US-0047597P.
PR   23-MAY-1997;   97US-0047598P.
PR   23-MAY-1997;   97US-0047599P.
PR   23-MAY-1997;   97US-0047600P.
PR   23-MAY-1997;   97US-0047601P.
PR   23-MAY-1997;   97US-0047612P.
PR   23-MAY-1997;   97US-0047613P.
PR   23-MAY-1997;   97US-0047614P.
PR   23-MAY-1997;   97US-0047615P.
PR   23-MAY-1997;   97US-0047617P.
PR   23-MAY-1997;   97US-0047618P.
PR   23-MAY-1997;   97US-0047632P.
PR   23-MAY-1997;   97US-0047633P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048974P.
PR   13-JUN-1997;   97US-0049610P.
PR   08-JUL-1997;   97US-0051926P.
PR   16-JUL-1997;   97US-0052874P.
PR   18-AUG-1997;   97US-0055724P.
PR   22-AUG-1997;   97US-0056630P.
PR   22-AUG-1997;   97US-0056631P.
PR   22-AUG-1997;   97US-0056632P.
PR   22-AUG-1997;   97US-0056636P.
PR   22-AUG-1997;   97US-0056637P.
PR   22-AUG-1997;   97US-0056662P.
PR   22-AUG-1997;   97US-0056664P.
PR   22-AUG-1997;   97US-0056845P.
PR   22-AUG-1997;   97US-0056862P.
PR   22-AUG-1997;   97US-0056864P.
PR   22-AUG-1997;   97US-0056872P.
PR   22-AUG-1997;   97US-0056874P.
PR   22-AUG-1997;   97US-0056875P.
PR   22-AUG-1997;   97US-0056876P.
PR   22-AUG-1997;   97US-0056877P.
PR   22-AUG-1997;   97US-0056878P.
PR   22-AUG-1997;   97US-0056879P.
PR   22-AUG-1997;   97US-0056880P.
PR   22-AUG-1997;   97US-0056881P.
PR   22-AUG-1997;   97US-0056882P.
PR   22-AUG-1997;   97US-0056884P.
```

PR 22-AUG-1997; 97US-0056886P.
PR 22-AUG-1997; 97US-0056887P.
PR 22-AUG-1997; 97US-0056888P.
PR 22-AUG-1997; 97US-0056889P.
PR 22-AUG-1997; 97US-0056892P.
PR 22-AUG-1997; 97US-0056893P.
PR 22-AUG-1997; 97US-0056894P.
PR 22-AUG-1997; 97US-0056903P.
PR 22-AUG-1997; 97US-0056908P.
PR 22-AUG-1997; 97US-0056909P.
PR 22-AUG-1997; 97US-0056910P.
PR 22-AUG-1997; 97US-0056911P.
PR 05-SEP-1997; 97US-0057650P.
PR 05-SEP-1997; 97US-0057669P.
PR 05-SEP-1997; 97US-0057761P.
PR 12-SEP-1997; 97US-0058785P.
PR 09-OCT-1997; 97US-0061660P.
PR 06-MAR-1998; 98WO-US004493.
PR 08-SEP-1998; 98US-00149476.
PR 17-MAR-2000; 2000US-0190068P.
XX
PA (RUBE/) RUBEN S M.
PA (ROSE/) ROSEN C A.
PA (SOPP/) SOPPET D R.
PA (CART/) CARTER K C.
PA (BEDN/) BEDNARIK D P.
PA (ENDR/) ENDRESS G A.
PA (YUGG/) YU G.
PA (NIJJ/) NI J.
PA (FENG/) FENG P.
PA (YOUN/) YOUNG P E.
PA (GREE/) GREENE J M.
PA (FERR/) FERRIE A M.
PA (DUAN/) DUAN D R.
PA (HUJJ/) HU J.
PA (FLOR/) FLORENCE K A.
PA (OLSE/) OLSEN H S.
PA (FISC/) FISCHER C L.
PA (EBNE/) EBNER R.
PA (BREW/) BREWER L A.
PA (MOOR/) MOORE P A.
PA (SHIY/) SHI Y.
PA (LAFL/) LAFLEUR D W.
PA (LIYY/) LI Y.
PA (ZENG/) ZENG Z.
PA (KYAW/) KYAW H.
XX
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 2003-521800/49.
DR N-PSDB; ACD82702.
XX
PT New genes and its encoded prostate cancer antigen proteins, useful for
PT preventing, treating, ameliorating or diagnosing e.g. prostate cancers,
PT thymic hypoplasia, multiple sclerosis, AIDS, angina pectoris or cerebral
PT ischemia.
XX
PS Claim 3; SEQ ID NO 381; 260pp; English.
XX
CC The present invention relates to the isolation of novel human secreted
CC proteins and the polynucleotide sequences encoding them. The invention
CC also discloses vectors, host cells, antibodies, and recombinant methods
CC for producing human secreted proteins. The polypeptide and polynucleotide
CC sequences for the secreted proteins are useful for preventing, treating,
CC ameliorating or diagnosing medical conditions such as hyperproliferative
CC disorders (e.g. leukaemia or breast cancers), wounds, reproductive
CC disorders, blood-related disorders (e.g. haemophilia or
CC thrombocytopaenia), immunodeficiencies (e.g. Wiskott-Aldrich syndrome or
CC thymic hypoplasia), autoimmune disorders (e.g. graft-versus-host disease,
CC multiple sclerosis or Hashimoto's thyroiditis), allergies (e.g. asthma),
CC viral or bacterial or fungal infections (e.g. AIDS or sepsis), renal
CC disorders (e.g. kidney failure), cardiovascular disorders (e.g. angina
CC pectoris, cerebral ischaemia or congenital heart defects), respiratory
CC disorders, neurological disorders (e.g. Alzheimer's disease or
CC Parkinson's disease), and inflammations (e.g. Crohn's disease). The
CC polynucleotide or polypeptide may also be used as vaccine adjuvants.
CC ABO34374-ABO34815 represent human secreted proteins or their fragments.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 40 AA;

Query Match 30.9%; Score 30; DB 6; Length 40;
Best Local Similarity 58.3%; Pred. No. 1.1e+03;
Matches 7; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIV 14
||| :| | ||
Db 27 NHLAFRILFFIV 38

RESULT 109
ADB32063
ID ADB32063 standard; peptide; 40 AA.
XX
AC ADB32063;
XX
DT 04-DEC-2003 (first entry)
XX
DE alphaA-integrin alpha subunit alphaE.
XX
KW Integrin; alphaV-beta3 integrin; RGD peptide ligand; modulator; agonist;
KW antagonist; alphaE.
XX
OS Unidentified.
XX
PN WO2003067219-A2.
XX
PD 14-AUG-2003.
XX
PF 07-FEB-2003; 2003WO-US003903.
XX
PR 07-FEB-2002; 2002US-0354773P.
XX
PA (GEHO) GEN HOSPITAL CORP.
XX
PI Arnaout AM;
XX
DR WPI; 2003-663639/62.
XX
PT Screening potential modulators of alphaVbeta3 integrin useful to identify
PT agonists and antagonists uses computer model of three-dimensional
PT structure including a binding site and data from an alphaVbeta3 integrin-
PT ligand complex.
XX
PS Disclosure; Page 5c; 48pp; English.
XX
CC The invention relates to a method for screening test compounds as
CC potential modulators of alphaV-beta3 integrin using a computer model of
CC the three-dimensional structure of alphaV-beta3 integrin which includes a
CC binding site. The model is based on atomic coordinates of defined alphaV-
CC beta3 integrin amino acids obtained from the structure of a complex of
CC alphaV-beta3 integrin with a known 'RGD peptide' ligand. The method is
CC useful to identify alphaV-beta3 integrin ligands that, because they bind
CC to alphaV-beta3 integrin, may be modulators e.g. agonists or antagonist
CC of alphaV-beta3 integrin activity. It is useful to ascertain whether a
CC specific test compound is a potential modulator and especially to greatly
CC reduce numbers of compounds which must be further tested for their
CC ability to modulate alphaV-beta3 integrin activity. The current sequence
CC represents the alphaA-integrin alpha subunit alphaE.
XX
SQ Sequence 40 AA;

```
  Query Match             30.9%;  Score 30;  DB 7;  Length 40;
  Best Local Similarity   46.2%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQE 17
              | ||: : |:| |
Db          7 LLSKLRYNIISME 19


RESULT 110
ADI23096
ID   ADI23096 standard; protein; 40 AA.
XX
AC   ADI23096;
XX
DT   22-APR-2004  (first entry)
XX
DE   Novel human secreted protein seq id 381.
XX
KW   cytostatic; gene therapy; cancer; human; secreted protein.
XX
OS   Homo sapiens.
XX
PN   US2003175858-A1.
XX
PD   18-SEP-2003.
XX
PF   18-JUN-2001; 2001US-00882171.
XX
PR   07-MAR-1997;   97US-0038621P.
PR   07-MAR-1997;   97US-0040162P.
PR   07-MAR-1997;   97US-0040163P.
PR   07-MAR-1997;   97US-0040333P.
PR   07-MAR-1997;   97US-0040334P.
PR   07-MAR-1997;   97US-0040336P.
PR   07-MAR-1997;   97US-0040626P.
PR   11-APR-1997;   97US-0043311P.
PR   11-APR-1997;   97US-0043312P.
PR   11-APR-1997;   97US-0043313P.
PR   11-APR-1997;   97US-0043314P.
PR   11-APR-1997;   97US-0043315P.
PR   11-APR-1997;   97US-0043568P.
PR   11-APR-1997;   97US-0043569P.
PR   11-APR-1997;   97US-0043576P.
PR   11-APR-1997;   97US-0043578P.
PR   11-APR-1997;   97US-0043580P.
PR   11-APR-1997;   97US-0043669P.
PR   11-APR-1997;   97US-0043670P.
PR   11-APR-1997;   97US-0043671P.
PR   11-APR-1997;   97US-0043672P.
PR   11-APR-1997;   97US-0043674P.
PR   23-MAY-1997;   97US-0047492P.
PR   23-MAY-1997;   97US-0047500P.
PR   23-MAY-1997;   97US-0047501P.
PR   23-MAY-1997;   97US-0047502P.
PR   23-MAY-1997;   97US-0047503P.
PR   23-MAY-1997;   97US-0047581P.
PR   23-MAY-1997;   97US-0047582P.
PR   23-MAY-1997;   97US-0047583P.
PR   23-MAY-1997;   97US-0047584P.
PR   23-MAY-1997;   97US-0047585P.
PR   23-MAY-1997;   97US-0047586P.
PR   23-MAY-1997;   97US-0047587P.
PR   23-MAY-1997;   97US-0047588P.
PR   23-MAY-1997;   97US-0047589P.
PR   23-MAY-1997;   97US-0047590P.
PR   23-MAY-1997;   97US-0047592P.
PR   23-MAY-1997;   97US-0047593P.
PR   23-MAY-1997;   97US-0047594P.
PR   23-MAY-1997;   97US-0047595P.
PR   23-MAY-1997;   97US-0047596P.
PR   23-MAY-1997;   97US-0047597P.
PR   23-MAY-1997;   97US-0047598P.
PR   23-MAY-1997;   97US-0047599P.
PR   23-MAY-1997;   97US-0047600P.
PR   23-MAY-1997;   97US-0047601P.
PR   23-MAY-1997;   97US-0047612P.
PR   23-MAY-1997;   97US-0047613P.
PR   23-MAY-1997;   97US-0047614P.
PR   23-MAY-1997;   97US-0047615P.
PR   23-MAY-1997;   97US-0047617P.
PR   23-MAY-1997;   97US-0047618P.
PR   23-MAY-1997;   97US-0047632P.
PR   23-MAY-1997;   97US-0047633P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048974P.
PR   13-JUN-1997;   97US-0049610P.
PR   08-JUL-1997;   97US-0051926P.
PR   16-JUL-1997;   97US-0052874P.
PR   18-AUG-1997;   97US-0055724P.
PR   22-AUG-1997;   97US-0056630P.
PR   22-AUG-1997;   97US-0056631P.
PR   22-AUG-1997;   97US-0056632P.
PR   22-AUG-1997;   97US-0056636P.
PR   22-AUG-1997;   97US-0056637P.
PR   22-AUG-1997;   97US-0056662P.
PR   22-AUG-1997;   97US-0056664P.
PR   22-AUG-1997;   97US-0056845P.
PR   22-AUG-1997;   97US-0056862P.
PR   22-AUG-1997;   97US-0056864P.
PR   22-AUG-1997;   97US-0056872P.
PR   22-AUG-1997;   97US-0056874P.
PR   22-AUG-1997;   97US-0056875P.
PR   22-AUG-1997;   97US-0056876P.
PR   22-AUG-1997;   97US-0056877P.
PR   22-AUG-1997;   97US-0056878P.
PR   22-AUG-1997;   97US-0056879P.
PR   22-AUG-1997;   97US-0056880P.
PR   22-AUG-1997;   97US-0056881P.
PR   22-AUG-1997;   97US-0056882P.
PR   22-AUG-1997;   97US-0056884P.
PR   22-AUG-1997;   97US-0056886P.
PR   22-AUG-1997;   97US-0056887P.
PR   22-AUG-1997;   97US-0056888P.
PR   22-AUG-1997;   97US-0056889P.
PR   22-AUG-1997;   97US-0056892P.
PR   22-AUG-1997;   97US-0056893P.
PR   22-AUG-1997;   97US-0056894P.
PR   22-AUG-1997;   97US-0056903P.
PR   22-AUG-1997;   97US-0056908P.
PR   22-AUG-1997;   97US-0056909P.
PR   22-AUG-1997;   97US-0056910P.
PR   22-AUG-1997;   97US-0056911P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057669P.
PR   05-SEP-1997;   97US-0057761P.
PR   12-SEP-1997;   97US-0058785P.
PR   09-OCT-1997;   97US-0061660P.
PR   06-MAR-1998;   98WO-US004493.
PR   08-SEP-1998;   98US-00149476.
PR   17-MAR-2000; 2000US-0190068P.
PR   16-MAR-2001; 2001US-00809391.
XX
PA   (RUBE/) RUBEN S M.
PA   (ROSE/) ROSEN C A.
PA   (SOPP/) SOPPET D R.
PA   (CART/) CARTER K C.
PA   (BEDN/) BEDNARIK D P.
PA   (ENDR/) ENDRESS G A.
PA   (YUGG/) YU G.
PA   (NIJJ/) NI J.
PA   (FENG/) FENG P.
PA   (YOUN/) YOUNG P E.
PA   (GREE/) GREENE J M.
PA   (FERR/) FERRIE A M.
```

PA (DUAN/) DUAN D R.
PA (HUJJ/) HU J.
PA (FLOR/) FLORENCE K A.
PA (OLSE/) OLSEN H S.
PA (FISC/) FISCHER C L.
PA (EBNE/) EBNER R.
PA (BREW/) BREWER L A.
PA (MOOR/) MOORE P A.
PA (SHIY/) SHI Y.
PA (LAFL/) LAFLEUR D W.
PA (LIYY/) LI Y.
PA (ZENG/) ZENG Z.
PA (KYAW/) KYAW H.
XX
PI Ruben SM, Rosen CA, Soppet DR, Carter KC, Bednarik DP;
PI Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM, Ferrie AM;
PI Duan DR, Hu J, Florence KA, Olsen HS, Fischer CL, Ebner R;
PI Brewer LA, Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX
DR WPI; 2003-898535/82.
DR N-PSDB; ADI22787.
XX
PT New nucleic acid molecule, useful for preparing a medicament for
PT diagnosing, preventing, treating or ameliorating a medical condition
PT e.g., cancer.
XX
PS Claim 11; SEQ ID NO 381; 256pp; English.
XX
CC The invention describes an isolated nucleic acid comprising a sequence
CC having 95 % identity with: a polynucleotide fragment of a sequence not
CC given in the specification, or its allelic variant; a polynucleotide
CC fragment of the cDNA sequence; a polynucleotide sequence encoding a
CC polypeptide, or its fragment, domain, epitope or species homologue; or a
CC polynucleotide that hybridises under stringent conditions to any one of
CC the sequences of (a)-(c). The nucleic acid is useful for preparing a
CC medicament for diagnosing, preventing, treating or ameliorating a medical
CC condition e.g., cancer. The is the amino acid sequence of a novel human
CC secreted protein of the invention.
XX
SQ Sequence 40 AA;

Query Match 30.9%; Score 30; DB 7; Length 40;
Best Local Similarity 58.3%; Pred. No. 1.1e+03;
Matches 7; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

```
Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38
```

RESULT 111
ADH74098
ID ADH74098 standard; protein; 40 AA.
XX
AC ADH74098;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human secreted protein #62.
XX
KW human; secreted protein; cancer; haematopoietic disorder;
KW endocrine disorder; immune system disease; inflammatory disorder.
XX
OS Homo sapiens.
XX
PN US2003225248-A1.
XX
PD 04-DEC-2003.
XX
PF 10-JUN-2002; 2002US-00164861.
XX
PR 07-MAR-1997; 97US-0038621P.
PR 07-MAR-1997; 97US-0040161P.
PR 07-MAR-1997; 97US-0040162P.
PR 07-MAR-1997; 97US-0040163P.
PR 07-MAR-1997; 97US-0040333P.
PR 07-MAR-1997; 97US-0040334P.
PR 07-MAR-1997; 97US-0040336P.
PR 07-MAR-1997; 97US-0040626P.
PR 11-APR-1997; 97US-0043311P.
PR 11-APR-1997; 97US-0043312P.
PR 11-APR-1997; 97US-0043313P.
PR 11-APR-1997; 97US-0043314P.
PR 11-APR-1997; 97US-0043315P.
PR 11-APR-1997; 97US-0043568P.
PR 11-APR-1997; 97US-0043569P.
PR 11-APR-1997; 97US-0043576P.
PR 11-APR-1997; 97US-0043578P.
PR 11-APR-1997; 97US-0043580P.
PR 11-APR-1997; 97US-0043669P.
PR 11-APR-1997; 97US-0043670P.
PR 11-APR-1997; 97US-0043671P.
PR 11-APR-1997; 97US-0043672P.
PR 11-APR-1997; 97US-0043674P.
PR 23-MAY-1997; 97US-0047492P.
PR 23-MAY-1997; 97US-0047500P.
PR 23-MAY-1997; 97US-0047501P.
PR 23-MAY-1997; 97US-0047502P.
PR 23-MAY-1997; 97US-0047503P.
PR 23-MAY-1997; 97US-0047581P.
PR 23-MAY-1997; 97US-0047582P.
PR 23-MAY-1997; 97US-0047583P.
PR 23-MAY-1997; 97US-0047584P.
PR 23-MAY-1997; 97US-0047585P.
PR 23-MAY-1997; 97US-0047586P.
PR 23-MAY-1997; 97US-0047587P.
PR 23-MAY-1997; 97US-0047588P.
PR 23-MAY-1997; 97US-0047589P.
PR 23-MAY-1997; 97US-0047590P.
PR 23-MAY-1997; 97US-0047592P.
PR 23-MAY-1997; 97US-0047593P.
PR 23-MAY-1997; 97US-0047594P.
PR 23-MAY-1997; 97US-0047595P.
PR 23-MAY-1997; 97US-0047596P.
PR 23-MAY-1997; 97US-0047597P.
PR 23-MAY-1997; 97US-0047598P.
PR 23-MAY-1997; 97US-0047599P.
PR 23-MAY-1997; 97US-0047600P.
PR 23-MAY-1997; 97US-0047601P.
PR 23-MAY-1997; 97US-0047612P.
PR 23-MAY-1997; 97US-0047613P.
PR 23-MAY-1997; 97US-0047614P.
PR 23-MAY-1997; 97US-0047615P.
PR 23-MAY-1997; 97US-0047617P.
PR 23-MAY-1997; 97US-0047618P.
PR 23-MAY-1997; 97US-0047632P.
PR 23-MAY-1997; 97US-0047633P.
PR 06-JUN-1997; 97US-0048964P.
PR 06-JUN-1997; 97US-0048974P.
PR 13-JUN-1997; 97US-0049610P.
PR 08-JUL-1997; 97US-0051926P.
PR 16-JUL-1997; 97US-0052874P.
PR 18-AUG-1997; 97US-0055724P.
PR 22-AUG-1997; 97US-0056630P.
PR 22-AUG-1997; 97US-0056631P.
PR 22-AUG-1997; 97US-0056632P.
PR 22-AUG-1997; 97US-0056636P.
PR 22-AUG-1997; 97US-0056637P.
PR 22-AUG-1997; 97US-0056662P.
PR 22-AUG-1997; 97US-0056664P.
PR 22-AUG-1997; 97US-0056845P.
PR 22-AUG-1997; 97US-0056862P.
PR 22-AUG-1997; 97US-0056864P.
PR 22-AUG-1997; 97US-0056872P.
PR 22-AUG-1997; 97US-0056874P.
PR 22-AUG-1997; 97US-0056875P.

```
PR   22-AUG-1997;   97US-0056876P.
PR   22-AUG-1997;   97US-0056877P.
PR   22-AUG-1997;   97US-0056878P.
PR   22-AUG-1997;   97US-0056879P.
PR   22-AUG-1997;   97US-0056880P.
PR   22-AUG-1997;   97US-0056881P.
PR   22-AUG-1997;   97US-0056882P.
PR   22-AUG-1997;   97US-0056884P.
PR   22-AUG-1997;   97US-0056886P.
PR   22-AUG-1997;   97US-0056887P.
PR   22-AUG-1997;   97US-0056888P.
PR   22-AUG-1997;   97US-0056889P.
PR   22-AUG-1997;   97US-0056892P.
PR   22-AUG-1997;   97US-0056893P.
PR   22-AUG-1997;   97US-0056894P.
PR   22-AUG-1997;   97US-0056903P.
PR   22-AUG-1997;   97US-0056908P.
PR   22-AUG-1997;   97US-0056909P.
PR   22-AUG-1997;   97US-0056910P.
PR   22-AUG-1997;   97US-0056911P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057669P.
PR   05-SEP-1997;   97US-0057761P.
PR   12-SEP-1997;   97US-0058785P.
PR   02-OCT-1997;   97US-0061060P.
PR   06-MAR-1998;   98WO-US004493.
PR   08-SEP-1998;   98US-00149476.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Rosen CA,  Soppet DR,  Carter KC,  Bednarik DP;
PI   Endress GA,  Yu G,  Ni J,  Feng P,  Young PE,  Greene JM,  Ferrie AM;
PI   Duan R,  Hu J,  Florence KA,  Olsen HS,  Fischer CL,  Ebner R;
PI   Brewer LA,  Moore PA,  Shi Y,  Lafleur DW,  Li Y,  Zeng Z,  Kyaw H;
XX
DR   WPI; 2004-131264/13.
DR   N-PSDB; ADH73789.
XX
PT   Isolated nucleic acid molecules encoding human secreted proteins, useful
PT   for preventing, diagnosing and treating disorders associated with
PT   aberrant expression and activity.
XX
PS   Claim 11; SEQ ID NO 381; 142pp; English.
XX
CC   The invention relates to isolated nucleic acid molecules and the human
CC   secreted proteins (SPs) they encode. The proteins and nucleic acids may
CC   be used in the prevention, diagnosis and treatment of diseases associated
CC   with inappropriate SP expression e.g. cancer, haematopoietic disorders,
CC   endocrine disorders, diseases of the immune system, inflammatory
CC   disorders and many others. Full details of disorders that may be
CC   prevented, diagnosed and/or treated by the above methods are given in the
CC   specification. The nucleic acid molecules may be used to produce their
CC   proteins. The nucleic acid and it's complementary sequences may also be
CC   used as DNA probes in diagnostic assays to detect and quantitate the
CC   presence of similar nucleic acids in samples, and therefore which
CC   patients may be in need of restorative therapy. The SPs may also be used
CC   as antigens in the production of antibodies against the proteins and in
CC   assays to identify modulators of SP expression and activity. The anti-SP
CC   antibodies and antagonists may also be used to down regulate expression
CC   and activity. The anti-SP antibodies may also be used as diagnostic
CC   agents for detecting the presence of the proteins in samples (e.g. by
CC   enzyme linked immunosorbant assay (ELISA)). The present sequence
CC   represents the amino acid sequence of a human secreted protein.
XX
SQ   Sequence 40 AA;

  Query Match             30.9%;  Score 30;  DB 8;  Length 40;
  Best Local Similarity   58.3%;  Pred. No. 1.1e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38
```

```
RESULT 112
AAM85472
ID   AAM85472 standard; protein; 41 AA.
XX
AC   AAM85472;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen SEQ ID NO:13065.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001354.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   06-SEP-2000; 2000US-0230437P.
PR   06-SEP-2000; 2000US-0230438P.
PR   08-SEP-2000; 2000US-0231242P.
PR   08-SEP-2000; 2000US-0231243P.
PR   08-SEP-2000; 2000US-0231244P.
PR   08-SEP-2000; 2000US-0231413P.
PR   08-SEP-2000; 2000US-0231414P.
PR   08-SEP-2000; 2000US-0232080P.
```

PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK58253.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and metastasis.
XX
PS Claim 11; SEQ ID NO 13065; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting the
CC nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention
XX
SQ Sequence 41 AA;

Query Match 30.9%; Score 30; DB 4; Length 41;
Best Local Similarity 71.4%; Pred. No. 1.2e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy          3 NHLNSKI 9
              ||||| :
Db          4 NHLNSSL 10
```

RESULT 113
ABP29414
ID ABP29414 standard; protein; 42 AA.
XX
AC ABP29414;
XX
DT 02-JUL-2002 (first entry)
XX
DE Streptococcus polypeptide SEQ ID NO 8004.
XX
KW Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
KW group A streptococcus; Streptococcus pyogenes; antibacterial;
KW antiinflammatory; infection; vaccine; meningitis; gene therapy.
XX
OS Streptococcus pyogenes.
XX
PN WO200234771-A2.
XX

PD 02-MAY-2002.
XX
PF 29-OCT-2001; 2001WO-GB004789.
XX
PR 27-OCT-2000; 2000GB-00026333.
PR 24-NOV-2000; 2000GB-00028727.
PR 07-MAR-2001; 2001GB-00005640.
XX
PA (CHIR-) CHIRON SPA.
PA (GENO-) INST GENOMIC RES.
XX
PI Telford J, Masignani V, Margarit Y RosI, Grandi G, Fraser C;
PI Tettelin H;
XX
DR WPI; 2002-352536/38.
DR N-PSDB; ABN70045.
XX
PT New Streptococcus protein for the treatment or prevention of infection or
PT disease caused by Streptococcus bacteria, such as meningitis, and for
PT detecting a compound that binds to the protein.
XX
PS Claim 1; Page 3927; 4525pp; English.
XX
CC The invention relates to a protein (ABP25413-ABP30895) from group B
CC streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
CC (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
CC the specification. The proteins have antibacterial and antiinflammatory
CC activity. (I), nucleic acids encoding (I), ABN66044-ABN71526 and
CC antibodies that bind (I) are used in the manufacture of medicaments for
CC the treatment or prevention of infection or disease caused by
CC Streptococcus bacteria, particularly S. agalactiae and S. pyrogenes.
CC Nucleic acids encoding (I) are used to detect Streptococcus in a
CC biological sample. (I) is used to determine whether a compound binds to
CC (I). A composition comprising (I) or a nucleic acid encoding (I), may be
CC used as a vaccine or diagnostic composition. The disease caused by
CC Streptococcus that is prevented or treated may be meningitis. Nucleic
CC acid encoding (I) may be used to recombinantly produce (I) and may be
CC used in gene therapy. Antibodies to (I) are used for affinity
CC chromatography, immunoassays, and distinguishing/identifying
CC Streptococcus proteins
XX
SQ Sequence 42 AA;

Query Match 30.9%; Score 30; DB 5; Length 42;
Best Local Similarity 54.5%; Pred. No. 1.2e+03;
Matches 6; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy          5 LNSKIAFKIVS 15
              |||| :| ::|
Db          6 LNSKESFFVIS 16
```

RESULT 114
ABB03481
ID ABB03481 standard; protein; 46 AA.
XX
AC ABB03481;
XX
DT 08-JAN-2002 (first entry)
XX
DE Human musculoskeletal system related polypeptide SEQ ID NO 1428.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein;
KW musculoskeletal system.
XX
OS Homo sapiens.
XX
PN WO200155367-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001338.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.

PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-451937/48.
DR N-PSDB; AAL35063.
XX
PT Isolated polypeptide for treating, preventing and/ or prognosing
PT disorders related to the musculoskeletal system including musculoskeletal
PT cancers and also for testing and detection e.g. diagnosis.
XX
PS Claim 11; SEQ ID NO 1428; 781pp + Sequence Listing; English.
XX
CC The invention relates to novel genes (AAL34669-AAL37666) and proteins
CC (ABB03087-ABB04109) associated with the musculoskeletal system useful for
CC preventing, treating or ameliorating medical conditions e.g. by protein
CC or gene therapy. The genes are isolated from a range of human tissues
CC disclosed in the specification. The nucleic acids, proteins, antibodies
CC and (ant)agonists are useful in the diagnosis, treatment and prevention
CC of: (a) cancer, e.g. breast and ovarian cancer and other cancers of the
CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,
CC lung, or urogenital; (b) immune disorders e.g. Addison's disease,
CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as
CC myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.
CC cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,
CC bacterial, fungal and parasitic infections. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 46 AA;

Query Match 30.9%; Score 30; DB 4; Length 46;
Best Local Similarity 41.7%; Pred. No. 1.4e+03;
Matches 5; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVSQ 16
|: ::|||: :|
Db 28 LSQEVAFKLSTQ 39

RESULT 115
ABU12775
ID ABU12775 standard; protein; 46 AA.
XX
AC ABU12775;
XX
DT 26-FEB-2003 (first entry)
XX
DE Novel human musculoskeletal system antigen #395.
XX
KW Musculoskeletal system antigen; cancer; metastasis; re-vascularisation;
KW thrombosis; arteriosclerosis; mineral content; cardiovascular condition;
KW wound; injury; burn; angiogenesis; ulcer; post-operative tissue repair;
KW limb regeneration; neuronal growth; neurodegenerative disorder;
KW Alzheimer's disease; Parkinson's disease; AIDS-related complex;
KW chondrocyte growth; bone regeneration; periodontal regeneration;
KW tissue transport; bone graft; skin aging; keratinocyte growth; hair loss;
KW melanocyte growth; cell proliferation; cell growth; organ transplant;
KW cell differentiation; body height; weight; hair colour; eye colour; skin;
KW percentage of adipose tissue; pigmentation; cosmetic surgery; metabolism;
KW biorhythm; caricadic rhythm; depression; tendency for violence; pain;
KW reproductive capability; hormone level; endocrine level; appetite;
KW libido; memory; stress; storage capability; fat content; lipid content;
KW protein content; carbohydrate content; vitamin content; cofactor content;
KW nutritional component.
XX
OS Homo sapiens.
XX
PN US2002147140-A1.
XX
PD 10-OCT-2002.
XX
PF 17-JAN-2001; 2001US-00764877.
XX
PR 31-JAN-2000; 2000US-0179065P.

PR 04-FEB-2000; 2000US-0180628P.
PR 28-JUN-2000; 2000US-0214886P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 22-AUG-2000; 2000US-0226868P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 08-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
XX
PA (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
DR WPI; 2003-128199/12.
DR N-PSDB; ABX58051.
XX
PT Isolated nucleic acid molecules encoding musculoskeletal system
PT associated polypeptides, useful for detecting disorders, e.g. cancer.
XX
PS Claim 11; SEQ ID NO 1428; 321pp; English.
XX
CC The invention describes an isolated nucleic acid molecule comprising a
CC sequence encoding musculoskeletal system associated polypeptides useful
CC for detecting disorders, e.g., cancer or cancer metastases, in animals or
CC humans. The nucleic acid: stimulates re-vascularisation of ischaemic
CC tissues associated with conditions such as thrombosis, arteriosclerosis,
CC and other cardiovascular conditions; treats wounds due to injuries,
CC burns, post-operative tissue repair, and ulcers; stimulates angiogenesis
CC and limb regeneration; stimulates neuronal growth; can treat and prevent
CC neuronal damage occurring in certain disorders or neurodegenerative
CC conditions, such as, Alzheimer's disease, Parkinson's disease, and AIDS-
CC related complex; stimulates chondrocyte growth, thus they can be used to
CC enhance bone and periodontal regeneration and aid in tissue transports or
CC bone grafts; prevents skin aging due to sunburn by stimulating
CC keratinocyte growth; prevents hair loss, since FGF family members
CC activate hair-forming cells and promotes melanocyte growth; stimulates
CC growth and differentiation of hematopoietic cells and bone marrow cells
CC when used in combination with other cytokines; maintains organs before
CC transplantation or for supporting cell culture of primary tissues;
CC induces tissue of mesodermal origin to differentiate in early embryos;
CC increases or decreases the differentiation or proliferation of embryonic
CC stem cells, besides, haematopoietic lineage; modulates mammalian
CC characteristics, such as, body height, weight, hair colour, eye colour,
CC skin, percentage of adipose tissue, pigmentation, size, and shape (e.g.,
CC cosmetic surgery); modulates mammalian metabolism; changes mammal's metal
CC state or physical state by influencing biorhythms, caricadic rhythms,
CC depression, tendency for violence, tolerance for pain, reproductive
CC capabilities, hormonal or endocrine levels, appetite, libido, memory, or
CC stress; increases or decreases storage capabilities, fat content, lipid,
CC protein, carbohydrate, vitamins, minerals, cofactors or other nutritional
CC components. This is the amino acid sequence of a novel human
CC musculoskeletal system antigen. Note: The sequence data for this patent
CC did not form part of the printed specification, but was obtained in
CC electronic format directly from the US patent office at
CC ftp.seqdata.uspto.gov/sequence.html?DocID=20020147140
XX
SQ Sequence 46 AA;

Query Match 30.9%; Score 30; DB 6; Length 46;
Best Local Similarity 41.7%; Pred. No. 1.4e+03;
Matches 5; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```
Qy          5 LNSKIAFKIVSQ 16
              |: ::|||: :|
Db         28 LSQEVAFKLSTQ 39
```

RESULT 116
ADJ28801
ID ADJ28801 standard; protein; 46 AA.
XX
AC ADJ28801;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human musculoskeletal system-associated protein - SEQ ID 1428.
XX
KW musculoskeletal system; cytostatic; osteopathic; cancer; osteoporosis;
KW gene therapy; vaccine; human.
XX
OS Homo sapiens.
XX
PN US2004009488-A1.
XX
PD 15-JAN-2004.
XX
PF 13-SEP-2002; 2002US-00242515.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.

PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
PR 17-JAN-2001; 2001US-00764877.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
DR WPI; 2004-090458/09.
DR N-PSDB; ADJ27778.
XX
PT New nucleic acid molecule, useful for preparing a medicament for
PT preventing, treating or ameliorating a medical condition e.g., cancer of
PT musculoskeletal tissues or osteoporosis.
XX
PS Claim 11; SEQ ID NO 1428; 289pp; English.
XX
CC The invention relates to a novel isolated musculoskeletal system-
CC associated nucleic acid molecule. The nucleic acid of the invention
CC demonstrates cytostatic and osteopathic activities and may be useful for
CC preparing a medicament for preventing, treating or ameliorating a medical
CC condition such as cancer of the musculoskeletal tissues or osteoporosis,
CC possibly via gene therapy or vaccine production. The current sequence is
CC that of the human musculoskeletal system-associated polypeptide of the
CC invention. The current sequence is not shown within the specification per
CC se but is available on the USPTO web-site
CC http:seqdata.uspto.gov/sequence.html?DocID=20040009488.

```
XX
SQ   Sequence 46 AA;

  Query Match             30.9%;  Score 30;  DB 8;  Length 46;
  Best Local Similarity   41.7%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              |: ::|||: :|
Db         28 LSQEVAFKLSTQ 39


RESULT 117
ABP33068
ID   ABP33068 standard; protein; 50 AA.
XX
AC   ABP33068;
XX
DT   09-JUL-2002  (first entry)
XX
DE   Human ORF2041 protein, SEQ ID NO:4082.
XX
KW   Human; ORF; open reading frame; ORFX; drug screening; diagnosis;
KW   disease monitoring; cytokine; cell proliferation; cell differentiation;
KW   immune modulation; haematopoiesis regulation; tissue growth;
KW   angiogenesis; activin; inhibin; chemotactic; chemokinetic; haemostatic;
KW   thrombolytic; tumour inhibition; bodily characteristic; fertility;
KW   behaviour; cancer; proliferative disorder; neurological disorder;
KW   cardiovascular disease; immune system disorder; organ transplantation;
KW   tissue growth disorder; tissue regeneration disorder; diabetes mellitus;
KW   hypothyroidism; cholesterol ester storage disease; infection; vulnerary;
KW   vasotropic; antipsoriatic; antidiabetic; cytostatic; nootropic;
KW   neuroprotective; antiatherosclerotic; anticoagulant; thrombolytic;
KW   cardiant; hypotensive; antithyroid; antiinflammatory; immunomodulator;
KW   dermatological; analgesic; virucide; antibacterial; fungicide.
XX
OS   Homo sapiens.
XX
PN   WO200190366-A2.
XX
PD   29-NOV-2001.
XX
PF   24-MAY-2001; 2001WO-US017076.
XX
PR   24-MAY-2000; 2000US-0206690P.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Leach MD,  Shimkets RA;
XX
DR   WPI; 2002-106200/14.
DR   N-PSDB; ABN77094.
XX
PT   Novel human polypeptides and polynucleotides useful for diagnosing,
PT   preventing and treating cardiovascular disease, neurodegenerative,
PT   hyperproliferative disorders and disorders related to organ
PT   transplantation.
XX
PS   Claim 10; Page 1278; 2508pp; English.
XX
CC   Sequences ABP31028-ABP35561 represent 4534 novel human proteins
CC   designated ORF (open reading frame) 1-4534, and sequences ABN75054-
CC   ABN79587 represent cDNAs encoding them. The invention also encompasses
CC   polypeptides at least 80% identical to the ORF1-ORF4534 (collectively
CC   referred to as ORFX) proteins, polynucleotides at least 85% identical to
CC   the ORFX nucleic acid sequences, vectors and host cells comprising ORFX
CC   polynucleotides, the recombinant production of ORFX proteins, antibodies
CC   specific for ORFX proteins, methods of detecting ORFX polynucleotides and
CC   polypeptides, methods of screening for modulators of ORFX expression or
CC   activity, and methods of screening individuals for a predisposition to an
CC   ORFX-associated disorder. The ORFX proteins of the invention have a wide
CC   range of biological activities, such as cytokine, cell proliferation,
CC   cell differentiation, immune modulation, haematopoiesis regulation,
CC   tissue growth, angiogenesis, activin or inhibin activity, chemotactic/
CC   chemokinetic activity, haemostatic activity, thrombolytic activity,
CC   receptor/ligand, antiinflammatory activity, tumour inhibition activity,
CC   and antiinfective activity, and may also be involved in the determination
CC   of bodily characteristics, fertility and behaviour. ORFX proteins,
CC   nucleic acids and antibodies may be used in the treatment of cancers,
CC   other proliferative disorders such as psoriasis and benign tumours,
CC   neurological disorders such as epilepsy and Alzheimer's disease,
CC   cardiovascular diseases, immune system disorders, disorders related to
CC   organ transplantation, disorders of tissue growth and regeneration,
CC   diseases such as diabetes mellitus, hypothyroidism, and cholesterol ester
CC   storage disease, and infectious diseases caused by viral, bacterial,
CC   fungal and other pathogens. ORFX nucleic acids may also be used as a
CC   source of primers and probes, in the detection of ORFX genomic sequences
CC   or transcripts, in the identification and cloning of homologous
CC   sequences, in genetic diagnosis, and in forensic biology. The ORFX
CC   nucleic acids may additionally be used to produce transgenic animals
CC   which may be useful for studying the function and/or activity of ORFX
CC   protein, and in drug screening. The ORFX proteins may also be used as
CC   immunogens to generate specific antibodies, which are useful in the
CC   diagnosis, treatment and monitoring of ORFX-associated diseases
XX
SQ   Sequence 50 AA;

  Query Match             30.9%;  Score 30;  DB 5;  Length 50;
  Best Local Similarity   37.5%;  Pred. No. 1.5e+03;
  Matches    6;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKIVSQ 16
              |  |:|  ||  : |:
Db         33 EEGHMNGLIAVTLCSR 48


RESULT 118
ABP30850
ID   ABP30850 standard; protein; 32 AA.
XX
AC   ABP30850;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Streptococcus polypeptide SEQ ID NO 10876.
XX
KW   Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
KW   group A streptococcus; Streptococcus pyogenes; antibacterial;
KW   antiinflammatory; infection; vaccine; meningitis; gene therapy.
XX
OS   Streptococcus agalactiae.
XX
PN   WO200234771-A2.
XX
PD   02-MAY-2002.
XX
PF   29-OCT-2001; 2001WO-GB004789.
XX
PR   27-OCT-2000; 2000GB-00026333.
PR   24-NOV-2000; 2000GB-00028727.
PR   07-MAR-2001; 2001GB-00005640.
XX
PA   (CHIR-) CHIRON SPA.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Telford J,  Masignani V,  Margarit Y RosI,  Grandi G,  Fraser C;
PI   Tettelin H;
XX
DR   WPI; 2002-352536/38.
DR   N-PSDB; ABN71481.
XX
PT   New Streptococcus protein for the treatment or prevention of infection or
PT   disease caused by Streptococcus bacteria, such as meningitis, and for
PT   detecting a compound that binds to the protein.
XX
PS   Claim 1; Page 4188; 4525pp; English.
```

XX
CC The invention relates to a protein (ABP25413-ABP30895) from group B
CC streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
CC (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
CC the specification. The proteins have antibacterial and antiinflammatory
CC activity. (I), nucleic acids encoding (I), ABN66044-ABN71526 and
CC antibodies that bind (I) are used in the manufacture of medicaments for
CC the treatment or prevention of infection or disease caused by
CC Streptococcus bacteria, particularly S. agalactiae and S. pyrogenes.
CC Nucleic acids encoding (I) are used to detect Streptococcus in a
CC biological sample. (I) is used to determine whether a compound binds to
CC (I). A composition comprising (I) or a nucleic acid encoding (I), may be
CC used as a vaccine or diagnostic composition. The disease caused by
CC Streptococcus that is prevented or treated may be meningitis. Nucleic
CC acid encoding (I) may be used to recombinantly produce (I) and may be
CC used in gene therapy. Antibodies to (I) are used for affinity
CC chromatography, immunoassays, and distinguishing/identifying
CC Streptococcus proteins
XX
SQ Sequence 32 AA;

Query Match 30.4%; Score 29.5; DB 5; Length 32;
Best Local Similarity 46.7%; Pred. No. 1.1e+03;
Matches 7; Conservative 3; Mismatches 4; Indels 1; Gaps 1;

Qy 6 NSKIAFKIVSQ-EPA 19
|::: || | |||
Db 16 NNRVKIKIACQYEPA 30

RESULT 119
ABP28726
ID ABP28726 standard; protein; 33 AA.
XX
AC ABP28726;
XX
DT 02-JUL-2002 (first entry)
XX
DE Streptococcus polypeptide SEQ ID NO 6628.
XX
KW Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
KW group A streptococcus; Streptococcus pyogenes; antibacterial;
KW antiinflammatory; infection; vaccine; meningitis; gene therapy.
XX
OS Streptococcus agalactiae.
XX
PN WO200234771-A2.
XX
PD 02-MAY-2002.
XX
PF 29-OCT-2001; 2001WO-GB004789.
XX
PR 27-OCT-2000; 2000GB-00026333.
PR 24-NOV-2000; 2000GB-00028727.
PR 07-MAR-2001; 2001GB-00005640.
XX
PA (CHIR-) CHIRON SPA.
PA (GENO-) INST GENOMIC RES.
XX
PI Telford J, Masignani V, Margarit Y RosI, Grandi G, Fraser C;
PI Tettelin H;
XX
DR WPI; 2002-352536/38.
DR N-PSDB; ABN69357.
XX
PT New Streptococcus protein for the treatment or prevention of infection or
PT disease caused by Streptococcus bacteria, such as meningitis, and for
PT detecting a compound that binds to the protein.
XX
PS Claim 1; Page 3825; 4525pp; English.
XX
CC The invention relates to a protein (ABP25413-ABP30895) from group B
CC streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
CC (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
CC the specification. The proteins have antibacterial and antiinflammatory
CC activity. (I), nucleic acids encoding (I), ABN66044-ABN71526 and
CC antibodies that bind (I) are used in the manufacture of medicaments for
CC the treatment or prevention of infection or disease caused by
CC Streptococcus bacteria, particularly S. agalactiae and S. pyrogenes.
CC Nucleic acids encoding (I) are used to detect Streptococcus in a
CC biological sample. (I) is used to determine whether a compound binds to
CC (I). A composition comprising (I) or a nucleic acid encoding (I), may be
CC used as a vaccine or diagnostic composition. The disease caused by
CC Streptococcus that is prevented or treated may be meningitis. Nucleic
CC acid encoding (I) may be used to recombinantly produce (I) and may be
CC used in gene therapy. Antibodies to (I) are used for affinity
CC chromatography, immunoassays, and distinguishing/identifying
CC Streptococcus proteins
XX
SQ Sequence 33 AA;

Query Match 30.4%; Score 29.5; DB 5; Length 33;
Best Local Similarity 41.2%; Pred. No. 1.1e+03;
Matches 7; Conservative 4; Mismatches 5; Indels 1; Gaps 1;

Qy 1 EPNHLN-SKIAFKIVSQ 16
:| |:| ::| ||
Db 7 QPEHININRIEIMPVSQ 23

RESULT 120
AAG56269
ID AAG56269 standard; protein; 44 AA.
XX
AC AAG56269;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 72301.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.

PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.

PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 30.4%; Score 29.5; DB 3; Length 44;
Best Local Similarity 33.3%; Pred. No. 1.6e+03;
Matches 6; Conservative 5; Mismatches 4; Indels 3; Gaps 1;

Qy 2 PNHLNSKIAFKIVSQEPA 19
Db 16 PSHIRSEV---VQPPEPA 30

RESULT 121
AAG60246
ID AAG60246 standard; protein; 44 AA.
XX
AC AAG60246;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 78013.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.

PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 30.4%; Score 29.5; DB 3; Length 44;
Best Local Similarity 33.3%; Pred. No. 1.6e+03;
Matches 6; Conservative 5; Mismatches 4; Indels 3; Gaps 1;

```
Qy          2 PNHLNSKIAFKIVSQEPA 19
              |:|: |::   :   |||
Db         16 PSHIRSEV---VQPPEPA 30
```

RESULT 122
AAO11779
ID AAO11779 standard; protein; 48 AA.
XX
AC AAO11779;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 25671.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorders; arthritis; inflammation.
XX
OS Homo sapiens.
XX
PN WO200164835-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US004927.
XX
PR 28-FEB-2000; 2000US-00515126.
PR 18-MAY-2000; 2000US-00577409.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-514838/56.
DR N-PSDB; AAI91710.
XX
PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing
PT and treating e.g. leukemia, inflammation and immune disorders.
XX
PS Claim 20; SEQ ID NO 25671; 1399pp + Sequence Listing; English.
XX
CC The invention relates to human polynucleotides (AAI79941-AAI93841) and
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 48 AA;

Query Match 30.4%; Score 29.5; DB 4; Length 48;
Best Local Similarity 37.5%; Pred. No. 1.7e+03;
Matches 6; Conservative 4; Mismatches 3; Indels 3; Gaps 1;

```
Qy          3 NHLNSKIAFKIVSQEP 18
              |||:|::    |  :|
```

```
Db          2 NHLSSRVG---VQDQP 14


RESULT 123
AAW42197
ID   AAW42197 standard; peptide; 20 AA.
XX
AC   AAW42197;
XX
DT   27-AUG-2003  (revised)
DT   25-MAR-2003  (revised)
DT   16-JUN-1998  (first entry)
XX
DE   T-cell epitope peptide 77 from Japanese cypress pollen antigen Chao2.
XX
KW   Japanese cypress pollen; antigen; T-cell epitope; Chao1; Chao2;
KW   diagnosis; allergy; spring tree pollen disease; pollinosis.
XX
OS   Chamaecyparis obtusa.
XX
PN   WO9747648-A1.
XX
PD   18-DEC-1997.
XX
PF   12-JUN-1997;   97WO-JP002031.
XX
PR   14-JUN-1996;   96JP-00153527.
XX
PA   (MEIP ) MEIJI MILK PROD CO LTD.
XX
PI   Kino K,  Dairiri K;
XX
DR   WPI; 1998-052242/05.
XX
PT   T-cell epitope peptide portion of Japanese cypress pollen antigens Chao1
PT   and Chao2 - used for diagnosis and treatment of spring tree pollen
PT   disease.
XX
PS   Claim 2; Page 50; 71pp; Japanese.
XX
CC   The present sequence represents a T-cell epitope peptide from Japanese
CC   cypress pollen antigen Chao2. The present invention describes peptides
CC   which correspond to the T-cell epitope sites on Japanese cypress pollen
CC   antigens Chao1 and Chao2. The peptides can be used as a reagent for the
CC   diagnosis of allergy to Japanese cypress pollen, and as an antigen in the
CC   treatment and prevention of spring tree pollen disease in which the
CC   pollinosis involves reactivity to Japanese cypress pollen. (Updated on 25
CC   -MAR-2003 to correct PI field.) (Updated on 27-AUG-2003 to correct OS
CC   field.)
XX
SQ   Sequence 20 AA;

  Query Match             29.9%;  Score 29;  DB 2;  Length 20;
  Best Local Similarity   38.5%;  Pred. No. 7.4e+02;
  Matches    5;  Conservative    4;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          7 SKIAFKIVSQEPA 19
              | :: |: | :||
Db          6 SNVSLKLTSGKPA 18


RESULT 124
ADB75643
ID   ADB75643 standard; peptide; 20 AA.
XX
AC   ADB75643;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human TM2 peptide SEQ ID NO:52.
XX
KW   antibody library; CD1 region; CD2 region; VH region; VL region;
KW   immunoglobulin; CD3 region; human; TM2.
XX
OS   Homo sapiens.
XX
PN   WO2003044198-A1.
XX
PD   30-MAY-2003.
XX
PF   22-NOV-2002; 2002WO-JP012236.
XX
PR   22-NOV-2001; 2001JP-00358602.
XX
PA   (UYKE-) UNIV KEIO.
XX
PI   Shimizu N,  Takayanagi A,  Okui M;
XX
DR   WPI; 2003-449818/42.
XX
PT   Highly stable artificial antibody libraries with super-repertory and
PT   little contamination from unexpressible ones, useful as tool in
PT   proteomics and e.g. for diagnosis and treating various diseases.
XX
PS   Example 3; Page 34; 108pp; Japanese.
XX
CC   The invention relates to a novel artificial single-stranded antibody
CC   library with superior-repertory. The library is created by using a cDNA
CC   library as template for amplifying a fragment containing the CD1 and CD2
CC   regions of the VH or VL region of immunoglobulin gene and a fragment
CC   containing the CD3 region by PCR, respectively, producing VH and VL
CC   libraries, transferring into a host, and displaying the single-stranded
CC   antibody on a phage surface. An antibody library of the invention is
CC   useful as a tool in proteomics and antibody chips and filters, for
CC   screening ligands for antigens, and for studying protein-DNA interaction,
CC   diagnosis and treating various diseases. The present sequence represents
CC   a peptide used in the invention.
XX
SQ   Sequence 20 AA;

  Query Match             29.9%;  Score 29;  DB 7;  Length 20;
  Best Local Similarity   50.0%;  Pred. No. 7.4e+02;
  Matches    5;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              |:||  || :
Db          3 PSHLVEKIVY 12


RESULT 125
AAP71423
ID   AAP71423 standard; protein; 21 AA.
XX
AC   AAP71423;
XX
DT   25-MAR-2003  (revised)
DT   03-MAY-1991  (first entry)
XX
DE   Immunomodulator peptide #2 inhibits HIV-T4 interaction.
XX
KW   AIDS; T4 cell receptor; immunomodulation.
XX
OS   Synthetic.
XX
PN   WO8703601-A.
XX
PD   18-JUN-1987.
XX
PF   08-DEC-1986;   86WO-FR000425.
XX
PR   06-DEC-1985;   85FR-00018155.
XX
PA   (INSP ) INST PASTEUR.
PA   (AUFR/) AUFRAY C.
PA   (CNRS ) CENT NAT RECH SCI.
XX
```

PI Auffray C, Montagnier L, Klatzmann D, Charron D;
XX
DR WPI; 1987-177935/25.
XX
PT New peptide derivs. contg. specified exposed tetra:peptide sequences -
PT inhibiting interaction of AIDS virus with T4 cell receptors.
XX
PS Claim 5; Page 48; 57pp; French.
XX
CC The peptide is a specific example of a peptide comprising the
CC tetrapeptide motif RFDS (pref. at position 7 to 10 and optionally having
CC RE at positions 1 and 2 and/or EL at positions 20 and 21). It interferes
CC with interaction between the AIDS virus and T4 receptors on lymphocytes.
CC The peptide also has immunomodulatory activity. It is useful in diagnosis
CC to detect antibodies to the region of the viral genome containing the
CC RFDS sequence. See also AAP71422 and AAP71424-P71437. (Updated on 25-MAR-
CC 2003 to correct PF field.) (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 21 AA;

Query Match 29.9%; Score 29; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 7.8e+02;
Matches 6; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 6 NSKIAFKIVSQE 17
:||:|| |::|
Db 9 DSKLAFHHVARE 20

RESULT 126
ADI40693
ID ADI40693 standard; peptide; 24 AA.
XX
AC ADI40693;
XX
DT 22-APR-2004 (first entry)
XX
DE Nef/SH3 domain inhibitory peptide #6.
XX
KW kidney cell dedifferentiation; Nef; Src family tyrosine kinase;
KW SH3 domain; HIV associated nephropathy; HIVAN; AIDS; dementia; anaemia;
KW lymphoma; myopathy; cardiomyopathy;
KW primary HIV-induced disease progression.
XX
OS Human immunodeficiency virus 1.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "Biotinylated"
XX
PN US2003229906-A1.
XX
PD 11-DEC-2003.
XX
PF 14-APR-2003; 2003US-00413785.
XX
PR 15-APR-2002; 2002US-0372557P.
XX
PA (GELM/) GELMAN I H.
PA (KLOT/) KLOTMAN P.
PA (ZHOU/) ZHOU M M.
XX
PI Gelman IH, Klotman P, Zhou MM;
XX
DR WPI; 2004-178661/17.
XX
PT Inhibiting kidney cell dedifferentiation for treating e.g., HIV
PT associated nephropathy by inhibiting the interaction of Nef with a Src
PT family tyrosine kinase SH3 domain of a polypeptide of the cell.
XX
PS Claim 9; SEQ ID NO 6; 42pp; English.
XX
CC The invention relates to a method of inhibiting kidney cell
CC dedifferentiation comprising inhibiting the interaction of Nef with a Src
CC family tyrosine kinase SH3 domain of a polypeptide of the cell. The
CC method is useful for inhibiting kidney cell dedifferentiation for
CC treating e.g., HIV associated nephropathy (HIVAN), AIDS, dementia,
CC anaemia, lymphoma, myopathy, cardiomyopathy or primary HIV-induced
CC disease progression. The present sequence represents the amino acid
CC sequence of a Nef/SH3 inhibitory peptide.
XX
SQ Sequence 24 AA;

Query Match 29.9%; Score 29; DB 8; Length 24;
Best Local Similarity 41.7%; Pred. No. 9.2e+02;
Matches 5; Conservative 2; Mismatches 5; Indels 0; Gaps 0;

Qy 8 KIAFKIVSQEPA 19
|: | : | ||
Db 8 KVGFPVTPQVPA 19

RESULT 127
AAU87955
ID AAU87955 standard; peptide; 26 AA.
XX
AC AAU87955;
XX
DT 05-JUN-2002 (first entry)
XX
DE Human PDZP5 domain #6.
XX
KW Human; PDZ domain; WW domain; rat; cow; mouse; fruitfly; protein therapy;
KW gene therapy; PDZ-mediated disease; inward potassium channel; WBP;
KW dimer inhibitor peptide; carboxylate binding loop.
XX
OS Homo sapiens.
XX
PN WO200207751-A1.
XX
PD 31-JAN-2002.
XX
PF 24-JUL-2001; 2001WO-US023269.
XX
PR 25-JUL-2000; 2000US-0221215P.
PR 28-NOV-2000; 2000US-00723810.
XX
PA (AXCE-) AXCELL BIOSCIENCES CORP.
XX
PI Herrero J, Pirozzi G, Uveges A;
XX
DR WPI; 2002-195842/25.
DR N-PSDB; ABK46567.
XX
PT Methods for identifying polypeptides comprising PDZ domains, the
PT polypeptides and their encoding nucleic acids, useful for the diagnosis
PT and treatment of PDZ related disorders.
XX
PS Claim 83; Page 216; 225pp; English.
XX
CC The invention relates to methods for identifying polypeptides comprising
CC PDZ domains, and their encoding nucleic acids. The sequences are used to
CC identify modulators of their expression, function and activity, for use
CC in the diagnosis and treatment of PDZ related disorders. Antibodies
CC against the proteins and cells that produce them may be used for the
CC treatment of PDZ-mediated disease states. Sequences AAU87843-AAU87974
CC represent proteins containing PDZ domains, fragments of these proteins
CC and other related peptides used in the methods of the invention
XX
SQ Sequence 26 AA;

Query Match 29.9%; Score 29; DB 5; Length 26;
Best Local Similarity 50.0%; Pred. No. 1e+03;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

```
Qy          3 NHLNSKIAFK 12
              :||| |  |:
Db         15 DHLNQKTQFE 24


RESULT 128
AAW72756
ID   AAW72756 standard; peptide; 28 AA.
XX
AC   AAW72756;
XX
DT   27-AUG-2003  (revised)
DT   12-JAN-1999  (first entry)
XX
DE   SpeI restriction endonuclease amino terminal 28 residue sequence.
XX
KW   Methylase; SpeI restriction endonuclease; recombinant DNA.
XX
OS   Sphaerotilus.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 20
FT                   /note= "unspecified"
XX
PN   EP869174-A2.
XX
PD   07-OCT-1998.
XX
PF   18-MAR-1998;   98EP-00302083.
XX
PR   20-MAR-1997;   97US-00821619.
XX
PA   (NEWE ) NEW ENGLAND BIOLABS INC.
XX
PI   Morgan RD,  Chang Z,  Mersha FB;
XX
DR   WPI; 1998-508490/44.
XX
PT   New DNA coding for {I SpeI}I restriction endonuclease and methylase -
PT   using host cells premodified with the methylase gene, and using a
PT   purification step which removes non-specific endonuclease and exonuclease
PT   contamination.
XX
PS   Example 1; Page 11; 23pp; English.
XX
CC   The present invention describes isolated DNA from Sphaerotilus species
CC   encoding the SpeI restriction endonuclease. Also described are: (1) a
CC   recombinant DNA vector comprising above DNA; (2) isolated DNA from ATCC
CC   No.98366 encoding the SpeI restriction endonuclease and methylase; (3) a
CC   cloning vector comprising DNA of (2); and (4) host cells transformed by
CC   vectors of (1) or (3). The SpeI enzyme recognises 5'-ACTA/GT-3', and
CC   cells as in (4) can be used to produce recombinant SpeI endonuclease. The
CC   present sequence represents the first 28 residues of SpeI restriction
CC   endonuclease from an example from the present invention. (Updated on 27-
CC   AUG-2003 to correct OS field.)
XX
SQ   Sequence 28 AA;

  Query Match             29.9%;  Score 29;  DB 2;  Length 28;
  Best Local Similarity   55.6%;  Pred. No. 1.1e+03;
  Matches    5;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKI 9
              :|| |||| :
Db          4 DPNKLNSAL 12


RESULT 129
ABB41309
ID   ABB41309 standard; peptide; 28 AA.
XX
AC   ABB41309;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #8815 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 33944; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 28 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 28;
  Best Local Similarity   42.9%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | ||| :| | : :|
Db          5 LKSKASFSIYAFDP 18


RESULT 130
AAM35097
ID   AAM35097 standard; protein; 28 AA.
XX
AC   AAM35097;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #9134 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
```

```
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 35366; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 28 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 28;
  Best Local Similarity   42.9%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | ||  :| |  : :|
Db          5 LKSKASFSIYAFDP 18


RESULT 131
ABB25278
ID   ABB25278 standard; protein; 28 AA.
XX
AC   ABB25278;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #7277 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000666.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts.
XX
PS   Claim 15; SEQ ID NO 27048; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart (see
CC   ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC   probe. The probes may be used for predicting, measuring and displaying
CC   gene expression in samples derived from the human heart via microarrays.
CC   By measuring gene expression, the probes are useful for predicting,
CC   diagnosing, grading, staging, monitoring and prognosing diseases of the
CC   human heart and vascular system e.g. cardiovascular disease,
CC   hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 28 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 28;
  Best Local Similarity   42.9%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | ||  :| |  : :|
Db          5 LKSKASFSIYAFDP 18


RESULT 132
AAM74981
ID   AAM74981 standard; protein; 28 AA.
XX
AC   AAM74981;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human bone marrow expressed probe encoded protein SEQ ID NO: 35287.
XX
KW   Human; bone marrow expressed exon; gene expression analysis; probe;
KW   microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS   Homo sapiens.
XX
PN   WO200157276-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000668.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488900/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human bone marrow.
XX
PS   Example 4; SEQ ID NO 35287; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
```

```
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention
XX
SQ   Sequence 28 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 28;
  Best Local Similarity   42.9%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | || :| | : :|
Db          5 LKSKASFSIYAFDP 18


RESULT 133
AAM62177
ID   AAM62177 standard; protein; 28 AA.
XX
AC   AAM62177;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 34282.
XX
KW   Human; brain expressed exon; gene expression analysis; probe; microarray;
KW   Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000667.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains.
XX
PS   Example 4; SEQ ID NO 34282; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 28 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 28;
  Best Local Similarity   42.9%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | || :| | : :|
Db          5 LKSKASFSIYAFDP 18


RESULT 134
ABG56752
ID   ABG56752 standard; peptide; 28 AA.
XX
AC   ABG56752;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 35400.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 35400; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 28 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 28;
  Best Local Similarity   42.9%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | || :| | : :|
Db          5 LKSKASFSIYAFDP 18


RESULT 135
ABG44713
ID   ABG44713 standard; peptide; 28 AA.
XX
AC   ABG44713;
XX
```

DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 34378.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesis; pulmonary hypertension;
KW hyaline membrane disease.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US000665.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.
XX
PS Claim 27; SEQ ID NO 34378; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of probes
CC ; the novel set of probes which hybridise at high stringency to a nucleic
CC acid expressed in the human lung; measuring gene expression in a sample
CC derived from human lung, comprising (a) contacting the array with a
CC collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of the
CC array; identifying exons in a eukaryotic genome, comprising (a)
CC algorithmically predicting at least one exon from genomic sequences of
CC the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene expression
CC analysis, and for identifying exons in a gene, particularly using human
CC lung derived mRNA and for the study of lung diseases such as asthma, lung
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC present sequence is a peptide/protein encoded by a single exon probe of
CC the invention. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 28 AA;

Query Match 29.9%; Score 29; DB 5; Length 28;
Best Local Similarity 42.9%; Pred. No. 1.1e+03;
Matches 6; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVSQEP 18
| || :| | : :|
Db 5 LKSKASFSIYAFDP 18

RESULT 136
ABG93608
ID ABG93608 standard; peptide; 28 AA.
XX
AC ABG93608;
XX
DT 25-NOV-2002 (first entry)
XX
DE Human P-glycoprotein tryptic peptide #128.
XX
KW Human; P-glycoprotein; tryptic digest; proteolytic cleavage product;
KW diabetes; Parkinson's disease; Alzheimer's disease; malaria; cholera;
KW human immunodeficiency virus infection; influenza; rabies; diphtheria;
KW cancer; multi-drug resistance; MDR.
XX
OS Homo sapiens.
XX
PN EP1223534-A1.
XX
PD 17-JUL-2002.
XX
PF 11-JAN-2002; 2002EP-00075095.
XX
PR 14-JAN-2001; 2001IL-00140881.
PR 19-OCT-2001; 2001US-00982172.
XX
PA (KATZ/) KATZ E I.
XX
PI Katz EI;
XX
DR WPI; 2002-645691/70.
XX
PT Generating amino acid sequences representative of desired polypeptide, by
PT computationally generating proteolytic cleavage products, analyzing and
PT selecting the set of products, thus generating amino acid sequences.
XX
PS Example 1; Page 15; 124pp; English.
XX
CC The invention relates to generating set of amino acid sequences (AAS)
CC representative of one desired polypeptide (I), involving computationally
CC generating a number of proteolytic cleavage products (PCP) from (I),
CC analysing the PCP according to one parameter defining a characteristic of
CC AAS and selecting a set of PCP according to a preset criteria for each
CC parameter, thus generating the set of AAS representative of (I). Also
CC included are (1) a computer readable storage media (II) comprising a
CC database of amino acid sequences corresponding to the polypeptide of
CC interest; (2) a system (III) for generating a database of amino acid
CC sequences corresponding to a polypeptide of interest, comprises a
CC processing unit which executes a software application configured for
CC generating the number of proteolytic cleavage products from one
CC polypeptide of interest, and analysing the number of proteolytic cleavage
CC products according to one parameter defining a characteristic of amino
CC acid sequence; (3) a kit for quantifying at least one polypeptide of
CC interest, comprises a number of peptides or antibodies each capable of
CC specifically recognising at least one peptide, where the number of

CC peptides is generated according to information derived from computational
CC analysis of the polypeptide of interest; and (4) quantifying one
CC polypeptide of interest in a biological sample, involving contacting the
CC biological sample with proteolytic agent, so as to obtain a proteolysed
CC biological sample, contacting the proteolysed biological sample with at
CC least one antibody and at least one peptide of a number of peptides, and
CC detecting presence, absence and/or level of antibody binding to thus
CC quantify one polypeptide of interest in the biological sample. The method
CC is useful for generating at least one antibody specific to a polypeptide
CC of interest. The peptides or antibodies generated may be used to diagnose
CC diabetes, Parkinson's disease, Alzheimer's disease, human
CC immunodeficiency virus infection, malaria, cholera, influenza, rabies,
CC diphtheria, cancer (e.g. breast, colon, cervix, melanoma, lung, ovary,
CC pancreas, prostate, lymphomas and leukaemias). The present sequence is a
CC predicted tryptic peptide from human P-glycoprotein generated to form
CC part of a kit for identifying multi-drug (MDR) resistance associated
CC proteins
XX
SQ Sequence 28 AA;

Query Match 29.9%; Score 29; DB 5; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 IVSQEP 18
||||||
Db 5 IVSQEP 10

RESULT 137
AAB27777
ID AAB27777 standard; protein; 29 AA.
XX
AC AAB27777;
XX
DT 30-JAN-2001 (first entry)
XX
DE Sequence homologous to protein fragment encoded by gene 42.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
OS Homo sapiens.
XX
PN WO200055201-A1.
XX
PD 21-SEP-2000.
XX
PF 09-MAR-2000; 2000WO-US006059.
XX
PR 12-MAR-1999; 99US-0124096P.
PR 03-DEC-1999; 99US-0168622P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Komatsoulis G;
XX
DR WPI; 2000-628182/60.
XX
PT Novel human secreted proteins useful for diagnosis, prevention and
PT treatment of disorders including neurological, cell proliferative,
PT cardiovascular, autoimmune/inflammatory disorders and microbial
PT infections.
XX
PS Disclosure; Page 54; 427pp; English.
XX
CC The invention relates to the isolation of genes AAC59157-C59205 encoding
CC the human secreted proteins AAB27682-B27730. This sequence represents a
CC peptide fragment homologous to the protein encoded by the gene given in
CC the descriptor line. The sequence is a search result from a BLASTX
CC homology search. The genes and proteins are useful for preventing,
CC ameliorating or treating medical conditions, e.g. by protein or gene
CC therapy. The genes are isolated from a range of human tissues disclosed
CC in the specification. The nucleic acids, proteins, antibodies and
CC (ant)agonists are useful in the diagnosis, treatment and prevention of:
CC (a) cancer, e.g. breast and ovarian cancer, and other cancers of the
CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,
CC lung, or urogenital; (b) immune disorders e.g. Addison's disease,
CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as
CC myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.
CC cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,
CC bacterial, fungal and parasitic infections
XX
SQ Sequence 29 AA;

Query Match 29.9%; Score 29; DB 3; Length 29;
Best Local Similarity 71.4%; Pred. No. 1.2e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EPNHLNS 7
: |||||
Db 6 QENHLNS 12

RESULT 138
AAW19976
ID AAW19976 standard; peptide; 31 AA.
XX
AC AAW19976;
XX
DT 25-MAR-2003 (revised)
DT 18-AUG-1997 (first entry)
XX
DE Fibronectin fragment P2, corresponds to aa 625-655.
XX
KW Fibronectin; structural; promote; disulphide bridge; cell culture;
KW extracellular matrix; migration; growth; metastasis; tumour; cancer;
KW neoplasia; fibronectin-fibronectin binding site; self-assembly;
KW type III repeat; C-terminal type I repeat.
XX
OS Homo sapiens.
XX
PN US5629291-A.
XX
PD 13-MAY-1997.
XX
PF 17-NOV-1994; 94US-00340812.
XX
PR 31-JAN-1992; 92US-00829462.
PR 16-FEB-1993; 93US-00021626.
XX
PA (LJOL-) LA JOLLA CANCER RES FOUND.
XX
PI Morla A, Ruoslahti EI;
XX
DR WPI; 1997-280300/25.
XX
PT Promoting extracellular fibronectin matrix formation - by contacting
PT cells with fibronectin fragments, useful in, e.g. cell culture.
XX
PS Example 1; Col 11; 42pp; English.
XX
CC AAW19976 and AAW19977 are peptide fragments of human fibronectin (FN)
CC type III-I repeat region. Certain peptides derived from this region
CC promote extracellular FN matrix formation in a cellular system in the
CC presence of FN. The peptides promote FN self-assembly by forming
CC disulphide cross-linked FN. Normal fibroblasts in tissue culture secrete
CC FN and assemble it into a matrix that is essential for adhesion, growth
CC and migration. Tumour cells fail to assemble FN into the extracellular
CC matrix (ECM), the lack of ECM is thought to contribute to the invasive
CC properties of tumour cells. Other peptides derived from the C-terminal

```
CC   type I repeat of FN are used to inhibit matrix formation by blocking the
CC   FN-FN, self assembly binding site. The peptides are used to control
CC   biological processes related to extracellular FN matrix formation, e.g in
CC   cell culture, directing tissue regeneration and ameliorating certain
CC   pathological conditions. Matrix formation- inhibiting peptides can
CC   prevent scar formation. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 31 AA;

  Query Match             29.9%;  Score 29;  DB 2;  Length 31;
  Best Local Similarity   83.3%;  Pred. No. 1.3e+03;
  Matches    5;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 PNHLNS 7
              | ||||
Db          5 PGHLNS 10


RESULT 139
AAW82987
ID   AAW82987 standard; peptide; 31 AA.
XX
AC   AAW82987;
XX
DT   10-FEB-1999  (first entry)
XX
DE   Human fibronectin III-1 repeat peptide fragment #2.
XX
KW   Human; fibronectin; type III repeat; binding site; inhibition;
KW   tumour cell migration; extracellular matrix assembly; scar formation;
KW   implant.
XX
OS   Homo sapiens.
XX
PN   US5837813-A.
XX
PD   17-NOV-1998.
XX
PF   01-JUN-1995;   95US-00460421.
XX
PR   31-JAN-1992;   92US-00829462.
PR   16-FEB-1993;   93US-00021626.
PR   17-NOV-1994;   94US-00340812.
XX
PA   (LJOL-) LA JOLLA CANCER RES FOUND.
XX
PI   Ruoslahti EI,  Morla A;
XX
DR   WPI; 1999-023534/02.
XX
PT   New recombinant fragments of the III-1 repeat of fibronectin - contain
PT   fibronectin binding site so modulate extracellular matrix assembly and
PT   cell migration and increase cell binding to surfaces.
XX
PS   Example 1; Col 11; 45pp; English.
XX
CC   The present sequence represents a fragment of the III-1 repeat of
CC   fibronectin. The present invention describes a fragment of the III-1
CC   repeat of fibronectin which is capable of binding fibronectin. The
CC   protein fragment inhibits fibronectin-fibronectin binding, and so
CC   modulates (enhances or inhibits, depending on concentration) fibronectin
CC   extracellular matrix assembly and related processes. The protein fragment
CC   can be used to inhibit the migration of tumour cells, inhibit scar
CC   formation and promote cell attachment to surfaces such as implants. The
CC   protein fragment may also be used to target molecules to fibronectin-
CC   containing tissues and cells, or for affinity isolation of fibronectin
XX
SQ   Sequence 31 AA;

  Query Match             29.9%;  Score 29;  DB 2;  Length 31;
  Best Local Similarity   83.3%;  Pred. No. 1.3e+03;
  Matches    5;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 PNHLNS 7
              | ||||
Db          5 PGHLNS 10


RESULT 140
AAB39245
ID   AAB39245 standard; protein; 31 AA.
XX
AC   AAB39245;
XX
DT   02-FEB-2001  (first entry)
XX
DE   Gene 9 human secreted protein homologous amino acid sequence #125.
XX
KW   Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
KW   antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
KW   nootropic; neuroprotective; antibacterial; virucide; fungicide; neoplasm;
KW   opthalmalogical; autoimmune disease; rheumatoid arthritis; angiogenesis;
KW   hyperproliferative disorder; cardiovascular disorder; infection;
KW   cerebrovascular disorder; nervous system disorder; ocular disorder;
KW   wound healing; chemotaxis.
XX
OS   Homo sapiens.
XX
PN   WO200056754-A1.
XX
PD   28-SEP-2000.
XX
PF   16-MAR-2000; 2000WO-US006792.
XX
PR   19-MAR-1999;   99US-0125362P.
PR   10-DEC-1999;   99US-0169980P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen GA,  Ruben SM,  Komatsoulis G;
XX
DR   WPI; 2000-579483/54.
XX
PT   Isolated nucleic acid molecule encoding a human secreted protein is used
PT   in preventing, treating or ameliorating a medical condition.
XX
PS   Disclosure; Page 25; 434pp; English.
XX
CC   The polynucleotide sequences given in AAC74223-C74279 encode the human
CC   secreted proteins represented in AAB39179-B39226. Sequences AAB39227-
CC   B39308 are alternative proteins encoded by the genes, and also protein
CC   sequences with which they share homology. The proteins have activities
CC   based on the tissues and cells in which they are expressed. Examples of
CC   activities include: immunosuppressive; antiarthritic; antirheumatic;
CC   antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
CC   nootropic; neuroprotective; antibacterial; virucide; fungicide; and
CC   opthalmalogical. The human secreted proteins, polynucleotides,
CC   antagonists and agonists of the invention may be useful in the treatment,
CC   prevention, and/or diagnosis of various disease, disorders and conditions
CC   such as autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC   disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC   e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC   angiogenesis, nervous system disorders e.g. Alzheimer's disease,
CC   infections caused by bacteria, viruses and fungi and ocular disorders
CC   e.g. corneal infection. The polypeptides can also be used to aid wound
CC   healing and epithelial cell proliferation, to regenerate tissues,
CC   maintain organs before transplantation, in chemotaxis and as a food
CC   additive or preservative e.g. to increase storage capabilities. Sequences
CC   AAC74214-C74222 and AAB39178 are used during the isolation and
CC   characterisation of the genes of the invention
XX
SQ   Sequence 31 AA;

  Query Match             29.9%;  Score 29;  DB 3;  Length 31;
  Best Local Similarity   71.4%;  Pred. No. 1.3e+03;
  Matches    5;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy          1 EPNHLNS 7
              : |||||
Db          1 QENHLNS 7
```

RESULT 141
ABO55532
ID ABO55532 standard; protein; 32 AA.
XX
AC ABO55532;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #1766.
XX
KW Human; gene expression; single exon probe; microarray;
KW alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 29166; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridises under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-
CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above- mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 32 AA;

```
  Query Match             29.9%;  Score 29;  DB 8;  Length 32;
  Best Local Similarity   71.4%;  Pred. No. 1.3e+03;
  Matches    5;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          12 KIVSQEP 18
               |:||:||
Db          17 KVVSREP 23
```

RESULT 142
AAM42284
ID AAM42284 standard; protein; 33 AA.
XX
AC AAM42284;
XX
DT 19-OCT-2001 (first entry)
XX
DE Human breast or ovarian antigen SEQ ID NO: 161.
XX
KW Human; breast antigen; ovarian antigen; cancer; metastasis; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200155324-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001344.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.

PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488785/53.
DR N-PSDB; AAI62511.
XX
PT New isolated nucleic acids and polypeptides, useful for diagnosing,
PT treating and/or preventing human diseases and disorders.
XX
PS Claim 11; SEQ ID NO 161; 520pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of ovarian and breast antigens. These are shown in AAI62467-
CC AAI62572 and AAM42240-AAM42345. The sequences can be used in the
CC diagnosis, prevention and treatment of breast and ovarian cancers, and
CC their metastases. The present sequence is a protein of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 33 AA;

Query Match 29.9%; Score 29; DB 4; Length 33;
Best Local Similarity 50.0%; Pred. No. 1.4e+03;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

```
Qy          2 PNHLNSKIAF 11
              || | |:: |
Db         14 PNKLTSQLTF 23
```

RESULT 143
AAM96243
ID AAM96243 standard; protein; 33 AA.
XX
AC AAM96243;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human reproductive system related antigen SEQ ID NO: 4901.
XX
KW Human; reproductive system related antigen; reproductive system disorder;
KW cancer; gene therapy.

XX
OS Homo sapiens.
XX
PN WO200155320-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001339.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX

PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465570/50.
DR N-PSDB; AAL02213.
XX
PT Isolated nucleic acid molecule encoding a reproductive system antigen is
PT used in preventing, treating or ameliorating a medical condition.
XX
PS Claim 11; SEQ ID NO 4901; 1297pp + Sequence Listing; English.
XX
CC The present invention provides the protein and coding sequences of a
CC number of human reproductive system related antigens. These can be used
CC in the prevention and treatment of reproductive system disorders,
CC including cancer. The present sequence is a protein of the invention
XX
SQ Sequence 33 AA;

Query Match 29.9%; Score 29; DB 4; Length 33;
Best Local Similarity 50.0%; Pred. No. 1.4e+03;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAF 11
|| | |:: |
Db 14 PNKLTSQLTF 23

RESULT 144
ADE01861
ID ADE01861 standard; peptide; 33 AA.
XX
AC ADE01861;
XX
DT 29-JAN-2004 (first entry)
XX
DE Hybrid polypeptide pharmacokinetic enhancer peptide, SEQ ID No 368.
XX
KW hybrid; enhancer; anti-fusogenic; antiviral; virucide; antidiabetic;
KW pharmacokinetic; fusogenic; insulin; diabetes.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "Residue is modified by acetyl group"
FT Modified-site 33
FT /note= "C-terminal amide"
XX
PN US6348568-B1.
XX
PD 19-FEB-2002.
XX
PF 20-MAY-1999; 99US-00315304.
XX
PR 20-MAY-1998; 98US-00082279.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Barney S, Guthrie KI, Merutka G, Anwer MK, Lambert DM;
XX
DR WPI; 2002-424396/45.
XX
PT New hybrid polypeptide for modulating fusogenic events for e.g. antiviral
PT activity, has enhancer peptide sequence derived from retroviral envelope
PT protein sequences linked to core polypeptide e.g. therapeutic protein.
XX
PS Disclosure; SEQ ID NO 368; 70pp; English.
XX
CC The invention relates to a novel hybrid polypeptide comprising an
CC enhancer peptide sequence linked to a core polypeptide. The enhancer
CC peptide sequence comprises WQEWEQKI or WASLWEWF. The invention also
CC includes novel peptides that exhibit anti-fusogenic activity, antiviral
CC activity and/or ability to modulate intracellular processes. The novel
CC hybrid polypeptide has virucide and antidiabetic activity. The enhancer
CC peptide sequence enhances pharmacokinetic properties of any core
CC polypeptide, for example, a polypeptide useful for the treatment or
CC prevention of a disease, or an imaging agent useful for imaging
CC structures in vivo. The core polypeptides and hybrid polypeptides are
CC useful for modulating fusogenic events and exhibit antifusogenic or
CC antiviral activity. The novel hybrid polypeptide is useful for decreasing
CC viral infection and modulating intracellular processes involving coiled-
CC coil peptide interactions. The novel hybrid polypeptide comprises insulin
CC or its fragment, so the core polypeptide is useful for ameliorating the
CC symptoms of forms of diabetes. The novel hybrid polypeptide is also
CC useful as a part of prognosis for preventing disorders including fusion
CC events and viral infection that involves cell-cell and/or virus-cell
CC fusion, and for diagnosis and in vivo imaging methods. This sequence
CC represents an enhancer peptide of the invention.
XX
SQ Sequence 33 AA;

Query Match 29.9%; Score 29; DB 5; Length 33;
Best Local Similarity 40.0%; Pred. No. 1.4e+03;
Matches 6; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
| | | | |:: ||
Db 13 NKXNGTDAVKLIKQE 27

RESULT 145
ADI40691
ID ADI40691 standard; peptide; 33 AA.
XX
AC ADI40691;
XX
DT 22-APR-2004 (first entry)
XX
DE Nef/SH3 domain inhibitory peptide #4.
XX
KW kidney cell dedifferentiation; Nef; Src family tyrosine kinase;
KW SH3 domain; HIV associated nephropathy; HIVAN; AIDS; dementia; anaemia;
KW lymphoma; myopathy; cardiomyopathy;
KW primary HIV-induced disease progression.
XX
OS Human immunodeficiency virus 1.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "Biotinylated"
XX
PN US2003229906-A1.
XX
PD 11-DEC-2003.
XX
PF 14-APR-2003; 2003US-00413785.
XX
PR 15-APR-2002; 2002US-0372557P.
XX
PA (GELM/) GELMAN I H.
PA (KLOT/) KLOTMAN P.
PA (ZHOU/) ZHOU M M.
XX
PI Gelman IH, Klotman P, Zhou MM;
XX
DR WPI; 2004-178661/17.
XX
PT Inhibiting kidney cell dedifferentiation for treating e.g., HIV
PT associated nephropathy by inhibiting the interaction of Nef with a Src
PT family tyrosine kinase SH3 domain of a polypeptide of the cell.
XX
PS Claim 9; SEQ ID NO 4; 42pp; English.
XX
CC The invention relates to a method of inhibiting kidney cell

```
CC   dedifferentiation comprising inhibiting the interaction of Nef with a Src
CC   family tyrosine kinase SH3 domain of a polypeptide of the cell. The
CC   method is useful for inhibiting kidney cell dedifferentiation for
CC   treating e.g., HIV associated nephropathy (HIVAN), AIDS, dementia,
CC   anaemia, lymphoma, myopathy, cardiomyopathy or primary HIV-induced
CC   disease progression. The present sequence represents the amino acid
CC   sequence of a Nef/SH3 inhibitory peptide.
XX
SQ   Sequence 33 AA;

  Query Match             29.9%;  Score 29;  DB 8;  Length 33;
  Best Local Similarity   41.7%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    2;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          8 KIAFKIVSQEPA 19
              |: | :  | ||
Db         17 KVGFPVTPQVPA 28


RESULT 146
AAW30694
ID   AAW30694 standard; peptide; 34 AA.
XX
AC   AAW30694;
XX
DT   11-JAN-1999  (first entry)
XX
DE   Repro-PC-1.0 immunogenic peptide 42.
XX
KW   Repro-PC-1.0; prostate cancer; marker; synaptotagmin; human; diagnosis;
KW   vaccine; therapy; immunogen.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Binding-site    11. .14
FT                   /note= "MHC Class I or Class II binding motif"
FT   Binding-site    14. .17
FT                   /note= "MHC Class I or Class II binding motif"
FT   Binding-site    20. .24
FT                   /note= "MHC Class I or Class II binding motif"
XX
PN   WO9839447-A1.
XX
PD   11-SEP-1998.
XX
PF   06-MAR-1998;   98WO-US004488.
XX
PR   07-MAR-1997;   97US-0041246P.
PR   15-MAY-1997;   97US-0047811P.
XX
PA   (REPR-) REPROGEN INC.
XX
PI   French CK,  Schneider PA,  Yamamoto KK;
XX
DR   WPI; 1998-506363/43.
XX
PT   New isolated Repro-PC-1.0 polynucleotide(s) - are used to develop
PT   products for the detection and prophylactic and therapeutic treatment of
PT   prostate cancer.
XX
PS   Disclosure; Page 42; 87pp; English.
XX
CC   This peptide corresponds to amino acid residues 42-75 of Repro-PC-1.0
CC   (see AAW74584), a novel human prostate cancer-specific marker. It
CC   includes MHC Class I or MHC Class II binding motifs. The invention
CC   provides Repro-PC-1.0 polypeptides and immunogenic peptides (see AAW30693
CC   -98) capable of inducing a Class I MHC- restricted cytotoxic T-lymphocyte
CC   response or a Class II MHC-restricted immune response against cells
CC   expressing Repro-PC-1.0. These can be used in vaccines against Repro-PC-
CC   1.0
XX
SQ   Sequence 34 AA;

  Query Match             29.9%;  Score 29;  DB 2;  Length 34;
  Best Local Similarity   60.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              | :||||  |
Db         23 PENLNSKKKF 32


RESULT 147
AAY89007
ID   AAY89007 standard; peptide; 34 AA.
XX
AC   AAY89007;
XX
DT   23-MAY-2000  (first entry)
XX
DE   Core polypeptide fragment T No. 371.
XX
KW   Retrovirus; hybrid polypeptide; enhancer; gp41; envelope protein; HIV-1;
KW   HIV-2; SIV; pharmacokinetic; half-life; growth factor; cytokine; viral;
KW   anti-fusogenic; differentiation factor; interleukin; interferon;
KW   colony stimulating factor; hormone; angiogenic factor.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 17
FT                   /note= "indicated as U in the specification"
XX
PN   WO9959615-A1.
XX
PD   25-NOV-1999.
XX
PF   20-MAY-1999;   99WO-US011219.
XX
PR   20-MAY-1998;   98US-00082279.
XX
PA   (TRIM-) TRIMERIS INC.
XX
PI   Barney S,  Guthrie KI,  Merutka G,  Anwer MK,  Lambert DM;
XX
DR   WPI; 2000-136792/12.
XX
PT   A new hybrid polypeptide with enhanced pharmacokinetic properties
PT   comprises enhancer sequence.
XX
PS   Disclosure; Page 28; 124pp; English.
XX
CC   The invention relates to hybrid polypeptides comprising enhancer peptide
CC   sequence linked to core polypeptides. The enhancer polypeptides are
CC   derived from various retroviral envelope (gp41) protein sequences,
CC   especially from HIV-1, HIV-2 and SIV. The enhancer peptides enhance the
CC   pharmacokinetic properties such as increasing the half-life of any core
CC   polypeptide that they are linked to. The core polypeptides are any
CC   polypeptide that may be introduced into a living system and that can
CC   function as a pharmacoligically useful peptide for the treatment or
CC   prevention of a disease. The core polypeptides are bioactive peptides
CC   selected from a growth factor, cytokine, differentiation factor,
CC   interleukin, interferon, colony stimulating factor, hormone or angiogenic
CC   factor. The peptides of the invention can be used for inhibiting viral
CC   infection and can be used in anti-viral and anti-fusogenic treatments.
CC   Sequences AAY88651-Y90055 represent core polypeptide fragments that can
CC   be used in the invention. Some sequences among those indicated also
CC   comprise enhancer fragments at terminal ends and form hybrid polypeptides
XX
SQ   Sequence 34 AA;

  Query Match             29.9%;  Score 29;  DB 3;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;
```

```
Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         15 NKXNGTDAVKLIKQE 29
```

RESULT 148
AAY89008
ID AAY89008 standard; peptide; 34 AA.
XX
AC AAY89008;
XX
DT 23-MAY-2000 (first entry)
XX
DE Core polypeptide fragment T No. 372.
XX
KW Retrovirus; hybrid polypeptide; enhancer; gp41; envelope protein; HIV-1;
KW HIV-2; SIV; pharmacokinetic; half-life; growth factor; cytokine; viral;
KW anti-fusogenic; differentiation factor; interleukin; interferon;
KW colony stimulating factor; hormone; angiogenic factor.
XX
OS Unidentified.
XX
FH Key   Location/Qualifiers
FT Misc-difference 16
FT   /note= "indicated as U in the specification"
XX
PN WO9959615-A1.
XX
PD 25-NOV-1999.
XX
PF 20-MAY-1999; 99WO-US011219.
XX
PR 20-MAY-1998; 98US-00082279.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Barney S, Guthrie KI, Merutka G, Anwer MK, Lambert DM;
XX
DR WPI; 2000-136792/12.
XX
PT A new hybrid polypeptide with enhanced pharmacokinetic properties
PT comprises enhancer sequence.
XX
PS Disclosure; Page 28; 124pp; English.
XX
CC The invention relates to hybrid polypeptides comprising enhancer peptide
CC sequence linked to core polypeptides. The enhancer polypeptides are
CC derived from various retroviral envelope (gp41) protein sequences,
CC especially from HIV-1, HIV-2 and SIV. The enhancer peptides enhance the
CC pharmacokinetic properties such as increasing the half-life of any core
CC polypeptide that they are linked to. The core polypeptides are any
CC polypeptide that may be introduced into a living system and that can
CC function as a pharmacoligically useful peptide for the treatment or
CC prevention of a disease. The core polypeptides are bioactive peptides
CC selected from a growth factor, cytokine, differentiation factor,
CC interleukin, interferon, colony stimulating factor, hormone or angiogenic
CC factor. The peptides of the invention can be used for inhibiting viral
CC infection and can be used in anti-viral and anti-fusogenic treatments.
CC Sequences AAY88651-Y90055 represent core polypeptide fragments that can
CC be used in the invention. Some sequences among those indicated also
CC comprise enhancer fragments at terminal ends and form hybrid polypeptides
XX
SQ Sequence 34 AA;

```
  Query Match             29.9%;  Score 29;  DB 3;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         14 NKXNGTDAVKLIKQE 28
```

RESULT 149
AAY89009
ID AAY89009 standard; peptide; 34 AA.
XX
AC AAY89009;
XX
DT 23-MAY-2000 (first entry)
XX
DE Core polypeptide fragment T No. 373.
XX
KW Retrovirus; hybrid polypeptide; enhancer; gp41; envelope protein; HIV-1;
KW HIV-2; SIV; pharmacokinetic; half-life; growth factor; cytokine; viral;
KW anti-fusogenic; differentiation factor; interleukin; interferon;
KW colony stimulating factor; hormone; angiogenic factor.
XX
OS Unidentified.
XX
FH Key   Location/Qualifiers
FT Misc-difference 15
FT   /note= "indicated as U in the specification"
XX
PN WO9959615-A1.
XX
PD 25-NOV-1999.
XX
PF 20-MAY-1999; 99WO-US011219.
XX
PR 20-MAY-1998; 98US-00082279.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Barney S, Guthrie KI, Merutka G, Anwer MK, Lambert DM;
XX
DR WPI; 2000-136792/12.
XX
PT A new hybrid polypeptide with enhanced pharmacokinetic properties
PT comprises enhancer sequence.
XX
PS Disclosure; Page 28; 124pp; English.
XX
CC The invention relates to hybrid polypeptides comprising enhancer peptide
CC sequence linked to core polypeptides. The enhancer polypeptides are
CC derived from various retroviral envelope (gp41) protein sequences,
CC especially from HIV-1, HIV-2 and SIV. The enhancer peptides enhance the
CC pharmacokinetic properties such as increasing the half-life of any core
CC polypeptide that they are linked to. The core polypeptides are any
CC polypeptide that may be introduced into a living system and that can
CC function as a pharmacoligically useful peptide for the treatment or
CC prevention of a disease. The core polypeptides are bioactive peptides
CC selected from a growth factor, cytokine, differentiation factor,
CC interleukin, interferon, colony stimulating factor, hormone or angiogenic
CC factor. The peptides of the invention can be used for inhibiting viral
CC infection and can be used in anti-viral and anti-fusogenic treatments.
CC Sequences AAY88651-Y90055 represent core polypeptide fragments that can
CC be used in the invention. Some sequences among those indicated also
CC comprise enhancer fragments at terminal ends and form hybrid polypeptides
XX
SQ Sequence 34 AA;

```
  Query Match             29.9%;  Score 29;  DB 3;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         13 NKXNGTDAVKLIKQE 27
```

RESULT 150
AAB54800
ID AAB54800 standard; peptide; 34 AA.
XX
AC AAB54800;

XX
DT 05-MAR-2001 (first entry)
XX
DE RSV antiviral activity exhibiting peptide SEQ ID NO:17.
XX
KW Long lasting fusion peptide inhibitor; viral infection; antiviral;
KW antifusogenic; mobile blood component; measles virus; MeV; SIV;
KW simian immunodeficiency virus; human parainfluenza virus; HPIV; RSV;
KW human respiratory syncytial virus; human immunodeficiency virus; HIV.
XX
OS Human respiratory syncytial virus.
XX
PN WO200069902-A1.
XX
PD 23-NOV-2000.
XX
PF 17-MAY-2000; 2000WO-US013651.
XX
PR 17-MAY-1999; 99US-0134406P.
PR 10-SEP-1999; 99US-0153406P.
XX
PA (CONJ-) CONJUCHEM INC.
XX
PI Bridon DP, Dufresne RP, Boudjellab N, Robitaille M, Milner PG;
XX
DR WPI; 2001-007496/01.
XX
PT A modified peptide and a reactive group which is reactive with amino
PT groups, hydroxyl groups, or thiol groups on blood components to form
PT stable covalent bonds useful for treatment of viral infections, e.g.
PT human immunodeficiency virus.
XX
PS Claim 9; Page 179; 211pp; English.
XX
CC The present invention describes a modified anti-viral peptide (I)
CC comprising a peptide that exhibits anti-viral activity and a reactive
CC group which is reactive with amino groups, hydroxyl groups, or thiol
CC groups on blood components to form stable covalent bonds. (I) has anti-
CC viral and anti-fusogenic activities. (I) inhibits viral infection of
CC cells by inhibiting cell-cell fusion or free virus infection or to reduce
CC the level of membrane fusion events between two or more entities, e.g.,
CC virus-cell or cell-cell, relative to the level of membrane fusion that
CC occurs in the absence of the peptide. (I) is useful in the treatment of
CC patients who are suffering from viral infection, e.g. HIV, RSV, HPIV,
CC MeV, and SIV. (I) may be administered prophylactically to previously
CC uninfected individuals. This is useful in cases where an individual has
CC been subjected to a high risk of exposure to a virus. By bonding of long-
CC lived components of the blood, such as immunoglobin, serum albumin, red
CC blood cells and platelets the activity is extended for days to weeks.
CC This is due to improved stability in vivo and a reduced susceptibility to
CC peptidase or protease degradation. This minimises the need for more
CC frequent, or even continual, administration of the peptides. AAB54784 to
CC AAB55431 represent peptides used in the exemplification of the present
CC invention
XX
SQ Sequence 34 AA;

Query Match 29.9%; Score 29; DB 4; Length 34;
Best Local Similarity 33.3%; Pred. No. 1.4e+03;
Matches 5; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
| :| |:: ||
Db 12 NKMNGDAKVKLIKQE 26

RESULT 151
AAB92259
ID AAB92259 standard; peptide; 34 AA.
XX
AC AAB92259;
XX
DT 22-JUN-2001 (first entry)
XX
DE Virus related peptide SEQ ID NO:1435.
XX
KW Protection; endogenous therapeutic peptide; peptidase; conjugation;
KW blood component; modification; succinimidyl; maleimido group; amino;
KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200069900-A2.
XX
PD 23-NOV-2000.
XX
PF 17-MAY-2000; 2000WO-US013576.
XX
PR 17-MAY-1999; 99US-0134406P.
PR 10-SEP-1999; 99US-0153406P.
PR 15-OCT-1999; 99US-0159783P.
XX
PA (CONJ-) CONJUCHEM INC.
XX
PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudeau K;
XX
DR WPI; 2001-112059/12.
XX
PT Modifying and attaching therapeutic peptides to albumin prevents
PT peptidase degradation, useful for increasing length of in vivo activity.
XX
PS Disclosure; Page 668; 733pp; English.
XX
CC The present invention describes a modified therapeutic peptide (I)
CC comprising a therapeutically active amino acid region (III) and a
CC reactive group (II) (e.g. succinimidyl and maleimido groups) attached to
CC a less therapeutically active amino acid region (IV), which covalently
CC bonds with amino/hydroxyl/thiol groups on blood components to form a
CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.
CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth
CC factors and neurotransmitters, to protect them from peptidase activity in
CC vivo for the treatment of various disorders. Endogenous therapeutic
CC peptides are not suitable as drug candidates as they require frequent
CC administration due to rapid degradation by peptidases in the body.
CC Modifying and attaching therapeutic peptides to albumin prevents or
CC reduces the action of peptidases to increase length of activity (half
CC life) and specificity as bonding to large molecules decreases
CC intracellular uptake and interference with physiological processes.
CC AAB90829 to AAB92441 represent peptides which can be used in the
CC exemplification of the present invention
XX
SQ Sequence 34 AA;

Query Match 29.9%; Score 29; DB 4; Length 34;
Best Local Similarity 33.3%; Pred. No. 1.4e+03;
Matches 5; Conservative 3; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
| :| |:: ||
Db 12 NKMNGDAKVKLIKQE 26

RESULT 152
AAB77362
ID AAB77362 standard; peptide; 34 AA.
XX
AC AAB77362;
XX
DT 19-APR-2001 (first entry)
XX
DE Core polypeptide T371.
XX
KW Core polypeptide; enhancer; antiviral; anti-HIV; virucide; hepatotropic;
KW antiinflammatory; hybrid polypeptide; coiled-coil peptide interaction;
KW fusion-related disorder; bacterial infection; viral infection.

XX
OS Unidentified.
XX
PN WO200103723-A1.
XX
PD 18-JAN-2001.
XX
PF 10-JUL-2000; 2000WO-US018772.
XX
PR 09-JUL-1999; 99US-00350641.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Barney S, Guthrie KI, Merutka G, Anwer MK, Lambert DM;
XX
DR WPI; 2001-147136/15.
XX
PT New hybrid polypeptide, useful for preventing, treating and diagnosing
PT e.g. viral infections, comprises an enhancer peptide linked to a core
PT polypeptide.
XX
PS Disclosure; Page 38; 151pp; English.
XX
CC The present sequence is a core polypeptide which may be linked to an
CC enhancer peptide to form a novel hybrid polypeptide. The hybrid
CC polypeptide exhibits enhanced pharmacokinetic properties relative to
CC those exhibited by the core polypeptide when introduced into a living
CC system. It is used to increase the in vitro or ex vivo half-life of the
CC core polypeptide. The hybrid and core polypeptides can be used for
CC modulating fusogenic events and intracellular processes involving coiled-
CC coil peptide interactions. Other uses include preventing, treating and/or
CC diagnosing disorders involving fusion events (e.g. modulation of
CC neurotransmitter exchange and sperm-egg fusion), intracellular processes
CC involving coiled-coil peptides (e.g. bacterial infections) and viral
CC infections that involve cell-cell and/or virus-cell fusion (e.g. viral
CC infections caused by human immunodeficiency virus, respiratory syncytial
CC virus, Epstein-Barr virus, hepatitis B virus, Mason-Pfizer virus and
CC polio virus). The enhancer peptide sequence increases the half-life and
CC reduces the clearance rate of therapeutic peptides, which increases their
CC efficacy and minimises the incidence and severity of adverse side
CC effects. In addition, this increases the sensitivity of the diagnostic
CC procedure in which they are used
XX
SQ Sequence 34 AA;

Query Match 29.9%; Score 29; DB 4; Length 34;
Best Local Similarity 40.0%; Pred. No. 1.4e+03;
Matches 6; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
| | | | |:: ||
Db 15 NKXNGTDAVKLIKQE 29

RESULT 153
AAB77364
ID AAB77364 standard; peptide; 34 AA.
XX
AC AAB77364;
XX
DT 19-APR-2001 (first entry)
XX
DE Core polypeptide T373.
XX
KW Core polypeptide; enhancer; antiviral; anti-HIV; virucide; hepatotropic;
KW antiinflammatory; hybrid polypeptide; coiled-coil peptide interaction;
KW fusion-related disorder; bacterial infection; viral infection.
XX
OS Unidentified.
XX
PN WO200103723-A1.
XX
PD 18-JAN-2001.
XX
PF 10-JUL-2000; 2000WO-US018772.
XX
PR 09-JUL-1999; 99US-00350641.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Barney S, Guthrie KI, Merutka G, Anwer MK, Lambert DM;
XX
DR WPI; 2001-147136/15.
XX
PT New hybrid polypeptide, useful for preventing, treating and diagnosing
PT e.g. viral infections, comprises an enhancer peptide linked to a core
PT polypeptide.
XX
PS Disclosure; Page 38; 151pp; English.
XX
CC The present sequence is a core polypeptide which may be linked to an
CC enhancer peptide to form a novel hybrid polypeptide. The hybrid
CC polypeptide exhibits enhanced pharmacokinetic properties relative to
CC those exhibited by the core polypeptide when introduced into a living
CC system. It is used to increase the in vitro or ex vivo half-life of the
CC core polypeptide. The hybrid and core polypeptides can be used for
CC modulating fusogenic events and intracellular processes involving coiled-
CC coil peptide interactions. Other uses include preventing, treating and/or
CC diagnosing disorders involving fusion events (e.g. modulation of
CC neurotransmitter exchange and sperm-egg fusion), intracellular processes
CC involving coiled-coil peptides (e.g. bacterial infections) and viral
CC infections that involve cell-cell and/or virus-cell fusion (e.g. viral
CC infections caused by human immunodeficiency virus, respiratory syncytial
CC virus, Epstein-Barr virus, hepatitis B virus, Mason-Pfizer virus and
CC polio virus). The enhancer peptide sequence increases the half-life and
CC reduces the clearance rate of therapeutic peptides, which increases their
CC efficacy and minimises the incidence and severity of adverse side
CC effects. In addition, this increases the sensitivity of the diagnostic
CC procedure in which they are used
XX
SQ Sequence 34 AA;

Query Match 29.9%; Score 29; DB 4; Length 34;
Best Local Similarity 40.0%; Pred. No. 1.4e+03;
Matches 6; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
| | | | |:: ||
Db 13 NKXNGTDAVKLIKQE 27

RESULT 154
AAB77363
ID AAB77363 standard; peptide; 34 AA.
XX
AC AAB77363;
XX
DT 19-APR-2001 (first entry)
XX
DE Core polypeptide T372.
XX
KW Core polypeptide; enhancer; antiviral; anti-HIV; virucide; hepatotropic;
KW antiinflammatory; hybrid polypeptide; coiled-coil peptide interaction;
KW fusion-related disorder; bacterial infection; viral infection.
XX
OS Unidentified.
XX
PN WO200103723-A1.
XX
PD 18-JAN-2001.
XX
PF 10-JUL-2000; 2000WO-US018772.
XX
PR 09-JUL-1999; 99US-00350641.
XX
PA (TRIM-) TRIMERIS INC.

```
XX
PI   Barney S,  Guthrie KI,  Merutka G,  Anwer MK,  Lambert DM;
XX
DR   WPI; 2001-147136/15.
XX
PT   New hybrid polypeptide, useful for preventing, treating and diagnosing
PT   e.g. viral infections, comprises an enhancer peptide linked to a core
PT   polypeptide.
XX
PS   Disclosure; Page 38; 151pp; English.
XX
CC   The present sequence is a core polypeptide which may be linked to an
CC   enhancer peptide to form a novel hybrid polypeptide. The hybrid
CC   polypeptide exhibits enhanced pharmacokinetic properties relative to
CC   those exhibited by the core polypeptide when introduced into a living
CC   system. It is used to increase the in vitro or ex vivo half-life of the
CC   core polypeptide. The hybrid and core polypeptides can be used for
CC   modulating fusogenic events and intracellular processes involving coiled-
CC   coil peptide interactions. Other uses include preventing, treating and/or
CC   diagnosing disorders involving fusion events (e.g. modulation of
CC   neurotransmitter exchange and sperm-egg fusion), intracellular processes
CC   involving coiled-coil peptides (e.g. bacterial infections) and viral
CC   infections that involve cell-cell and/or virus-cell fusion (e.g. viral
CC   infections caused by human immunodeficiency virus, respiratory syncytial
CC   virus, Epstein-Barr virus, hepatitis B virus, Mason-Pfizer virus and
CC   polio virus). The enhancer peptide sequence increases the half-life and
CC   reduces the clearance rate of therapeutic peptides, which increases their
CC   efficacy and minimises the incidence and severity of adverse side
CC   effects. In addition, this increases the sensitivity of the diagnostic
CC   procedure in which they are used
XX
SQ   Sequence 34 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         14 NKXNGTDAVKLIKQE 28


RESULT 155
ABB00367
ID   ABB00367 standard; peptide; 34 AA.
XX
AC   ABB00367;
XX
DT   03-JAN-2002  (first entry)
XX
DE   RSV F2 protein DP178/107-like region peptide T372.
XX
KW   Human immunodeficiency virus; HIV; respiratory syncytial virus; RSV;
KW   virucide; heptad repeat region; transmembrane protein; gp41; HR1; HR2;
KW   infection.
XX
OS   Human respiratory syncytial virus.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "N-terminal is substituted by Ac"
FT   Modified-site   34
FT                   /note= "C-terminal amide"
XX
PN   WO200164013-A2.
XX
PD   07-SEP-2001.
XX
PF   07-FEB-2001; 2001WO-US003988.
XX
PR   29-FEB-2000; 2000US-00515965.
XX
PA   (TRIM-) TRIMERIS INC.
XX
PI   Antczak JB,  Delmedico MK,  Erickson JB,  Lambert DM,  Sista P;
XX
DR   WPI; 2001-514829/56.
XX
PT   Heptad repeat region peptide analogs useful for inhibiting virus/cells
PT   fusion, useful for treating HIV and Respiratory Syncytial Virus
PT   infection.
XX
PS   Example; Page 40; 587pp; English.
XX
CC   The invention relates to isolated analogues of the heptad repeat region
CC   peptides DP178 and DP107. DP178 and DP107 correspond to amino acids 638-
CC   673 (heptad repeat region HR2) and 558-595 (heptad repeat region HR1)
CC   respectively, of HIV-1LAI transmembrane protein gp41. The HR1 and HR2
CC   regions of proteins interact non-covalently with each other and/or with
CC   peptides derived from them. This interaction is required for normal
CC   infectivity of viruses such as RSV and HIV. The heptad repeat region
CC   peptide analogues may be used to inhibit respiratory syncytial virus
CC   (RSV) infection in a cell. They may also be used to inhibit HIV
CC   infection. The present sequence is a peptide provided in the
CC   specification
XX
SQ   Sequence 34 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         14 NKXNGTDAVKLIKQE 28


RESULT 156
ABB00368
ID   ABB00368 standard; peptide; 34 AA.
XX
AC   ABB00368;
XX
DT   03-JAN-2002  (first entry)
XX
DE   RSV F2 protein DP178/107-like region peptide T373.
XX
KW   Human immunodeficiency virus; HIV; respiratory syncytial virus; RSV;
KW   virucide; heptad repeat region; transmembrane protein; gp41; HR1; HR2;
KW   infection.
XX
OS   Human respiratory syncytial virus.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "N-terminal is substituted by Ac"
FT   Modified-site   34
FT                   /note= "C-terminal amide"
XX
PN   WO200164013-A2.
XX
PD   07-SEP-2001.
XX
PF   07-FEB-2001; 2001WO-US003988.
XX
PR   29-FEB-2000; 2000US-00515965.
XX
PA   (TRIM-) TRIMERIS INC.
XX
PI   Antczak JB,  Delmedico MK,  Erickson JB,  Lambert DM,  Sista P;
XX
DR   WPI; 2001-514829/56.
XX
PT   Heptad repeat region peptide analogs useful for inhibiting virus/cells
PT   fusion, useful for treating HIV and Respiratory Syncytial Virus
PT   infection.
```

XX
PS Example; Page 40; 587pp; English.
XX
CC The invention relates to isolated analogues of the heptad repeat region
CC peptides DP178 and DP107. DP178 and DP107 correspond to amino acids 638-
CC 673 (heptad repeat region HR2) and 558-595 (heptad repeat region HR1)
CC respectively, of HIV-1LAI transmembrane protein gp41. The HR1 and HR2
CC regions of proteins interact non-covalently with each other and/or with
CC peptides derived from them. This interaction is required for normal
CC infectivity of viruses such as RSV and HIV. The heptad repeat region
CC peptide analogues may be used to inhibit respiratory syncytial virus
CC (RSV) infection in a cell. They may also be used to inhibit HIV
CC infection. The present sequence is a peptide provided in the
CC specification
XX
SQ Sequence 34 AA;

Query Match 29.9%; Score 29; DB 4; Length 34;
Best Local Similarity 40.0%; Pred. No. 1.4e+03;
Matches 6; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
| | | |:: ||
Db 13 NKXNGTDAVKLIKQE 27

RESULT 157
ABB00366
ID ABB00366 standard; peptide; 34 AA.
XX
AC ABB00366;
XX
DT 03-JAN-2002 (first entry)
XX
DE RSV F2 protein DP178/107-like region peptide T371.
XX
KW Human immunodeficiency virus; HIV; respiratory syncytial virus; RSV;
KW virucide; heptad repeat region; transmembrane protein; gp41; HR1; HR2;
KW infection.
XX
OS Human respiratory syncytial virus.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "N-terminal is substituted by Ac"
FT Modified-site 34
FT /note= "C-terminal amide"
XX
PN WO200164013-A2.
XX
PD 07-SEP-2001.
XX
PF 07-FEB-2001; 2001WO-US003988.
XX
PR 29-FEB-2000; 2000US-00515965.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Antczak JB, Delmedico MK, Erickson JB, Lambert DM, Sista P;
XX
DR WPI; 2001-514829/56.
XX
PT Heptad repeat region peptide analogs useful for inhibiting virus/cells
PT fusion, useful for treating HIV and Respiratory Syncytial Virus
PT infection.
XX
PS Example; Page 40; 587pp; English.
XX
CC The invention relates to isolated analogues of the heptad repeat region
CC peptides DP178 and DP107. DP178 and DP107 correspond to amino acids 638-
CC 673 (heptad repeat region HR2) and 558-595 (heptad repeat region HR1)
CC respectively, of HIV-1LAI transmembrane protein gp41. The HR1 and HR2
CC regions of proteins interact non-covalently with each other and/or with
CC peptides derived from them. This interaction is required for normal
CC infectivity of viruses such as RSV and HIV. The heptad repeat region
CC peptide analogues may be used to inhibit respiratory syncytial virus
CC (RSV) infection in a cell. They may also be used to inhibit HIV
CC infection. The present sequence is a peptide provided in the
CC specification
XX
SQ Sequence 34 AA;

Query Match 29.9%; Score 29; DB 4; Length 34;
Best Local Similarity 40.0%; Pred. No. 1.4e+03;
Matches 6; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQE 17
| | | |:: ||
Db 15 NKXNGTDAVKLIKQE 29

RESULT 158
AAU12917
ID AAU12917 standard; peptide; 34 AA.
XX
AC AAU12917;
XX
DT 21-NOV-2001 (first entry)
XX
DE DP178-like/DP107-like peptide T-373.
XX
KW Anti-retroviral; DP178-like; DP107-like; transmembrane protein gp41;
KW antifusogenic; antiviral; HIV transmission; mutant; mutein.
XX
OS Human immunodeficiency virus 1; isolate LAI.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "N-terminal is substituted by Ac"
FT Modified-site 34
FT /note= "C-terminal amide"
XX
PN WO200151673-A2.
XX
PD 19-JUL-2001.
XX
PF 05-JUL-2000; 2000WO-US035727.
XX
PR 09-JUL-1999; 99US-00350841.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Jeffs P, Lackey JW, Erickson JB, Lawless MK, Merutka G;
XX
DR WPI; 2001-442157/47.
XX
PT Identifying a compound that inhibits the formation of or disrupts a
PT DP107/DP178 complex, especially compounds with antifusogenic, antiviral
PT or intracellular modulatory activity, by detecting the formation of a
PT DP107/DP178 complex.
XX
PS Disclosure; Page 60; 259pp; English.
XX
CC The present invention relates to peptides which exhibit anti-retroviral
CC activity. The peptides of the invention (AAU12559-AAU14009) comprise
CC DP178-like and DP107-like peptides. The DP178 peptide corresponds to
CC amino acids 639-673 of the transmembrane protein gp41 from human
CC immunodeficiency virus 1 (HIV-1) isolate LAI. The DP107 peptide
CC corresponds to amino acids 558-595 of gp41 from HIV-1LAI. The invention
CC also relates to a method of identifying compounds that inhibit the
CC formation of or disrupts a DP107/DP178 complex. The method comprises
CC detecting the formation of a DP107/DP178 complex, both in the presence or
CC absence of a test compound, in a reaction mixture containing DP107 and
CC DP178 peptides. The method is useful for identifying compounds, including
CC small molecule compounds, which may themselves exhibit antifusogenic,

```
CC   antiviral or intracellular modulatory activity. The DP178-like/DP107-like
CC   peptides are useful to inhibit human and non-human retroviral,
CC   particularly HIV, transmission to uninfected cells. The present sequence
CC   represents one of the DP178-like/DP107-like peptides of the invention
XX
SQ   Sequence 34 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         13 NKXNGTDAVKLIKQE 27


RESULT 159
AAU12916
ID   AAU12916 standard; peptide; 34 AA.
XX
AC   AAU12916;
XX
DT   21-NOV-2001  (first entry)
XX
DE   DP178-like/DP107-like peptide T-372.
XX
KW   Anti-retroviral; DP178-like; DP107-like; transmembrane protein gp41;
KW   antifusogenic; antiviral; HIV transmission; mutant; mutein.
XX
OS   Human immunodeficiency virus 1; isolate LAI.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "N-terminal is substituted by Ac"
FT   Modified-site   34
FT                   /note= "C-terminal amide"
XX
PN   WO200151673-A2.
XX
PD   19-JUL-2001.
XX
PF   05-JUL-2000; 2000WO-US035727.
XX
PR   09-JUL-1999;   99US-00350841.
XX
PA   (TRIM-) TRIMERIS INC.
XX
PI   Jeffs P,  Lackey JW,  Erickson JB,  Lawless MK,  Merutka G;
XX
DR   WPI; 2001-442157/47.
XX
PT   Identifying a compound that inhibits the formation of or disrupts a
PT   DP107/DP178 complex, especially compounds with antifusogenic, antiviral
PT   or intracellular modulatory activity, by detecting the formation of a
PT   DP107/DP178 complex.
XX
PS   Disclosure; Page 60; 259pp; English.
XX
CC   The present invention relates to peptides which exhibit anti-retroviral
CC   activity. The peptides of the invention (AAU12559-AAU14009) comprise
CC   DP178-like and DP107-like peptides. The DP178 peptide corresponds to
CC   amino acids 639-673 of the transmembrane protein gp41 from human
CC   immunodeficiency virus 1 (HIV-1) isolate LAI. The DP107 peptide
CC   corresponds to amino acids 558-595 of gp41 from HIV-1LAI. The invention
CC   also relates to a method of identifying compounds that inhibit the
CC   formation of or disrupts a DP107/DP178 complex. The method comprises
CC   detecting the formation of a DP107/DP178 complex, both in the presence or
CC   absence of a test compound, in a reaction mixture containing DP107 and
CC   DP178 peptides. The method is useful for identifying compounds, including
CC   small molecule compounds, which may themselves exhibit antifusogenic,
CC   antiviral or intracellular modulatory activity. The DP178-like/DP107-like
CC   peptides are useful to inhibit human and non-human retroviral,
CC   particularly HIV, transmission to uninfected cells. The present sequence
CC   represents one of the DP178-like/DP107-like peptides of the invention
XX
SQ   Sequence 34 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         14 NKXNGTDAVKLIKQE 28


RESULT 160
AAU12915
ID   AAU12915 standard; peptide; 34 AA.
XX
AC   AAU12915;
XX
DT   21-NOV-2001  (first entry)
XX
DE   DP178-like/DP107-like peptide T-371.
XX
KW   Anti-retroviral; DP178-like; DP107-like; transmembrane protein gp41;
KW   antifusogenic; antiviral; HIV transmission; mutant; mutein.
XX
OS   Human immunodeficiency virus 1; isolate LAI.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   1
FT                   /note= "N-terminal is substituted by Ac"
FT   Modified-site   34
FT                   /note= "C-terminal amide"
XX
PN   WO200151673-A2.
XX
PD   19-JUL-2001.
XX
PF   05-JUL-2000; 2000WO-US035727.
XX
PR   09-JUL-1999;   99US-00350841.
XX
PA   (TRIM-) TRIMERIS INC.
XX
PI   Jeffs P,  Lackey JW,  Erickson JB,  Lawless MK,  Merutka G;
XX
DR   WPI; 2001-442157/47.
XX
PT   Identifying a compound that inhibits the formation of or disrupts a
PT   DP107/DP178 complex, especially compounds with antifusogenic, antiviral
PT   or intracellular modulatory activity, by detecting the formation of a
PT   DP107/DP178 complex.
XX
PS   Disclosure; Page 60; 259pp; English.
XX
CC   The present invention relates to peptides which exhibit anti-retroviral
CC   activity. The peptides of the invention (AAU12559-AAU14009) comprise
CC   DP178-like and DP107-like peptides. The DP178 peptide corresponds to
CC   amino acids 639-673 of the transmembrane protein gp41 from human
CC   immunodeficiency virus 1 (HIV-1) isolate LAI. The DP107 peptide
CC   corresponds to amino acids 558-595 of gp41 from HIV-1LAI. The invention
CC   also relates to a method of identifying compounds that inhibit the
CC   formation of or disrupts a DP107/DP178 complex. The method comprises
CC   detecting the formation of a DP107/DP178 complex, both in the presence or
CC   absence of a test compound, in a reaction mixture containing DP107 and
CC   DP178 peptides. The method is useful for identifying compounds, including
CC   small molecule compounds, which may themselves exhibit antifusogenic,
CC   antiviral or intracellular modulatory activity. The DP178-like/DP107-like
CC   peptides are useful to inhibit human and non-human retroviral,
CC   particularly HIV, transmission to uninfected cells. The present sequence
CC   represents one of the DP178-like/DP107-like peptides of the invention
```

XX
SQ Sequence 34 AA;

Query Match 29.9%; Score 29; DB 4; Length 34;
Best Local Similarity 40.0%; Pred. No. 1.4e+03;
Matches 6; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

```
Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         15 NKXNGTDAVKLIKQE 29
```

RESULT 161
ADE01862
ID ADE01862 standard; peptide; 34 AA.
XX
AC ADE01862;
XX
DT 29-JAN-2004 (first entry)
XX
DE Hybrid polypeptide pharmacokinetic enhancer peptide, SEQ ID No 369.
XX
KW hybrid; enhancer; anti-fusogenic; antiviral; virucide; antidiabetic;
KW pharmacokinetic; fusogenic; insulin; diabetes.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "Residue is modified by acetyl group"
FT Modified-site 34
FT /note= "C-terminal amide"
XX
PN US6348568-B1.
XX
PD 19-FEB-2002.
XX
PF 20-MAY-1999; 99US-00315304.
XX
PR 20-MAY-1998; 98US-00082279.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Barney S, Guthrie KI, Merutka G, Anwer MK, Lambert DM;
XX
DR WPI; 2002-424396/45.
XX
PT New hybrid polypeptide for modulating fusogenic events for e.g. antiviral
PT activity, has enhancer peptide sequence derived from retroviral envelope
PT protein sequences linked to core polypeptide e.g. therapeutic protein.
XX
PS Disclosure; SEQ ID NO 369; 70pp; English.
XX
CC The invention relates to a novel hybrid polypeptide comprising an
CC enhancer peptide sequence linked to a core polypeptide. The enhancer
CC peptide sequence comprises WQEWEQKI or WASLWEWF. The invention also
CC includes novel peptides that exhibit anti-fusogenic activity, antiviral
CC activity and/or ability to modulate intracellular processes. The novel
CC hybrid polypeptide has virucide and antidiabetic activity. The enhancer
CC peptide sequence enhances pharmacokinetic properties of any core
CC polypeptide, for example, a polypeptide useful for the treatment or
CC prevention of a disease, or an imaging agent useful for imaging
CC structures in vivo. The core polypeptides and hybrid polypeptides are
CC useful for modulating fusogenic events and exhibit antifusogenic or
CC antiviral activity. The novel hybrid polypeptide is useful for decreasing
CC viral infection and modulating intracellular processes involving coiled-
CC coil peptide interactions. The novel hybrid polypeptide comprises insulin
CC or its fragment, so the core polypeptide is useful for ameliorating the
CC symptoms of forms of diabetes. The novel hybrid polypeptide is also
CC useful as a part of prognosis for preventing disorders including fusion
CC events and viral infection that involves cell-cell and/or virus-cell
CC fusion, and for diagnosis and in vivo imaging methods. This sequence
CC represents an enhancer peptide of the invention.

XX
SQ Sequence 34 AA;

Query Match 29.9%; Score 29; DB 5; Length 34;
Best Local Similarity 40.0%; Pred. No. 1.4e+03;
Matches 6; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

```
Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         13 NKXNGTDAVKLIKQE 27
```

RESULT 162
ADE01860
ID ADE01860 standard; peptide; 34 AA.
XX
AC ADE01860;
XX
DT 29-JAN-2004 (first entry)
XX
DE Hybrid polypeptide pharmacokinetic enhancer peptide, SEQ ID No 367.
XX
KW hybrid; enhancer; anti-fusogenic; antiviral; virucide; antidiabetic;
KW pharmacokinetic; fusogenic; insulin; diabetes.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "Residue is modified by acetyl group"
FT Modified-site 34
FT /note= "C-terminal amide"
XX
PN US6348568-B1.
XX
PD 19-FEB-2002.
XX
PF 20-MAY-1999; 99US-00315304.
XX
PR 20-MAY-1998; 98US-00082279.
XX
PA (TRIM-) TRIMERIS INC.
XX
PI Barney S, Guthrie KI, Merutka G, Anwer MK, Lambert DM;
XX
DR WPI; 2002-424396/45.
XX
PT New hybrid polypeptide for modulating fusogenic events for e.g. antiviral
PT activity, has enhancer peptide sequence derived from retroviral envelope
PT protein sequences linked to core polypeptide e.g. therapeutic protein.
XX
PS Disclosure; SEQ ID NO 367; 70pp; English.
XX
CC The invention relates to a novel hybrid polypeptide comprising an
CC enhancer peptide sequence linked to a core polypeptide. The enhancer
CC peptide sequence comprises WQEWEQKI or WASLWEWF. The invention also
CC includes novel peptides that exhibit anti-fusogenic activity, antiviral
CC activity and/or ability to modulate intracellular processes. The novel
CC hybrid polypeptide has virucide and antidiabetic activity. The enhancer
CC peptide sequence enhances pharmacokinetic properties of any core
CC polypeptide, for example, a polypeptide useful for the treatment or
CC prevention of a disease, or an imaging agent useful for imaging
CC structures in vivo. The core polypeptides and hybrid polypeptides are
CC useful for modulating fusogenic events and exhibit antifusogenic or
CC antiviral activity. The novel hybrid polypeptide is useful for decreasing
CC viral infection and modulating intracellular processes involving coiled-
CC coil peptide interactions. The novel hybrid polypeptide comprises insulin
CC or its fragment, so the core polypeptide is useful for ameliorating the
CC symptoms of forms of diabetes. The novel hybrid polypeptide is also
CC useful as a part of prognosis for preventing disorders including fusion
CC events and viral infection that involves cell-cell and/or virus-cell
CC fusion, and for diagnosis and in vivo imaging methods. This sequence
CC represents an enhancer peptide of the invention.

```
XX
SQ   Sequence 34 AA;

  Query Match             29.9%;  Score 29;  DB 5;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |   | |:: ||
Db         15 NKXNGTDAVKLIKQE 29


RESULT 163
ABP29370
ID   ABP29370 standard; protein; 37 AA.
XX
AC   ABP29370;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Streptococcus polypeptide SEQ ID NO 7916.
XX
KW   Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
KW   group A streptococcus; Streptococcus pyogenes; antibacterial;
KW   antiinflammatory; infection; vaccine; meningitis; gene therapy.
XX
OS   Streptococcus pyogenes.
XX
PN   WO200234771-A2.
XX
PD   02-MAY-2002.
XX
PF   29-OCT-2001; 2001WO-GB004789.
XX
PR   27-OCT-2000; 2000GB-00026333.
PR   24-NOV-2000; 2000GB-00028727.
PR   07-MAR-2001; 2001GB-00005640.
XX
PA   (CHIR-) CHIRON SPA.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Telford J,  Masignani V,  Margarit Y RosI,  Grandi G,  Fraser C;
PI   Tettelin H;
XX
DR   WPI; 2002-352536/38.
DR   N-PSDB; ABN70001.
XX
PT   New Streptococcus protein for the treatment or prevention of infection or
PT   disease caused by Streptococcus bacteria, such as meningitis, and for
PT   detecting a compound that binds to the protein.
XX
PS   Claim 1; Page 3921; 4525pp; English.
XX
CC   The invention relates to a protein (ABP25413-ABP30895) from group B
CC   streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
CC   (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
CC   the specification. The proteins have antibacterial and antiinflammatory
CC   activity. (I), nucleic acids encoding (I), ABN66044-ABN71526 and
CC   antibodies that bind (I) are used in the manufacture of medicaments for
CC   the treatment or prevention of infection or disease caused by
CC   Streptococcus bacteria, particularly S. agalactiae and S. pyrogenes.
CC   Nucleic acids encoding (I) are used to detect Streptococcus in a
CC   biological sample. (I) is used to determine whether a compound binds to
CC   (I). A composition comprising (I) or a nucleic acid encoding (I), may be
CC   used as a vaccine or diagnostic composition. The disease caused by
CC   Streptococcus that is prevented or treated may be meningitis. Nucleic
CC   acid encoding (I) may be used to recombinantly produce (I) and may be
CC   used in gene therapy. Antibodies to (I) are used for affinity
CC   chromatography, immunoassays, and distinguishing/identifying
CC   Streptococcus proteins
XX
SQ   Sequence 37 AA;

  Query Match             29.9%;  Score 29;  DB 5;  Length 37;
  Best Local Similarity   66.7%;  Pred. No. 1.6e+03;
  Matches    6;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          8 KIAFKIVSQ 16
              ||: |||:|
Db         12 KISLKIVAQ 20


RESULT 164
ADD90380
ID   ADD90380 standard; protein; 37 AA.
XX
AC   ADD90380;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Novel human secreted protein seq id 11 protein feature seq id 195.
XX
KW   gene therapy; cytostatic; cancer; human; secreted protein.
XX
OS   Homo sapiens.
XX
PN   US2003199683-A1.
XX
PD   23-OCT-2003.
XX
PF   30-MAR-2001; 2001US-00820649.
XX
PR   30-JUL-1997;   97US-0054209P.
PR   30-JUL-1997;   97US-0054211P.
PR   30-JUL-1997;   97US-0054212P.
PR   30-JUL-1997;   97US-0054213P.
PR   30-JUL-1997;   97US-0054214P.
PR   30-JUL-1997;   97US-0054215P.
PR   30-JUL-1997;   97US-0054217P.
PR   30-JUL-1997;   97US-0054218P.
PR   30-JUL-1997;   97US-0054234P.
PR   30-JUL-1997;   97US-0054236P.
PR   18-AUG-1997;   97US-0055968P.
PR   18-AUG-1997;   97US-0055969P.
PR   18-AUG-1997;   97US-0055972P.
PR   19-AUG-1997;   97US-0056534P.
PR   19-AUG-1997;   97US-0056543P.
PR   19-AUG-1997;   97US-0056554P.
PR   19-AUG-1997;   97US-0056561P.
PR   19-AUG-1997;   97US-0056727P.
PR   19-AUG-1997;   97US-0056729P.
PR   19-AUG-1997;   97US-0056730P.
PR   29-JUL-1998;   98WO-US015949.
PR   26-JAN-1999;   99US-00236557.
PR   21-SEP-2000;  2000US-00666987.
XX
PA   (RUBE/) RUBEN S M.
PA   (FENG/) FENG P.
PA   (LAFL/) LAFLEUR D W.
PA   (MOOR/) MOORE P A.
PA   (SHIY/) SHI Y.
PA   (KYAW/) KYAW H.
PA   (LIYY/) LI Y.
PA   (ZENG/) ZENG Z.
PA   (CART/) CARTER K C.
PA   (ENDR/) ENDRESS G A.
PA   (WEIY/) WEI Y.
PA   (FANP/) FAN P.
PA   (ROSE/) ROSEN C A.
XX
PI   Ruben SM,  Feng P,  Lafleur DW,  Moore PA,  Shi Y,  Kyaw H,  Li Y;
PI   Zeng Z,  Carter KC,  Endress GA,  Wei Y,  Fan P,  Rosen CA;
XX
DR   WPI; 2003-852813/79.
XX
PT   New nucleic acid molecule, useful for preparing a medicament for
```

PT preventing, treating or ameliorating a medical condition e.g., cancer.
XX
PS Disclosure; SEQ ID NO 195; 213pp; English.
XX
CC The invention describes novel isolated human nucleic acids. The nucleic
CC acid is useful for preparing a medicament for preventing, treating or
CC ameliorating a medical condition e.g., cancer, and in gene therapy. This
CC is the amino acid sequence of polypeptide feature of a novel human
CC secreted protein of the invention.
XX
SQ Sequence 37 AA;

Query Match 29.9%; Score 29; DB 7; Length 37;
Best Local Similarity 54.5%; Pred. No. 1.6e+03;
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKI 13
:|| || ||
Db 11 HHLKSKFHLKI 21

RESULT 165
ADG90199
ID ADG90199 standard; peptide; 37 AA.
XX
AC ADG90199;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human secreted protein gene 1 extra polypeptide #3.
XX
KW Secreted protein; gene therapy; neural disorder; immune system disorders;
KW muscular disorder; reproductive disorder; gastrointestinal disorder;
KW pulmonary disorder; cardiovascular disorder; renal disorder;
KW proliferative disorder; cancer; systemic lupus erythematosus;
KW rheumatoid arthritis; multiple sclerosis; thyroiditis; anaemia;
KW Grave's disease; diabetes; hepatitis; asthma; allergy; nephritis;
KW Parkinson's disease; Alzheimer's disease; atherosclerosis;
KW myocardial infarction; AIDS; infection; human.
XX
OS Homo sapiens.
XX
PN US2003166541-A1.
XX
PD 04-SEP-2003.
XX
PF 04-JUN-2002; 2002US-00160162.
XX
PR 30-JUL-1997; 97US-0054209P.
PR 30-JUL-1997; 97US-0054211P.
PR 30-JUL-1997; 97US-0054212P.
PR 30-JUL-1997; 97US-0054213P.
PR 30-JUL-1997; 97US-0054214P.
PR 30-JUL-1997; 97US-0054215P.
PR 30-JUL-1997; 97US-0054217P.
PR 30-JUL-1997; 97US-0054218P.
PR 30-JUL-1997; 97US-0054234P.
PR 30-JUL-1997; 97US-0054236P.
PR 18-AUG-1997; 97US-0055968P.
PR 18-AUG-1997; 97US-0055969P.
PR 18-AUG-1997; 97US-0055972P.
PR 19-AUG-1997; 97US-0056534P.
PR 19-AUG-1997; 97US-0056543P.
PR 19-AUG-1997; 97US-0056554P.
PR 19-AUG-1997; 97US-0056561P.
PR 19-AUG-1997; 97US-0056727P.
PR 19-AUG-1997; 97US-0056729P.
PR 19-AUG-1997; 97US-0056730P.
PR 29-JUL-1998; 98WO-US015949.
PR 26-JAN-1999; 99US-00236557.
PR 05-JUN-2001; 2001US-0295558P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Feng P, Lafleur DW, Moore PA, Shi Y, Kyaw H, Li Y;
PI Zeng Z, Carter KC, Endress GA, Wei Y, Fan P, Rosen CA;
XX
DR WPI; 2003-874923/81.
XX
PT Nucleic acids encoding 83 secreted polypeptides, useful for preventing,
PT diagnosing and treating disorders related to their aberrant expression
PT and activity.
XX
PS Disclosure; SEQ ID NO 195; 308pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule encoding a
CC secreted protein that is at least 95% identical to a polynucleotide
CC fragment of any of the nucleotide sequences listed in table 1A of the
CC specification, which is hybridisable to the nucleotide sequences, a
CC polynucleotide encoding a polypeptide (or a polypeptide fragment, domain
CC or epitope of any of the amino acid sequences) listed in table 1A of the
CC specification, a polynucleotide which is an (allelic) variant of the
CC nucleotide sequences listed in the specification, a polynucleotide which
CC encodes a species homologue of the above amino acid sequences, a
CC polynucleotide capable of hybridising under stringent conditions to any
CC of the above polynucleotides, where the polynucleotide does not hybridise
CC under stringent conditions to a nucleic acid molecule having a nucleotide
CC sequence of only A or T residues. Also included are a recombinant vector
CC comprising the above nucleic acid molecule, making a recombinant host
CC cell comprising the above nucleic acid molecule, an isolated polypeptide
CC comprising a sequence that is at least 95% identical to the polypeptide
CC (or its fragment, domain, epitope, secreted form, (allelic) variant or
CC homologue) encoded by the above nucleic acid molecule, an isolated
CC antibody that binds specifically to the above polypeptide, a recombinant
CC host cell produced by the above method and that expresses the above
CC polypeptide, making an isolated polypeptide, preventing, treating or
CC ameliorating a medical condition, diagnosing a pathological condition or
CC a susceptibility to a pathological condition in a subject, identifying a
CC binding partner to the above polypeptide, the gene corresponding to the
CC cDNA sequence given in the specification, and identifying an activity in
CC a biological assay. The nucleic acid molecule and polypeptide are useful
CC in diagnosing, preventing, prognosing or treating diseases or disorders
CC associated with aberrant expression and/or activity of the above
CC polypeptide, such as neural disorders, immune system disorders, muscular
CC disorders, reproductive disorders, gastrointestinal disorders, pulmonary
CC disorders, cardiovascular disorders, renal disorders, proliferative
CC disorders and/or cancers. In particular, these diseases are systemic
CC lupus erythematosus, rheumatoid arthritis, multiple sclerosis,
CC thyroiditis, anaemia, Grave's disease, diabetes, hepatitis, asthma,
CC allergies, nephritis, Parkinson's disease, Alzheimer's disease,
CC atherosclerosis, myocardial infarction, AIDS and infections. The methods
CC may be used for identifying agonists and antagonists of the
CC polynucleotide and polypeptide. The present sequence is a protein from
CC one of the 83 disclosed secreted protein genes.
XX
SQ Sequence 37 AA;

Query Match 29.9%; Score 29; DB 7; Length 37;
Best Local Similarity 54.5%; Pred. No. 1.6e+03;
Matches 6; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKI 13
:|| || ||
Db 11 HHLKSKFHLKI 21

RESULT 166
ADL26415
ID ADL26415 standard; peptide; 37 AA.
XX
AC ADL26415;
XX
DT 17-JUN-2004 (first entry)
XX
DE Synthetic peptide 1554 derived from a conserved region of HCV.
XX

KW HCV; hepatitis C virus; virucide; vaccine; MHC; HLA;
KW major histocompatibility complex; human leukocyte antigen.
XX
OS Synthetic.
XX
PN WO2004024182-A2.
XX
PD 25-MAR-2004.
XX
PF 27-AUG-2003; 2003WO-EP009482.
XX
PR 13-SEP-2002; 2002AT-00001376.
PR 27-FEB-2003; 2003WO-EP002005.
PR 11-JUL-2003; 2003EP-00450171.
XX
PA (INTE-) INTERCELL AG.
XX
PI Buschle M, Habel A, Klade C, Mattner F, Otava O, Vytvytska O;
PI Zauner W, Zinke S, Kirlappos H;
XX
DR WPI; 2004-269899/25.
XX
PT Isolating Hepatitis C Virus peptides (HPs) which have a binding capacity
PT to a MHC/HLA molecule or a complex comprising the HCV-peptide and the
PT molecule by separating the complex from the HCV-peptides which do not
PT bind to the molecule.
XX
PS Example 1; Page 32; 73pp; English.
XX
CC The invention relates to a novel method for isolating Hepatitis C Virus
CC (HCV) peptides (HPs). The method of the invention has virucide activity,
CC and may be useful in producing a vaccine. The method is useful for
CC isolating Hepatitis C Virus peptides (HPs) which have a binding capacity
CC to a MHC/HLA molecule or a complex comprising the HCV-peptide and the
CC MHC/HLA molecule for preparing a vaccine against HCV infection. The T
CC cells, a T cell clone or a T cell population or preparation is useful for
CC identifying heteroclitic epitopes or for preparing a composition for
CC treating HCV infection. The present sequence represents a synthetic
CC peptide derived from a conserved region of HCV.
XX
SQ Sequence 37 AA;

Query Match 29.9%; Score 29; DB 8; Length 37;
Best Local Similarity 55.6%; Pred. No. 1.6e+03;
Matches 5; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 9 IAFKIVSQE 17
:|||::| |
Db 29 VAFKVMSGE 37

RESULT 167
AAU87961
ID AAU87961 standard; peptide; 38 AA.
XX
AC AAU87961;
XX
DT 05-JUN-2002 (first entry)
XX
DE Human WW domain #14.
XX
KW Human; PDZ domain; WW domain; rat; cow; mouse; fruitfly; protein therapy;
KW gene therapy; PDZ-mediated disease; inward potassium channel; WBP;
KW dimer inhibitor peptide; carboxylate binding loop.
XX
OS Homo sapiens.
XX
PN WO200207751-A1.
XX
PD 31-JAN-2002.
XX
PF 24-JUL-2001; 2001WO-US023269.
XX
PR 25-JUL-2000; 2000US-0221215P.
PR 28-NOV-2000; 2000US-00723810.
XX
PA (AXCE-) AXCELL BIOSCIENCES CORP.
XX
PI Herrero J, Pirozzi G, Uveges A;
XX
DR WPI; 2002-195842/25.
XX
PT Methods for identifying polypeptides comprising PDZ domains, the
PT polypeptides and their encoding nucleic acids, useful for the diagnosis
PT and treatment of PDZ related disorders.
XX
PS Disclosure; Fig 20; 225pp; English.
XX
CC The invention relates to methods for identifying polypeptides comprising
CC PDZ domains, and their encoding nucleic acids. The sequences are used to
CC identify modulators of their expression, function and activity, for use
CC in the diagnosis and treatment of PDZ related disorders. Antibodies
CC against the proteins and cells that produce them may be used for the
CC treatment of PDZ-mediated disease states. Sequences AAU87843-AAU87974
CC represent proteins containing PDZ domains, fragments of these proteins
CC and other related peptides used in the methods of the invention
XX
SQ Sequence 38 AA;

Query Match 29.9%; Score 29; DB 5; Length 38;
Best Local Similarity 50.0%; Pred. No. 1.6e+03;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFK 12
:||| | |:
Db 21 DHLNQKTQFE 30

RESULT 168
AAE22590
ID AAE22590 standard; peptide; 38 AA.
XX
AC AAE22590;
XX
DT 26-JUL-2002 (first entry)
XX
DE BS203 consensus sequence antigenic peptide #4.
XX
KW BS203 protein; therapy; breast disease; tumour; metastasis; cancer.
XX
OS Unidentified.
XX
PN US2002042049-A1.
XX
PD 11-APR-2002.
XX
PF 16-FEB-1999; 99US-00250883.
XX
PR 08-JUL-1997; 97US-00889316.
XX
PA (RUSS/) RUSSELL J C.
PA (COLP/) COLPITTS T L.
XX
PI Russell JC, Colpitts TL;
XX
DR WPI; 2002-315123/35.
XX
PT Detecting a target BS203 polynucleotide in a test sample, is useful for
PT diagnosing diseases of the breast, specifically breast cancer.
XX
PS Claim 7; Page 39; 45pp; English.
XX
CC The invention relates to a set of contiguous and partially overlapping
CC cDNA sequences and polypeptides encoded thereby, designated as BS203. The
CC invention also provides antibodies which specifically bind to BS203-
CC encoded polypeptide or protein, and agonists or inhibitors which prevent

CC action of the tissue-specific BS203 polypeptide, are useful for the
CC therapeutic treatment of breast disease, tumours or metastases. The
CC sequences of the invention are useful for detecting, diagnosing, staging,
CC monitoring, prognosticating, in vivo imaging, preventing or treating, or
CC determining the predisposition of an individual to diseases and
CC conditions of the breast, such as breast cancer. The present sequence is
CC BS203 consensus sequence antigenic peptide
XX
SQ Sequence 38 AA;

Query Match 29.9%; Score 29; DB 5; Length 38;
Best Local Similarity 83.3%; Pred. No. 1.6e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4 HLNSKI 9
||||||:
Db 18 HLNSKL 23

RESULT 169
AAW20028
ID AAW20028 standard; protein; 39 AA.
XX
AC AAW20028;
XX
DT 25-MAR-2003 (revised)
DT 18-SEP-1997 (first entry)
XX
DE Human acidic fibroblast growth factor exon 3 product.
XX
KW FGF; fibroblast growth factor; basic; acidic; wound healing;
KW neurodegenerative disease; Parkinson's; Alzheimer's disease;
KW bone fracture; biologically active; embolism; bacteriophage.
XX
OS Homo sapiens.
XX
PN US5604293-A.
XX
PD 18-FEB-1997.
XX
PF 01-APR-1994; 94US-00221462.
XX
PR 12-SEP-1985; 85US-00775521.
PR 16-DEC-1985; 85US-00809163.
PR 30-MAY-1986; 86US-00869382.
PR 15-MAY-1987; 87US-00050706.
PR 30-MAR-1992; 92US-00860688.
XX
PA (SCIO-) SCIOS INC.
XX
PI Fiddes JC, Abraham JA;
XX
DR WPI; 1997-234676/21.
DR N-PSDB; AAT71234.
XX
PT New high purity, recombinant human basic fibroblast growth factor - for
PT promoting wound healing and treating neuro:degenerative diseases,
PT suitable for production on large scale.
XX
PS Example 3; Fig 2c; 34pp; English.
XX
CC AAW20028 is the exon 3 product of human acidic fibroblast growth factor
CC (aFGF) derived from bacteriophage lambda-HAG-3. DNA encoding this product
CC was used to produce a recombinant aFGF protein. FGF is used to promote
CC healing of wounds, bone fractures, damaged myocardial tissue etc. and,
CC since it increases neuronal survival and promotes neurite outgrowth, may
CC also be used in treatment of neurological disorders such as Alzheimer's
CC and Parkinson's diseases. bFGF (basic FGF) may also be used for detection
CC of specific inhibitors; for treatment of cell cultures in vitro before
CC transplant and for inducing release of tissue plasminogen activator or
CC collagenase, e.g. for treatment of a chronic tendency to form embolism.
CC Recombinant FGFs can be produced on a large scale. (Updated on 25-MAR-
CC 2003 to correct PF field.)
XX
SQ Sequence 39 AA;

Query Match 29.9%; Score 29; DB 2; Length 39;
Best Local Similarity 50.0%; Pred. No. 1.7e+03;
Matches 6; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EPNHLNSKIAFK 12
| || |: |: |
Db 14 EENHYNTYISKK 25

RESULT 170
AAB53950
ID AAB53950 standard; protein; 39 AA.
XX
AC AAB53950;
XX
DT 09-MAR-2001 (first entry)
XX
DE Human colon cancer antigen protein sequence SEQ ID NO:1490.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW immunomodulatory; muscular; gynaecological; gastrointestinal;
KW nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW neural disorder; immune system disorder; muscular disorder;
KW reproductive disorder; gastrointestinal disorder; renal disorder;
KW infectious disease; cardiovascular disorder.
XX
OS Homo sapiens.
XX
PN WO200055351-A1.
XX
PD 21-SEP-2000.
XX
PF 08-MAR-2000; 2000WO-US005883.
XX
PR 12-MAR-1999; 99US-0124270P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
DR WPI; 2000-587534/55.
DR N-PSDB; AAC98707.
XX
PT Colon cancer associated gene sequences, referred to as colon cancer
PT antigens, useful for the treatment, prevention, and diagnosis of colon
PT disorders such as colon cancer.
XX
PS Claim 11; Page 2050; 2104pp; English.
XX
CC AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC called human colon cancer antigens, given in AAB53234 to AAB54006. The
CC human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC can be used in gene therapy. The colon cancer antigen polynucleotides,
CC proteins and antibodies to the proteins are useful for the prevention,
CC treatment and diagnosis of colon disorders, such as colon cancer. The
CC polynucleotides may be used in diagnostics and research, such as for
CC chromosome identification, and as hybridisation probes. The proteins may
CC also be used to prevent diseases such as neural disorders, immune system
CC disorders, muscular disorders, reproductive disorders, gastrointestinal
CC disorders, wounds, renal disorders, infectious diseases, and
CC cardiovascular disorders. AAC98764 to AAC98772 and AAB54007 represent
CC sequences used in the exemplification of the present invention
XX
SQ Sequence 39 AA;

Query Match 29.9%; Score 29; DB 3; Length 39;
Best Local Similarity 37.5%; Pred. No. 1.7e+03;

```
  Matches    6;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |  :  : :||  || |
Db         14 NLMTGRHSFKTYSQXP 29


RESULT 171
ABO55502
ID   ABO55502 standard; protein; 40 AA.
XX
AC   ABO55502;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human genome derived single exon protein #1736.
XX
KW   Human; gene expression; single exon probe; microarray;
KW   alternative splicing event; genomic alteration.
XX
OS   Homo sapiens.
XX
PN   US2003194704-A1.
XX
PD   16-OCT-2003.
XX
PF   03-APR-2002; 2002US-00029386.
XX
PR   03-APR-2002; 2002US-00029386.
XX
PA   (PENN/) PENN S G.
PA   (RANK/) RANK D R.
PA   (HANZ/) HANZEL D K.
XX
PI   Penn SG,  Rank DR,  Hanzel DK;
XX
DR   WPI; 2004-119264/12.
XX
PT   New human genome-derived single exon nucleic acid probes useful for human
PT   gene expression analysis, for identifying or characterizing alternative
PT   splicing events, for assessing genomic alterations or as tools for
PT   surveying tissues.
XX
PS   Claim 45; SEQ ID NO 29136; 80pp; English.
XX
CC   The invention relates to a nucleic acid probe for measuring human gene
CC   expression, comprising any of the 27,400 fully defined nucleotide
CC   sequences in the specification, or their complements or fragments, and
CC   encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC   fully defined in the specification. The probe is a single exon probe that
CC   hybridises under high stringency conditions to a nucleic acid molecule
CC   expressed in human cells or tissues. Also included are a spatially-
CC   addressable set of single exon nucleic acid probes for measuring human
CC   gene expression (comprising a plurality of single exon nucleic acid
CC   probes cited above, where each of the plurality of probes is separately
CC   and addressably isolatable or amplifiable from the plurality), a single
CC   exon microarray for measuring human gene expression, a method of
CC   measuring human gene expression, a vector comprising the single exon
CC   probe cited above, an ORF-encoded peptide comprising at least 8
CC   contiguous amino acids of any of the above- mentioned amino acid
CC   sequences (optionally with conservative amino acid substitutions), an
CC   isolated antibody that binds specifically to a peptide cited above,
CC   methods of selling and/or licensing single exon probes or microarrays to
CC   a customer desiring to measure gene expression, a method of providing
CC   human gene expression data by subscription, and a computer-readable
CC   storage medium which contains a database having a plurality of records
CC   (each record including data on the expression of a single exon probe
CC   cited above. The probe, methods and apparatus are useful in gene
CC   expression analysis. The probes may be used as tools for surveying
CC   tissues to detect the presence of expressed messages that contain their
CC   specific exon, or in constructing genome-derived single exon microarrays.
CC   In addition, the probes are used in identifying and characterising
CC   alternative splicing events, in detecting and characterising gross
CC   alterations in the genomic locus that includes their exon, in assessing
CC   smaller genomic alterations, in priming the synthesis of nucleic acids,
CC   or in expressing the ORF-encoded peptide. The present sequence is a human
CC   single exon probe protein of the invention. Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from USPTO at
CC   seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ   Sequence 40 AA;

  Query Match             29.9%;  Score 29;  DB 8;  Length 40;
  Best Local Similarity   54.5%;  Pred. No. 1.7e+03;
  Matches    6;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKI 13
              ||||: |   |
Db         27 NHLNNTIVSHI 37


RESULT 172
ABO59597
ID   ABO59597 standard; protein; 41 AA.
XX
AC   ABO59597;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human genome derived single exon protein #5831.
XX
KW   Human; gene expression; single exon probe; microarray;
KW   alternative splicing event; genomic alteration.
XX
OS   Homo sapiens.
XX
PN   US2003194704-A1.
XX
PD   16-OCT-2003.
XX
PF   03-APR-2002; 2002US-00029386.
XX
PR   03-APR-2002; 2002US-00029386.
XX
PA   (PENN/) PENN S G.
PA   (RANK/) RANK D R.
PA   (HANZ/) HANZEL D K.
XX
PI   Penn SG,  Rank DR,  Hanzel DK;
XX
DR   WPI; 2004-119264/12.
XX
PT   New human genome-derived single exon nucleic acid probes useful for human
PT   gene expression analysis, for identifying or characterizing alternative
PT   splicing events, for assessing genomic alterations or as tools for
PT   surveying tissues.
XX
PS   Claim 45; SEQ ID NO 33231; 80pp; English.
XX
CC   The invention relates to a nucleic acid probe for measuring human gene
CC   expression, comprising any of the 27,400 fully defined nucleotide
CC   sequences in the specification, or their complements or fragments, and
CC   encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC   fully defined in the specification. The probe is a single exon probe that
CC   hybridises under high stringency conditions to a nucleic acid molecule
CC   expressed in human cells or tissues. Also included are a spatially-
CC   addressable set of single exon nucleic acid probes for measuring human
CC   gene expression (comprising a plurality of single exon nucleic acid
CC   probes cited above, where each of the plurality of probes is separately
CC   and addressably isolatable or amplifiable from the plurality), a single
CC   exon microarray for measuring human gene expression, a method of
CC   measuring human gene expression, a vector comprising the single exon
CC   probe cited above, an ORF-encoded peptide comprising at least 8
CC   contiguous amino acids of any of the above- mentioned amino acid
CC   sequences (optionally with conservative amino acid substitutions), an
```

CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 41 AA;

Query Match 29.9%; Score 29; DB 8; Length 41;
Best Local Similarity 83.3%; Pred. No. 1.8e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 4 HLNSKI 9
: |||||:
Db 35 HLNSKL 40

RESULT 173
AAB64605
ID AAB64605 standard; protein; 42 AA.
XX
AC AAB64605;
XX
DT 22-MAR-2001 (first entry)
XX
DE Human secreted protein BLAST search protein SEQ ID NO: 115.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
OS Homo sapiens.
XX
PN WO200077197-A1.
XX
PD 21-DEC-2000.
XX
PF 01-JUN-2000; 2000WO-US014934.
XX
PR 11-JUN-1999; 99US-0138599P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PA (ROSE/) ROSEN C A.
XX
PI Rosen CA, Ruben SM, Komatsoulis GA;
XX
DR WPI; 2001-032312/04.
XX
PT Isolated nucleic acid molecule encoding a human secreted protein is used
PT in preventing, treating or ameliorating a medical condition.
XX
PS Disclosure; Page 512; 558pp; English.
XX
CC The invention relates to the isolation of genes AAF32757-F32803 encoding
CC the human secreted proteins AAB64549-B64594. The sequence is a search
CC result from a BLASTX homology search. The genes and proteins are useful
CC for preventing, ameliorating or treating medical conditions, e.g. by
CC protein or gene therapy. The genes are isolated from a range of human
CC tissues disclosed in the specification. The nucleic acids, proteins,
CC antibodies and (ant)agonists are useful in the diagnosis, treatment and
CC prevention of: (a) cancer, e.g. breast and ovarian cancer, and other
CC cancers of the adrenal gland, bone, bone marrow, breast, gastrointestinal
CC tract, liver, lung, or urogenital; (b) immune disorders e.g. Addison's
CC disease, allergies, autoimmune haemolytic anaemia, autoimmune
CC thyroiditis, diabetes mellitus, Crohn's disease, multiple sclerosis,
CC rheumatoid arthritis and ulcerative colitis; (c) cardiovascular disorders
CC such as myocardial ischaemias; (d) wound healing; (e) neurological
CC diseases e.g. cerebral anoxia and epilepsy; and (f) infectious diseases
CC such as viral, bacterial, fungal and parasitic infections
XX
SQ Sequence 42 AA;

Query Match 29.9%; Score 29; DB 4; Length 42;
Best Local Similarity 71.4%; Pred. No. 1.8e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EPNHLNS 7
: |||||
Db 19 QENHLNS 25

RESULT 174
AAG09091
ID AAG09091 standard; protein; 43 AA.
XX
AC AAG09091;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 6886.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.

PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.

PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 29.9%; Score 29; DB 3; Length 43;
Best Local Similarity 33.3%; Pred. No. 1.9e+03;
Matches 6; Conservative 4; Mismatches 8; Indels 0; Gaps 0;

Qy 1 EPNHLNSKIAFKIVSQEP 18
|| :|: :| | :|
Db 16 EPRNLHEALAAPAESSKP 33

RESULT 175
ABG90950
ID ABG90950 standard; protein; 44 AA.
XX
AC ABG90950;
XX
DT 29-NOV-2002 (first entry)
XX
DE Human colon specific polypeptide, #23.
XX
KW Human; colon specific nucleic acid; CSNA; colon specific polypeptide;
KW CSP; vaccine; diagnosis; metastasis; colon cancer; cancer;
KW immune response; staging; imaging; colorectal cancer; gene therapy;
KW transgenic; engineered colon tissue.
XX
OS Homo sapiens.
XX
PN WO200264744-A2.
XX
PD 22-AUG-2002.
XX
PF 12-FEB-2002; 2002WO-US004240.
XX
PR 13-FEB-2001; 2001US-0268291P.
XX
PA (DIAD-) DIADEXUS INC.
XX
PI Piderit A, Macina RA, Sun Y, Liu C;
XX
DR WPI; 2002-657591/70.
DR N-PSDB; ABS67098, ABS67099.
XX
PT New colon specific nucleic acid, useful in gene therapy or as vaccines
PT for treating colon cancer or colorectal cancer, or non-cancerous colon
PT diseases, as well as for diagnosing, monitoring or staging these
PT diseases.
XX
PS Claim 11; Page 182; 187pp; English.
XX
CC The invention discloses isolated colon specific nucleic acids (CSNAs) and
CC the polypeptides (CSPs) that they encode. The colon specific nucleic
CC acids and polypeptides are useful as vaccines. The colon specific nucleic
CC acid and polypeptide are also useful for diagnosing and monitoring the
CC presence and metastases of colon cancer in a patient. The antibody that
CC specifically binds to the colon specific polypeptide is useful for
CC determining the presence of a colon specific protein in a sample, as well
CC as for treating a patient with cancer, particularly by inducing an immune
CC response against the colon cancer cell expressing the colon specific
CC nucleic acid molecule or polypeptide. In particular, these colon specific
CC genes and proteins are useful for identifying, diagnosing, monitoring,
CC staging, imaging and treating colon cancer (e.g. colorectal cancer) and
CC non-cancerous disease states in the colon. These are also useful in gene
CC therapy, production of transgenic animals and cells and in the production
CC of engineered colon tissue for treatment and research. The sequences
CC presented in ABG90928-ABG90963 are the human CSPs encoded by the CSNAs
XX
SQ Sequence 44 AA;

Query Match 29.9%; Score 29; DB 5; Length 44;
Best Local Similarity 38.5%; Pred. No. 1.9e+03;
Matches 5; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVS 15
| | :|| : ::|
Db 18 NTLTTKIKYSLIS 30

RESULT 176
ABJ04320
ID ABJ04320 standard; protein; 44 AA.
XX
AC ABJ04320;
XX
DT 11-OCT-2002 (first entry)
XX
DE Human colon specific protein SEQ ID NO: 94.
XX
KW Human; colon specific gene; colon specific protein; colon cancer;
KW colorectal cancer; colon disease; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200242460-A2.
XX
PD 30-MAY-2002.
XX
PF 21-NOV-2001; 2001WO-US043611.
XX
PR 22-NOV-2000; 2000US-0252505P.
XX
PA (DIAD-) DIADEXUS INC.
XX
PI Macina RA, Recipon H, Pluta J, Ghosh MG, Sun Y, Liu C;
XX
DR WPI; 2002-583378/62.
XX
PT Novel colon specific polypeptides and polynucleotides useful for
PT detecting, diagnosing, monitoring, treating, staging and predicting
PT cancers in humans having cancer and non-cancerous colon disease.
XX
PS Claim 11; Page 211; 228pp; English.
XX
CC The present invention provides protein and coding sequences of human
CC colon specific genes and proteins. These can be used in the treatment of
CC colonic diseases, including colon and colorectal cancers. The present
CC sequence is a protein of the invention
XX
SQ Sequence 44 AA;

Query Match 29.9%; Score 29; DB 5; Length 44;
Best Local Similarity 38.5%; Pred. No. 1.9e+03;
Matches 5; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVS 15
| | :|| : ::|
Db 18 NTLTTKIKYSLIS 30

RESULT 177
ABU61907
ID ABU61907 standard; protein; 44 AA.
XX
AC ABU61907;
XX
DT 18-AUG-2003 (first entry)
XX
DE Mouse glycoprotein 110 fragment #7.
XX
KW Mouse; glycoprotein 110; cytostatic; immunostimulant; immunogen; tumour;

KW cDNA vaccine; cytotoxic lymphocyte; peripheral blood.
XX
OS Mus musculus.
XX
PN US6514493-B1.
XX
PD 04-FEB-2003.
XX
PF 21-JUL-1997; 97US-00897843.
XX
PR 21-JUL-1997; 97US-00897843.
XX
PA (UYPI-) UNIV PITTSBURGH.
XX
PI Deleo AB, Loftus D, Appella E;
XX
DR WPI; 2003-478760/45.
XX
PT A new isolated cDNA molecule useful for the treatment of tumors comprises
PT a polynucleotide sequence encoding a protein fragment of murine
PT glycoprotein 110 containing 938 amino acids.
XX
PS Example 7; Fig 1G; 27pp; English.
XX
CC The invention relates to an isolated cDNA molecule (A) comprising a
CC polynucleotide sequence (not shown) encoding a protein fragment of murine
CC glycoprotein (gp) 110 appearing as ABU61901 (of 938 amino acids or their
CC conservative variants). Also included are a cDNA vaccine for inducing
CC resistance to tumors comprising (A) and an antigen presenting cell
CC transfected with (A). The cDNA is useful in the preparation of a vaccine
CC for inducing resistance to tumours in a patient (comprising transfecting
CC (A) into an antigen presenting cell (preferably a dendritic cell) and
CC administering the cell to the patient or distributing (A) on a particle
CC surface to form particulate polynucleotide and inoculating the patient
CC with the particulate polynucleotide). Variants of the gp peptide encoded
CC by the cDNA molecule are capable of inducing anti-gp 110 cytotoxic
CC lymphocytes in the peripheral blood of the normal individuals to induce
CC vaccination or in the treatment of tumours expressing gp 110 by causing
CC tumour rejection. The present sequence is a fragment of the mouse GP110
CC protein
XX
SQ Sequence 44 AA;

Query Match 29.9%; Score 29; DB 6; Length 44;
Best Local Similarity 38.9%; Pred. No. 1.9e+03;
Matches 7; Conservative 4; Mismatches 5; Indels 2; Gaps 1;

```
Qy          2 PNHLNSKIAFKIVSQEPA 19
              |:|||  : |  :|:  |
Db         25 PSHLN--LVFLFLSRAAA 40
```

RESULT 178
AAG59379
ID AAG59379 standard; protein; 45 AA.
XX
AC AAG59379;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 76802.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.

XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.

PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 29.9%; Score 29; DB 3; Length 45;
Best Local Similarity 62.5%; Pred. No. 2e+03;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

```
Qy          1 EPNHLNSK 8
              |||| :|
Db         23 EPNHNKNK 30
```

RESULT 179
ABB50392
ID ABB50392 standard; protein; 46 AA.
XX
AC ABB50392;
XX
DT 07-FEB-2002 (first entry)
XX
DE Human secreted protein encoded by gene 92 SEQ ID NO:340.
XX
KW Human; secreted protein; immunomodulatory; antisclerotic; anti-HIV;
KW dermatological; immunosuppressive; antiinflammatory; immunostimulant;
KW cytostatic; cardiant; vascular; anti-angiogenic; ophthalmological;
KW neuroprotective; nootropic; anticonvulsant; antialzheimers; vulnerary;
KW antiparkinsonian; antimicrobial; gene therapy; vaccine; immune disorder;
KW multiple sclerosis; systemic lupus erythematosus; HIV infection; cancer;
KW human immunodeficiency virus; hyperproliferative disorder; wound healing;
KW Gaucher's disease; cardiovascular disease; Scimitar syndrome; chemotaxis;
KW Chaga's cardiomyopathy; coronary arteriosclerosis; angiogenic disorder;
KW corneal graft neovascularisation; diabetic retinopathy; regeneration;
KW neurological disorder; Huntington's chorea; Alzheimer's disease;
KW Parkinson's disease; infectious disease; chromosome 19.
XX
OS Homo sapiens.
XX
PN WO200162891-A2.
XX
PD 30-AUG-2001.

```
XX
PF   21-FEB-2001; 2001WO-US005614.
XX
PR   24-FEB-2000; 2000US-0184836P.
PR   29-MAR-2000; 2000US-0193170P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ni J,  Ebner R,  Lafleur DW,  Moore PA,  Olsen HS,  Rosen CA;
PI   Ruben SM,  Soppet DR,  Young PE,  Shi Y,  Florence KA,  Wei Y;
PI   Florence C,  Hu J,  Li Y,  Kyaw H,  Fischer CL,  Ferrie AM,  Fan P;
PI   Feng P,  Endress GA,  Dillon PJ,  Carter KC,  Brewer LA,  Yu G,  Zeng Z;
PI   Greene JM;
XX
DR   WPI; 2001-625724/72.
DR   N-PSDB; ABA83285.
XX
PT   Nucleic acids encoding 207 human secreted polypeptides, useful for
PT   preventing, diagnosing and/or treating, e.g. cancers, Parkinson's disease
PT   and diabetic retinopathy.
XX
PS   Claim 11; Page 1126; 1533pp; English.
XX
CC   ABB50301 to ABB51287 and ABA83194 to ABA83441 represent human secreted
CC   proteins (I) and polynucleotide (II) sequences. (I) and (II) have various
CC   activities based on the tissues and cells the genes are expressed in.
CC   Example of these activities include: immunomodulatory; antisclerotic;
CC   dermatological; immunosuppressive; antiinflammatory; immunostimulant;
CC   anti-HIV; cytostatic; cardiant; anti-angiogenic; ophthalmological;
CC   neuroprotective; nootropic; anticonvulsant; antialzheimers; vascular;
CC   antiparkinsonian; antimicrobial; and vulnerary. (I) and (II) can be used
CC   in gene therapy and vaccine production. (I) and (II) can be used in the
CC   prevention, diagnosis and treatment of immune disorders (e.g. multiple
CC   sclerosis, systemic lupus erythematosus and human immunodeficiency virus
CC   (HIV) infections), hyperproliferative disorders (e.g. cancers and
CC   Gaucher's disease), cardiovascular diseases (e.g. Scimitar syndrome,
CC   Chaga's cardiomyopathy and coronary arteriosclerosis), angiogenic
CC   disorders (e.g. corneal graft neovascularisation and diabetic
CC   retinopathy), neurological disorders (e.g. Huntington's chorea,
CC   Alzheimer's disease and Parkinson's disease), infectious diseases and/or
CC   for promoting wound healing, regeneration and/or chemotaxis. ABA83185 to
CC   ABA83193 and ABB50300 represent sequences used in the exemplification of
CC   the present invention
XX
SQ   Sequence 46 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 46;
  Best Local Similarity   37.5%;  Pred. No. 2e+03;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |   |:  :|| |::|
Db         26 NLFTSQKIYKIYSEKP 41


RESULT 180
ABO44649
ID   ABO44649 standard; protein; 46 AA.
XX
AC   ABO44649;
XX
DT   02-OCT-2003  (first entry)
XX
DE   Novel human secreted protein #92.
XX
KW   Human; gene therapy; autoimmune disorder; multiple sclerosis; cancer;
KW   systemic lupus erythematosus; haematopoietic cell disorder; allergy;
KW   agammaglobulinaemia; ataxia telangiectasia; blood coagulation disorder;
KW   afibrinogenaemia; thrombocytopenia; graft-versus-host disease; arthritis;
KW   inflammatory condition; ischaemia-reperfusion injury; infectious disease;
KW   hyperproliferative disorder; purpura; viral infection; regeneration;
KW   bacterial infection; ulcer; Alzheimer's disease.
XX
OS   Homo sapiens.
XX
PN   US2003065160-A1.
XX
PD   03-APR-2003.
XX
PF   07-DEC-2001; 2001US-00004860.
XX
PR   06-JUN-1997;   97US-0048875P.
PR   06-JUN-1997;   97US-0048876P.
PR   06-JUN-1997;   97US-0048877P.
PR   06-JUN-1997;   97US-0048878P.
PR   06-JUN-1997;   97US-0048880P.
PR   06-JUN-1997;   97US-0048881P.
PR   06-JUN-1997;   97US-0048882P.
PR   06-JUN-1997;   97US-0048883P.
PR   06-JUN-1997;   97US-0048884P.
PR   06-JUN-1997;   97US-0048885P.
PR   06-JUN-1997;   97US-0048892P.
PR   06-JUN-1997;   97US-0048893P.
PR   06-JUN-1997;   97US-0048894P.
PR   06-JUN-1997;   97US-0048895P.
PR   06-JUN-1997;   97US-0048896P.
PR   06-JUN-1997;   97US-0048897P.
PR   06-JUN-1997;   97US-0048898P.
PR   06-JUN-1997;   97US-0048899P.
PR   06-JUN-1997;   97US-0048900P.
PR   06-JUN-1997;   97US-0048901P.
PR   06-JUN-1997;   97US-0048915P.
PR   06-JUN-1997;   97US-0048916P.
PR   06-JUN-1997;   97US-0048917P.
PR   06-JUN-1997;   97US-0048949P.
PR   06-JUN-1997;   97US-0048962P.
PR   06-JUN-1997;   97US-0048963P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048970P.
PR   06-JUN-1997;   97US-0048971P.
PR   06-JUN-1997;   97US-0048972P.
PR   06-JUN-1997;   97US-0048974P.
PR   06-JUN-1997;   97US-0049019P.
PR   06-JUN-1997;   97US-0049020P.
PR   06-JUN-1997;   97US-0049373P.
PR   06-JUN-1997;   97US-0049374P.
PR   06-JUN-1997;   97US-0049375P.
PR   05-SEP-1997;   97US-0057584P.
PR   05-SEP-1997;   97US-0057627P.
PR   05-SEP-1997;   97US-0057628P.
PR   05-SEP-1997;   97US-0057629P.
PR   05-SEP-1997;   97US-0057634P.
PR   05-SEP-1997;   97US-0057635P.
PR   05-SEP-1997;   97US-0057642P.
PR   05-SEP-1997;   97US-0057643P.
PR   05-SEP-1997;   97US-0057644P.
PR   05-SEP-1997;   97US-0057645P.
PR   05-SEP-1997;   97US-0057646P.
PR   05-SEP-1997;   97US-0057647P.
PR   05-SEP-1997;   97US-0057648P.
PR   05-SEP-1997;   97US-0057649P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057651P.
PR   05-SEP-1997;   97US-0057654P.
PR   05-SEP-1997;   97US-0057661P.
PR   05-SEP-1997;   97US-0057662P.
PR   05-SEP-1997;   97US-0057666P.
PR   05-SEP-1997;   97US-0057667P.
PR   05-SEP-1997;   97US-0057668P.
PR   05-SEP-1997;   97US-0057760P.
PR   05-SEP-1997;   97US-0057761P.
PR   05-SEP-1997;   97US-0057762P.
PR   05-SEP-1997;   97US-0057763P.
PR   05-SEP-1997;   97US-0057764P.
PR   05-SEP-1997;   97US-0057765P.
PR   05-SEP-1997;   97US-0057769P.
```

```
PR   05-SEP-1997;   97US-0057770P.
PR   05-SEP-1997;   97US-0057771P.
PR   05-SEP-1997;   97US-0057774P.
PR   05-SEP-1997;   97US-0057775P.
PR   05-SEP-1997;   97US-0057776P.
PR   05-SEP-1997;   97US-0057777P.
PR   05-SEP-1997;   97US-0057778P.
PR   18-DEC-1997;   97US-0070923P.
PR   04-JUN-1998;   98WO-US011422.
PR   15-JUL-1998;   98US-0092921P.
PR   30-JUL-1998;   98US-0094657P.
PR   04-DEC-1998;   98US-00205258.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Young P,  Greene JM,  Ferrie AM,  Ruben SM,  Rosen CA,  Hu J;
PI   Olsen HS,  Ebner R,  Brewer LA,  Moore PA,  Shi Y,  Florence C;
PI   Florence K,  Lafleur DW,  Ni J,  Fan P,  Wei Y,  Fischer CL,  Soppet DR;
PI   Li Y,  Zeng Z,  Kyaw H,  Yu G,  Feng P,  Dillon PJ,  Endress GA;
PI   Carter KC;
XX
DR   WPI; 2003-540804/51.
DR   N-PSDB; ACH04786.
XX
PT   New isolated protein, useful for preparing a composition for diagnosing
PT   or treating cancer, inflammatory, immune or infectious diseases.
XX
PS   Disclosure; SEQ ID NO 340; 172pp; English.
XX
CC   The invention relates to an isolated HEMAE80 protein. The protein is
CC   useful for preparing a composition for diagnosing or treating autoimmune
CC   disorders e.g. multiple sclerosis and systemic lupus erythematosus;
CC   haematopoietic cell disorders e.g. agammaglobulinaemia and ataxia
CC   telangiectasia; blood coagulation disorders e.g. afibrinogenaemia and
CC   thrombocytopenia; allergy; graft-versus-host disease; inflammatory
CC   conditions e.g. ischaemia-reperfusion injury and arthritis;
CC   hyperproliferative disorders e.g. cancer and purpura; infectious disease
CC   e.g. viral infection and bacterial infection. The polynucleotide or
CC   protein can be used to regenerate damaged tissue e.g. ulcers and
CC   Alzheimer's disease. The present sequence represents the amino acid
CC   sequence of a novel human secreted protein. Note: The sequence data for
CC   this patent did not form part of the printed specification but was
CC   obtained in electronic format directly from USPTO at
CC   seqdata.uspto.gov/sequence.html?DocID=20030065160
XX
SQ   Sequence 46 AA;

  Query Match             29.9%;  Score 29;  DB 6;  Length 46;
  Best Local Similarity   37.5%;  Pred. No. 2e+03;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |   |:  :|| |::|
Db         26 NLFTSQKIYKIYSEKP 41


RESULT 181
ABO26129
ID   ABO26129 standard; protein; 46 AA.
XX
AC   ABO26129;
XX
DT   10-SEP-2003  (first entry)
XX
DE   Human protein from novel secreted protein gene 92.
XX
KW   Human; secreted protein; precerebellin-like protein;
KW   neurodegenerative disorder; behavioural disorder; Alzheimer's disease;
KW   Parkinson's disease; Huntington's disease; schizophrenia; mania;
KW   dementia; paranoia; psychosis; autism; immune disorder; infection;
KW   inflammation; allergy; liver disorder; hepatoblastoma; jaundice;
KW   hepatitis; immunological disorder; AIDS; leukaemia; rheumatoid arthritis;
KW   sepsis; acne; psoriasis; cancer.
XX
OS   Homo sapiens.
XX
PN   US6525174-B1.
XX
PD   25-FEB-2003.
XX
PF   04-DEC-1998;   98US-00205258.
XX
PR   06-JUN-1997;   97US-0048875P.
PR   06-JUN-1997;   97US-0048876P.
PR   06-JUN-1997;   97US-0048877P.
PR   06-JUN-1997;   97US-0048878P.
PR   06-JUN-1997;   97US-0048880P.
PR   06-JUN-1997;   97US-0048881P.
PR   06-JUN-1997;   97US-0048882P.
PR   06-JUN-1997;   97US-0048883P.
PR   06-JUN-1997;   97US-0048884P.
PR   06-JUN-1997;   97US-0048885P.
PR   06-JUN-1997;   97US-0048892P.
PR   06-JUN-1997;   97US-0048893P.
PR   06-JUN-1997;   97US-0048894P.
PR   06-JUN-1997;   97US-0048895P.
PR   06-JUN-1997;   97US-0048896P.
PR   06-JUN-1997;   97US-0048897P.
PR   06-JUN-1997;   97US-0048898P.
PR   06-JUN-1997;   97US-0048899P.
PR   06-JUN-1997;   97US-0048900P.
PR   06-JUN-1997;   97US-0048901P.
PR   06-JUN-1997;   97US-0048915P.
PR   06-JUN-1997;   97US-0048916P.
PR   06-JUN-1997;   97US-0048917P.
PR   06-JUN-1997;   97US-0048949P.
PR   06-JUN-1997;   97US-0048962P.
PR   06-JUN-1997;   97US-0048963P.
PR   06-JUN-1997;   97US-0048964P.
PR   06-JUN-1997;   97US-0048970P.
PR   06-JUN-1997;   97US-0048971P.
PR   06-JUN-1997;   97US-0048972P.
PR   06-JUN-1997;   97US-0048974P.
PR   06-JUN-1997;   97US-0049019P.
PR   06-JUN-1997;   97US-0049020P.
PR   06-JUN-1997;   97US-0049373P.
PR   06-JUN-1997;   97US-0049374P.
PR   06-JUN-1997;   97US-0049375P.
PR   05-SEP-1997;   97US-0057584P.
PR   05-SEP-1997;   97US-0057627P.
PR   05-SEP-1997;   97US-0057628P.
PR   05-SEP-1997;   97US-0057629P.
PR   05-SEP-1997;   97US-0057634P.
PR   05-SEP-1997;   97US-0057635P.
PR   05-SEP-1997;   97US-0057642P.
PR   05-SEP-1997;   97US-0057643P.
PR   05-SEP-1997;   97US-0057644P.
PR   05-SEP-1997;   97US-0057645P.
PR   05-SEP-1997;   97US-0057646P.
PR   05-SEP-1997;   97US-0057647P.
PR   05-SEP-1997;   97US-0057648P.
PR   05-SEP-1997;   97US-0057649P.
PR   05-SEP-1997;   97US-0057650P.
PR   05-SEP-1997;   97US-0057651P.
PR   05-SEP-1997;   97US-0057654P.
PR   05-SEP-1997;   97US-0057661P.
PR   05-SEP-1997;   97US-0057662P.
PR   05-SEP-1997;   97US-0057666P.
PR   05-SEP-1997;   97US-0057667P.
PR   05-SEP-1997;   97US-0057668P.
PR   05-SEP-1997;   97US-0057760P.
PR   05-SEP-1997;   97US-0057761P.
PR   05-SEP-1997;   97US-0057762P.
PR   05-SEP-1997;   97US-0057763P.
PR   05-SEP-1997;   97US-0057764P.
PR   05-SEP-1997;   97US-0057765P.
```

PR 05-SEP-1997; 97US-0057769P.
PR 05-SEP-1997; 97US-0057770P.
PR 05-SEP-1997; 97US-0057771P.
PR 05-SEP-1997; 97US-0057774P.
PR 05-SEP-1997; 97US-0057775P.
PR 05-SEP-1997; 97US-0057776P.
PR 05-SEP-1997; 97US-0057777P.
PR 05-SEP-1997; 97US-0057778P.
PR 18-DEC-1997; 97US-0070923P.
PR 04-JUN-1998; 98WO-US011422.
PR 15-JUL-1998; 98US-0092921P.
PR 30-JUL-1998; 98US-0094657P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Young P, Greene JM, Ferrie AM, Ruben SM, Rosen CA, Hu J;
PI Olsen HS, Ebner R, Brewer LA, Moore PA, Shi Y, Florence C;
PI Florence K, Lafleur DW, Ni J, Fan P, Wei Y, Fischer CL, Soppet DR;
PI Li Y, Zeng Z, Kyaw H, Yu G, Feng P, Dillon PJ, Endress GA;
PI Carter KC;
XX
DR WPI; 2003-511926/48.
DR N-PSDB; ACD44596.
XX
PT New precerebellin-like protein, useful for diagnosing or treating
PT neurodegenerative and behavioral disorders, immune disorders, liver
PT disorders, and cancer.
XX
PS Disclosure; SEQ ID NO 340; 156pp; English.
XX
CC The invention relates to an isolated protein comprising amino acid
CC residues 33-205 or 1-205 of a a novel human secreted protein appearing as
CC ABO26252. The protein is encoded by one of 238 disclosed cDNA sequences
CC encoding 238 secreted proteins. ABO26252 is a precerebellin-like protein.
CC Also included are a composition comprising the protein and a carrier and
CC an isolated protein produced by expressing the protein cited above by a
CC cell, and recovering the protein. The proteins are useful for diagnosing
CC or treating neurodegenerative and behavioural disorders (e.g. Alzheimer's
CC disease, Parkinson's disease, Huntington's disease, schizophrenia, mania,
CC dementia, paranoia, psychoses or autism), immune disorders (e.g.
CC infection, inflammation, allergy), liver disorders (e.g. hepatoblastoma,
CC jaundice, hepatitis), immunological disorders (e.g. AIDS, leukaemia,
CC rheumatoid arthritis, sepsis, acne, psoriasis) and cancer. The present
CC sequence is one of the 238 disclosed novel secreted proteins. Note: The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from USPTO
CC at:- seqdata.uspto.gov/sequence.html?DocID=6525174B1
XX
SQ Sequence 46 AA;

Query Match 29.9%; Score 29; DB 7; Length 46;
Best Local Similarity 37.5%; Pred. No. 2e+03;
Matches 6; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

Qy 3 NHLNSKIAFKIVSQEP 18
Db 26 NLFTSQKIYKIYSEKP 41

RESULT 182
AAB44907
ID AAB44907 standard; protein; 47 AA.
XX
AC AAB44907;
XX
DT 09-FEB-2001 (first entry)
XX
DE Human secreted protein encoded by gene 28 homologue.
XX
KW Human; secreted protein; cytostatic; antiarthritic; antiasthmatic;
KW immunosuppressive; antiarteriosclerotic; antiinflammatory; nootropic;
KW neuroprotective; antidiabetic; tranquiliser; vulnerary; antibacterial;
KW antipsoriatic; antiarrhythmic; antirheumatic; cardiant; anti-HIV;
KW autoimmune disorder; allergic condition; cardiovascular disorder; cancer;
KW neurological disease; tissue repair.
XX
OS Homo sapiens.
XX
PN WO200055176-A2.
XX
PD 21-SEP-2000.
XX
PF 09-MAR-2000; 2000WO-US006057.
XX
PR 12-MAR-1999; 99US-0124142P.
PR 11-JUN-1999; 99US-0138597P.
PR 03-DEC-1999; 99US-0168666P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Komatsoulis G;
XX
DR WPI; 2000-638176/61.
XX
PT Novel 49 human secreted proteins useful for diagnosis, prevention and
PT treatment of disorders including neurological, cell proliferative,
PT cardiovascular, and autoimmune/inflammatory disorders and microbial
PT infections.
XX
PS Disclosure; Page 396; 405pp; English.
XX
CC This invention describes a novel isolated polypeptide (I) comprising an
CC amino acid sequence at least 95 % identical to a polypeptide sequence
CC selected from 49 polypeptides encoded by polynucleotide sequences
CC included in American Type Culture Collection (ATCC) deposit number
CC 203917, defined in the specification. The products of the invention have
CC cytostatic, antiarthritic, antiasthmatic, immunosuppressive, nootropic;
CC antiarteriosclerotic, antiinflammatory, neuroprotective, antidiabetic,
CC tranquiliser, vulnerary, antibacterial, antipsoriatic, antiarrhythmic,
CC antirheumatic, cardiant and anti-HIV activity. (I) or a nucleic acid (II)
CC encoding (I) is useful for preventing, treating or ameliorating a medical
CC condition and for diagnosing a pathological condition or susceptibility
CC to the condition. (I) is useful for identifying a binding partner which
CC affects the activity of the polypeptide and for identifying an activity
CC in a biological sample. (I), (II) or an antibody (IV) specific to (I) is
CC also useful for treating or preventing a disease, disorder or condition
CC associated with aberrant expression of (I). Diseases treated or diagnosed
CC include immune disorders such as autoimmune diseases, blood protein
CC disorders, anemia, allergic reactions and conditions such as asthma,
CC organ rejection or graft-versus-host disease, inflammation, hyper
CC proliferative disorders, cardiovascular disorders such as arterioarterial
CC fistula, arrhythmias, arteriosclerosis, coronary thrombosis, organ
CC regeneration, cancer, neovascular glaucoma, diabetic retinopathy,
CC rheumatoid arthritis, psoriasis, diseases associated with increased
CC apoptosis that include acquired immunodeficiency syndrome (AIDS),
CC neurological diseases such as Parkinson's disease, viral, bacterial,
CC fungal or parasitic diseases. They are also used to repair, replace or
CC protect tissue damage by congenital defects, to treat trauma, in surgery,
CC including cosmetic plastic surgery, to treat fibrosis, reperfusion injury
CC or systemic cytokine damage, to stimulate chondrocyte growth, to prevent
CC skin aging due to sunburn, to change a mammal's mental state or physical
CC state by influencing biorhythms, cardiac rhythms, depression, memory,
CC stress and for accelerating wound healing. (I), (II) and/or their agonist
CC or antagonist are useful as food additives or preservatives to increase
CC or decrease storage capabilities, fat content, lipid, protein,
CC carbohydrate, vitamin, mineral or other nutritional components. (I) is
CC useful for screening therapeutic compounds. (II) is useful in forensic
CC biology for detecting DNA sequences and as diagnostic probes for
CC detecting the presence of specific mRNA in a particular cell type
XX
SQ Sequence 47 AA;

Query Match 29.9%; Score 29; DB 3; Length 47;
Best Local Similarity 71.4%; Pred. No. 2.1e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 EPNHLNS 7
              : |||||
Db         19 QENHLNS 25
```

RESULT 183
ABG02562
ID ABG02562 standard; protein; 47 AA.
XX
AC ABG02562;
XX
DT 13-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #2553.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US008631.
XX
PR 31-MAR-2000; 2000US-00540217.
PR 23-AUG-2000; 2000US-00649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS66749.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity.
XX
PS Claim 20; SEQ ID NO 32921; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC sequences. (I) is useful as hybridisation probes, polymerase chain
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC and in recombinant production of (II). The polynucleotides are also used
CC in diagnostics as expressed sequence tags for identifying expressed
CC genes. (I) is useful in gene therapy techniques to restore normal
CC activity of (II) or to treat disease states involving (II). (II) is
CC useful for generating antibodies against it, detecting or quantitating a
CC polypeptide in tissue, as molecular weight markers and as a food
CC supplement. (II) and its binding partners are useful in medical imaging
CC of sites expressing (II). (I) and (II) are useful for treating disorders
CC involving aberrant protein expression or biological activity. The
CC polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC amino acid sequences of the invention. Note: The sequence data for this
CC patent did not appear in the printed specification, but was obtained in
CC electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 47 AA;

```
  Query Match             29.9%;  Score 29;  DB 4;  Length 47;
  Best Local Similarity   35.3%;  Pred. No. 2.1e+03;
  Matches    6;  Conservative    3;  Mismatches    8;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQEP 18
              |:    :|: |  | ||
```

```
Db          9 PHPETGRISAKFTSMEP 25
```

RESULT 184
AAM47156
ID AAM47156 standard; peptide; 47 AA.
XX
AC AAM47156;
XX
DT 12-FEB-2002 (first entry)
XX
DE Modular enzyme system related ACP-domain N-terminal peptide SRF2_1.
XX
KW Modular enzyme system; cyclic gene synthesis; repetitive coding sequence;
KW antibiotic; non-ribosomal peptide synthetase; NRPS; PKS;
KW polyketide synthase; actinomycin biosynthase.
XX
OS Bacillus subtilis.
XX
PN WO200181564-A2.
XX
PD 01-NOV-2001.
XX
PF 25-APR-2001; 2001WO-DE001578.
XX
PR 26-APR-2000; 2000DE-01021267.
XX
PA (ACTI-) ACTINODRUG PHARM GMBH.
XX
PI Schauwecker F;
XX
DR WPI; 2002-049276/06.
XX
PT Preparing DNA encoding modular protein for e.g. producing new enzymes for
PT synthesis of polyketide antibiotics, comprises cyclic integration of
PT fragments into a vector.
XX
PS Example 1; Fig 9; 83pp; German.
XX
CC The present invention relates to the preparation of DNA, in a circular
CC vector, that encodes one or more segments of a modular polypeptide. DNA
CC or DNA libraries produced this way are used to produce modular
CC polypeptides, particularly enzymes, which can be used to act on
CC substrates to produce compounds for therapeutic testing. Enzymes of
CC particular interest are those involved in non-ribosomal peptide synthesis
CC or polyketide synthesis, and compounds for testing are particularly
CC macrolide antibiotics, including penicillins, vancomycins or
CC erythromycins, but may also be modular receptors. The present sequence is
CC a peptide used in the exemplification of the invention
XX
SQ Sequence 47 AA;

```
  Query Match             29.9%;  Score 29;  DB 5;  Length 47;
  Best Local Similarity   20.0%;  Pred. No. 2.1e+03;
  Matches    3;  Conservative    7;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIVSQEP 18
              | : ::  |:: ::|
Db         20 HFHKEVPIKVLFEKP 34
```

RESULT 185
AAM47171
ID AAM47171 standard; peptide; 47 AA.
XX
AC AAM47171;
XX
DT 29-AUG-2003 (revised)
DT 12-FEB-2002 (first entry)
XX
DE Modular enzyme system related ACP-domain N-terminal peptide CYSA_2.
XX
KW Modular enzyme system; cyclic gene synthesis; repetitive coding sequence;

KW antibiotic; non-ribosomal peptide synthetase; NRPS; PKS;
KW polyketide synthase; actinomycin biosynthase.
XX
OS Tolypocladium inflatum.
XX
PN WO200181564-A2.
XX
PD 01-NOV-2001.
XX
PF 25-APR-2001; 2001WO-DE001578.
XX
PR 26-APR-2000; 2000DE-01021267.
XX
PA (ACTI-) ACTINODRUG PHARM GMBH.
XX
PI Schauwecker F;
XX
DR WPI; 2002-049276/06.
XX
PT Preparing DNA encoding modular protein for e.g. producing new enzymes for
PT synthesis of polyketide antibiotics, comprises cyclic integration of
PT fragments into a vector.
XX
PS Example 1; Fig 9; 83pp; German.
XX
CC The present invention relates to the preparation of DNA, in a circular
CC vector, that encodes one or more segments of a modular polypeptide. DNA
CC or DNA libraries produced this way are used to produce modular
CC polypeptides, particularly enzymes, which can be used to act on
CC substrates to produce compounds for therapeutic testing. Enzymes of
CC particular interest are those involved in non-ribosomal peptide synthesis
CC or polyketide synthesis, and compounds for testing are particularly
CC macrolide antibiotics, including penicillins, vancomycins or
CC erythromycins, but may also be modular receptors. The present sequence is
CC a peptide used in the exemplification of the invention. (Updated on 29-
CC AUG-2003 to standardise OS field)
XX
SQ Sequence 47 AA;

Query Match 29.9%; Score 29; DB 5; Length 47;
Best Local Similarity 42.9%; Pred. No. 2.1e+03;
Matches 6; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVSQEP 18
||::|| | : |
Db 21 LNAQIAVKDIFDRP 34

RESULT 186
ABO54785
ID ABO54785 standard; protein; 47 AA.
XX
AC ABO54785;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #1019.
XX
KW Human; gene expression; single exon probe; microarray;
KW alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
DR WPI; 2004-119264/12.
XX
PT New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
PT surveying tissues.
XX
PS Claim 45; SEQ ID NO 28419; 80pp; English.
XX
CC The invention relates to a nucleic acid probe for measuring human gene
CC expression, comprising any of the 27,400 fully defined nucleotide
CC sequences in the specification, or their complements or fragments, and
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences
CC fully defined in the specification. The probe is a single exon probe that
CC hybridises under high stringency conditions to a nucleic acid molecule
CC expressed in human cells or tissues. Also included are a spatially-
CC addressable set of single exon nucleic acid probes for measuring human
CC gene expression (comprising a plurality of single exon nucleic acid
CC probes cited above, where each of the plurality of probes is separately
CC and addressably isolatable or amplifiable from the plurality), a single
CC exon microarray for measuring human gene expression, a method of
CC measuring human gene expression, a vector comprising the single exon
CC probe cited above, an ORF-encoded peptide comprising at least 8
CC contiguous amino acids of any of the above- mentioned amino acid
CC sequences (optionally with conservative amino acid substitutions), an
CC isolated antibody that binds specifically to a peptide cited above,
CC methods of selling and/or licensing single exon probes or microarrays to
CC a customer desiring to measure gene expression, a method of providing
CC human gene expression data by subscription, and a computer-readable
CC storage medium which contains a database having a plurality of records
CC (each record including data on the expression of a single exon probe
CC cited above. The probe, methods and apparatus are useful in gene
CC expression analysis. The probes may be used as tools for surveying
CC tissues to detect the presence of expressed messages that contain their
CC specific exon, or in constructing genome-derived single exon microarrays.
CC In addition, the probes are used in identifying and characterising
CC alternative splicing events, in detecting and characterising gross
CC alterations in the genomic locus that includes their exon, in assessing
CC smaller genomic alterations, in priming the synthesis of nucleic acids,
CC or in expressing the ORF-encoded peptide. The present sequence is a human
CC single exon probe protein of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030194704
XX
SQ Sequence 47 AA;

Query Match 29.9%; Score 29; DB 8; Length 47;
Best Local Similarity 44.4%; Pred. No. 2.1e+03;
Matches 4; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2 PNHLNSKIA 10
|:|| |:::
Db 38 PSHLKSEVS 46

RESULT 187
AAB34265
ID AAB34265 standard; protein; 48 AA.
XX
AC AAB34265;
XX
DT 02-FEB-2001 (first entry)
XX
DE Human secreted protein BLAST search protein SEQ ID NO: 111.
XX
KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;

KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
OS Homo sapiens.
XX
PN WO200055352-A2.
XX
PD 21-SEP-2000.
XX
PF 09-MAR-2000; 2000WO-US006044.
XX
PR 12-MAR-1999; 99US-0124099P.
PR 03-DEC-1999; 99US-0168661P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Komatsoulis G;
XX
DR WPI; 2000-602124/57.
XX
PT Novel human secreted proteins useful for diagnosis, prevention and
PT treatment of disorders including neurological, cell proliferative,
PT cardiovascular, autoimmune and inflammatory disorders and microbial
PT infections.
XX
PS Disclosure; Page 366; 383pp; English.
XX
CC The invention relates to the isolation of genes AAC59507-C59556 encoding
CC the human secreted proteins AAB34218-B34264) This sequence represents a
CC peptide fragment homologous to the protein encoded by the gene isolated
CC in the present invention. The sequence is a search result from a BLASTX
CC homology search. The genes and proteins are useful for preventing,
CC ameliorating or treating medical conditions, e.g. by protein or gene
CC therapy. The genes are isolated from a range of human tissues disclosed
CC in the specification. The nucleic acids, proteins, antibodies and
CC (ant)agonists are useful in the diagnosis, treatment and prevention of:
CC (a) cancer, e.g. breast and ovarian cancer, and other cancers of the
CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,
CC lung, or urogenital; (b) immune disorders e.g. Addison's disease,
CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as
CC myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.
CC cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,
CC bacterial, fungal and parasitic infections
XX
SQ Sequence 48 AA;

Query Match 29.9%; Score 29; DB 3; Length 48;
Best Local Similarity 71.4%; Pred. No. 2.1e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 EPNHLNS 7
              : |||||
Db         17 QENHLNS 23
```

RESULT 188
AAB58239
ID AAB58239 standard; protein; 48 AA.
XX
AC AAB58239;
XX
DT 14-MAR-2001 (first entry)
XX
DE Lung cancer associated polypeptide sequence SEQ ID 577.
XX
KW Human; lung cancer associated protein; neuroprotective; cytostatic;
KW cardioactive; immunomodulatory; muscular active; vulnerary;
KW gastrointestinal; nephrotropic; antiinfective; gynecological;
KW antibacterial; diagnosis; neural disorder; immune disorder; reproductive;
KW proliferative disorder; wound healing; infectious disease.
XX
OS Homo sapiens.
XX
PN WO200055180-A2.
XX
PD 21-SEP-2000.
XX
PF 08-MAR-2000; 2000WO-US005918.
XX
PR 12-MAR-1999; 99US-0124270P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PA (ROSE/) ROSEN C A.
XX
PI Ruben SM;
XX
DR WPI; 2000-587514/55.
DR N-PSDB; AAF18115.
XX
PT Lung cancer associated gene sequences, referred to as lung cancer
PT antigens, useful for treatment, prevention, and diagnosis of disorders
PT such as lung cancer.
XX
PS Claim 11; Page 1072; 1425pp; English.
XX
CC Polynucleotide sequences AAF17982 - AAF18424 encode human lung cancer
CC associated proteins represented in AAB58106 - AAB58548. Lung cancer
CC associated proteins and polynucleotide sequences, their agonists, and
CC antagonists may have neuroprotective; cytostatic; cardioactive;
CC immunomodulatory; muscular active general; vulnerary; gastrointestinal
CC general; nephrotropic; antiinfective; gynecological; or antibacterial
CC activity. The invention also includes antibodies specific for the protein
CC or polynucleotide sequences. The lung cancer associated polynucleotide
CC sequences may be used for detection of lung cancer, chromosome
CC identification, as chromosome markers, and for numerous other diagnostic
CC or research purposes. The proteins may be used to treat disorders such as
CC neural, immune, muscular, reproductive, gastrointestinal, pulmonary,
CC cardiovascular, renal, and proliferative disorders. The proteins may also
CC be used in the treatment of wounds and infectious diseases.
CC Polynucleotide sequences AAF18425 - AAF18433 and peptide AAB58549 are
CC used in the course of the invention for the identification and
CC characterisation of the polynucleotide and protein sequences
XX
SQ Sequence 48 AA;

Query Match 29.9%; Score 29; DB 3; Length 48;
Best Local Similarity 42.9%; Pred. No. 2.1e+03;
Matches 6; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

```
Qy          5 LNSKIAFKIVSQEP 18
              |:| :| |:   ||
Db          6 LHSSLAKKLPKNEP 19
```

RESULT 189
AAG73655
ID AAG73655 standard; protein; 48 AA.
XX
AC AAG73655;
XX
DT 03-SEP-2001 (first entry)
XX
DE Human colon cancer antigen protein SEQ ID NO:4419.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW colorectal carcinoma.
XX
OS Homo sapiens.
XX
PN WO200122920-A2.
XX
PD 05-APR-2001.
XX
PF 28-SEP-2000; 2000WO-US026524.

```
XX
PR   29-SEP-1999;   99US-0157137P.
PR   03-NOV-1999;   99US-0163280P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Barash SC,  Birse CE,  Rosen CA;
XX
DR   WPI; 2001-235357/24.
DR   N-PSDB; AAH33086.
XX
PT   Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT   useful for preventing, diagnosing and/or treating colorectal cancers.
XX
PS   Claim 11; Page 6239; 9803pp; English.
XX
CC   AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC   cancer-associated nucleic acid molecules (N) and proteins (P), where the
CC   proteins are collectively known as colon cancer antigens. The colon
CC   cancer antigens have cytostatic activity and can be used in gene therapy
CC   and vaccine production. N and P may be used in the prevention, diagnosis
CC   and treatment of diseases associated with inappropriate P expression. For
CC   example, N and P may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of P by expressing inactive proteins or to
CC   supplement the patients own production of P. Additionally, N may be used
CC   to produce the colon cancer-associated Ps, by inserting the nucleic acids
CC   into a host cell and culturing the cell to express the proteins. N and P
CC   can be used in the prevention, diagnosis and treatment of colorectal
CC   carcinomas and cancers. AAH37196 to AAH37204 and AAB77789 represent
CC   sequences used in the exemplification of the present invention. N.B.
CC   Pages 666 to 682 and page 7053 of the sequence listing were missing at
CC   time of publication, meaning no sequences are present for SEQ ID NO:1027
CC   to 1052, 7921 and 7922
XX
SQ   Sequence 48 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 48;
  Best Local Similarity   41.7%;  Pred. No. 2.1e+03;
  Matches    5;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              ||:|  | : |:
Db         10 NHINCYILYFII 21


RESULT 190
ABG01426
ID   ABG01426 standard; protein; 48 AA.
XX
AC   ABG01426;
XX
DT   13-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #1417.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US008631.
XX
PR   31-MAR-2000; 2000US-00540217.
PR   23-AUG-2000; 2000US-00649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS65613.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity.
XX
PS   Claim 20; SEQ ID NO 31785; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and polypeptide (II)
CC   sequences. (I) is useful as hybridisation probes, polymerase chain
CC   reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
CC   and in recombinant production of (II). The polynucleotides are also used
CC   in diagnostics as expressed sequence tags for identifying expressed
CC   genes. (I) is useful in gene therapy techniques to restore normal
CC   activity of (II) or to treat disease states involving (II). (II) is
CC   useful for generating antibodies against it, detecting or quantitating a
CC   polypeptide in tissue, as molecular weight markers and as a food
CC   supplement. (II) and its binding partners are useful in medical imaging
CC   of sites expressing (II). (I) and (II) are useful for treating disorders
CC   involving aberrant protein expression or biological activity. The
CC   polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
CC   amino acid sequences of the invention. Note: The sequence data for this
CC   patent did not appear in the printed specification, but was obtained in
CC   electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 48 AA;

  Query Match             29.9%;  Score 29;  DB 4;  Length 48;
  Best Local Similarity   55.6%;  Pred. No. 2.1e+03;
  Matches    5;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKI 13
              :|| :|:||
Db         36 VNSMVAYKI 44


RESULT 191
AAB32117
ID   AAB32117 standard; protein; 49 AA.
XX
AC   AAB32117;
XX
DT   14-FEB-2001  (first entry)
XX
DE   Human secreted protein BLAST search protein SEQ ID NO: 175.
XX
KW   Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW   antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW   vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW   cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW   neurological disease; infection; human; secreted protein.
XX
OS   Homo sapiens.
XX
PN   WO200058350-A1.
XX
PD   05-OCT-2000.
XX
PF   22-MAR-2000; 2000WO-US007483.
XX
PR   26-MAR-1999;   99US-0126596P.
PR   22-DEC-1999;   99US-0171552P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
```

```
PI   Rosen CA,  Ruben SM,  Komatsoulis G;
XX
DR   WPI; 2000-602357/57.
XX
PT   Nucleic acid molecules encoding human secreted proteins, used in
PT   preventing, treating or ameliorating a disorder, e.g. Alzheimer's and
PT   Parkinson's diseases and cancers.
XX
PS   Disclosure; Page 420; 423pp; English.
XX
CC   The invention relates to the isolation of genes AAC66410-C66458 encoding
CC   the human secreted proteins AAB32002-B32050. This sequence represents a
CC   peptide fragment homologous to the protein encoded by the gene given in
CC   the descriptor line. The sequence is a search result from a BLASTX
CC   homology search. The genes and proteins are useful for preventing,
CC   ameliorating or treating medical conditions, e.g. by protein or gene
CC   therapy. The genes are isolated from a range of human tissues disclosed
CC   in the specification. The nucleic acids, proteins, antibodies and
CC   (ant)agonists are useful in the diagnosis, treatment and prevention of:
CC   (a) cancer, e.g. breast and ovarian cancer, and other cancers of the
CC   adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,
CC   lung, or urogenital; (b) immune disorders e.g. Addison's disease,
CC   allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
CC   diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
CC   arthritis and ulcerative colitis; (c) cardiovascular disorders such as
CC   myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.
CC   cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,
CC   bacterial, fungal and parasitic infections
XX
SQ   Sequence 49 AA;

  Query Match             29.9%;  Score 29;  DB 3;  Length 49;
  Best Local Similarity   71.4%;  Pred. No. 2.2e+03;
  Matches    5;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EPNHLNS 7
              : |||||
Db         19 QENHLNS 25


RESULT 192
AAB45192
ID   AAB45192 standard; protein; 50 AA.
XX
AC   AAB45192;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Gene 26 human secreted protein homologous amino acid sequence #133.
XX
KW   Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
KW   antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
KW   nootropic; neuroprotective; antibacterial; virucide; fungicide; cancer;
KW   opthalmalogical; autoimmune disease; hyperproliferative disorder;
KW   cardiovascular disorder; cerebrovascular disorder; wound healing;
KW   nervous system disorder; aging; chemotaxis.
XX
OS   Homo sapiens.
XX
PN   WO200058467-A1.
XX
PD   05-OCT-2000.
XX
PF   22-MAR-2000; 2000WO-US007505.
XX
PR   26-MAR-1999;   99US-0126502P.
PR   17-DEC-1999;   99US-0172410P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM,  Komatsoulis G;
XX
DR   WPI; 2000-611712/58.
XX
PT   Nucleic acid molecules encoding human secreted proteins, used in
PT   preventing, treating or ameliorating a disorder, e.g. Alzheimer's and
PT   Parkinson's diseases and cancers.
XX
PS   Disclosure; Page 40; 440pp; English.
XX
CC   Polynucleotide sequences AAC80531-C80580 represent cDNA encoding human
CC   secreted proteins AAB45120-B45169. Sequences AAB45170-B45225 represent
CC   alternative polypeptides encoded by the genes, and amino acid sequences
CC   to which they are homologous. The genes and proteins have activities
CC   dependent on the tissues and cells in which they are expressed. Examples
CC   of their activities include immunosuppressive; antiarthritic;
CC   antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;
CC   cerebroprotective; nootropic; neuroprotective; antibacterial; virucide;
CC   fungicide; and opthalmalogical. The secreted proteins, polynucleotides,
CC   antagonists and agonists may be useful in treating, preventing and/or
CC   diagnosing diseases and disorders such as autoimmune diseases e.g.
CC   rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the
CC   breast or liver, cardiovascular disorders e.g. cardiac arrest,
CC   cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis, nervous
CC   system disorders e.g. Alzheimer's disease, infections caused by bacteria,
CC   viruses and fungi and ocular disorders e.g. corneal infection. The
CC   polypeptides can also be used to aid wound healing and epithelial cell
CC   proliferation, to prevent skin aging due to sunburn, to maintain organs
CC   before transplantation, for supporting cell culture of primary tissues,
CC   to regenerate tissues and in chemotaxis. The polypeptides can also be
CC   used as a food additive or preservative to increase or decrease storage
CC   capabilities. AAC80522-C80530 and AAB45119 represent sequences used in
CC   the isolation and characterisation of the genes and proteins of the
CC   invention
XX
SQ   Sequence 50 AA;

  Query Match             29.9%;  Score 29;  DB 3;  Length 50;
  Best Local Similarity   71.4%;  Pred. No. 2.2e+03;
  Matches    5;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EPNHLNS 7
              : |||||
Db         15 QENHLNS 21


RESULT 193
AAB29913
ID   AAB29913 standard; protein; 50 AA.
XX
AC   AAB29913;
XX
DT   09-FEB-2001  (first entry)
XX
DE   Human secreted protein BLAST search protein SEQ ID NO: 171.
XX
KW   Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW   antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW   vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW   cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW   neurological disease; infection; human; secreted protein.
XX
OS   Homo sapiens.
XX
PN   WO200061779-A1.
XX
PD   19-OCT-2000.
XX
PF   06-APR-2000; 2000WO-US009068.
XX
PR   09-APR-1999;   99US-0128699P.
PR   20-JAN-2000; 2000US-0177050P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Ruben SM,  Komatsoulis G;
```

XX
DR WPI; 2000-647424/62.
XX
PT Isolated nucleic acid molecule encoding a human secreted protein is used
PT in preventing, treating or ameliorating a medical condition.
XX
PS Disclosure; Page 489-490; 495pp; English.
XX
CC The invention relates to the isolation of genes AAC63410-C63458 encoding
CC the human secreted proteins AAB29802-B29850. This sequence represents a
CC peptide fragment homologous to the protein encoded by the gene given in
CC the descriptor line. The sequence is a search result from a BLASTX
CC homology search. The genes and proteins are useful for preventing,
CC ameliorating or treating medical conditions, e.g. by protein or gene
CC therapy. The genes are isolated from a range of human tissues disclosed
CC in the specification. The nucleic acids, proteins, antibodies and
CC (ant)agonists are useful in the diagnosis, treatment and prevention of:
CC (a) cancer, e.g. breast and ovarian cancer, and other cancers of the
CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,
CC lung, or urogenital; (b) immune disorders e.g. Addison's disease,
CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as
CC myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.
CC cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,
CC bacterial, fungal and parasitic infections
XX
SQ Sequence 50 AA;

Query Match 29.9%; Score 29; DB 3; Length 50;
Best Local Similarity 71.4%; Pred. No. 2.2e+03;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EPNHLNS 7
: |||||
Db 36 QENHLNS 42

RESULT 194
ABP29303
ID ABP29303 standard; protein; 50 AA.
XX
AC ABP29303;
XX
DT 02-JUL-2002 (first entry)
XX
DE Streptococcus polypeptide SEQ ID NO 7782.
XX
KW Streptococcus; GAS; GBS; group B streptococcus; Streptococcus agalactiae;
KW group A streptococcus; Streptococcus pyogenes; antibacterial;
KW antiinflammatory; infection; vaccine; meningitis; gene therapy.
XX
OS Streptococcus pyogenes.
XX
PN WO200234771-A2.
XX
PD 02-MAY-2002.
XX
PF 29-OCT-2001; 2001WO-GB004789.
XX
PR 27-OCT-2000; 2000GB-00026333.
PR 24-NOV-2000; 2000GB-00028727.
PR 07-MAR-2001; 2001GB-00005640.
XX
PA (CHIR-) CHIRON SPA.
PA (GENO-) INST GENOMIC RES.
XX
PI Telford J, Masignani V, Margarit Y RosI, Grandi G, Fraser C;
PI Tettelin H;
XX
DR WPI; 2002-352536/38.
DR N-PSDB; ABN69934.
XX
PT New Streptococcus protein for the treatment or prevention of infection or
PT disease caused by Streptococcus bacteria, such as meningitis, and for
PT detecting a compound that binds to the protein.
XX
PS Claim 1; Page 3913; 4525pp; English.
XX
CC The invention relates to a protein (ABP25413-ABP30895) from group B
CC streptococcus/GBS (Streptococcus agalactiae) or group A streptococcus/GAS
CC (Streptococcus pyogenes), comprising one of 5483 sequences (S1), given in
CC the specification. The proteins have antibacterial and antiinflammatory
CC activity. (I), nucleic acids encoding (I), ABN66044-ABN71526 and
CC antibodies that bind (I) are used in the manufacture of medicaments for
CC the treatment or prevention of infection or disease caused by
CC Streptococcus bacteria, particularly S. agalactiae and S. pyrogenes.
CC Nucleic acids encoding (I) are used to detect Streptococcus in a
CC biological sample. (I) is used to determine whether a compound binds to
CC (I). A composition comprising (I) or a nucleic acid encoding (I), may be
CC used as a vaccine or diagnostic composition. The disease caused by
CC Streptococcus that is prevented or treated may be meningitis. Nucleic
CC acid encoding (I) may be used to recombinantly produce (I) and may be
CC used in gene therapy. Antibodies to (I) are used for affinity
CC chromatography, immunoassays, and distinguishing/identifying
CC Streptococcus proteins
XX
SQ Sequence 50 AA;

Query Match 29.9%; Score 29; DB 5; Length 50;
Best Local Similarity 50.0%; Pred. No. 2.2e+03;
Matches 6; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 4 HLNSKIAPKIVS 15
| |: | |||
Db 25 HSNNSICINIVS 36

RESULT 195
ADD90406
ID ADD90406 standard; protein; 50 AA.
XX
AC ADD90406;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted protein seq id 26 protein feature seq id 221.
XX
KW gene therapy; cytostatic; cancer; human; secreted protein.
XX
OS Homo sapiens.
XX
PN US2003199683-A1.
XX
PD 23-OCT-2003.
XX
PF 30-MAR-2001; 2001US-00820649.
XX
PR 30-JUL-1997; 97US-0054209P.
PR 30-JUL-1997; 97US-0054211P.
PR 30-JUL-1997; 97US-0054212P.
PR 30-JUL-1997; 97US-0054213P.
PR 30-JUL-1997; 97US-0054214P.
PR 30-JUL-1997; 97US-0054215P.
PR 30-JUL-1997; 97US-0054217P.
PR 30-JUL-1997; 97US-0054218P.
PR 30-JUL-1997; 97US-0054234P.
PR 30-JUL-1997; 97US-0054236P.
PR 18-AUG-1997; 97US-0055968P.
PR 18-AUG-1997; 97US-0055969P.
PR 18-AUG-1997; 97US-0055972P.
PR 19-AUG-1997; 97US-0056534P.
PR 19-AUG-1997; 97US-0056543P.
PR 19-AUG-1997; 97US-0056554P.
PR 19-AUG-1997; 97US-0056561P.
PR 19-AUG-1997; 97US-0056727P.

PR 19-AUG-1997; 97US-0056729P.
PR 19-AUG-1997; 97US-0056730P.
PR 29-JUL-1998; 98WO-US015949.
PR 26-JAN-1999; 99US-00236557.
PR 21-SEP-2000; 2000US-00666987.
XX
PA (RUBE/) RUBEN S M.
PA (FENG/) FENG P.
PA (LAFL/) LAFLEUR D W.
PA (MOOR/) MOORE P A.
PA (SHIY/) SHI Y.
PA (KYAW/) KYAW H.
PA (LIYY/) LI Y.
PA (ZENG/) ZENG Z.
PA (CART/) CARTER K C.
PA (ENDR/) ENDRESS G A.
PA (WEIY/) WEI Y.
PA (FANP/) FAN P.
PA (ROSE/) ROSEN C A.
XX
PI Ruben SM, Feng P, Lafleur DW, Moore PA, Shi Y, Kyaw H, Li Y;
PI Zeng Z, Carter KC, Endress GA, Wei Y, Fan P, Rosen CA;
XX
DR WPI; 2003-852813/79.
XX
PT New nucleic acid molecule, useful for preparing a medicament for
PT preventing, treating or ameliorating a medical condition e.g., cancer.
XX
PS Disclosure; SEQ ID NO 221; 213pp; English.
XX
CC The invention describes novel isolated human nucleic acids. The nucleic
CC acid is useful for preparing a medicament for preventing, treating or
CC ameliorating a medical condition e.g., cancer, and in gene therapy. This
CC is the amino acid sequence of polypeptide feature of a novel human
CC secreted protein of the invention.
XX
SQ Sequence 50 AA;

Query Match 29.9%; Score 29; DB 7; Length 50;
Best Local Similarity 38.5%; Pred. No. 2.2e+03;
Matches 5; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAFKIV 14
|:|:| ||:
Db 30 PDHVNMSELVKII 42

RESULT 196
ADG90225
ID ADG90225 standard; protein; 50 AA.
XX
AC ADG90225;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human secreted protein gene 16 extra polypeptide #2.
XX
KW Secreted protein; gene therapy; neural disorder; immune system disorders;
KW muscular disorder; reproductive disorder; gastrointestinal disorder;
KW pulmonary disorder; cardiovascular disorder; renal disorder;
KW proliferative disorder; cancer; systemic lupus erythematosus;
KW rheumatoid arthritis; multiple sclerosis; thyroiditis; anaemia;
KW Grave's disease; diabetes; hepatitis; asthma; allergy; nephritis;
KW Parkinson's disease; Alzheimer's disease; atherosclerosis;
KW myocardial infarction; AIDS; infection; human.
XX
OS Homo sapiens.
XX
PN US2003166541-A1.
XX
PD 04-SEP-2003.
XX
PF 04-JUN-2002; 2002US-00160162.
XX
PR 30-JUL-1997; 97US-0054209P.
PR 30-JUL-1997; 97US-0054211P.
PR 30-JUL-1997; 97US-0054212P.
PR 30-JUL-1997; 97US-0054213P.
PR 30-JUL-1997; 97US-0054214P.
PR 30-JUL-1997; 97US-0054215P.
PR 30-JUL-1997; 97US-0054217P.
PR 30-JUL-1997; 97US-0054218P.
PR 30-JUL-1997; 97US-0054234P.
PR 30-JUL-1997; 97US-0054236P.
PR 18-AUG-1997; 97US-0055968P.
PR 18-AUG-1997; 97US-0055969P.
PR 18-AUG-1997; 97US-0055972P.
PR 19-AUG-1997; 97US-0056534P.
PR 19-AUG-1997; 97US-0056543P.
PR 19-AUG-1997; 97US-0056554P.
PR 19-AUG-1997; 97US-0056561P.
PR 19-AUG-1997; 97US-0056727P.
PR 19-AUG-1997; 97US-0056729P.
PR 19-AUG-1997; 97US-0056730P.
PR 29-JUL-1998; 98WO-US015949.
PR 26-JAN-1999; 99US-00236557.
PR 05-JUN-2001; 2001US-0295558P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Feng P, Lafleur DW, Moore PA, Shi Y, Kyaw H, Li Y;
PI Zeng Z, Carter KC, Endress GA, Wei Y, Fan P, Rosen CA;
XX
DR WPI; 2003-874923/81.
XX
PT Nucleic acids encoding 83 secreted polypeptides, useful for preventing,
PT diagnosing and treating disorders related to their aberrant expression
PT and activity.
XX
PS Disclosure; SEQ ID NO 221; 308pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule encoding a
CC secreted protein that is at least 95% identical to a polynucleotide
CC fragment of any of the nucleotide sequences listed in table 1A of the
CC specification, which is hybridisable to the nucleotide sequences, a
CC polynucleotide encoding a polypeptide (or a polypeptide fragment, domain
CC or epitope of any of the amino acid sequences) listed in table 1A of the
CC specification, a polynucleotide which is an (allelic) variant of the
CC nucleotide sequences listed in the specification, a polynucleotide which
CC encodes a species homologue of the above amino acid sequences, a
CC polynucleotide capable of hybridising under stringent conditions to any
CC of the above polynucleotides, where the polynucleotide does not hybridise
CC under stringent conditions to a nucleic acid molecule having a nucleotide
CC sequence of only A or T residues. Also included are a recombinant vector
CC comprising the above nucleic acid molecule, making a recombinant host
CC cell comprising the above nucleic acid molecule, an isolated polypeptide
CC comprising a sequence that is at least 95% identical to the polypeptide
CC (or its fragment, domain, epitope, secreted form, (allelic) variant or
CC homologue) encoded by the above nucleic acid molecule, an isolated
CC antibody that binds specifically to the above polypeptide, a recombinant
CC host cell produced by the above method and that expresses the above
CC polypeptide, making an isolated polypeptide, preventing, treating or
CC ameliorating a medical condition, diagnosing a pathological condition or
CC a susceptibility to a pathological condition in a subject, identifying a
CC binding partner to the above polypeptide, the gene corresponding to the
CC cDNA sequence given in the specification, and identifying an activity in
CC a biological assay. The nucleic acid molecule and polypeptide are useful
CC in diagnosing, preventing, prognosing or treating diseases or disorders
CC associated with aberrant expression and/or activity of the above
CC polypeptide, such as neural disorders, immune system disorders, muscular
CC disorders, reproductive disorders, gastrointestinal disorders, pulmonary
CC disorders, cardiovascular disorders, renal disorders, proliferative
CC disorders and/or cancers. In particular, these diseases are systemic
CC lupus erythematosus, rheumatoid arthritis, multiple sclerosis,
CC thyroiditis, anaemia, Grave's disease, diabetes, hepatitis, asthma,
CC allergies, nephritis, Parkinson's disease, Alzheimer's disease,

```
CC   atherosclerosis, myocardial infarction, AIDS and infections. The methods
CC   may be used for identifying agonists and antagonists of the
CC   polynucleotide and polypeptide. The present sequence is a protein from
CC   one of the 83 disclosed secreted protein genes.
XX
SQ   Sequence 50 AA;

  Query Match             29.9%;  Score 29;  DB 7;  Length 50;
  Best Local Similarity   38.5%;  Pred. No. 2.2e+03;
  Matches    5;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIV 14
              |:|:|     ||:
Db         30 PDHVNMSELVKII 42


RESULT 197
AAM33917
ID   AAM33917 standard; protein; 30 AA.
XX
AC   AAM33917;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #7954 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 34186; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 30 AA;

  Query Match             29.4%;  Score 28.5;  DB 4;  Length 30;
  Best Local Similarity   43.8%;  Pred. No. 1.5e+03;
  Matches    7;  Conservative    4;  Mismatches    4;  Indels    1;  Gaps    1;

Qy          3 NHLNSKIAFKIVSQEP 18
              || |   :|:||: :|
Db         13 NHKNLP-SFQIVTLDP 27


RESULT 198
AAM73727
ID   AAM73727 standard; protein; 30 AA.
XX
AC   AAM73727;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human bone marrow expressed probe encoded protein SEQ ID NO: 34033.
XX
KW   Human; bone marrow expressed exon; gene expression analysis; probe;
KW   microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS   Homo sapiens.
XX
PN   WO200157276-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000668.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488900/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human bone marrow.
XX
PS   Example 4; SEQ ID NO 34033; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention
XX
SQ   Sequence 30 AA;

  Query Match             29.4%;  Score 28.5;  DB 4;  Length 30;
  Best Local Similarity   43.8%;  Pred. No. 1.5e+03;
  Matches    7;  Conservative    4;  Mismatches    4;  Indels    1;  Gaps    1;

Qy          3 NHLNSKIAFKIVSQEP 18
              || |   :|:||: :|
Db         13 NHKNLP-SFQIVTLDP 27


RESULT 199
ABG55472
ID   ABG55472 standard; peptide; 30 AA.
XX
AC   ABG55472;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 34120.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
```

XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 27; SEQ ID NO 34120; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABG47348-ABG59930 represent human
CC liver single exon encoded peptides of the invention. Note: The sequence
CC information for this patent does not appear in the printed specification
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 30 AA;

Query Match 29.4%; Score 28.5; DB 4; Length 30;
Best Local Similarity 43.8%; Pred. No. 1.5e+03;
Matches 7; Conservative 4; Mismatches 4; Indels 1; Gaps 1;

Qy 3 NHLNSKIAFKIVSQEP 18
|| | :|:||: :|
Db 13 NHKNLP-SFQIVTLDP 27

RESULT 200
ABG43609
ID ABG43609 standard; peptide; 30 AA.
XX
AC ABG43609;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 33274.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesis; pulmonary hypertension;
KW hyaline membrane disease.
XX
OS Homo sapiens.

XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US000665.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.
XX
PS Claim 27; SEQ ID NO 33274; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of probes
CC ; the novel set of probes which hybridise at high stringency to a nucleic
CC acid expressed in the human lung; measuring gene expression in a sample
CC derived from human lung, comprising (a) contacting the array with a
CC collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of the
CC array; identifying exons in a eukaryotic genome, comprising (a)
CC algorithmically predicting at least one exon from genomic sequences of
CC the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene expression
CC analysis, and for identifying exons in a gene, particularly using human
CC lung derived mRNA and for the study of lung diseases such as asthma, lung
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC present sequence is a peptide/protein encoded by a single exon probe of
CC the invention. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 30 AA;

Query Match 29.4%; Score 28.5; DB 5; Length 30;
Best Local Similarity 43.8%; Pred. No. 1.5e+03;
Matches 7; Conservative 4; Mismatches 4; Indels 1; Gaps 1;

Qy 3 NHLNSKIAFKIVSQEP 18
|| | :|:||: :|

```
Db         13 NHKNLP-SFQIVTLDP 27


RESULT 201
AAW27823
ID   AAW27823 standard; protein; 42 AA.
XX
AC   AAW27823;
XX
DT   21-JUL-1998  (first entry)
XX
DE   Amino acid sequence of an ATP-dependent Clp proteinase chain clpL.
XX
KW   Staphylococcus aureus protein; ribozyme; antisense sequence; control;
KW   Staphylococcal gene; regulatory element; bacterial gene expression;
KW   vaccine; Staphylococcal infection; food poisoning; scaled skin syndrome;
KW   toxic shock syndrome.
XX
OS   Staphylococcus aureus.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1. .42
FT                   /note= "residues designated X are not defined in the
FT                   specification"
XX
PN   WO9730070-A1.
XX
PD   21-AUG-1997.
XX
PF   19-FEB-1997;   97WO-US002318.
XX
PR   20-FEB-1996;   96US-0011888P.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Black MT,  Burnham MK,  Hodgson JE,  Knowles DJC,  Nicholas RO;
PI   Pratt JM,  Reichard RW,  Rosenberg M,  Ward JM;
XX
DR   WPI; 1997-424969/39.
DR   N-PSDB; AAT83788.
XX
PT   Novel polypeptide(s) from Staphylococcus aureus strain WCUH29 - used to
PT   isolate antimicrobial compounds, and in vaccines against S. aureus
PT   infection.
XX
PS   Claim 6; Page 294; 989pp; English.
XX
CC   The present sequence represents a Staphylococcus aureus protein, that,
CC   based on homology with a Lactococcus protein, is believed to be an ATP-
CC   dependent Clp proteinase chain clpL. The DNA sequence was isolated from a
CC   library of clones of S. aureus WCUH 29 in Escherichia coli. The DNA
CC   sequence can be used in the construction of ribozymes and antisense
CC   sequences to control the expression of Staphylococcal genes. The DNA
CC   sequence is also useful as a source of regulatory elements for the
CC   control of bacterial gene expression. The present protein may be used to
CC   produce vaccines to enable a host to produce specific antibodies with
CC   antibacterial action. These vaccines and antibodies would protect a host
CC   against invasion by S. aureus, and conditions relating to Staphylococcal
CC   infection, e.g. Staphylococcal food poisoning, scaled skin syndrome, and
CC   toxic shock syndrome
XX
SQ   Sequence 42 AA;

  Query Match             29.4%;  Score 28.5;  DB 2;  Length 42;
  Best Local Similarity   50.0%;  Pred. No. 2.2e+03;
  Matches    8;  Conservative    1;  Mismatches    4;  Indels    3;  Gaps    1;

Qy          3 NHLNSKIAFKIVSQEP 18
              | | |||    ||  :|
Db         14 NRLRSKI---IVKDQP 26


RESULT 202
```

```
AAW78190
ID   AAW78190 standard; protein; 19 AA.
XX
AC   AAW78190;
XX
DT   13-APR-1999  (first entry)
XX
DE   Human secreted protein encoded by gene 65 clone HTDAG66.
XX
KW   Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW   diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW   developmental abnormality; foetal deficiency; blood; allergy; renal;
KW   immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW   inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW   cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW   osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW   endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 19
FT                   /label= unknown
XX
PN   WO9856804-A1.
XX
PD   17-DEC-1998.
XX
PF   11-JUN-1998;   98WO-US012125.
XX
PR   13-JUN-1997;   97US-0049547P.
PR   13-JUN-1997;   97US-0049548P.
PR   13-JUN-1997;   97US-0049549P.
PR   13-JUN-1997;   97US-0049550P.
PR   13-JUN-1997;   97US-0049566P.
PR   13-JUN-1997;   97US-0049606P.
PR   13-JUN-1997;   97US-0049607P.
PR   13-JUN-1997;   97US-0049608P.
PR   13-JUN-1997;   97US-0049609P.
PR   13-JUN-1997;   97US-0049610P.
PR   13-JUN-1997;   97US-0049611P.
PR   13-JUN-1997;   97US-0050901P.
PR   13-JUN-1997;   97US-0052989P.
PR   08-JUL-1997;   97US-0051919P.
PR   18-AUG-1997;   97US-0055984P.
PR   12-SEP-1997;   97US-0058665P.
PR   12-SEP-1997;   97US-0058668P.
PR   12-SEP-1997;   97US-0058669P.
PR   12-SEP-1997;   97US-0058750P.
PR   12-SEP-1997;   97US-0058971P.
PR   12-SEP-1997;   97US-0058972P.
PR   12-SEP-1997;   97US-0058975P.
PR   02-OCT-1997;   97US-0060834P.
PR   02-OCT-1997;   97US-0060841P.
PR   02-OCT-1997;   97US-0060844P.
PR   02-OCT-1997;   97US-0060865P.
PR   02-OCT-1997;   97US-0061059P.
PR   02-OCT-1997;   97US-0061060P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Moore PA,  Shi Y,  Rosen CA,  Ruben SM,  Lafleur DW,  Olsen HS;
PI   Ebner R,  Brewer LA,  Young P,  Greene JM,  Ferrie AM,  Yu G,  Ni J;
PI   Feng P;
XX
DR   WPI; 1999-080881/07.
DR   N-PSDB; AAX04375.
XX
PT   New isolated human genes and the secreted polypeptides they encode -
PT   useful for diagnosis and treatment of e.g. cancers, neurological
PT   disorders, immune diseases, inflammation or blood disorders.
XX
PS   Claim 11; Page 300-301; 380pp; English.
```

```
XX
CC   This sequence represents a secreted human protein encoded by the gene
CC   clone detailed in the descriptor line. The gene can be used to generate
CC   fusion proteins by linking to the gene to a human immunoglobulin Fc
CC   portion (e.g. AAX04302) for increasing the stability of the fused protein
CC   as compared to the human protein only. The invention relates to 86 novel
CC   genes and their fragments (nucleic acid sequences: AAX04311-X04410; amino
CC   acid sequences AAW78126-W78225) which are useful for preventing, treating
CC   or ameliorating medical conditions e.g. by protein or gene therapy. Also,
CC   pathological conditions can be diagnosed by determining the amount of the
CC   new polypeptides in a sample or by determining the presence of mutations
CC   in the new polynucleotides. Specific uses are described for each of the
CC   86 polynucleotides, based on which tissues they are most highly expressed
CC   in (see AAX04311 for described uses)
XX
SQ   Sequence 19 AA;

  Query Match             28.9%;  Score 28;  DB 2;  Length 19;
  Best Local Similarity   62.5%;  Pred. No. 1e+03;
  Matches    5;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKI 9
              | ||  ||
Db          5 PTHLEGKI 12


RESULT 203
ABB40664
ID   ABB40664 standard; peptide; 19 AA.
XX
AC   ABB40664;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #8170 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 33299; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 19 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 19;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              | |:: |  |||
Db          6 NYKLSVKFSSQE 17


RESULT 204
AAM34425
ID   AAM34425 standard; protein; 19 AA.
XX
AC   AAM34425;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #8462 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 34694; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 19 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 19;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              | |:: |  |||
Db          6 NYKLSVKFSSQE 17


RESULT 205
AAM74313
ID   AAM74313 standard; protein; 19 AA.
```

```
XX
AC   AAM74313;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human bone marrow expressed probe encoded protein SEQ ID NO: 34619.
XX
KW   Human; bone marrow expressed exon; gene expression analysis; probe;
KW   microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS   Homo sapiens.
XX
PN   WO200157276-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000668.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488900/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human bone marrow.
XX
PS   Example 4; SEQ ID NO 34619; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention
XX
SQ   Sequence 19 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 19;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              | |:: |  |||
Db          6 NYKLSVKFSSQE 17


RESULT 206
AAM61524
ID   AAM61524 standard; protein; 19 AA.
XX
AC   AAM61524;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 33629.
XX
KW   Human; brain expressed exon; gene expression analysis; probe; microarray;
KW   Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000667.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains.
XX
PS   Example 4; SEQ ID NO 33629; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 19 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 19;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              | |:: |  |||
Db          6 NYKLSVKFSSQE 17


RESULT 207
ABG56112
ID   ABG56112 standard; peptide; 19 AA.
XX
AC   ABG56112;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 34760.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
```

```
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 34760; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 19 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 19;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              | |:: |  |||
Db          6 NYKLSVKFSSQE 17


RESULT 208
ABG44240
ID   ABG44240 standard; peptide; 19 AA.
XX
AC   ABG44240;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 33905.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US000665.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples.
XX
PS   Claim 27; SEQ ID NO 33905; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of probes
CC   ; the novel set of probes which hybridise at high stringency to a nucleic
CC   acid expressed in the human lung; measuring gene expression in a sample
CC   derived from human lung, comprising (a) contacting the array with a
CC   collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of the
CC   array; identifying exons in a eukaryotic genome, comprising (a)
CC   algorithmically predicting at least one exon from genomic sequences of
CC   the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene expression
CC   analysis, and for identifying exons in a gene, particularly using human
CC   lung derived mRNA and for the study of lung diseases such as asthma, lung
CC   cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC   disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC   tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC   Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC   histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC   Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC   dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC   present sequence is a peptide/protein encoded by a single exon probe of
CC   the invention. Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 19 AA;

  Query Match             28.9%;  Score 28;  DB 5;  Length 19;
  Best Local Similarity   50.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              | |:: |  |||
Db          6 NYKLSVKFSSQE 17


RESULT 209
ABB09679
ID   ABB09679 standard; peptide; 21 AA.
XX
AC   ABB09679;
XX
DT   11-JUN-2002  (first entry)
XX
DE   Synthetic pentacosapeptide based from spinigerine.
XX
KW   Spinigerine; antibacterial; antifungal; bacterial infection;
KW   fungal infection; disease resistance.
XX
OS   Synthetic.
XX
```

PN WO200200836-A2.
XX
PD 03-JAN-2002.
XX
PF 29-JUN-2001; 2001WO-FR002100.
XX
PR 29-JUN-2000; 2000FR-00008436.
XX
PA (CNRS) CNRS CENT NAT RECH SCI.
PA (ENTO-) ENTOMED.
XX
PI Bulet P, Hoffmann J, Lamberty M;
XX
DR WPI; 2002-171585/22.
XX
PT New pentacosapeptides and derivatives, e.g. spinigerine isolated from
PT termites, useful as antibacterial and antifungal agents for treating or
PT preventing infections in humans, animals or plants.
XX
PS Claim 8; Page 15; 21pp; French.
XX
CC ABB09677-80 represent pentacosapeptides, which are based on a combination
CC of basic, hydrophobic and negatively charged or polar/large amino acid
CC residues. The parent peptide is a natural product designated spinigerine.
CC The peptides are antibacterial and antifungal agents. The peptides may be
CC used for treating or preventing bacterial or fungal infections in humans,
CC animals or plants. They are effective against Gram positive and Gram
CC negative bacteria, filamentous fungi, yeasts and plant pathogenic
CC bacteria and fungi. Plant cells may be transformed with nucleic acid
CC sequences expressing peptides of the invention to impart disease
CC resistance to plants
XX
SQ Sequence 21 AA;

Query Match 28.9%; Score 28; DB 5; Length 21;
Best Local Similarity 36.4%; Pred. No. 1.2e+03;
Matches 4; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 4 HLNSKIAFKIV 14
|:: |:| |::
Db 1 HVDKKVADKVL 11

RESULT 210
ABG93535
ID ABG93535 standard; peptide; 22 AA.
XX
AC ABG93535;
XX
DT 25-NOV-2002 (first entry)
XX
DE Human P-glycoprotein tryptic peptide #55.
XX
KW Human; P-glycoprotein; tryptic digest; proteolytic cleavage product;
KW diabetes; Parkinson's disease; Alzheimer's disease; malaria; cholera;
KW human immunodeficiency virus infection; influenza; rabies; diphtheria;
KW cancer; multi-drug resistance; MDR.
XX
OS Homo sapiens.
XX
PN EP1223534-A1.
XX
PD 17-JUL-2002.
XX
PF 11-JAN-2002; 2002EP-00075095.
XX
PR 14-JAN-2001; 2001IL-00140881.
PR 19-OCT-2001; 2001US-00982172.
XX
PA (KATZ/) KATZ E I.
XX
PI Katz EI;
XX
DR WPI; 2002-645691/70.
XX
PT Generating amino acid sequences representative of desired polypeptide, by
PT computationally generating proteolytic cleavage products, analyzing and
PT selecting the set of products, thus generating amino acid sequences.
XX
PS Example 1; Page 13; 124pp; English.
XX
CC The invention relates to generating set of amino acid sequences (AAS)
CC representative of one desired polypeptide (I), involving computationally
CC generating a number of proteolytic cleavage products (PCP) from (I),
CC analysing the PCP according to one parameter defining a characteristic of
CC AAS and selecting a set of PCP according to a preset criteria for each
CC parameter, thus generating the set of AAS representative of (I). Also
CC included are (1) a computer readable storage media (II) comprising a
CC database of amino acid sequences corresponding to the polypeptide of
CC interest; (2) a system (III) for generating a database of amino acid
CC sequences corresponding to a polypeptide of interest, comprises a
CC processing unit which executes a software application configured for
CC generating the number of proteolytic cleavage products from one
CC polypeptide of interest, and analysing the number of proteolytic cleavage
CC products according to one parameter defining a characteristic of amino
CC acid sequence; (3) a kit for quantifying at least one polypeptide of
CC interest, comprises a number of peptides or antibodies each capable of
CC specifically recognising at least one peptide, where the number of
CC peptides is generated according to information derived from computational
CC analysis of the polypeptide of interest; and (4) quantifying one
CC polypeptide of interest in a biological sample, involving contacting the
CC biological sample with proteolytic agent, so as to obtain a proteolysed
CC biological sample, contacting the proteolysed biological sample with at
CC least one antibody and at least one peptide of a number of peptides, and
CC detecting presence, absence and/or level of antibody binding to thus
CC quantify one polypeptide of interest in the biological sample. The method
CC is useful for generating at least one antibody specific to a polypeptide
CC of interest. The peptides or antibodies generated may be used to diagnose
CC diabetes, Parkinson's disease, Alzheimer's disease, human
CC immunodeficiency virus infection, malaria, cholera, influenza, rabies,
CC diphtheria, cancer (e.g. breast, colon, cervix, melanoma, lung, ovary,
CC pancreas, prostate, lymphomas and leukaemias). The present sequence is a
CC predicted tryptic peptide from human P-glycoprotein generated to form
CC part of a kit for identifying multi-drug (MDR) resistance associated
CC proteins
XX
SQ Sequence 22 AA;

Query Match 28.9%; Score 28; DB 5; Length 22;
Best Local Similarity 83.3%; Pred. No. 1.2e+03;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 13 IVSQEP 18
:|||||
Db 5 VVSQEP 10

RESULT 211
AAY36341
ID AAY36341 standard; protein; 23 AA.
XX
AC AAY36341;
XX
DT 17-SEP-1999 (first entry)
XX
DE Fragment of human secreted protein encoded by gene 1.
XX
KW Human; secreted protein; cancer; tumour; developmental abnormality;
KW foetal deficiency; blood disorder; immune system disorder; inflammation;
KW autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW digestive disorder; endocrine disorder; infection; AIDS.
XX
OS Homo sapiens.
XX

PN WO9931117-A1.
XX
PD 24-JUN-1999.
XX
PF 17-DEC-1998; 98WO-US027059.
XX
PR 18-DEC-1997; 97US-0068006P.
PR 18-DEC-1997; 97US-0068007P.
PR 18-DEC-1997; 97US-0068008P.
PR 18-DEC-1997; 97US-0068053P.
PR 18-DEC-1997; 97US-0068054P.
PR 18-DEC-1997; 97US-0068057P.
PR 18-DEC-1997; 97US-0068064P.
PR 18-DEC-1997; 97US-0070923P.
PR 19-DEC-1997; 97US-0068169P.
PR 19-DEC-1997; 97US-0068365P.
PR 19-DEC-1997; 97US-0068367P.
PR 19-DEC-1997; 97US-0068368P.
PR 19-DEC-1997; 97US-0068369P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Moore PA, Ruben SM, Carter KC, Shi Y, Rosen CA, Soppet DR;
PI Kyaw H, Wei Y, Florence K, Duan RD, Florence C, Greene JM, Feng P;
PI Ferrie AM, Yu G, Janat F, Ni J;
XX
DR WPI; 1999-418749/35.
XX
PT New isolated human genes encoding secreted polypeptides.
XX
PS Disclosure; Page 312; 537pp; English.
XX
CC AAX97916 to AAX98029 represent 110 isolated human secreted protein genes.
CC AAY36224 to AAY36727 represent the secreted proteins encoded by the 110
CC human genes. The genes and their corresponding secreted polypeptides are
CC useful for preventing, treating or ameliorating medical conditions, e.g.
CC by protein or gene therapy. Also pathological conditions can be diagnosed
CC by determining the amount of the new polypeptides in a sample or by
CC determining the presence of mutations in the new genes. Specific uses are
CC described for each of the 110 genes, based on which tissues they are most
CC highly expressed in, and include developing products for the diagnosis or
CC treatment of cancer, tumours, developmental abnormalities and foetal
CC deficiencies, blood disorders, diseases of the immune system, autoimmune
CC diseases, inflammation, allergies, Alzheimer's and cognitive disorders,
CC schizophrenia, arthritis, asthma, psoriasis, sepsis, skin disorders,
CC atherosclerosis, diabetes, cardiovascular disorders, kidney disorders,
CC digestive/endocrine disorders, infections and AIDS. The polypeptides are
CC also useful for identifying their binding partners. The sequences given
CC in AAX97907 to AAX97915 and AAY36223 are used in the exemplification of
CC the present invention
XX
SQ Sequence 23 AA;

Query Match 28.9%; Score 28; DB 2; Length 23;
Best Local Similarity 27.8%; Pred. No. 1.3e+03;
Matches 5; Conservative 7; Mismatches 6; Indels 0; Gaps 0;

Qy 1 EPNHLNSKIAFKIVSQEP 18
|| |::::|::: |
Db 5 EPQCGASRLSWKMLNSSP 22

RESULT 212
AAM15118
ID AAM15118 standard; protein; 23 AA.
XX
AC AAM15118;
XX
DT 12-OCT-2001 (first entry)
XX
DE Peptide #1552 encoded by probe for measuring cervical gene expression.
XX
KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer.
XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000670.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human cervical epithelial cells.
XX
PS Claim 27; SEQ ID NO 19944; 487pp; English.
XX
CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore
CC useful in grading and/or staging of diseases of the cervix, notably
CC cervical cancer. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 23 AA;

Query Match 28.9%; Score 28; DB 4; Length 23;
Best Local Similarity 42.9%; Pred. No. 1.3e+03;
Matches 6; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVSQEP 18
| | :: :| |||
Db 4 LKSFLSIQISKQEP 17

RESULT 213
ABB34112
ID ABB34112 standard; peptide; 23 AA.
XX
AC ABB34112;
XX
DT 04-FEB-2002 (first entry)
XX
DE Peptide #1618 encoded by human foetal liver single exon probe.
XX
KW Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000669.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.

```
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 26747; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 23 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 23;
  Best Local Similarity   42.9%;  Pred. No. 1.3e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | | :: :|  |||
Db          4 LKSFLSIQISKQEP 17


RESULT 214
AAM27573
ID   AAM27573 standard; protein; 23 AA.
XX
AC   AAM27573;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #1610 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 27842; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 23 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 23;
  Best Local Similarity   42.9%;  Pred. No. 1.3e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | | :: :|  |||
Db          4 LKSFLSIQISKQEP 17


RESULT 215
ABB28942
ID   ABB28942 standard; peptide; 23 AA.
XX
AC   ABB28942;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Peptide #1593 encoded by breast cell single exon nucleic acid probe.
XX
KW   Human; microarray; single exon probe; gene expression; breast; disease;
KW   cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157271-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000662.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-496933/54.
XX
PT   New spatially-addressable set of single exon nucleic acid probes, useful
PT   for measuring gene expression in sample derived from human breast,
PT   comprises number of single exon nucleic acid probes.
XX
PS   Claim 27; SEQ ID NO 11910; 327pp + Sequence Listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting the
CC   probes with a collection of detectably labelled nucleic acids derived
CC   from mRNA of human breast, and then measuring the label bound to each
CC   probe of the microarray. The probes are useful for verifying the
CC   expression of regions of genomic DNA predicted to encode proteins. They
CC   are useful for gene discovery, and for determining predisposition and/or
CC   prognosing breast disease. Gene expression analysis is useful for
CC   assessing the toxicity of chemical agents on cells. The microarray of
```

```
CC   this invention presents a far greater diversity of probes for measuring
CC   gene expression, with far less bias than expressed sequence tag
CC   microarrays. The method is suitable for rapid production of functional
CC   information from genomic sequence. The present sequence is a peptide
CC   encoded by a single exon nucleic acid probe of the invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 23 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 23;
  Best Local Similarity   42.9%;  Pred. No. 1.3e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | |  ::  :|  |||
Db          4 LKSFLSIQISKQEP 17


RESULT 216
ABB19553
ID   ABB19553 standard; protein; 23 AA.
XX
AC   ABB19553;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #1552 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000666.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts.
XX
PS   Claim 15; SEQ ID NO 21323; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart (see
CC   ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC   probe. The probes may be used for predicting, measuring and displaying
CC   gene expression in samples derived from the human heart via microarrays.
CC   By measuring gene expression, the probes are useful for predicting,
CC   diagnosing, grading, staging, monitoring and prognosing diseases of the
CC   human heart and vascular system e.g. cardiovascular disease,
CC   hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 23 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 23;
  Best Local Similarity   42.9%;  Pred. No. 1.3e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | |  ::  :|  |||
Db          4 LKSFLSIQISKQEP 17


RESULT 217
AAM67281
ID   AAM67281 standard; protein; 23 AA.
XX
AC   AAM67281;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human bone marrow expressed probe encoded protein SEQ ID NO: 27587.
XX
KW   Human; bone marrow expressed exon; gene expression analysis; probe;
KW   microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS   Homo sapiens.
XX
PN   WO200157276-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000668.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488900/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human bone marrow.
XX
PS   Example 4; SEQ ID NO 27587; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention
XX
SQ   Sequence 23 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 23;
  Best Local Similarity   42.9%;  Pred. No. 1.3e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | |  ::  :|  |||
Db          4 LKSFLSIQISKQEP 17


RESULT 218
AAM54900
ID   AAM54900 standard; protein; 23 AA.
```

XX
AC AAM54900;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 27005.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX
PS Example 4; SEQ ID NO 27005; 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention
XX
SQ Sequence 23 AA;

Query Match 28.9%; Score 28; DB 4; Length 23;
Best Local Similarity 42.9%; Pred. No. 1.3e+03;
Matches 6; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVSQEP 18
| | :: :| |||
Db 4 LKSFLSIQISKQEP 17

RESULT 219
ABG48943
ID ABG48943 standard; peptide; 23 AA.
XX
AC ABG48943;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID No 27591.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 27; SEQ ID NO 27591; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABG47348-ABG59930 represent human
CC liver single exon encoded peptides of the invention. Note: The sequence
CC information for this patent does not appear in the printed specification
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 23 AA;

Query Match 28.9%; Score 28; DB 4; Length 23;
Best Local Similarity 42.9%; Pred. No. 1.3e+03;
Matches 6; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVSQEP 18
| | :: :| |||
Db 4 LKSFLSIQISKQEP 17

RESULT 220
AAM02859
ID AAM02859 standard; protein; 23 AA.
XX
AC AAM02859;
XX
DT 09-OCT-2001 (first entry)
XX
DE Peptide #1541 encoded by probe for measuring breast gene expression.
XX
KW Probe; human; breast disease; breast cancer; development disorder;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS Homo sapiens.
XX
PN WO200157270-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000661.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.

```
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression in
PT   a human breast.
XX
PS   Claim 27; SEQ ID NO 11599; 322pp; English.
XX
CC   The present invention relates to novel single exon nucleic acid probes
CC   (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for measuring human gene expression in
CC   a human breast sample, where the probe hybridises at high stringency to a
CC   nucleic acid expressed in the human breast. The probes are useful for
CC   predicting, diagnosing, grading, staging, monitoring and prognosing
CC   diseases of the human breast, particularly those diseases with polygenic
CC   aetiology. The diseases include: breast cancer, disorders of development,
CC   inflammatory diseases of the breast, fibrocystic changes, proliferative
CC   breast disease and non-carcinoma tumours. Note: The sequence data for
CC   this patent did not form part of the printed specification, but was
CC   obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 23 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 23;
  Best Local Similarity   42.9%;  Pred. No. 1.3e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | | :: :|  |||
Db          4 LKSFLSIQISKQEP 17


RESULT 221
ABG36928
ID   ABG36928 standard; peptide; 23 AA.
XX
AC   ABG36928;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 26593.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US000665.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples.
XX
PS   Claim 27; SEQ ID NO 26593; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of probes
CC   ; the novel set of probes which hybridise at high stringency to a nucleic
CC   acid expressed in the human lung; measuring gene expression in a sample
CC   derived from human lung, comprising (a) contacting the array with a
CC   collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of the
CC   array; identifying exons in a eukaryotic genome, comprising (a)
CC   algorithmically predicting at least one exon from genomic sequences of
CC   the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene expression
CC   analysis, and for identifying exons in a gene, particularly using human
CC   lung derived mRNA and for the study of lung diseases such as asthma, lung
CC   cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC   disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC   tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC   Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC   histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC   Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC   dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC   present sequence is a peptide/protein encoded by a single exon probe of
CC   the invention. Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 23 AA;

  Query Match             28.9%;  Score 28;  DB 5;  Length 23;
  Best Local Similarity   42.9%;  Pred. No. 1.3e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | | :: :|  |||
Db          4 LKSFLSIQISKQEP 17


RESULT 222
ADA11735
ID   ADA11735 standard; protein; 23 AA.
XX
AC   ADA11735;
XX
DT   06-NOV-2003  (first entry)
XX
```

```
DE   Human novel secreted protein associated polypeptide #5.
XX
KW   cancer; inflammation; immune disorder; neurological disorder;
KW   blood clotting disorder; food additive; food preservative;
KW   storage capability; fat content; nutritional component; human;
KW   secreted protein.
XX
OS   Homo sapiens.
XX
PN   US2003055236-A1.
XX
PD   20-MAR-2003.
XX
PF   14-MAR-2002; 2002US-00097065.
XX
PR   18-DEC-1997;   97US-0068006P.
PR   18-DEC-1997;   97US-0068007P.
PR   18-DEC-1997;   97US-0068008P.
PR   18-DEC-1997;   97US-0068053P.
PR   18-DEC-1997;   97US-0068054P.
PR   18-DEC-1997;   97US-0068057P.
PR   18-DEC-1997;   97US-0068064P.
PR   18-DEC-1997;   97US-0070923P.
PR   19-DEC-1997;   97US-0068169P.
PR   19-DEC-1997;   97US-0068365P.
PR   19-DEC-1997;   97US-0068367P.
PR   19-DEC-1997;   97US-0068368P.
PR   19-DEC-1997;   97US-0068369P.
PR   17-DEC-1998;   98WO-US027059.
PR   17-JUN-1999;   99US-00334595.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Moore PA,  Ruben SM,  Carter KC,  Shi Y,  Rosen CA,  Soppet DR;
PI   Kyaw H,  Wei Y,  Florence KA,  Duan DR,  Florence C,  Greene JM,  Feng P;
PI   Ferrie AM,  Yu G,  Janat F,  Ni J;
XX
DR   WPI; 2003-567105/53.
XX
PT   New secreted HKABT24 nucleic acid molecules and polypeptides, useful for
PT   preventing, treating, or ameliorating a medical condition, such as
PT   cancer, inflammation, immune disorders, neurological and blood clotting
PT   disorders.
XX
PS   Disclosure; Page 4; 118pp; English.
XX
CC   The invention relates to an isolated HKABT24 nucleic acid molecule. The
CC   polypeptides, nucleic acids and antibodies are useful for diagnosing a
CC   pathological condition or a susceptibility to a pathological condition,
CC   for preventing, treating, or ameliorating a medical condition, such as
CC   cancer, inflammation and other immune disorders, neurological and blood
CC   clotting disorders. The nucleic acids are also useful for chromosome
CC   identification, radiation hybrid mapping or long-range restriction
CC   mapping. The polypeptides and antibodies are useful for providing
CC   immunological probes for differential identification of the tissues
CC   immunohistochemistry assays. The polypeptide, polynucleotide, agonist or
CC   antagonist may also be used as a food additive or preservative to
CC   increase or decrease storage capabilities, fat content or other
CC   nutritional components. The present sequence represents the amino acid
CC   sequence of a novel human secreted protein associated polypeptide. Note:
CC   The sequence data for this patent did not form part of the printed
CC   specification but was obtained in electronic format directly from USPTO
CC   at seqdata.uspto.gov.uk/sequence.html?DocID=20030055236.
XX
SQ   Sequence 23 AA;

  Query Match             28.9%;  Score 28;  DB 6;  Length 23;
  Best Local Similarity   27.8%;  Pred. No. 1.3e+03;
  Matches    5;  Conservative    7;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKIVSQEP 18
              ||    |::::|:::  |
Db          5 EPQCGASRLSWKMLNSSP 22


RESULT 223
AAM19000
ID   AAM19000 standard; protein; 24 AA.
XX
AC   AAM19000;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #5434 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000670.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human cervical epithelial cells.
XX
PS   Claim 27; SEQ ID NO 23826; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 24 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 24;
  Best Local Similarity   41.7%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              |::::|| |:: |
Db          6 LSARLAFVIIFQ 17


RESULT 224
AAG76249
ID   AAG76249 standard; protein; 24 AA.
XX
AC   AAG76249;
XX
DT   03-SEP-2001  (first entry)
XX
DE   Human colon cancer antigen protein SEQ ID NO:7013.
```

XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW colorectal carcinoma.
XX
OS Homo sapiens.
XX
PN WO200122920-A2.
XX
PD 05-APR-2001.
XX
PF 28-SEP-2000; 2000WO-US026524.
XX
PR 29-SEP-1999; 99US-0157137P.
PR 03-NOV-1999; 99US-0163280P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Birse CE, Rosen CA;
XX
DR WPI; 2001-235357/24.
DR N-PSDB; AAH35654.
XX
PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT useful for preventing, diagnosing and/or treating colorectal cancers.
XX
PS Claim 11; Page 8455-8456; 9803pp; English.
XX
CC AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC cancer-associated nucleic acid molecules (N) and proteins (P), where the
CC proteins are collectively known as colon cancer antigens. The colon
CC cancer antigens have cytostatic activity and can be used in gene therapy
CC and vaccine production. N and P may be used in the prevention, diagnosis
CC and treatment of diseases associated with inappropriate P expression. For
CC example, N and P may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of P by expressing inactive proteins or to
CC supplement the patients own production of P. Additionally, N may be used
CC to produce the colon cancer-associated Ps, by inserting the nucleic acids
CC into a host cell and culturing the cell to express the proteins. N and P
CC can be used in the prevention, diagnosis and treatment of colorectal
CC carcinomas and cancers. AAH37196 to AAH37204 and AAB77789 represent
CC sequences used in the exemplification of the present invention. N.B.
CC Pages 666 to 682 and page 7053 of the sequence listing were missing at
CC time of publication, meaning no sequences are present for SEQ ID NO:1027
CC to 1052, 7921 and 7922
XX
SQ Sequence 24 AA;

Query Match 28.9%; Score 28; DB 4; Length 24;
Best Local Similarity 54.5%; Pred. No. 1.4e+03;
Matches 6; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy          3 NHLNSKIAFKI 13
              : | |||:|:|
Db          1 HELPSKISFEI 11
```

RESULT 225
AAM70819
ID AAM70819 standard; protein; 25 AA.
XX
AC AAM70819;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 31125.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 31125; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention
XX
SQ Sequence 25 AA;

Query Match 28.9%; Score 28; DB 4; Length 25;
Best Local Similarity 44.4%; Pred. No. 1.5e+03;
Matches 4; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

```
Qy         10 AFKIVSQEP 18
                |||:: ::|
Db          3 AFKVMMEKP 11
```

RESULT 226
ABG52538
ID ABG52538 standard; peptide; 25 AA.
XX
AC ABG52538;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID No 31186.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX

```
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 31186; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 25 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 25;
  Best Local Similarity   44.4%;  Pred. No. 1.5e+03;
  Matches    4;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         10 AFKIVSQEP 18
              |||:: ::|
Db          3 AFKVMMEKP 11


RESULT 227
ABB09677
ID   ABB09677 standard; peptide; 25 AA.
XX
AC   ABB09677;
XX
DT   11-JUN-2002  (first entry)
XX
DE   Synthetic pentacosapeptide based from spinigerine.
XX
KW   Spinigerine; antibacterial; antifungal; bacterial infection;
KW   fungal infection; disease resistance.
XX
OS   Synthetic.
XX
PN   WO200200836-A2.
XX
PD   03-JAN-2002.
XX
PF   29-JUN-2001; 2001WO-FR002100.
XX
PR   29-JUN-2000; 2000FR-00008436.
XX
PA   (CNRS ) CNRS CENT NAT RECH SCI.
PA   (ENTO-) ENTOMED.
XX
PI   Bulet P,  Hoffmann J,  Lamberty M;
XX
DR   WPI; 2002-171585/22.
XX
PT   New pentacosapeptides and derivatives, e.g. spinigerine isolated from
PT   termites, useful as antibacterial and antifungal agents for treating or
PT   preventing infections in humans, animals or plants.
XX
PS   Claim 8; Page 15; 21pp; French.
XX
CC   ABB09677-80 represent pentacosapeptides, which are based on a combination
CC   of basic, hydrophobic and negatively charged or polar/large amino acid
CC   residues. The parent peptide is a natural product designated spinigerine.
CC   The peptides are antibacterial and antifungal agents. The peptides may be
CC   used for treating or preventing bacterial or fungal infections in humans,
CC   animals or plants. They are effective against Gram positive and Gram
CC   negative bacteria, filamentous fungi, yeasts and plant pathogenic
CC   bacteria and fungi. Plant cells may be transformed with nucleic acid
CC   sequences expressing peptides of the invention to impart disease
CC   resistance to plants
XX
SQ   Sequence 25 AA;

  Query Match             28.9%;  Score 28;  DB 5;  Length 25;
  Best Local Similarity   36.4%;  Pred. No. 1.5e+03;
  Matches    4;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIV 14
              |:: |:| |::
Db          1 HVDKKVADKVL 11


RESULT 228
AAY12738
ID   AAY12738 standard; protein; 26 AA.
XX
AC   AAY12738;
XX
DT   21-JUN-1999  (first entry)
XX
DE   Human 5' EST secreted protein SEQ ID NO:328.
XX
KW   Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW   forensic; gene therapy; chromosome mapping; signal peptide;
KW   upstream regulatory sequence; cytokine activity; cell proliferation;
KW   differentiation; haematopoiesis regulation; tissue growth regulation;
KW   reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW   thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS   Homo sapiens.
XX
PN   WO9906549-A2.
XX
PD   11-FEB-1999.
XX
PF   31-JUL-1998;   98WO-IB001231.
XX
PR   01-AUG-1997;   97US-00905279.
XX
PA   (GEST ) GENSET.
XX
PI   Dumas Milne Edwards J,  Duclert A,  Lacroix B;
XX
DR   WPI; 1999-153779/13.
DR   N-PSDB; AAX51516.
XX
PT   New nucleic acids encoding human secreted proteins - obtained from cDNA
PT   libraries derived from testis, ovary, uterus and spleen tissue.
XX
PS   Claim 34; Page 418; 522pp; English.
XX
CC   AAX51459 to AAX51691 represent 5' expressed sequence tags (ESTs) for
CC   human secreted proteins, and encode the proteins given in AAY12681 to
CC   AAY12913, respectively. The proteins given represent the signal peptide
CC   and an N-terminal fragment of a secreted protein. The nucleic acid
CC   sequences can be used for producing secreted human gene products. They
CC   can also be used to develop products for diagnosis and therapy. The
CC   proteins obtained may have cytokine activity, cell
CC   proliferation/differentiation activity, haematopoiesis regulating
CC   activity, tissue growth regulating activity, reproductive hormone
CC   regulating activity, chemotactic/ chemokinetic activity, haemostatic and
CC   thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC   activity, tumour inhibition activity or other activities. The products
CC   can be used in forensic, gene therapy and chromosome mapping procedures.
CC   The sequences can also be used for obtaining corresponding promoter
```

CC sequences. The nucleic acids encoding the signal peptide can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell
XX
SQ Sequence 26 AA;

Query Match 28.9%; Score 28; DB 2; Length 26;
Best Local Similarity 40.0%; Pred. No. 1.5e+03;
Matches 4; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAF 11
|:|:: | :|
Db 16 PSHIDLKCSF 25

RESULT 229
ADH17225
ID ADH17225 standard; peptide; 27 AA.
XX
AC ADH17225;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human D-AKAP2 AKB domain mutant peptide - SEQ ID 39.
XX
KW D-AKAP; dual-specific A-kinase anchor protein; regulatory subunit; PKA;
KW cyclic AMP-dependent protein kinase; cAMP; neurological;
KW neurodegenerative; Alzheimer's disease; cardiovascular; proliferative;
KW lipid metabolism; diabetes; obesity; retinitis pigmentosa; autoimmune;
KW lupus erythematosus; human; D-AKAP2; AKAP-10; SNP;
KW single nucleotide polymorphism; AKB domain; A-kinase binding; mutant;
KW mutein.
XX
OS Synthetic.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Misc-difference 13
FT /note= "Wild-type Ala substituted for Asn"
FT Misc-difference 24
FT /label= Ile, Val
FT /note= "Residue corresponds to a SNP (single nucleotide
FT polymorphism at residue 646 within the native protein"
XX
PN WO2003093296-A2.
XX
PD 13-NOV-2003.
XX
PF 01-MAY-2003; 2003WO-US013698.
XX
PR 03-MAY-2002; 2002US-0377852P.
PR 07-MAR-2003; 2003US-0453408P.
XX
PA (SEQU-) SEQUENOM INC.
PA (REGC) UNIV CALIFORNIA.
XX
PI Braun A, Cantor CR, Kammerer SM, Taylor S, Hamuro LB, Cook C;
PI Olson G, Self C;
XX
DR WPI; 2003-903647/82.
XX
PT New isolated NOVX polypeptides and polynucleotides, useful for
PT preventing, diagnosing or treating NOVX-associated disorders, e.g.
PT osteoarthritis, obesity, atherosclerosis, cancer, Parkinson's disease,
PT asthma, or infections.
XX
PS Claim 28; SEQ ID NO 39; 149pp; English.
XX
CC The invention relates to a novel isolated mutein of a D-AKAP2 (dual-
CC specific A-kinase anchor protein) polypeptide where the mutein exhibits
CC modified binding to a regulatory subunit of PKA (cyclic AMP [cAMP]-
CC dependent protein kinase) compared to a native D-AKAP. The polypeptide of
CC the invention may be useful for treating or preventing neurological and
CC neurodegenerative disorders such as Alzheimer's disease, cardiovascular
CC disorders, proliferative disorders and lipid-metabolism disorders
CC including diabetes, obesity and retinitis pigmentosa, as well as
CC autoimmune disorders e.g. lupus erythematosus. The current sequence is
CC that of the human D-AKAP2 AKB (A-kinase binding) domain mutant peptide of
CC the invention.
XX
SQ Sequence 27 AA;

Query Match 28.9%; Score 28; DB 7; Length 27;
Best Local Similarity 72.7%; Pred. No. 1.6e+03;
Matches 8; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5 LNSKIAFKIVS 15
|| ||| ||
Db 12 LNWKIAKMIVS 22

RESULT 230
ADD35429
ID ADD35429 standard; peptide; 28 AA.
XX
AC ADD35429;
XX
DT 15-JAN-2004 (first entry)
XX
DE Pseudomonas aeruginosa peptide deformylase peptide #1.
XX
KW crystallised recombinant protein; metabolism; Staphylococcus aureus;
KW Streptococcus pneumoniae; Helicobacter pylori; Escherichia coli;
KW Pseudomonas aeruginosa; vaccine.
XX
OS Pseudomonas aeruginosa.
XX
PN WO2003044185-A2.
XX
PD 30-MAY-2003.
XX
PF 21-NOV-2002; 2002WO-CA001768.
XX
PR 21-NOV-2001; 2001US-0332160P.
PR 27-NOV-2001; 2001US-0333661P.
PR 27-NOV-2001; 2001US-0333665P.
PR 18-DEC-2001; 2001US-0341770P.
PR 19-DEC-2001; 2001US-0341954P.
PR 19-DEC-2001; 2001US-0342003P.
PR 20-DEC-2001; 2001US-0342542P.
PR 21-DEC-2001; 2001US-0344252P.
PR 28-DEC-2001; 2001US-0343570P.
PR 28-DEC-2001; 2001US-0343606P.
PR 28-DEC-2001; 2001US-0343679P.
XX
PA (AFFI-) AFFINIUM PHARM INC.
XX
PI Edwards A, Dharamsi A, Vedadi M, Alam MZ, Awrey D, Beattie B;
PI Canadien V, Domagala M, Houston S, Mansoury K, Necakov S, Nethery K;
PI Ng I, Pinder B, Sheldrick B, Vallee F, Wrezel O;
XX
DR WPI; 2003-513596/48.
XX
PT New crystallized recombinant polypeptides from Staphylococcus aureus,
PT Streptococcus pneumoniae, Helicobacter pylori or Pseudomonas aeruginosa
PT involved in general metabolism, useful as drug targets for pathogenic
PT bacteria.
XX
PS Disclosure; SEQ ID NO 28; 277pp; English.
XX
CC The invention comprises a crystallised recombinant protein that is
CC involved in general metabolism, the recombinant protein may be from
CC Staphylococcus aureus, Streptococcus pneumoniae, Helicobacter pylori,
CC Escherichia coli or Pseudomonas aeruginosa. The crystallised recombinant
CC protein of the invention is useful in the prevention (vaccine) or
CC treatment of a disease or disorder caused by S. pneumoniae, H. pylori, E.

```
CC   coli or P. aeruginosa. The present amino acid sequence was used in the
CC   exemplification of the invention.
XX
SQ   Sequence 28 AA;

  Query Match             28.9%;  Score 28;  DB 7;  Length 28;
  Best Local Similarity   55.6%;  Pred. No. 1.7e+03;
  Matches    5;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKI 9
              | :||| |:
Db         12 ECDHLNGKL 20


RESULT 231
ABB43186
ID   ABB43186 standard; peptide; 29 AA.
XX
AC   ABB43186;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #10692 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 35821; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 29 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 29;
  Best Local Similarity   33.3%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              || |: |:: ::
Db         10 NSGISLKVIQED 21


RESULT 232
AAM37026
ID   AAM37026 standard; protein; 29 AA.
XX
AC   AAM37026;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #11063 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 37295; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 29 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 29;
  Best Local Similarity   33.3%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              || |: |:: ::
Db         10 NSGISLKVIQED 21


RESULT 233
ABB26285
ID   ABB26285 standard; protein; 29 AA.
XX
AC   ABB26285;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #8284 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
```

XX
PN WO200157274-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000666.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488899/53.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX
PS Claim 15; SEQ ID NO 28055; 530pp; English.
XX
CC The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart (see
CC ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC probe. The probes may be used for predicting, measuring and displaying
CC gene expression in samples derived from the human heart via microarrays.
CC By measuring gene expression, the probes are useful for predicting,
CC diagnosing, grading, staging, monitoring and prognosing diseases of the
CC human heart and vascular system e.g. cardiovascular disease,
CC hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 29 AA;

Query Match 28.9%; Score 28; DB 4; Length 29;
Best Local Similarity 33.3%; Pred. No. 1.7e+03;
Matches 4; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy 6 NSKIAFKIVSQE 17
|| |: |:: ::
Db 10 NSGISLKVIQED 21

RESULT 234
AAM76919
ID AAM76919 standard; protein; 29 AA.
XX
AC AAM76919;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 37225.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 37225; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention
XX
SQ Sequence 29 AA;

Query Match 28.9%; Score 28; DB 4; Length 29;
Best Local Similarity 33.3%; Pred. No. 1.7e+03;
Matches 4; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy 6 NSKIAFKIVSQE 17
|| |: |:: ::
Db 10 NSGISLKVIQED 21

RESULT 235
AAM64096
ID AAM64096 standard; protein; 29 AA.
XX
AC AAM64096;
XX
DT 05-NOV-2001 (first entry)
XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 36201.
XX
KW Human; brain expressed exon; gene expression analysis; probe; microarray;
KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000667.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT brains.
XX

```
PS   Example 4; SEQ ID NO 36201; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 29 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 29;
  Best Local Similarity   33.3%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              || |: |:: ::
Db         10 NSGISLKVIQED 21


RESULT 236
ABG58582
ID   ABG58582 standard; peptide; 29 AA.
XX
AC   ABG58582;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 37230.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 37230; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 29 AA;

  Query Match             28.9%;  Score 28;  DB 4;  Length 29;
  Best Local Similarity   33.3%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              || |: |:: ::
Db         10 NSGISLKVIQED 21


RESULT 237
ABG46030
ID   ABG46030 standard; peptide; 29 AA.
XX
AC   ABG46030;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 35695.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US000665.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples.
XX
PS   Claim 27; SEQ ID NO 35695; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of probes
CC   ; the novel set of probes which hybridise at high stringency to a nucleic
CC   acid expressed in the human lung; measuring gene expression in a sample
CC   derived from human lung, comprising (a) contacting the array with a
CC   collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of the
CC   array; identifying exons in a eukaryotic genome, comprising (a)
```

```
CC   algorithmically predicting at least one exon from genomic sequences of
CC   the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene expression
CC   analysis, and for identifying exons in a gene, particularly using human
CC   lung derived mRNA and for the study of lung diseases such as asthma, lung
CC   cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC   disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC   tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC   Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC   histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC   Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC   dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC   present sequence is a peptide/protein encoded by a single exon probe of
CC   the invention. Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 29 AA;

  Query Match             28.9%;  Score 28;  DB 5;  Length 29;
  Best Local Similarity   33.3%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQE 17
              || |: |:: ::
Db         10 NSGISLKVIQED 21


RESULT 238
AAU97881
ID   AAU97881 standard; peptide; 29 AA.
XX
AC   AAU97881;
XX
DT   21-AUG-2002  (first entry)
XX
DE   Mouse angiostatin C-terminal peptide.
XX
KW   Plasminogen; mouse; angiostatin detection; immunological detection.
XX
OS   Mus sp.
XX
PN   JP2002112768-A.
XX
PD   16-APR-2002.
XX
PF   04-OCT-2000; 2000JP-00304946.
XX
PR   04-OCT-2000; 2000JP-00304946.
XX
PA   (IGAK-) IGAKU SEIBUTSUGAKU KENKYUSHO KK.
XX
DR   WPI; 2002-448751/48.
XX
PT   Angiotensin specific binding monoclonal antibody composed of residues 79-
PT   84 of plasminogen of human being, mouse and rat used for detection of
PT   angiostatin.
XX
PS   Example 1; Fig 2; 16pp; Japanese.
XX
CC   The invention describes immunological detection of angiostatin with a
CC   monoclonal antibody. This sequence represents the mouse angiostatin C-
CC   terminal peptide used in the creation of an angiotensin specific binding
CC   monoclonal antibody
XX
SQ   Sequence 29 AA;

  Query Match             28.9%;  Score 28;  DB 5;  Length 29;
  Best Local Similarity   46.2%;  Pred. No. 1.7e+03;
  Matches    6;  Conservative    2;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          7 SKIAFKIVSQEPA 19
              | :    |||||:
Db          8 SVVELPTVSQEPS 20


RESULT 239
AAW30507
ID   AAW30507 standard; peptide; 30 AA.
XX
AC   AAW30507;
XX
DT   26-OCT-1998  (first entry)
XX
DE   DP-1 transcription factor antagonist peptide H7.
XX
KW   DP-1; transcription factor; antagonist; E2F protein; apoptosis;
KW   cell proliferation; cardiovascular cell; restenosis; tumour;
KW   surgical stent; therapy.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         3. .9
FT                   /note= "Claim 3"
FT   Peptide         5. .15
FT                   /note= "Claim 3"
XX
PN   WO9828334-A1.
XX
PD   02-JUL-1998.
XX
PF   22-DEC-1997;   97WO-GB003506.
XX
PR   20-DEC-1996;   96GB-00026589.
XX
PA   (PROL-) PROLIFIX LTD.
XX
PI   La Thangue NB,  Bandara LR;
XX
DR   WPI; 1998-377596/32.
XX
PT   Polypeptide fragments of the DP-1 transcription factor - used for
PT   inducing apoptosis, specifically in tumour and cardiovascular cells, e.g.
PT   for preventing re-stenosis.
XX
PS   Claim 4; Page 44; 55pp; English.
XX
CC   Peptide H7 comprises amino acid residues 170-199 in the DEF box (I) (see
CC   AAW30501) of transcription factor DP1. Claimed peptides (II) (see
CC   AAW30504-07) containing one or both of 2 motifs (see AAW30502-03) of the
CC   DEF box are capable of antagonising the heterodimerisation of a DP
CC   protein with an E2F protein. Also claimed are variants of these peptides,
CC   especially containing substitutions of residues corresponding to residues
CC   167, 169, 171 and 175 of DP-1, fusion proteins (III) comprising (I) or
CC   (II) and a membrane translocation sequence (see AAW30508), expression
CC   vectors encoding (I)-(III) and host cells. (I)-(III) are used
CC   therapeutically to induce apoptosis, specifically in tumour or
CC   cardiovascular cells, either in vivo or in vitro, e.g. for purging bone
CC   marrow. Surgical stents comprising (I)-(III) are used to treat or prevent
CC   restenosis in patients who have undergone angioplasty. (I)-(III) function
CC   by inactivating the DNA-binding activity of DP/E2F heterodimers. They are
CC   also used as research reagents, as positive controls in assays for
CC   identifying antagonists of DP-1/E2F dimerisation and as immunoassay
CC   agents. Also described is the use of sequences antisense to nucleic acids
```

```
CC   encoding (I)-(III) to control DP levels in cells, particularly by gene
CC   therapy. When formulated with cytotoxic or cytostatic agents, (I)-(III)
CC   enhance cell killing
XX
SQ   Sequence 30 AA;

  Query Match             28.9%;  Score 28;  DB 2;  Length 30;
  Best Local Similarity   46.2%;  Pred. No. 1.8e+03;
  Matches    6;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQE 17
              ||  :|  |:|:|
Db          4 LNVLMAMNIISKE 16


RESULT 240
AAB28613
ID   AAB28613 standard; protein; 31 AA.
XX
AC   AAB28613;
XX
DT   12-FEB-2001  (first entry)
XX
DE   Human c-myc epitope and His6 tag peptide.
XX
KW   Human; beta-2-microglobulin; beta2M; C17;
KW   haemopoietic stem/precursor cell; HSPC; mesenchymal stem cell division;
KW   DNA fingerprinting; bone disease; c-myc epitope; His6.
XX
OS   Homo sapiens.
XX
PN   WO200063382-A1.
XX
PD   26-OCT-2000.
XX
PF   14-APR-2000; 2000WO-US009904.
XX
PR   15-APR-1999;   99US-0129463P.
XX
PA   (OSIR-) OSIRIS THERAPEUTICS INC.
XX
PI   Liu X,  Cheng L;
XX
DR   WPI; 2000-647518/62.
XX
PT   New isolated nucleic acid encoding a human hematopoietic stem/precursor
PT   cell polypeptide called C17, for increasing the rate of multiplication of
PT   mesenchymal stem cells in vitro and for chromosome mapping and DNA
PT   fingerprinting.
XX
PS   Example 4; Page 42; 68pp; English.
XX
CC   The present sequence was used in a method for the isolation of a human
CC   haematopoietic stem/precursor cell (hHSPC) polypeptide called C17. The
CC   C17 polynucleotide may be used to increase the rate of multiplication of
CC   human mesenchymal stem cells in vitro and to determine the presence of
CC   growth-stimulating receptors on the surface of a cell. The C17
CC   polypeptide may be used to generate polyclonal sera or monoclonal
CC   antibodies specific for C17. The polynucleotide is used as a marker for
CC   chromosome mapping and DNA fingerprinting. It is also used for detecting
CC   genetic mutations in order to diagnose diseases, such as those affecting
CC   bone formation
XX
SQ   Sequence 31 AA;

  Query Match             28.9%;  Score 28;  DB 3;  Length 31;
  Best Local Similarity   29.4%;  Pred. No. 1.9e+03;
  Matches    5;  Conservative    7;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKIVSQE 17
              :|: : | :  |::|:|
Db          2 DPSSVPSFLEQKLISEE 18


RESULT 241
AAG08759
ID   AAG08759 standard; protein; 31 AA.
XX
AC   AAG08759;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Arabidopsis thaliana protein fragment SEQ ID NO: 6423.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence.
XX
OS   Arabidopsis thaliana.
XX
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-00301439.
XX
PR   25-FEB-1999;   99US-0121825P.
PR   05-MAR-1999;   99US-0123180P.
PR   09-MAR-1999;   99US-0123548P.
PR   23-MAR-1999;   99US-0125788P.
PR   25-MAR-1999;   99US-0126264P.
PR   29-MAR-1999;   99US-0126785P.
PR   01-APR-1999;   99US-0127462P.
PR   06-APR-1999;   99US-0128234P.
PR   08-APR-1999;   99US-0128714P.
PR   16-APR-1999;   99US-0129845P.
PR   19-APR-1999;   99US-0130077P.
PR   21-APR-1999;   99US-0130449P.
PR   23-APR-1999;   99US-0130510P.
PR   23-APR-1999;   99US-0130891P.
PR   28-APR-1999;   99US-0131449P.
PR   30-APR-1999;   99US-0132048P.
PR   30-APR-1999;   99US-0132407P.
PR   04-MAY-1999;   99US-0132484P.
PR   05-MAY-1999;   99US-0132485P.
PR   06-MAY-1999;   99US-0132486P.
PR   06-MAY-1999;   99US-0132487P.
PR   07-MAY-1999;   99US-0132863P.
PR   11-MAY-1999;   99US-0134256P.
PR   14-MAY-1999;   99US-0134218P.
PR   14-MAY-1999;   99US-0134219P.
PR   14-MAY-1999;   99US-0134221P.
PR   14-MAY-1999;   99US-0134370P.
PR   18-MAY-1999;   99US-0134768P.
PR   19-MAY-1999;   99US-0134941P.
PR   20-MAY-1999;   99US-0135124P.
PR   21-MAY-1999;   99US-0135353P.
PR   24-MAY-1999;   99US-0135629P.
PR   25-MAY-1999;   99US-0136021P.
PR   27-MAY-1999;   99US-0136392P.
PR   28-MAY-1999;   99US-0136782P.
PR   01-JUN-1999;   99US-0137222P.
PR   03-JUN-1999;   99US-0137528P.
PR   04-JUN-1999;   99US-0137502P.
PR   07-JUN-1999;   99US-0137724P.
PR   08-JUN-1999;   99US-0138094P.
PR   10-JUN-1999;   99US-0138540P.
PR   10-JUN-1999;   99US-0138847P.
PR   14-JUN-1999;   99US-0139119P.
PR   16-JUN-1999;   99US-0139452P.
PR   16-JUN-1999;   99US-0139453P.
PR   17-JUN-1999;   99US-0139492P.
PR   18-JUN-1999;   99US-0139454P.
PR   18-JUN-1999;   99US-0139455P.
PR   18-JUN-1999;   99US-0139456P.
PR   18-JUN-1999;   99US-0139457P.
```

PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.
PR 27-AUG-1999; 99US-0151066P.
PR 27-AUG-1999; 99US-0151080P.
PR 30-AUG-1999; 99US-0151303P.
PR 31-AUG-1999; 99US-0151438P.
PR 01-SEP-1999; 99US-0151930P.
PR 07-SEP-1999; 99US-0152363P.
PR 10-SEP-1999; 99US-0153070P.
PR 13-SEP-1999; 99US-0153758P.
PR 15-SEP-1999; 99US-0154018P.
PR 16-SEP-1999; 99US-0154039P.
PR 20-SEP-1999; 99US-0154779P.
PR 22-SEP-1999; 99US-0155139P.
PR 23-SEP-1999; 99US-0155486P.
PR 24-SEP-1999; 99US-0155659P.
PR 28-SEP-1999; 99US-0156458P.
PR 29-SEP-1999; 99US-0156596P.
PR 04-OCT-1999; 99US-0157117P.
PR 05-OCT-1999; 99US-0157753P.
PR 06-OCT-1999; 99US-0157865P.
PR 07-OCT-1999; 99US-0158029P.
PR 08-OCT-1999; 99US-0158232P.
PR 12-OCT-1999; 99US-0158369P.
PR 13-OCT-1999; 99US-0159293P.
PR 13-OCT-1999; 99US-0159294P.
PR 13-OCT-1999; 99US-0159295P.
PR 14-OCT-1999; 99US-0159329P.
PR 14-OCT-1999; 99US-0159330P.
PR 14-OCT-1999; 99US-0159331P.
PR 14-OCT-1999; 99US-0159637P.
PR 14-OCT-1999; 99US-0159638P.
PR 18-OCT-1999; 99US-0159584P.
PR 21-OCT-1999; 99US-0160741P.
PR 21-OCT-1999; 99US-0160767P.
PR 21-OCT-1999; 99US-0160768P.
PR 21-OCT-1999; 99US-0160770P.
PR 21-OCT-1999; 99US-0160814P.
PR 21-OCT-1999; 99US-0160815P.
PR 22-OCT-1999; 99US-0160980P.
PR 22-OCT-1999; 99US-0160981P.
PR 22-OCT-1999; 99US-0160989P.
PR 25-OCT-1999; 99US-0161404P.
PR 25-OCT-1999; 99US-0161405P.
PR 25-OCT-1999; 99US-0161406P.
PR 26-OCT-1999; 99US-0161359P.
PR 26-OCT-1999; 99US-0161360P.
PR 26-OCT-1999; 99US-0161361P.
PR 28-OCT-1999; 99US-0161920P.
PR 28-OCT-1999; 99US-0161992P.
PR 28-OCT-1999; 99US-0161993P.
PR 29-OCT-1999; 99US-0162142P.

Query Match 28.9%; Score 28; DB 3; Length 31;
Best Local Similarity 35.7%; Pred. No. 1.9e+03;
Matches 5; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

```
Qy          6 NSKIAFKIVSQEPA 19
              || :: | ::: ||
Db          4 NSPLSIKALTRGPA 17
```

RESULT 242
ABU02095
ID ABU02095 standard; protein; 34 AA.
XX
AC ABU02095;
XX

```
DT   23-OCT-2003  (revised)
DT   11-FEB-2003  (first entry)
XX
DE   S. pneumoniae type 4 strain protein from coding region #1672.
XX
KW   Bacterial meningitis; pneumonia; sepsis; otitis media; ear infection;
KW   antiinflammatory; antibacterial; immunostimulant; auditory; respiratory;
KW   gene therapy; vaccine.
XX
OS   Streptococcus pneumoniae; type 4 strain.
XX
PN   WO200277021-A2.
XX
PD   03-OCT-2002.
XX
PF   27-MAR-2002; 2002WO-IB002163.
XX
PR   27-MAR-2001; 2001GB-00007658.
XX
PA   (CHIR-) CHIRON SPA.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Masignani V, Tettelin H, Fraser C;
XX
DR   WPI; 2003-040579/03.
DR   N-PSDB; ABX07384.
XX
PT   New proteins and nucleic acid molecules from Streptococcus pneumoniae,
PT   useful as medicaments for treating or preventing a disease or infection
PT   due to streptococcus bacteria, such as pneumonia, sepsis, otitis media or
PT   ear infection.
XX
PS   Claim 1; SEQ ID NO 3344; 56pp; English.
XX
CC   The invention relates to a protein comprising or having at least 50%
CC   identity to any of the 2469 amino acid sequences, identified in the
CC   specification (available on a computer readable format), or its fragment,
CC   expressed from 2469 of 2489 identified DNA coding regions from the
CC   Streptococcus pneumoniae type 4 strain genomic sequence appearing as
CC   ABS56454. Also included are an antibody which binds one of the proteins,
CC   treating a patient by administering the protein, DNA or antibody (in a
CC   composition), a kit comprising first and second primers, which are the
CC   nucleic acid cited above or fragments between nucleotides 8-100 of a
CC   sequence not defined in the specification, for amplifying a target
CC   sequence contained within a Streptococcus nucleic acid sequence, where
CC   the first primer is substantially complementary to the target sequence
CC   and the second primer is substantially complementary to the complement of
CC   the target sequence, and where the parts of the primers having
CC   substantial complementarity define the termini of the target sequence to
CC   be amplified, assay comprising contacting a test compound with the
CC   protein, and determining whether the test compound binds to the protein
CC   and a Streptococcus pneumoniae bacterium, where one or more genes
CC   encoding the proteins has been rendered inactive. The proteins, nucleic
CC   acid molecules, antibody and compositions are useful as medicaments for
CC   treating or preventing a disease or infection due to streptococcus
CC   bacteria, particularly S. pneumoniae, such as pneumonia, sepsis, otitis
CC   media or ear infection. They are also useful in developing vaccines,
CC   diagnostics and antibiotics. The methods are useful for identifying
CC   immunodominant proteins. The present sequence is one of the 2469 proteins
CC   expressed by the identified coding regions from the genomic sequence.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences. (Updated on 23-OCT-2003 to
CC   standardise OS field)
XX
SQ   Sequence 34 AA;

  Query Match             28.9%;  Score 28;  DB 6;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 2.1e+03;
  Matches    6;  Conservative    3;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIVSQEP 18
              |:  |:  | :|| |
Db         20 HILQKMKNKKLSQNP 34


RESULT 243
AAW30501
ID   AAW30501 standard; peptide; 37 AA.
XX
AC   AAW30501;
XX
DT   26-OCT-1998  (first entry)
XX
DE   DP-1 transcription factor peptide H (DEF box).
XX
KW   DP-1; transcription factor; antagonist; E2F protein; apoptosis;
KW   cell proliferation; cardiovascular cell; restenosis; tumour;
KW   surgical stent; therapy.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9828334-A1.
XX
PD   02-JUL-1998.
XX
PF   22-DEC-1997;   97WO-GB003506.
XX
PR   20-DEC-1996;   96GB-00026589.
XX
PA   (PROL-) PROLIFIX LTD.
XX
PI   La Thangue NB,  Bandara LR;
XX
DR   WPI; 1998-377596/32.
XX
PT   Polypeptide fragments of the DP-1 transcription factor - used for
PT   inducing apoptosis, specifically in tumour and cardiovascular cells, e.g.
PT   for preventing re-stenosis.
XX
PS   Claim 1; Page 44; 55pp; English.
XX
CC   Peptide H (I) comprises residues 163-199, i.e. the DEF box region, of
CC   transcription factor DP1. Claimed fragments (II) (see AAW30502-07) of (I)
CC   are capable of antagonising the heterodimerisation of a DP protein with
CC   an E2F protein. Also claimed are fusion proteins (III) comprising (I) or
CC   (II) and a membrane translocation sequence (see AAW30508), expression
CC   vectors encoding (I)-(III) and host cells. (I)-(III) are used
CC   therapeutically to induce apoptosis, specifically in tumour or
CC   cardiovascular cells, either in vivo or in vitro, e.g. for purging bone
CC   marrow. Surgical stents comprising (I)-(III) are used to treat or prevent
CC   restenosis in patients who have undergone angioplasty. (I)-(III) function
CC   by inactivating the DNA-binding activity of DP/E2F heterodimers. They are
CC   also used as research reagents, as positive controls in assays for
CC   identifying antagonists of DP-1/E2F dimerisation and as immunoassay
CC   agents. Also described is the use of sequences antisense to nucleic acids
CC   encoding (I)-(III) to control DP levels in cells, particularly by gene
CC   therapy. When formulated with cytotoxic or cytostatic agents, (I)-(III)
CC   enhance cell killing
XX
SQ   Sequence 37 AA;

  Query Match             28.9%;  Score 28;  DB 2;  Length 37;
  Best Local Similarity   46.2%;  Pred. No. 2.3e+03;
  Matches    6;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQE 17
              ||  :|  |:|:|
Db         11 LNVLMAMNIISKE 23


RESULT 244
AAR58093
ID   AAR58093 standard; peptide; 38 AA.
XX
```

AC AAR58093;
XX
DT 20-SEP-1994 (first entry)
XX
DE [Asn13]-hPTH(1-38)-OH.
XX
KW Human parathyroid hormone; hPTH; variant; analogue; calcium; depletion;
KW fixation; resorption; osteopathy; osteoporosis; hypoparathyroidism.
XX
OS Synthetic.
XX
PN GB2269176-A.
XX
PD 02-FEB-1994.
XX
PF 12-JUL-1993; 93GB-00014384.
XX
PR 15-JUL-1992; 92GB-00015009.
PR 18-DEC-1992; 92GB-00026415.
PR 23-DEC-1992; 92GB-00026859.
PR 23-DEC-1992; 92GB-00026861.
PR 28-JAN-1993; 93GB-00001691.
PR 28-JAN-1993; 93GB-00001692.
PR 14-APR-1993; 93GB-00007673.
PR 19-APR-1993; 93GB-00008033.
XX
PA (SANO) SANDOZ LTD.
XX
PI Lewis I, Schneider H, Waelchli R, Rainer A;
XX
DR WPI; 1994-018352/03.
XX
PT New active para-thyroid hormone variants - used for treating or
PT preventing osteoporosis etc.
XX
PS Example 90; Page 38; 92pp; English.
XX
CC This peptide is an example of a highly generic formula covering
CC parathyroid hormone variants useful for treating or preventing bone
CC conditions associated with calcium depletion/resorption, in cases where
CC calcium fixation is required (esp. osteoporosis) or to treat
CC hypoparathyroidism
XX
SQ Sequence 38 AA;

Query Match 28.9%; Score 28; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 2.4e+03;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 NHLNS 7
|||||
Db 13 NHLNS 17

RESULT 245
AAY13001
ID AAY13001 standard; protein; 38 AA.
XX
AC AAY13001;
XX
DT 22-JUN-1999 (first entry)
XX
DE Human secreted protein encoded by 5' EST SEQ ID NO: 15.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS Homo sapiens.
XX
PN WO9906552-A2.
XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB001236.
XX
PR 01-AUG-1997; 97US-00905223.
XX
PA (GEST) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Lacroix B;
XX
DR WPI; 1999-153782/13.
DR N-PSDB; AAX51801.
XX
PT New isolated brain-derived nucleic acids - used to develop products which
PT may have cytokine, immune, regulatory, haematopoiesis regulating, anti-
PT inflammatory or tumour inhibition activity.
XX
PS Claim 34; Page 444; 577pp; English.
XX
CC AAX51787 to AAX52019 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins, and encode the proteins given in AAY12987 to
CC AAY13219, respectively. The proteins given represent the signal peptide
CC and an N-terminal fragment of a secreted protein. The nucleic acid
CC sequences can be used for producing secreted human gene products. They
CC can also be used to develop products for diagnosis and therapy. The
CC proteins obtained may have cytokine activity, cell
CC proliferation/differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/ chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptide can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell
XX
SQ Sequence 38 AA;

Query Match 28.9%; Score 28; DB 2; Length 38;
Best Local Similarity 66.7%; Pred. No. 2.4e+03;
Matches 4; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 PNHLNS 7
|:|:||
Db 24 PSHINS 29

RESULT 246
AAM15186
ID AAM15186 standard; protein; 38 AA.
XX
AC AAM15186;
XX
DT 12-OCT-2001 (first entry)
XX
DE Peptide #1620 encoded by probe for measuring cervical gene expression.
XX
KW Probe; human; microarray; gene expression; cervical epithelial cell;
KW cervical cancer.
XX
OS Homo sapiens.
XX
PN WO200157278-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000670.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.

PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488901/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human cervical epithelial cells.
XX
PS Claim 27; SEQ ID NO 20012; 487pp; English.
XX
CC The present invention relates to human single exon nucleic acid probes
CC (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC can be used to produce a single exon microarray, which can be used for
CC measuring human gene expression in a sample derived from human cervical
CC epithelial cells. By measuring gene expression, the probes are therefore
CC useful in grading and/or staging of diseases of the cervix, notably
CC cervical cancer. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 38 AA;

Query Match 28.9%; Score 28; DB 4; Length 38;
Best Local Similarity 50.0%; Pred. No. 2.4e+03;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAF 11
||| | : :|
Db 23 PNHDNKQQSF 32

RESULT 247
ABB34179
ID ABB34179 standard; peptide; 38 AA.
XX
AC ABB34179;
XX
DT 04-FEB-2002 (first entry)
XX
DE Peptide #1685 encoded by human foetal liver single exon probe.
XX
KW Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000669.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human fetal liver.
XX
PS Claim 27; SEQ ID NO 26814; 639pp + Sequence Listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for measuring
CC human gene expression in a sample derived from human foetal liver. The
CC single exon nucleic acid probes may be used for predicting, measuring and
CC displaying gene expression in samples derived from human fetal liver. The
CC present sequence is a peptide encoded by a single exon nucleic acid probe
CC of the invention. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 38 AA;

Query Match 28.9%; Score 28; DB 4; Length 38;
Best Local Similarity 50.0%; Pred. No. 2.4e+03;
Matches 5; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAF 11
||| | : :|
Db 23 PNHDNKQQSF 32

RESULT 248
AAM27645
ID AAM27645 standard; protein; 38 AA.
XX
AC AAM27645;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #1682 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
KW genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 27; SEQ ID NO 27914; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders
XX
SQ Sequence 38 AA;

```
  Query Match             28.9%;  Score 28;  DB 4;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 2.4e+03;
  Matches    5;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              |||  |  : :|
Db         23 PNHDNKQQSF 32
```

```
RESULT 249
ABB29012
ID   ABB29012 standard; peptide; 38 AA.
XX
AC   ABB29012;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Peptide #1663 encoded by breast cell single exon nucleic acid probe.
XX
KW   Human; microarray; single exon probe; gene expression; breast; disease;
KW   cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157271-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000662.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-496933/54.
XX
PT   New spatially-addressable set of single exon nucleic acid probes, useful
PT   for measuring gene expression in sample derived from human breast,
PT   comprises number of single exon nucleic acid probes.
XX
PS   Claim 27; SEQ ID NO 11980; 327pp + Sequence Listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting the
CC   probes with a collection of detectably labelled nucleic acids derived
CC   from mRNA of human breast, and then measuring the label bound to each
CC   probe of the microarray. The probes are useful for verifying the
CC   expression of regions of genomic DNA predicted to encode proteins. They
CC   are useful for gene discovery, and for determining predisposition and/or
CC   prognosing breast disease. Gene expression analysis is useful for
CC   assessing the toxicity of chemical agents on cells. The microarray of
CC   this invention presents a far greater diversity of probes for measuring
CC   gene expression, with far less bias than expressed sequence tag
CC   microarrays. The method is suitable for rapid production of functional
CC   information from genomic sequence. The present sequence is a peptide
CC   encoded by a single exon nucleic acid probe of the invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 38 AA;
```

```
  Query Match             28.9%;  Score 28;  DB 4;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 2.4e+03;
  Matches    5;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              |||  |  : :|
Db         23 PNHDNKQQSF 32
```

```
RESULT 250
ABB19620
ID   ABB19620 standard; protein; 38 AA.
XX
AC   ABB19620;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #1619 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000666.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts.
XX
PS   Claim 15; SEQ ID NO 21390; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart (see
CC   ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC   probe. The probes may be used for predicting, measuring and displaying
CC   gene expression in samples derived from the human heart via microarrays.
CC   By measuring gene expression, the probes are useful for predicting,
CC   diagnosing, grading, staging, monitoring and prognosing diseases of the
CC   human heart and vascular system e.g. cardiovascular disease,
CC   hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 38 AA;
```

```
  Query Match             28.9%;  Score 28;  DB 4;  Length 38;
  Best Local Similarity   50.0%;  Pred. No. 2.4e+03;
  Matches    5;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              |||  |  : :|
Db         23 PNHDNKQQSF 32
```

Search completed: October 19, 2004, 19:10:33
Job time : 190 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: October 19, 2004, 19:13:59 ; Search time 128 Seconds
(without alignments)
47.993 Million cell updates/sec

Title: US-10-799-005A-1
Perfect score: 97
Sequence: 1 EPNHLNSKIAFKIVSQEPA 19

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1360919 seqs, 323318874 residues

Total number of hits satisfying chosen parameters: 132574

Minimum DB seq length: 19
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 500 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/1/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/1/pubpaa/US10D_PUBCOMB.pep:*
17: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
18: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep:*
19: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	38	39.2	22	14	US-10-376-121A-55	Sequence 55, Appl
2	38	39.2	39	15	US-10-424-599-261716	Sequence 261716,
3	37	38.1	42	15	US-10-424-599-155906	Sequence 155906,
4	36	37.1	50	15	US-10-424-599-283885	Sequence 283885,
5	35	36.1	38	15	US-10-424-599-223392	Sequence 223392,
6	35	36.1	44	15	US-10-424-599-234416	Sequence 234416,
7	34	35.1	38	15	US-10-424-599-185636	Sequence 185636,
8	34	35.1	50	15	US-10-424-599-257987	Sequence 257987,
9	33	34.0	26	9	US-09-864-761-43939	Sequence 43939, A
10	33	34.0	35	15	US-10-424-599-144376	Sequence 144376,
11	33	34.0	38	16	US-10-437-963-164005	Sequence 164005,
12	33	34.0	39	15	US-10-424-599-208257	Sequence 208257,
13	33	34.0	46	15	US-10-424-599-199633	Sequence 199633,
14	33	34.0	49	15	US-10-424-599-187478	Sequence 187478,
15	32.5	33.5	36	9	US-09-864-761-35774	Sequence 35774, A
16	32	33.0	27	15	US-10-424-599-267189	Sequence 267189,
17	32	33.0	43	15	US-10-425-114-68647	Sequence 68647, A
18	32	33.0	43	16	US-10-437-963-131784	Sequence 131784,
19	32	33.0	45	15	US-10-424-599-245137	Sequence 245137,
20	32	33.0	47	15	US-10-424-599-250836	Sequence 250836,
21	32	33.0	48	9	US-09-864-761-33571	Sequence 33571, A
22	31.5	32.5	47	15	US-10-424-599-233753	Sequence 233753,
23	31	32.0	21	14	US-10-084-813-333	Sequence 333, App
24	31	32.0	21	14	US-10-084-813-334	Sequence 334, App
25	31	32.0	30	16	US-10-437-963-150845	Sequence 150845,
26	31	32.0	33	11	US-09-801-348-29	Sequence 29, Appl
27	31	32.0	34	10	US-09-764-891-4356	Sequence 4356, Ap
28	31	32.0	34	14	US-10-062-831-72	Sequence 72, Appl
29	31	32.0	34	14	US-10-205-428-383	Sequence 383, App
30	31	32.0	34	14	US-10-062-599-72	Sequence 72, Appl
31	31	32.0	42	15	US-10-424-599-227023	Sequence 227023,
32	31	32.0	43	14	US-10-029-386-33676	Sequence 33676, A
33	31	32.0	44	9	US-09-864-761-41924	Sequence 41924, A
34	31	32.0	46	15	US-10-424-599-181955	Sequence 181955,
35	31	32.0	47	11	US-09-984-429-87	Sequence 87, Appl
36	31	32.0	47	14	US-10-393-840-84	Sequence 84, Appl
37	31	32.0	47	15	US-10-424-599-223920	Sequence 223920,
38	31	32.0	48	14	US-10-150-111-87	Sequence 87, Appl
39	31	32.0	48	15	US-10-424-599-156398	Sequence 156398,
40	31	32.0	50	9	US-09-764-860-359	Sequence 359, App
41	31	32.0	50	14	US-10-074-095-359	Sequence 359, App
42	31	32.0	50	14	US-10-212-872-359	Sequence 359, App
43	31	32.0	50	15	US-10-424-599-181551	Sequence 181551,
44	31	32.0	50	16	US-10-767-701-52857	Sequence 52857, A
45	30.5	31.4	19	14	US-10-153-344-10	Sequence 10, Appl
46	30.5	31.4	37	15	US-10-424-599-212560	Sequence 212560,
47	30.5	31.4	40	15	US-10-282-122A-71852	Sequence 71852, A
48	30.5	31.4	40	15	US-10-424-599-144936	Sequence 144936,
49	30	30.9	25	14	US-10-139-794-103	Sequence 103, App
50	30	30.9	26	9	US-09-864-761-48976	Sequence 48976, A
51	30	30.9	27	10	US-09-933-767-898	Sequence 898, App
52	30	30.9	27	10	US-09-933-767-899	Sequence 899, App
53	30	30.9	27	14	US-10-004-860-898	Sequence 898, App
54	30	30.9	27	14	US-10-004-860-899	Sequence 899, App
55	30	30.9	27	14	US-10-023-282-898	Sequence 898, App
56	30	30.9	27	14	US-10-023-282-899	Sequence 899, App
57	30	30.9	30	9	US-09-995-494-87	Sequence 87, Appl
58	30	30.9	30	14	US-10-011-585A-181	Sequence 181, App
59	30	30.9	30	15	US-10-424-599-207820	Sequence 207820,
60	30	30.9	30	15	US-10-296-734-654	Sequence 654, App
61	30	30.9	30	15	US-10-296-734-656	Sequence 656, App
62	30	30.9	31	14	US-10-050-704-215	Sequence 215, App
63	30	30.9	31	16	US-10-798-512-215	Sequence 215, App
64	30	30.9	32	14	US-10-106-698-5968	Sequence 5968, Ap
65	30	30.9	33	14	US-10-300-083-13	Sequence 13, Appl
66	30	30.9	34	15	US-10-424-599-154283	Sequence 154283,
67	30	30.9	36	16	US-10-437-963-139274	Sequence 139274,
68	30	30.9	36	16	US-10-437-963-176739	Sequence 176739,
69	30	30.9	39	10	US-09-809-391-545	Sequence 545, App
70	30	30.9	39	10	US-09-882-171-545	Sequence 545, App
71	30	30.9	39	10	US-09-962-756-202	Sequence 202, App
72	30	30.9	39	14	US-10-132-585-4	Sequence 4, Appli
73	30	30.9	39	14	US-10-106-698-5006	Sequence 5006, Ap
74	30	30.9	39	14	US-10-164-861-545	Sequence 545, App
75	30	30.9	39	14	US-10-253-471-202	Sequence 202, App
76	30	30.9	39	15	US-10-253-493-202	Sequence 202, App
77	30	30.9	40	10	US-09-809-391-381	Sequence 381, App
78	30	30.9	40	10	US-09-882-171-381	Sequence 381, App
79	30	30.9	40	14	US-10-144-259-29	Sequence 29, Appl
80	30	30.9	40	14	US-10-164-861-381	Sequence 381, App
81	30	30.9	40	15	US-10-424-599-267336	Sequence 267336,
82	30	30.9	44	15	US-10-424-599-278809	Sequence 278809,
83	30	30.9	44	16	US-10-437-963-154105	Sequence 154105,
84	30	30.9	45	15	US-10-424-599-228808	Sequence 228808,
85	30	30.9	46	9	US-09-764-877-1428	Sequence 1428, Ap
86	30	30.9	46	15	US-10-242-515-1428	Sequence 1428, Ap
87	30	30.9	47	15	US-10-424-599-264089	Sequence 264089,

88	30	30.9	48	15	US-10-424-599-208160	Sequence 208160,
89	30	30.9	48	15	US-10-424-599-264585	Sequence 264585,
90	30	30.9	49	15	US-10-424-599-231764	Sequence 231764,
91	30	30.9	49	15	US-10-424-599-239689	Sequence 239689,
92	30	30.9	49	15	US-10-424-599-244508	Sequence 244508,
93	30	30.9	49	16	US-10-437-963-134140	Sequence 134140,
94	30	30.9	50	11	US-09-864-408A-4082	Sequence 4082, Ap
95	30	30.9	50	16	US-10-437-963-125237	Sequence 125237,
96	29	29.9	24	14	US-10-164-359-12	Sequence 12, Appl
97	29	29.9	24	14	US-10-413-785-6	Sequence 6, Appli
98	29	29.9	26	16	US-10-437-963-177203	Sequence 177203,
99	29	29.9	28	9	US-09-864-761-40576	Sequence 40576, A
100	29	29.9	28	9	US-09-982-172-128	Sequence 128, App
101	29	29.9	32	14	US-10-029-386-29166	Sequence 29166, A
102	29	29.9	33	10	US-09-764-891-4901	Sequence 4901, Ap
103	29	29.9	33	14	US-10-091-414-161	Sequence 161, App
104	29	29.9	33	14	US-10-413-785-4	Sequence 4, Appli
105	29	29.9	34	14	US-10-351-641-1670	Sequence 1670, Ap
106	29	29.9	34	14	US-10-351-641-1671	Sequence 1671, Ap
107	29	29.9	34	14	US-10-351-641-1672	Sequence 1672, Ap
108	29	29.9	34	16	US-10-437-963-179203	Sequence 179203,
109	29	29.9	37	10	US-09-820-649-195	Sequence 195, App
110	29	29.9	37	14	US-10-160-162-195	Sequence 195, App
111	29	29.9	37	16	US-10-437-963-107393	Sequence 107393,
112	29	29.9	38	9	US-09-250-883-21	Sequence 21, Appl
113	29	29.9	39	9	US-09-925-299-1490	Sequence 1490, Ap
114	29	29.9	39	9	US-09-071-838-175	Sequence 175, App
115	29	29.9	39	10	US-09-925-299-1490	Sequence 1490, Ap
116	29	29.9	39	14	US-10-213-512-175	Sequence 175, App
117	29	29.9	39	15	US-10-424-599-282214	Sequence 282214,
118	29	29.9	40	14	US-10-029-386-29136	Sequence 29136, A
119	29	29.9	41	14	US-10-029-386-33231	Sequence 33231, A
120	29	29.9	41	16	US-10-437-963-140191	Sequence 140191,
121	29	29.9	42	15	US-10-424-599-238139	Sequence 238139,
122	29	29.9	42	15	US-10-424-599-271865	Sequence 271865,
123	29	29.9	43	16	US-10-437-963-151559	Sequence 151559,
124	29	29.9	44	9	US-09-989-919-94	Sequence 94, Appl
125	29	29.9	44	15	US-10-424-599-221932	Sequence 221932,
126	29	29.9	45	16	US-10-437-963-124421	Sequence 124421,
127	29	29.9	46	10	US-09-933-767-340	Sequence 340, App
128	29	29.9	46	14	US-10-004-860-340	Sequence 340, App
129	29	29.9	46	14	US-10-023-282-340	Sequence 340, App
130	29	29.9	46	15	US-10-424-599-143969	Sequence 143969,
131	29	29.9	46	15	US-10-424-599-194850	Sequence 194850,
132	29	29.9	46	15	US-10-424-599-196352	Sequence 196352,
133	29	29.9	47	14	US-10-029-386-28419	Sequence 28419, A
134	29	29.9	47	15	US-10-424-599-162168	Sequence 162168,
135	29	29.9	47	15	US-10-424-599-166629	Sequence 166629,
136	29	29.9	47	16	US-10-767-701-54392	Sequence 54392, A
137	29	29.9	48	9	US-09-925-302-577	Sequence 577, App
138	29	29.9	48	10	US-09-925-302-577	Sequence 577, App
139	29	29.9	48	14	US-10-106-698-4429	Sequence 4429, Ap
140	29	29.9	48	15	US-10-424-599-232693	Sequence 232693,
141	29	29.9	49	15	US-10-424-599-155980	Sequence 155980,
142	29	29.9	49	15	US-10-424-599-270499	Sequence 270499,
143	29	29.9	50	10	US-09-820-649-221	Sequence 221, App
144	29	29.9	50	14	US-10-160-162-221	Sequence 221, App
145	28.5	29.4	30	9	US-09-864-761-47206	Sequence 47206, A
146	28.5	29.4	33	15	US-10-424-599-147555	Sequence 147555,
147	28.5	29.4	39	15	US-10-424-599-210402	Sequence 210402,
148	28.5	29.4	43	16	US-10-437-963-154010	Sequence 154010,
149	28	28.9	19	9	US-09-864-761-44631	Sequence 44631, A
150	28	28.9	22	9	US-09-982-172-55	Sequence 55, Appl
151	28	28.9	22	14	US-10-242-056-70	Sequence 70, Appl
152	28	28.9	22	14	US-10-262-794A-70	Sequence 70, Appl
153	28	28.9	23	9	US-09-864-761-34851	Sequence 34851, A
154	28	28.9	23	14	US-10-097-065-263	Sequence 263, App
155	28	28.9	23	14	US-10-372-876-263	Sequence 263, App
156	28	28.9	24	9	US-09-864-761-49103	Sequence 49103, A
157	28	28.9	24	14	US-10-106-698-7023	Sequence 7023, Ap
158	28	28.9	24	15	US-10-424-599-167867	Sequence 167867,
159	28	28.9	25	9	US-09-864-761-46865	Sequence 46865, A
160	28	28.9	26	9	US-09-752-723-12	Sequence 12, Appl
161	28	28.9	26	9	US-09-752-723-13	Sequence 13, Appl
162	28	28.9	27	14	US-10-428-254A-39	Sequence 39, Appl
163	28	28.9	29	9	US-09-864-761-41583	Sequence 41583, A
164	28	28.9	29	16	US-10-437-963-145993	Sequence 145993,
165	28	28.9	30	9	US-09-900-147-6	Sequence 6, Appli
166	28	28.9	32	16	US-10-437-963-151427	Sequence 151427,
167	28	28.9	34	9	US-09-971-980-49	Sequence 49, Appl
168	28	28.9	34	15	US-10-424-599-227024	Sequence 227024,
169	28	28.9	35	15	US-10-424-599-238675	Sequence 238675,
170	28	28.9	36	15	US-10-424-599-201942	Sequence 201942,
171	28	28.9	37	9	US-09-900-147-1	Sequence 1, Appli
172	28	28.9	37	15	US-10-424-599-246064	Sequence 246064,
173	28	28.9	37	16	US-10-437-963-167974	Sequence 167974,
174	28	28.9	38	9	US-09-864-761-34918	Sequence 34918, A
175	28	28.9	38	14	US-10-144-929-247	Sequence 247, App
176	28	28.9	38	15	US-10-144-929-247	Sequence 247, App
177	28	28.9	39	10	US-09-962-756-203	Sequence 203, App
178	28	28.9	39	10	US-09-962-756-220	Sequence 220, App
179	28	28.9	39	14	US-10-253-471-203	Sequence 203, App
180	28	28.9	39	14	US-10-253-471-220	Sequence 220, App
181	28	28.9	39	15	US-10-253-493-203	Sequence 203, App
182	28	28.9	39	15	US-10-253-493-220	Sequence 220, App
183	28	28.9	40	10	US-09-942-024-62	Sequence 62, Appl
184	28	28.9	40	10	US-09-942-098-62	Sequence 62, Appl
185	28	28.9	40	15	US-10-261-161-87	Sequence 87, Appl
186	28	28.9	41	9	US-09-764-869-1048	Sequence 1048, Ap
187	28	28.9	41	14	US-10-091-504-1048	Sequence 1048, Ap
188	28	28.9	41	15	US-10-227-577-1048	Sequence 1048, Ap
189	28	28.9	41	15	US-10-424-599-227706	Sequence 227706,
190	28	28.9	41	16	US-10-437-963-203041	Sequence 203041,
191	28	28.9	42	10	US-09-933-767-557	Sequence 557, App
192	28	28.9	42	14	US-10-004-860-557	Sequence 557, App
193	28	28.9	42	14	US-10-023-282-557	Sequence 557, App
194	28	28.9	43	10	US-09-994-595-40	Sequence 40, Appl
195	28	28.9	44	15	US-10-424-599-165064	Sequence 165064,
196	28	28.9	44	16	US-10-437-963-182095	Sequence 182095,
197	28	28.9	45	10	US-09-764-872-311	Sequence 311, App
198	28	28.9	45	15	US-10-378-029-86	Sequence 86, Appl
199	28	28.9	45	15	US-10-424-599-175974	Sequence 175974,
200	28	28.9	45	15	US-10-424-599-200307	Sequence 200307,
201	28	28.9	45	15	US-10-424-599-213833	Sequence 213833,
202	28	28.9	45	15	US-10-424-599-227298	Sequence 227298,
203	28	28.9	45	15	US-10-424-599-277857	Sequence 277857,
204	28	28.9	46	14	US-10-004-378A-59	Sequence 59, Appl
205	28	28.9	46	15	US-10-424-599-221525	Sequence 221525,
206	28	28.9	46	15	US-10-424-599-254250	Sequence 254250,
207	28	28.9	46	15	US-10-424-599-272996	Sequence 272996,
208	28	28.9	47	9	US-09-864-761-33481	Sequence 33481, A
209	28	28.9	47	14	US-10-106-698-5380	Sequence 5380, Ap
210	28	28.9	47	16	US-10-437-963-161590	Sequence 161590,
211	28	28.9	48	15	US-10-424-599-214433	Sequence 214433,
212	28	28.9	48	15	US-10-424-599-242667	Sequence 242667,
213	28	28.9	48	16	US-10-437-963-113492	Sequence 113492,
214	28	28.9	49	15	US-10-424-599-188532	Sequence 188532,
215	28	28.9	49	15	US-10-424-599-217183	Sequence 217183,
216	28	28.9	49	15	US-10-424-599-224025	Sequence 224025,
217	28	28.9	50	14	US-10-083-357-970	Sequence 970, App
218	28	28.9	50	15	US-10-424-599-188812	Sequence 188812,
219	28	28.9	50	15	US-10-424-599-208956	Sequence 208956,
220	28	28.9	50	16	US-10-437-963-128124	Sequence 128124,
221	28	28.9	50	16	US-10-437-963-160977	Sequence 160977,
222	28	28.9	50	16	US-10-437-963-194803	Sequence 194803,
223	27.5	28.4	41	15	US-10-424-599-209626	Sequence 209626,
224	27.5	28.4	41	15	US-10-424-599-249169	Sequence 249169,
225	27.5	28.4	44	16	US-10-437-963-110359	Sequence 110359,
226	27.5	28.4	45	15	US-10-424-599-163952	Sequence 163952,
227	27.5	28.4	45	15	US-10-424-599-206168	Sequence 206168,
228	27.5	28.4	45	16	US-10-437-963-147299	Sequence 147299,
229	27.5	28.4	50	15	US-10-424-599-232526	Sequence 232526,
230	27	27.8	21	9	US-09-946-175-7	Sequence 7, Appli
231	27	27.8	21	10	US-09-883-343A-12	Sequence 12, Appl
232	27	27.8	21	10	US-09-883-343A-80	Sequence 80, Appl
233	27	27.8	22	13	US-10-097-079-56	Sequence 56, Appl

234	27	27.8	23	9	US-09-925-442-26	Sequence 26, Appl
235	27	27.8	23	9	US-09-925-442-28	Sequence 28, Appl
236	27	27.8	23	13	US-10-097-079-57	Sequence 57, Appl
237	27	27.8	24	10	US-09-994-595-111	Sequence 111, App
238	27	27.8	24	13	US-10-097-079-58	Sequence 58, Appl
239	27	27.8	25	13	US-10-097-079-59	Sequence 59, Appl
240	27	27.8	25	15	US-10-449-831A-45	Sequence 45, Appl
241	27	27.8	26	9	US-09-752-723-3	Sequence 3, Appli
242	27	27.8	26	9	US-09-752-723-10	Sequence 10, Appl
243	27	27.8	26	9	US-09-752-723-11	Sequence 11, Appl
244	27	27.8	26	9	US-09-752-723-14	Sequence 14, Appl
245	27	27.8	26	9	US-09-752-723-19	Sequence 19, Appl
246	27	27.8	26	9	US-09-752-723-20	Sequence 20, Appl
247	27	27.8	26	9	US-09-347-064-14	Sequence 14, Appl
248	27	27.8	26	9	US-09-985-157-3	Sequence 3, Appli
249	27	27.8	26	13	US-10-097-079-60	Sequence 60, Appl
250	27	27.8	26	14	US-10-044-967-3	Sequence 3, Appli
251	27	27.8	27	9	US-09-864-761-33935	Sequence 33935, A
252	27	27.8	27	10	US-09-883-343A-11	Sequence 11, Appl
253	27	27.8	27	13	US-10-097-079-55	Sequence 55, Appl
254	27	27.8	27	13	US-10-097-079-61	Sequence 61, Appl
255	27	27.8	27	14	US-10-403-340-18	Sequence 18, Appl
256	27	27.8	27	15	US-10-424-599-183287	Sequence 183287,
257	27	27.8	27	15	US-10-424-599-275012	Sequence 275012,
258	27	27.8	28	13	US-10-097-079-54	Sequence 54, Appl
259	27	27.8	28	13	US-10-097-079-62	Sequence 62, Appl
260	27	27.8	28	13	US-10-097-079-65	Sequence 65, Appl
261	27	27.8	28	13	US-10-097-079-79	Sequence 79, Appl
262	27	27.8	29	13	US-10-097-079-53	Sequence 53, Appl
263	27	27.8	29	13	US-10-097-079-63	Sequence 63, Appl
264	27	27.8	30	9	US-09-864-761-43586	Sequence 43586, A
265	27	27.8	30	13	US-10-097-079-52	Sequence 52, Appl
266	27	27.8	30	13	US-10-097-079-64	Sequence 64, Appl
267	27	27.8	30	15	US-10-296-734-934	Sequence 934, App
268	27	27.8	31	13	US-10-097-079-3	Sequence 3, Appli
269	27	27.8	31	13	US-10-097-079-4	Sequence 4, Appli
270	27	27.8	31	13	US-10-097-079-5	Sequence 5, Appli
271	27	27.8	31	13	US-10-097-079-6	Sequence 6, Appli
272	27	27.8	31	13	US-10-097-079-7	Sequence 7, Appli
273	27	27.8	31	13	US-10-097-079-8	Sequence 8, Appli
274	27	27.8	31	13	US-10-097-079-9	Sequence 9, Appli
275	27	27.8	31	13	US-10-097-079-10	Sequence 10, Appl
276	27	27.8	31	13	US-10-097-079-11	Sequence 11, Appl
277	27	27.8	31	13	US-10-097-079-12	Sequence 12, Appl
278	27	27.8	31	13	US-10-097-079-13	Sequence 13, Appl
279	27	27.8	31	13	US-10-097-079-14	Sequence 14, Appl
280	27	27.8	31	13	US-10-097-079-15	Sequence 15, Appl
281	27	27.8	31	13	US-10-097-079-20	Sequence 20, Appl
282	27	27.8	31	13	US-10-097-079-21	Sequence 21, Appl
283	27	27.8	31	13	US-10-097-079-22	Sequence 22, Appl
284	27	27.8	31	13	US-10-097-079-23	Sequence 23, Appl
285	27	27.8	31	13	US-10-097-079-24	Sequence 24, Appl
286	27	27.8	31	13	US-10-097-079-25	Sequence 25, Appl
287	27	27.8	31	13	US-10-097-079-26	Sequence 26, Appl
288	27	27.8	31	13	US-10-097-079-27	Sequence 27, Appl
289	27	27.8	31	13	US-10-097-079-28	Sequence 28, Appl
290	27	27.8	31	13	US-10-097-079-29	Sequence 29, Appl
291	27	27.8	31	13	US-10-097-079-30	Sequence 30, Appl
292	27	27.8	31	13	US-10-097-079-31	Sequence 31, Appl
293	27	27.8	31	13	US-10-097-079-36	Sequence 36, Appl
294	27	27.8	31	13	US-10-097-079-37	Sequence 37, Appl
295	27	27.8	31	13	US-10-097-079-38	Sequence 38, Appl
296	27	27.8	31	13	US-10-097-079-39	Sequence 39, Appl
297	27	27.8	31	13	US-10-097-079-40	Sequence 40, Appl
298	27	27.8	31	13	US-10-097-079-41	Sequence 41, Appl
299	27	27.8	31	13	US-10-097-079-50	Sequence 50, Appl
300	27	27.8	31	13	US-10-097-079-74	Sequence 74, Appl
301	27	27.8	31	13	US-10-097-079-81	Sequence 81, Appl
302	27	27.8	31	13	US-10-097-079-82	Sequence 82, Appl
303	27	27.8	31	13	US-10-097-079-83	Sequence 83, Appl
304	27	27.8	31	13	US-10-097-079-84	Sequence 84, Appl
305	27	27.8	31	13	US-10-097-079-85	Sequence 85, Appl
306	27	27.8	31	13	US-10-097-079-86	Sequence 86, Appl
307	27	27.8	31	13	US-10-097-079-87	Sequence 87, Appl
308	27	27.8	31	13	US-10-097-079-88	Sequence 88, Appl
309	27	27.8	32	11	US-09-833-245-330	Sequence 330, App
310	27	27.8	32	16	US-10-437-963-166189	Sequence 166189,
311	27	27.8	33	14	US-10-106-698-8420	Sequence 8420, Ap
312	27	27.8	34	9	US-09-925-299-1467	Sequence 1467, Ap
313	27	27.8	34	9	US-09-764-878-188	Sequence 188, App
314	27	27.8	34	10	US-09-925-299-1467	Sequence 1467, Ap
315	27	27.8	34	13	US-10-097-079-46	Sequence 46, Appl
316	27	27.8	34	14	US-10-079-854-188	Sequence 188, App
317	27	27.8	35	14	US-10-083-357-1226	Sequence 1226, Ap
318	27	27.8	35	14	US-10-351-641-714	Sequence 714, App
319	27	27.8	36	10	US-09-994-595-123	Sequence 123, App
320	27	27.8	36	14	US-10-029-386-28656	Sequence 28656, A
321	27	27.8	36	15	US-10-424-599-169046	Sequence 169046,
322	27	27.8	36	15	US-10-424-599-283590	Sequence 283590,
323	27	27.8	37	16	US-10-767-701-60505	Sequence 60505, A
324	27	27.8	38	10	US-09-820-843A-38	Sequence 38, Appl
325	27	27.8	38	16	US-10-437-963-164859	Sequence 164859,
326	27	27.8	38	16	US-10-437-963-204505	Sequence 204505,
327	27	27.8	39	9	US-09-864-761-48219	Sequence 48219, A
328	27	27.8	39	10	US-09-764-891-4834	Sequence 4834, Ap
329	27	27.8	39	10	US-09-962-756-183	Sequence 183, App
330	27	27.8	39	13	US-10-002-344A-217	Sequence 217, App
331	27	27.8	39	14	US-10-091-572-383	Sequence 383, App
332	27	27.8	39	14	US-10-253-471-183	Sequence 183, App
333	27	27.8	39	15	US-10-253-493-183	Sequence 183, App
334	27	27.8	39	15	US-10-424-599-210762	Sequence 210762,
335	27	27.8	40	14	US-10-044-967-15	Sequence 15, Appl
336	27	27.8	40	15	US-10-424-599-239821	Sequence 239821,
337	27	27.8	41	9	US-09-939-980-290	Sequence 290, App
338	27	27.8	41	15	US-10-424-599-223079	Sequence 223079,
339	27	27.8	41	15	US-10-424-599-235834	Sequence 235834,
340	27	27.8	41	16	US-10-437-963-177601	Sequence 177601,
341	27	27.8	42	9	US-09-864-761-40467	Sequence 40467, A
342	27	27.8	42	15	US-10-424-599-160893	Sequence 160893,
343	27	27.8	42	15	US-10-424-599-232103	Sequence 232103,
344	27	27.8	42	15	US-10-424-599-281552	Sequence 281552,
345	27	27.8	42	16	US-10-437-963-193223	Sequence 193223,
346	27	27.8	42	16	US-10-437-963-202185	Sequence 202185,
347	27	27.8	43	14	US-10-321-857-101	Sequence 101, App
348	27	27.8	43	14	US-10-318-675-101	Sequence 101, App
349	27	27.8	43	15	US-10-424-599-161900	Sequence 161900,
350	27	27.8	43	15	US-10-424-599-215316	Sequence 215316,
351	27	27.8	43	15	US-10-424-599-218865	Sequence 218865,
352	27	27.8	43	16	US-10-437-963-191091	Sequence 191091,
353	27	27.8	44	9	US-09-864-761-34932	Sequence 34932, A
354	27	27.8	44	16	US-10-437-963-115350	Sequence 115350,
355	27	27.8	44	16	US-10-437-963-182200	Sequence 182200,
356	27	27.8	46	9	US-09-864-761-34336	Sequence 34336, A
357	27	27.8	47	9	US-09-864-761-42909	Sequence 42909, A
358	27	27.8	47	14	US-10-172-088-15	Sequence 15, Appl
359	27	27.8	47	14	US-10-080-505-18	Sequence 18, Appl
360	27	27.8	47	15	US-10-424-599-188562	Sequence 188562,
361	27	27.8	47	15	US-10-424-599-277798	Sequence 277798,
362	27	27.8	47	16	US-10-437-963-181528	Sequence 181528,
363	27	27.8	47	16	US-10-687-046-18	Sequence 18, Appl
364	27	27.8	48	9	US-09-864-761-45286	Sequence 45286, A
365	27	27.8	48	15	US-10-424-599-151612	Sequence 151612,
366	27	27.8	48	15	US-10-424-599-188994	Sequence 188994,
367	27	27.8	48	15	US-10-424-599-284006	Sequence 284006,
368	27	27.8	48	16	US-10-437-963-109710	Sequence 109710,
369	27	27.8	48	16	US-10-437-963-157793	Sequence 157793,
370	27	27.8	49	9	US-09-925-299-1268	Sequence 1268, Ap
371	27	27.8	49	9	US-09-975-143-37	Sequence 37, Appl
372	27	27.8	49	10	US-09-925-299-1268	Sequence 1268, Ap
373	27	27.8	49	15	US-10-424-599-150751	Sequence 150751,
374	27	27.8	49	15	US-10-424-599-193666	Sequence 193666,
375	27	27.8	50	11	US-09-864-408A-4470	Sequence 4470, Ap
376	26.5	27.3	32	15	US-10-424-599-215031	Sequence 215031,
377	26.5	27.3	39	9	US-09-864-761-45336	Sequence 45336, A
378	26.5	27.3	43	9	US-09-764-860-344	Sequence 344, App
379	26.5	27.3	43	14	US-10-074-095-344	Sequence 344, App

380	26.5	27.3	43	14	US-10-212-872-344	Sequence 344, App
381	26.5	27.3	44	15	US-10-424-599-189988	Sequence 189988,
382	26.5	27.3	50	9	US-09-071-838-167	Sequence 167, App
383	26.5	27.3	50	14	US-10-213-512-167	Sequence 167, App
384	26	26.8	19	9	US-09-900-147-15	Sequence 15, Appl
385	26	26.8	20	15	US-10-241-814-6	Sequence 6, Appli
386	26	26.8	21	9	US-09-867-852-76	Sequence 76, Appl
387	26	26.8	21	10	US-09-883-343A-78	Sequence 78, Appl
388	26	26.8	21	10	US-09-883-343A-79	Sequence 79, Appl
389	26	26.8	21	13	US-10-095-407-12	Sequence 12, Appl
390	26	26.8	21	15	US-10-613-472-76	Sequence 76, Appl
391	26	26.8	21	16	US-10-613-765-76	Sequence 76, Appl
392	26	26.8	22	14	US-10-216-122-55	Sequence 55, Appl
393	26	26.8	24	10	US-09-843-221A-133	Sequence 133, App
394	26	26.8	24	14	US-10-062-831-130	Sequence 130, App
395	26	26.8	24	14	US-10-062-599-130	Sequence 130, App
396	26	26.8	25	9	US-09-864-761-38703	Sequence 38703, A
397	26	26.8	25	14	US-10-062-710-51	Sequence 51, Appl
398	26	26.8	25	14	US-10-239-313A-292	Sequence 292, App
399	26	26.8	25	14	US-10-239-313A-695	Sequence 695, App
400	26	26.8	25	16	US-10-327-598-238	Sequence 238, App
401	26	26.8	25	16	US-10-327-598-241	Sequence 241, App
402	26	26.8	25	16	US-10-327-598-242	Sequence 242, App
403	26	26.8	26	9	US-09-864-761-42561	Sequence 42561, A
404	26	26.8	27	10	US-09-759-130B-4	Sequence 4, Appli
405	26	26.8	27	16	US-10-741-790-4	Sequence 4, Appli
406	26	26.8	28	9	US-09-864-761-47268	Sequence 47268, A
407	26	26.8	28	10	US-09-843-221A-97	Sequence 97, Appl
408	26	26.8	28	10	US-09-776-724A-199	Sequence 199, App
409	26	26.8	30	15	US-10-296-734-862	Sequence 862, App
410	26	26.8	31	14	US-10-007-280A-196	Sequence 196, App
411	26	26.8	31	14	US-10-026-911-6	Sequence 6, Appli
412	26	26.8	31	15	US-10-424-599-225534	Sequence 225534,
413	26	26.8	32	9	US-09-864-761-42160	Sequence 42160, A
414	26	26.8	32	10	US-09-791-551-34	Sequence 34, Appl
415	26	26.8	32	17	US-10-473-391-6	Sequence 6, Appli
416	26	26.8	33	9	US-09-864-761-38289	Sequence 38289, A
417	26	26.8	33	13	US-10-001-870-162	Sequence 162, App
418	26	26.8	33	14	US-10-081-816-65	Sequence 65, Appl
419	26	26.8	33	14	US-10-081-816-82	Sequence 82, Appl
420	26	26.8	33	14	US-10-029-386-33454	Sequence 33454, A
421	26	26.8	33	15	US-10-424-599-159317	Sequence 159317,
422	26	26.8	33	15	US-10-424-599-208024	Sequence 208024,
423	26	26.8	33	16	US-10-767-701-37662	Sequence 37662, A
424	26	26.8	34	9	US-09-864-761-39271	Sequence 39271, A
425	26	26.8	34	10	US-09-843-221A-92	Sequence 92, Appl
426	26	26.8	34	10	US-09-843-221A-128	Sequence 128, App
427	26	26.8	34	15	US-10-424-599-225047	Sequence 225047,
428	26	26.8	35	14	US-10-029-386-28655	Sequence 28655, A
429	26	26.8	35	15	US-10-154-884B-11172	Sequence 11172, A
430	26	26.8	35	15	US-10-424-599-197484	Sequence 197484,
431	26	26.8	36	10	US-09-983-802-550	Sequence 550, App
432	26	26.8	36	10	US-09-984-490-550	Sequence 550, App
433	26	26.8	36	11	US-09-973-278-352	Sequence 352, App
434	26	26.8	36	14	US-10-007-521-28	Sequence 28, Appl
435	26	26.8	36	14	US-10-395-896-63	Sequence 63, Appl
436	26	26.8	36	15	US-10-424-599-153883	Sequence 153883,
437	26	26.8	36	15	US-10-424-599-268480	Sequence 268480,
438	26	26.8	37	15	US-10-424-599-183833	Sequence 183833,
439	26	26.8	37	15	US-10-424-599-213809	Sequence 213809,
440	26	26.8	39	10	US-09-962-756-181	Sequence 181, App
441	26	26.8	39	10	US-09-962-756-231	Sequence 231, App
442	26	26.8	39	14	US-10-074-475-184	Sequence 184, App
443	26	26.8	39	14	US-10-105-232-500	Sequence 500, App
444	26	26.8	39	14	US-10-189-437-487	Sequence 487, App
445	26	26.8	39	14	US-10-253-471-181	Sequence 181, App
446	26	26.8	39	14	US-10-253-471-231	Sequence 231, App
447	26	26.8	39	15	US-10-253-493-181	Sequence 181, App
448	26	26.8	39	15	US-10-253-493-231	Sequence 231, App
449	26	26.8	39	15	US-10-424-599-222805	Sequence 222805,
450	26	26.8	39	15	US-10-424-599-245403	Sequence 245403,
451	26	26.8	39	15	US-10-424-599-277722	Sequence 277722,
452	26	26.8	40	9	US-09-864-761-44640	Sequence 44640, A
453	26	26.8	40	10	US-09-774-639-327	Sequence 327, App
454	26	26.8	40	10	US-09-969-730-205	Sequence 205, App
455	26	26.8	40	10	US-09-962-756-189	Sequence 189, App
456	26	26.8	40	14	US-10-253-471-189	Sequence 189, App
457	26	26.8	40	15	US-10-621-363-205	Sequence 205, App
458	26	26.8	40	15	US-10-253-493-189	Sequence 189, App
459	26	26.8	40	15	US-10-424-599-165830	Sequence 165830,
460	26	26.8	40	16	US-10-437-963-126913	Sequence 126913,
461	26	26.8	41	9	US-09-864-761-42980	Sequence 42980, A
462	26	26.8	41	9	US-09-984-245-340	Sequence 340, App
463	26	26.8	41	10	US-09-966-262-340	Sequence 340, App
464	26	26.8	41	10	US-09-983-966-340	Sequence 340, App
465	26	26.8	41	14	US-10-059-395-340	Sequence 340, App
466	26	26.8	41	14	US-10-143-090-340	Sequence 340, App
467	26	26.8	41	14	US-10-029-386-30156	Sequence 30156, A
468	26	26.8	41	15	US-10-424-599-163528	Sequence 163528,
469	26	26.8	41	15	US-10-424-599-182910	Sequence 182910,
470	26	26.8	41	15	US-10-424-599-193757	Sequence 193757,
471	26	26.8	42	15	US-10-424-599-145615	Sequence 145615,
472	26	26.8	42	15	US-10-424-599-159505	Sequence 159505,
473	26	26.8	42	15	US-10-424-599-160122	Sequence 160122,
474	26	26.8	42	15	US-10-424-599-233462	Sequence 233462,
475	26	26.8	42	16	US-10-437-963-105289	Sequence 105289,
476	26	26.8	42	16	US-10-437-963-191657	Sequence 191657,
477	26	26.8	42	16	US-10-615-659-24	Sequence 24, Appl
478	26	26.8	42	16	US-10-635-977-24	Sequence 24, Appl
479	26	26.8	43	9	US-09-864-761-36609	Sequence 36609, A
480	26	26.8	43	14	US-10-106-698-7520	Sequence 7520, Ap
481	26	26.8	43	14	US-10-321-857-40	Sequence 40, Appl
482	26	26.8	43	14	US-10-318-675-40	Sequence 40, Appl
483	26	26.8	43	15	US-10-424-599-166886	Sequence 166886,
484	26	26.8	43	15	US-10-424-599-166956	Sequence 166956,
485	26	26.8	43	15	US-10-424-599-172280	Sequence 172280,
486	26	26.8	43	15	US-10-424-599-203308	Sequence 203308,
487	26	26.8	43	15	US-10-424-599-211265	Sequence 211265,
488	26	26.8	43	16	US-10-437-963-176997	Sequence 176997,
489	26	26.8	43	16	US-10-437-963-197090	Sequence 197090,
490	26	26.8	44	9	US-09-864-761-41489	Sequence 41489, A
491	26	26.8	44	9	US-09-864-761-41562	Sequence 41562, A
492	26	26.8	44	9	US-09-864-761-42633	Sequence 42633, A
493	26	26.8	44	10	US-09-764-891-3149	Sequence 3149, Ap
494	26	26.8	44	14	US-10-205-428-327	Sequence 327, App
495	26	26.8	44	15	US-10-424-599-174572	Sequence 174572,
496	26	26.8	44	15	US-10-424-599-190751	Sequence 190751,
497	26	26.8	44	15	US-10-424-599-204272	Sequence 204272,
498	26	26.8	44	15	US-10-424-599-268962	Sequence 268962,
499	26	26.8	44	15	US-10-335-977-7743	Sequence 7743, Ap
500	26	26.8	44	15	US-10-276-774-2578	Sequence 2578, Ap

ALIGNMENTS

```
RESULT 1
US-10-376-121A-55
; Sequence 55, Application US/10376121A
; Publication No. US20030216544A1
;   GENERAL INFORMATION:
;        APPLICANT: Harley, John
;        TITLE OF INVENTION: METHODS AND REAGENTS FOR DIAGNOSIS OF
;                            AUTOANTIBODIES
;        NUMBER OF SEQUENCES: 218
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Patrea L. Pabst
;             STREET: Suite 2000, 1201 West Peachtree Street, N.E.
;             CITY: Atlanta
;             STATE: GA
;             COUNTRY: USA
;             ZIP: 30309-3400
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;         CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/376,121A
;             FILING DATE: 27-Mar-2003
;             CLASSIFICATION: <Unknown>
;         PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 07/867,819
;             FILING DATE: April 13, 1992
;             APPLICATION NUMBER: 07/648,205
;             FILING DATE: January 31, 1991
;             APPLICATION NUMBER: 07/472,947
;             FILING DATE: January 31, 1990
;         ATTORNEY/AGENT INFORMATION:
;             NAME: Pabst, Patrea L.
;             REGISTRATION NUMBER: 31,284
;             REFERENCE/DOCKET NUMBER: OMRF114CIP(2)DIV(2)
;         TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (404)-817-8473
;             TELEFAX: (404)-817-8588
;    INFORMATION FOR SEQ ID NO: 55:
;         SEQUENCE CHARACTERISTICS:
;             LENGTH: 22 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;         MOLECULE TYPE: peptide
;         FEATURE:
;             NAME/KEY:  Binding-site
;             LOCATION:  1..14
;         SEQUENCE DESCRIPTION: SEQ ID NO: 55:
US-10-376-121A-55

  Query Match             39.2%;  Score 38;  DB 14;  Length 22;
  Best Local Similarity   53.3%;  Pred. No. 28;
  Matches    8;  Conservative    2;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||| ||  :| : ||
Db          5 NHLKSKEVWKALLQE 19


RESULT 2
US-10-424-599-261716
; Sequence 261716, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 261716
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_78352C.1.pep
US-10-424-599-261716

  Query Match             39.2%;  Score 38;  DB 15;  Length 39;
  Best Local Similarity   50.0%;  Pred. No. 54;
  Matches    6;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIVS 15
              ||:||: |::|:
Db          8 HLHSKVFFQVVT 19


RESULT 3
US-10-424-599-155906
; Sequence 155906, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 155906
;   LENGTH: 42
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_111803C.1.pep
US-10-424-599-155906

  Query Match             38.1%;  Score 37;  DB 15;  Length 42;
  Best Local Similarity   77.8%;  Pred. No. 86;
  Matches    7;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAF 11
              :|||| |||
Db         13 DHLNSNIAF 21


RESULT 4
US-10-424-599-283885
; Sequence 283885, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 283885
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_98372C.1.pep
US-10-424-599-283885

  Query Match             37.1%;  Score 36;  DB 15;  Length 50;
  Best Local Similarity   41.2%;  Pred. No. 1.5e+02;
  Matches    7;  Conservative    2;  Mismatches    8;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQEP 18
              | ||| |  | ::   |
Db         21 PAHLNKKNCFVLIINWP 37


RESULT 5
US-10-424-599-223392
; Sequence 223392, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
```

```
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 223392
;   LENGTH: 38
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_43754C.1.pep
US-10-424-599-223392

  Query Match             36.1%;  Score 35;  DB 15;  Length 38;
  Best Local Similarity   41.2%;  Pred. No. 1.7e+02;
  Matches    7;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQEP 18
              |  | : ||| ::| |
Db         10 PRLLQTHIAFHLLSNSP 26


RESULT 6
US-10-424-599-234416
; Sequence 234416, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 234416
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(44)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_53705C.1.pep
US-10-424-599-234416

  Query Match             36.1%;  Score 35;  DB 15;  Length 44;
  Best Local Similarity   46.7%;  Pred. No. 1.9e+02;
  Matches    7;  Conservative    2;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              | :| |||:  |  |
Db          1 NQINDKIAYSFVYLE 15


RESULT 7
US-10-424-599-185636
; Sequence 185636, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 185636
;   LENGTH: 38
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_138643C.1.pep
US-10-424-599-185636

  Query Match             35.1%;  Score 34;  DB 15;  Length 38;
  Best Local Similarity   61.5%;  Pred. No. 2.4e+02;
  Matches    8;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIV 14
              |  |  |||| |:|
Db         21 PIHGISKIALKVV 33


RESULT 8
US-10-424-599-257987
; Sequence 257987, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 257987
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_74986C.1.pep
US-10-424-599-257987

  Query Match             35.1%;  Score 34;  DB 15;  Length 50;
  Best Local Similarity   50.0%;  Pred. No. 3.3e+02;
  Matches    5;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIA 10
              ||:|:| ::|
Db         11 EPSHVNVRLA 20


RESULT 9
US-09-864-761-43939
; Sequence 43939, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
```

```
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 43939
;    LENGTH: 26
;    TYPE: PRT
;    ORGANISM: Homo sapiens
;    FEATURE:
;    OTHER INFORMATION: MAP TO AC004827.1
;    OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.56
;    OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.59
;    OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.64
;    OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 0.71
;    OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.7
US-09-864-761-43939

  Query Match             34.0%;  Score 33;  DB 9;  Length 26;
  Best Local Similarity   43.8%;  Pred. No. 2.3e+02;
  Matches    7;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              | |  |   :|: |||
Db          2 NTLERKTPIQILGQEP 17


RESULT 10
US-10-424-599-144376
; Sequence 144376, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 144376
;    LENGTH: 35
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT3847_101385C.1.pep
US-10-424-599-144376

  Query Match             34.0%;  Score 33;  DB 15;  Length 35;
  Best Local Similarity   45.5%;  Pred. No. 3.3e+02;
  Matches    5;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKI 13
              ||:|: : :||
Db         15 NHINTLLHYKI 25


RESULT 11
US-10-437-963-164005
; Sequence 164005, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 164005
;    LENGTH: 38
;    TYPE: PRT
;    ORGANISM: Oryza sativa
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT4530_62948C.1.pep
US-10-437-963-164005

  Query Match             34.0%;  Score 33;  DB 16;  Length 38;
  Best Local Similarity   41.2%;  Pred. No. 3.6e+02;
  Matches    7;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQEP 18
              |  | :  || |:| :|
Db         22 PPPLKNSPAFSILSHDP 38


RESULT 12
US-10-424-599-208257
; Sequence 208257, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 208257
;    LENGTH: 39
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT3847_30081C.1.pep
US-10-424-599-208257

  Query Match             34.0%;  Score 33;  DB 15;  Length 39;
  Best Local Similarity   50.0%;  Pred. No. 3.7e+02;
  Matches    7;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;
```

```
Qy          4 HLNSKIAFKIVSQE 17
              |    :   | |||||
Db         26 HFTQQSCFLIVSQE 39


RESULT 13
US-10-424-599-199633
; Sequence 199633, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 199633
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_22293C.1.pep
US-10-424-599-199633

  Query Match             34.0%;  Score 33;  DB 15;  Length 46;
  Best Local Similarity   33.3%;  Pred. No. 4.4e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              :| | :  | |:: |
Db         30 SHRNKRFLFSIITSE 44


RESULT 14
US-10-424-599-187478
; Sequence 187478, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 187478
;   LENGTH: 49
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_140304C.1.pep
US-10-424-599-187478

  Query Match             34.0%;  Score 33;  DB 15;  Length 49;
  Best Local Similarity   41.7%;  Pred. No. 4.7e+02;
  Matches    5;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFK 12
              || |:| : : |
Db          8 EPKHINGRPSLK 19


RESULT 15
US-09-864-761-35774
; Sequence 35774, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 35774
;   LENGTH: 36
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AP000470.1
;   OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 1.4
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 5.3
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 2.2
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.9
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL =   1
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.6
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 2.4
;   OTHER INFORMATION: EST_HUMAN HIT: AA722296.1, EVALUE 4.00e-03
;   OTHER INFORMATION: SWISSPROT HIT: P55859, EVALUE 6.20e+00
US-09-864-761-35774

  Query Match             33.5%;  Score 32.5;  DB 9;  Length 36;
  Best Local Similarity   53.8%;  Pred. No. 4.1e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKI 13
              |||| || : | :
```

```
Db         19 EPNH-NSLLVFPL 30


RESULT 16
US-10-424-599-267189
; Sequence 267189, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 267189
;   LENGTH: 27
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_83292C.1.pep
US-10-424-599-267189

  Query Match             33.0%;  Score 32;  DB 15;  Length 27;
  Best Local Similarity   50.0%;  Pred. No. 3.6e+02;
  Matches    6;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              || |: :|: ||
Db          8 LNFKVDYKLYSQ 19


RESULT 17
US-10-425-114-68647
; Sequence 68647, Application US/10425114
; Publication No. US20040034888A1
; GENERAL INFORMATION:
;  APPLICANT: Liu, Jingdong
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Screen, Steven E
;  APPLICANT:  Tabaska, Jack E
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53313)B
;  CURRENT APPLICATION NUMBER: US/10/425,114
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 73128
; SEQ ID NO 68647
;   LENGTH: 43
;   TYPE: PRT
;   ORGANISM: Zea mays
;   FEATURE:
;   OTHER INFORMATION: Clone ID: UC-ZMFLMO17310A12_FLI.pep
US-10-425-114-68647

  Query Match             33.0%;  Score 32;  DB 15;  Length 43;
  Best Local Similarity   38.9%;  Pred. No. 6e+02;
  Matches    7;  Conservative    3;  Mismatches    8;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKIVSQEP 18
              :|  | |||  ::  | |
Db          7 QPPSLASKIRHRLSKQTP 24


RESULT 18
US-10-437-963-131784
; Sequence 131784, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 131784
;   LENGTH: 43
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_33817C.1.pep
US-10-437-963-131784

  Query Match             33.0%;  Score 32;  DB 16;  Length 43;
  Best Local Similarity   50.0%;  Pred. No. 6e+02;
  Matches    6;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              :||   |:||:|
Db         25 SHLQWSISFKLV 36


RESULT 19
US-10-424-599-245137
; Sequence 245137, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 245137
;   LENGTH: 45
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_6338C.1.pep
US-10-424-599-245137

  Query Match             33.0%;  Score 32;  DB 15;  Length 45;
  Best Local Similarity   44.4%;  Pred. No. 6.3e+02;
  Matches    4;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKI 9
              :|||:|  :
Db          2 QPNHINVSV 10


RESULT 20
US-10-424-599-250836
; Sequence 250836, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
```

```
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 250836
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_68534C.1.pep
US-10-424-599-250836

  Query Match             33.0%;  Score 32;  DB 15;  Length 47;
  Best Local Similarity   66.7%;  Pred. No. 6.6e+02;
  Matches    6;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy         11 FKIVSQEPA 19
              ||||:: ||
Db         11 FKIVNETPA 19


RESULT 21
US-09-864-761-33571
; Sequence 33571, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 33571
;   LENGTH: 48
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AP000111.1
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL =   4
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 4.6
;   OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 5.1
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 3.5
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 4.1
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 8.5
;   OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 3.2
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 4.7
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL =   6
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 4.3
;   OTHER INFORMATION: EST_HUMAN HIT: BF109229.1, EVALUE 1.00e-17
;   OTHER INFORMATION: EST_HUMAN HIT: AI738554.1, EVALUE 6.00e-13
;   OTHER INFORMATION: SWISSPROT HIT: P48551, EVALUE 2.00e-21
US-09-864-761-33571

  Query Match             33.0%;  Score 32;  DB 9;  Length 48;
  Best Local Similarity   33.3%;  Pred. No. 6.8e+02;
  Matches    5;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||:|  : |  : :|
Db         14 NHINVMVKFPSIVEE 28


RESULT 22
US-10-424-599-233753
; Sequence 233753, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 233753
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_53103C.1.pep
US-10-424-599-233753

  Query Match             32.5%;  Score 31.5;  DB 15;  Length 47;
  Best Local Similarity   33.3%;  Pred. No. 8.1e+02;
  Matches    6;  Conservative    7;  Mismatches    2;  Indels    3;  Gaps    1;

Qy          2 PNHLNSKIAF---KIVSQ 16
              |:|::| : :   |:||:
Db          9 PHHIHSSLIYFPTKLVSK 26


RESULT 23
US-10-084-813-333
; Sequence 333, Application US/10084813
; Publication No. US20030068615A1
; GENERAL INFORMATION:
;  APPLICANT: SAXINGER, CARL
;  TITLE OF INVENTION: POLYPEPTIDES THAT BIND HIV GP120 AND RELATED NUCLEIC
;  TITLE OF INVENTION:  ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
;  FILE REFERENCE: 215875
```

```
;  CURRENT APPLICATION NUMBER: US/10/084,813
;  CURRENT FILING DATE:  2002-02-27
;  PRIOR APPLICATION NUMBER: PCT/US00/23505
;  PRIOR FILING DATE: 2000-08-25
;  PRIOR APPLICATION NUMBER: US 60/151,270
;  PRIOR FILING DATE: 1999-08-27
;  NUMBER OF SEQ ID NOS: 1242
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 333
;   LENGTH: 21
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: binding peptide
US-10-084-813-333

  Query Match             32.0%;  Score 31;  DB 14;  Length 21;
  Best Local Similarity   38.5%;  Pred. No. 4e+02;
  Matches    5;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQEP 18
              | ::: | |:|:|
Db          8 NKEVSVKRVTQDP 20


RESULT 24
US-10-084-813-334
; Sequence 334, Application US/10084813
; Publication No. US20030068615A1
; GENERAL INFORMATION:
;  APPLICANT: SAXINGER, CARL
;  TITLE OF INVENTION: POLYPEPTIDES THAT BIND HIV GP120 AND RELATED NUCLEIC
;  TITLE OF INVENTION:  ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
;  FILE REFERENCE: 215875
;  CURRENT APPLICATION NUMBER: US/10/084,813
;  CURRENT FILING DATE:  2002-02-27
;  PRIOR APPLICATION NUMBER: PCT/US00/23505
;  PRIOR FILING DATE: 2000-08-25
;  PRIOR APPLICATION NUMBER: US 60/151,270
;  PRIOR FILING DATE: 1999-08-27
;  NUMBER OF SEQ ID NOS: 1242
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 334
;   LENGTH: 21
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: binding peptide
US-10-084-813-334

  Query Match             32.0%;  Score 31;  DB 14;  Length 21;
  Best Local Similarity   38.5%;  Pred. No. 4e+02;
  Matches    5;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQEP 18
              | ::: | |:|:|
Db          3 NKEVSVKRVTQDP 15


RESULT 25
US-10-437-963-150845
; Sequence 150845, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 150845
;   LENGTH: 30
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_51044C.1.pep
US-10-437-963-150845

  Query Match             32.0%;  Score 31;  DB 16;  Length 30;
  Best Local Similarity   50.0%;  Pred. No. 5.9e+02;
  Matches    7;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVSQEPA 19
              ||   || ||  |:
Db          4 NSHAYFKTVSNPPS 17


RESULT 26
US-09-801-348-29
; Sequence 29, Application US/09801348
; Publication No. US20040166530A1
; GENERAL INFORMATION:
;  APPLICANT: Harper, Jeffrey W.
;  APPLICANT: Elledge, Stephen J.
;  TITLE OF INVENTION: F-BOX PROTEINS AND GENES
;  FILE REFERENCE: BCM-03510
;  CURRENT APPLICATION NUMBER: US/09/801,348
;  CURRENT FILING DATE: 2001-07-31
;  EARLIER APPLICATION NUMBER: 09/172,841
;  EARLIER FILING DATE: 1998-10-15
;  EARLIER APPLICATION NUMBER: 08/951,621
;  EARLIER FILING DATE: 1997-10-16
;  NUMBER OF SEQ ID NOS: 60
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 29
;   LENGTH: 33
;   TYPE: PRT
;   ORGANISM: Mus musculus
US-09-801-348-29

  Query Match             32.0%;  Score 31;  DB 11;  Length 33;
  Best Local Similarity   58.3%;  Pred. No. 6.6e+02;
  Matches    7;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              | ::| ||| ||
Db          1 LPAEITFKIFSQ 12


RESULT 27
US-09-764-891-4356
; Sequence 4356, Application US/09764891
; Publication No. US20030077808A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC006
;  CURRENT APPLICATION NUMBER: US/09/764,891
;  CURRENT FILING DATE:  2001-01-17
;  Prior application data removed - consult PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 10231
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4356
;   LENGTH: 34
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
```

```
;   LOCATION: (3)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (20)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-891-4356

  Query Match             32.0%;  Score 31;  DB 10;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 6.8e+02;
  Matches    6;  Conservative    3;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              :|||  |   |:| :
Db         12 HHLNQVIKXNIISNK 26


RESULT 28
US-10-062-831-72
; Sequence 72, Application US/10062831
; Publication No. US20030105297A1
; GENERAL INFORMATION:
;  APPLICANT: Steven M. Ruben, et al.
;  TITLE OF INVENTION: 32 Human Secreted Proteins
;  FILE REFERENCE: PZ006P1
;  CURRENT APPLICATION NUMBER: US/10/062,831
;  CURRENT FILING DATE:  2002-02-05
;  PRIOR APPLICATION NUMBER: 09/690,454
;  PRIOR FILING DATE: 1998-11-10
;  PRIOR APPLICATION NUMBER: PCT/US98/10868
;  PRIOR FILING DATE: May 28, 1998
;  PRIOR APPLICATION NUMBER: 60/044,039
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/048,093
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/048,190
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/050,935
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/048,101
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/048,356
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/056,250
;  PRIOR FILING DATE: August 29, 1997
;  PRIOR APPLICATION NUMBER: 60/056,296
;  PRIOR FILING DATE: August 29, 1997
;  PRIOR APPLICATION NUMBER: 60/056,293
;  PRIOR FILING DATE: August 29, 1997
;  NUMBER OF SEQ ID NOS: 229
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 72
;   LENGTH: 34
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (34)
;   OTHER INFORMATION: Xaa equals stop translation
US-10-062-831-72

  Query Match             32.0%;  Score 31;  DB 14;  Length 34;
  Best Local Similarity   47.4%;  Pred. No. 6.8e+02;
  Matches    9;  Conservative    2;  Mismatches    4;  Indels    4;  Gaps    1;

Qy          5 LNSKIAFKIV----SQEPA 19
              ||||:   :|    || ||
Db         11 LNSKLVAAVVNLKASQMPA 29


RESULT 29
US-10-205-428-383
; Sequence 383, Application US/10205428
; Publication No. US20030108907A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PA117C1
;  CURRENT APPLICATION NUMBER: US/10/205,428
;  CURRENT FILING DATE:  2002-07-26
;  PRIOR APPLICATION NUMBER: 09/764,892
;  PRIOR FILING DATE: 2001-01-17
;  PRIOR APPLICATION NUMBER: 60/179,065
;  PRIOR FILING DATE: 2000-01-31
;  PRIOR APPLICATION NUMBER: 60/180,628
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: 60/214,886
;  PRIOR FILING DATE: 2000-06-28
;  PRIOR APPLICATION NUMBER: 60/217,487
;  PRIOR FILING DATE: 2000-07-11
;  PRIOR APPLICATION NUMBER: 60/225,758
;  PRIOR FILING DATE: 2000-08-14
;  PRIOR APPLICATION NUMBER: 60/220,963
;  PRIOR FILING DATE: 2000-07-26
;  PRIOR APPLICATION NUMBER: 60/217,496
;  PRIOR FILING DATE: 2000-07-11
;  PRIOR APPLICATION NUMBER: 60/225,447
;  PRIOR FILING DATE: 2000-08-14
;  PRIOR APPLICATION NUMBER: 60/218,290
;  PRIOR FILING DATE: 2000-07-14
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 1019
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 383
;   LENGTH: 34
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (3)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (20)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-10-205-428-383

  Query Match             32.0%;  Score 31;  DB 14;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 6.8e+02;
  Matches    6;  Conservative    3;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              :|||  |   |:| :
Db         12 HHLNQVIKXNIISNK 26


RESULT 30
US-10-062-599-72
; Sequence 72, Application US/10062599
; Publication No. US20030195346A1
; GENERAL INFORMATION:
;  APPLICANT: Steven M. Ruben, et al.
;  TITLE OF INVENTION: 32 Human Secreted Proteins
;  FILE REFERENCE: PZ006P1
;  CURRENT APPLICATION NUMBER: US/10/062,599
;  CURRENT FILING DATE:  2002-02-05
;  PRIOR APPLICATION NUMBER: 09/690,454
;  PRIOR FILING DATE: 2000-10-18
;  PRIOR APPLICATION NUMBER: 09/189,144
;  PRIOR FILING DATE: 1998-11-10
;  PRIOR APPLICATION NUMBER: 60/044,039
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/048,093
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/048,190
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/050,935
```

```
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/048,101
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/048,356
;  PRIOR FILING DATE: May 30, 1997
;  PRIOR APPLICATION NUMBER: 60/056,250
;  PRIOR FILING DATE: August 29, 1997
;  PRIOR APPLICATION NUMBER: 60/056,296
;  PRIOR FILING DATE: August 29, 1997
;  PRIOR APPLICATION NUMBER: 60/056,293
;  PRIOR FILING DATE: August 29, 1997
;  NUMBER OF SEQ ID NOS: 229
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 72
;   LENGTH: 34
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (34)
;   OTHER INFORMATION: Xaa equals stop translation
US-10-062-599-72

  Query Match             32.0%;  Score 31;  DB 14;  Length 34;
  Best Local Similarity   47.4%;  Pred. No. 6.8e+02;
  Matches    9;  Conservative    2;  Mismatches    4;  Indels    4;  Gaps    1;

Qy          5 LNSKIAFKIV----SQEPA 19
              ||||:   :|    || ||
Db         11 LNSKLVAAVVNLKASQMPA 29


RESULT 31
US-10-424-599-227023
; Sequence 227023, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 227023
;   LENGTH: 42
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_47031C.1.pep
US-10-424-599-227023

  Query Match             32.0%;  Score 31;  DB 15;  Length 42;
  Best Local Similarity   50.0%;  Pred. No. 8.6e+02;
  Matches    5;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFK 12
              ||::  |||:
Db         26 NHIHGDIAFE 35


RESULT 32
US-10-029-386-33676
; Sequence 33676, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 33676
;   LENGTH: 43
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC004030.1
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.42
US-10-029-386-33676

  Query Match             32.0%;  Score 31;  DB 14;  Length 43;
  Best Local Similarity   41.7%;  Pred. No. 8.8e+02;
  Matches    5;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKI 13
              | ||:| :|: :
Db         15 PIHLHSNVAWTV 26


RESULT 33
US-09-864-761-41924
; Sequence 41924, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
```

```
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 41924
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC022211.2
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.5
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 2.6
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 2.3
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 3.5
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 2.8
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 3.4
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 3.9
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 3.4
;   OTHER INFORMATION: SWISSPROT HIT: P55855, EVALUE 3.00e-20
;   OTHER INFORMATION: EST_HUMAN HIT: BF574192.1, EVALUE 4.00e-19
US-09-864-761-41924

  Query Match             32.0%;  Score 31;  DB 9;  Length 44;
  Best Local Similarity   33.3%;  Pred. No. 9.1e+02;
  Matches    8;  Conservative    3;  Mismatches    5;  Indels    8;  Gaps    1;

Qy          3 NHLNSKIA--------FKIVSQEP 18
              :|:| |:|        |||    |
Db          9 DHINLKVAGQDGSVVQFKIKRHTP 32


RESULT 34
US-10-424-599-181955
; Sequence 181955, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 181955
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_135319C.1.pep
US-10-424-599-181955

  Query Match             32.0%;  Score 31;  DB 15;  Length 46;
  Best Local Similarity   44.4%;  Pred. No. 9.5e+02;
  Matches    8;  Conservative    2;  Mismatches    8;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQEPA 19
              | |:|:  | || |   |
Db         27 PIHVNNGCATKIESSPVA 44


RESULT 35
US-09-984-429-87
; Sequence 87, Application US/09984429
; Publication No. US20040010132A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: 53 Human Secreted Proteins
;  FILE REFERENCE: PZ018P2
;  CURRENT APPLICATION NUMBER: US/09/984,429
;  CURRENT FILING DATE:  2001-10-30
;  PRIOR APPLICATION NUMBER: 60/244,591
;  PRIOR FILING DATE: 2000-11-01
;  PRIOR APPLICATION NUMBER: 09/288,143
;  PRIOR FILING DATE: 1999-04-08
;  PRIOR APPLICATION NUMBER: PCT/US98/21142
;  PRIOR FILING DATE: 1998-10-08
;  PRIOR APPLICATION NUMBER: 60/061,463
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/061,529
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/071,498
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/061,527
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/061,536
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/061,532
;  PRIOR FILING DATE: 1997-10-09
;  NUMBER OF SEQ ID NOS: 727
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 87
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-984-429-87

  Query Match             32.0%;  Score 31;  DB 11;  Length 47;
  Best Local Similarity   45.5%;  Pred. No. 9.8e+02;
  Matches    5;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          9 IAFKIVSQEPA 19
              :||:: :| ||
Db         19 VAFRLTNQIPA 29


RESULT 36
US-10-393-840-84
; Sequence 84, Application US/10393840
; Publication No. US20030229922A1
; GENERAL INFORMATION:
;  APPLICANT: Bloksberg, Leonard N.
;  TITLE OF INVENTION: Materials and Methods for the
;  TITLE OF INVENTION:  Modification of Plant Cell Wall Polysaccharides
;  FILE REFERENCE: 11000.1012c3
;  CURRENT APPLICATION NUMBER: US/10/393,840
;  CURRENT FILING DATE:  2003-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,800
;  PRIOR FILING DATE: 2000-08-10
;  PRIOR APPLICATION NUMBER: US 09/170,862
;  PRIOR FILING DATE: 1998-10-13
;  PRIOR APPLICATION NUMBER: US 60/148,426
;  PRIOR FILING DATE: 1999-08-11
;  PRIOR APPLICATION NUMBER: PCT NZ/99/00169
;  PRIOR FILING DATE: 1999-10-08
;  NUMBER OF SEQ ID NOS: 956
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 84
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Eucalyptus grandis
US-10-393-840-84

  Query Match             32.0%;  Score 31;  DB 14;  Length 47;
  Best Local Similarity   50.0%;  Pred. No. 9.8e+02;
  Matches    7;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              |:|  ||| | ::|
Db          4 LDSADAFKSVRRDP 17


RESULT 37
US-10-424-599-223920
; Sequence 223920, Application US/10424599
```

```
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 223920
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_44229C.1.pep
US-10-424-599-223920

  Query Match             32.0%;  Score 31;  DB 15;  Length 47;
  Best Local Similarity   31.2%;  Pred. No. 9.8e+02;
  Matches    5;  Conservative    4;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              | ||::  |  : : |
Db         19 NFLNAEAVFDCIGEPP 34


RESULT 38
US-10-150-111-87
; Sequence 87, Application US/10150111
; Publication No. US20030078386A1
; GENERAL INFORMATION:
;  APPLICANT: Rubin et al.
;  TITLE OF INVENTION: Secreted Protein HPEAD48
;  FILE REFERENCE: PZ018P1D1
;  CURRENT APPLICATION NUMBER: US/10/150,111
;  CURRENT FILING DATE:  2002-05-20
;  PRIOR APPLICATION NUMBER: 09/288,143
;  PRIOR FILING DATE: 1999-04-08
;  PRIOR APPLICATION NUMBER: PCT/US98/21142
;  PRIOR FILING DATE: 1998-10-08
;  PRIOR APPLICATION NUMBER: 60/061,463
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/061,529
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/071,498
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/061,527
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/061,536
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: 60/061,532
;  PRIOR FILING DATE: 1997-10-09
;  NUMBER OF SEQ ID NOS: 219
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 87
;   LENGTH: 48
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (48)
;   OTHER INFORMATION: Xaa equals stop translation
US-10-150-111-87

  Query Match             32.0%;  Score 31;  DB 14;  Length 48;
  Best Local Similarity   45.5%;  Pred. No. 1e+03;
  Matches    5;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          9 IAFKIVSQEPA 19
              :||:: :| ||
Db         19 VAFRLTNQIPA 29


RESULT 39
US-10-424-599-156398
; Sequence 156398, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 156398
;   LENGTH: 48
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_112248C.1.pep
US-10-424-599-156398

  Query Match             32.0%;  Score 31;  DB 15;  Length 48;
  Best Local Similarity   37.5%;  Pred. No. 1e+03;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |:: ||: | : |  |
Db          9 NNIYSKLLFSLSSLPP 24


RESULT 40
US-09-764-860-359
; Sequence 359, Application US/09764860
; Patent No. US20020094953A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC008
;  CURRENT APPLICATION NUMBER: US/09/764,860
;  CURRENT FILING DATE:  2001-01-17
;  Prior application data removed - consult PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 1198
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 359
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-764-860-359

  Query Match             32.0%;  Score 31;  DB 9;  Length 50;
  Best Local Similarity   60.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              | |:| | ||
Db         36 PPHVNWKTAF 45


RESULT 41
US-10-074-095-359
; Sequence 359, Application US/10074095
; Publication No. US20030077704A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC008C1
;  CURRENT APPLICATION NUMBER: US/10/074,095
;  CURRENT FILING DATE:  2002-02-14
```

; PRIOR APPLICATION NUMBER: 09/764,860
; PRIOR FILING DATE: 2001-01-17
; PRIOR APPLICATION NUMBER: 60/179,065
; PRIOR FILING DATE: 2000-01-31
; PRIOR APPLICATION NUMBER: 60/180,628
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: 60/214,886
; PRIOR FILING DATE: 2000-06-28
; PRIOR APPLICATION NUMBER: 60/217,487
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/225,758
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/220,963
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: 60/217,496
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/225,447
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/218,290
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: 60/225,757
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/226,868
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/216,647
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: 60/225,267
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/216,880
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: 60/225,270
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/251,869
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/235,834
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: 60/234,274
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: 60/234,223
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: 60/228,924
; PRIOR FILING DATE: 2000-08-30
; PRIOR APPLICATION NUMBER: 60/224,518
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/236,369
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/224,519
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/220,964
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: 60/241,809
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/249,299
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/236,327
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/241,785
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/244,617
; PRIOR FILING DATE: 2000-11-01
; PRIOR APPLICATION NUMBER: 60/225,268
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/236,368
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/251,856
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/251,868
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/229,344
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/234,997
; PRIOR FILING DATE: 2000-09-25
; PRIOR APPLICATION NUMBER: 60/229,343
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,345
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,287
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,513
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: 60/231,413
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: 60/229,509
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: 60/236,367
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/237,039
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,038
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/236,370
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/236,802
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,037
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,040
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/240,960
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/239,935
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/239,937
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/241,787
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/246,474
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/246,532
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/249,216
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,210
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/226,681
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/225,759
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/225,213
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/227,182
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/225,214
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/235,836
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: 60/230,438
; PRIOR FILING DATE: 2000-09-06
; PRIOR APPLICATION NUMBER: 60/215,135
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: 60/225,266
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/249,218
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,208
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,213
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,212
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,207
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,245
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,244
; PRIOR FILING DATE: 2000-11-17

```
;  PRIOR APPLICATION NUMBER: 60/249,217
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,211
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,215
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,264
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,214
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,297
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/232,400
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/231,242
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/232,081
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/232,080
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/231,414
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/231,244
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/233,064
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/233,063
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/232,397
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/232,399
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/232,401
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/241,808
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/241,826
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/241,786
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/241,221
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/246,475
;  PRIOR FILING DATE: 2000-11-08
;  PRIOR APPLICATION NUMBER: 60/231,243
;  PRIOR FILING DATE: 2000-09-08

  Query Match             32.0%;  Score 31;  DB 14;  Length 50;
  Best Local Similarity   60.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              | |:| | ||
Db         36 PPHVNWKTAF 45


RESULT 42
US-10-212-872-359
; Sequence 359, Application US/10212872
; Publication No. US20030215893A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC008C2
;  CURRENT APPLICATION NUMBER: US/10/212,872
;  CURRENT FILING DATE:  2002-08-07
;  Prior application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 1198
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 359
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-212-872-359

  Query Match             32.0%;  Score 31;  DB 14;  Length 50;
  Best Local Similarity   60.0%;  Pred. No. 1e+03;
  Matches    6;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              | |:| | ||
Db         36 PPHVNWKTAF 45


RESULT 43
US-10-424-599-181551
; Sequence 181551, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 181551
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_134955C.1.pep
US-10-424-599-181551

  Query Match             32.0%;  Score 31;  DB 15;  Length 50;
  Best Local Similarity   70.0%;  Pred. No. 1e+03;
  Matches    7;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          6 NSKIAFKIVS 15
              | || | |||
Db         11 NHKICFPIVS 20


RESULT 44
US-10-767-701-52857
; Sequence 52857, Application US/10767701
; Publication No. US20040172684A1
; GENERAL INFORMATION:
;  APPLICANT: Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof For Plant Improvement
;  FILE REFERENCE: 38-21(53535)B
;  CURRENT APPLICATION NUMBER: US/10/767,701
;  CURRENT FILING DATE:  2004-01-29
;  NUMBER OF SEQ ID NOS: 63128
; SEQ ID NO 52857
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Sorghum bicolor
;   FEATURE:
;   OTHER INFORMATION: Clone ID: 13152278.pep
US-10-767-701-52857

  Query Match             32.0%;  Score 31;  DB 16;  Length 50;
  Best Local Similarity   83.3%;  Pred. No. 1e+03;
  Matches    5;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 EPNHLN 6
              |||||:
Db         23 EPNHLH 28
```

```
RESULT 45
US-10-153-344-10
; Sequence 10, Application US/10153344
; Publication No. US20030004124A1
; GENERAL INFORMATION:
;  APPLICANT: ROTHMAN, JOEL
;  APPLICANT:  BLOSS, TIM
;  APPLICANT:  WITZE, ERIC
;  TITLE OF INVENTION: BTF3:  AN INHIBITOR OF APOPTOSIS
;  FILE REFERENCE: 407T-300410US
;  CURRENT APPLICATION NUMBER: US/10/153,344
;  CURRENT FILING DATE:  2002-08-27
;  PRIOR APPLICATION NUMBER: US 60/292,559
;  PRIOR FILING DATE: 2001-05-21
;  NUMBER OF SEQ ID NOS: 35
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 10
;   LENGTH: 19
;   TYPE: PRT
;   ORGANISM: Caenorhabditis elegans
US-10-153-344-10

  Query Match             31.4%;  Score 30.5;  DB 14;  Length 19;
  Best Local Similarity   47.1%;  Pred. No. 4.3e+02;
  Matches    8;  Conservative    4;  Mismatches    2;  Indels    3;  Gaps    1;

Qy          3 NHLNSKIAFKIVSQEPA 19
              :|| :|   ||:|:| |
Db          2 DHLRAK---KILSREDA 15


RESULT 46
US-10-424-599-212560
; Sequence 212560, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 212560
;   LENGTH: 37
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_33969C.1.pep
US-10-424-599-212560

  Query Match             31.4%;  Score 30.5;  DB 15;  Length 37;
  Best Local Similarity   50.0%;  Pred. No. 9.1e+02;
  Matches    7;  Conservative    3;  Mismatches    1;  Indels    3;  Gaps    1;

Qy          2 PNHLNSKIAFKIVS 15
              || |||   :|::|
Db          3 PNSLNS---YKVLS 13


RESULT 47
US-10-282-122A-71852
; Sequence 71852, Application US/10282122A
; Publication No. US20040029129A1
; GENERAL INFORMATION:
;  APPLICANT: Wang, Liangsu
;  APPLICANT:  Zamudio, Carlos
;  APPLICANT:  Malone, Cheryl
;  APPLICANT:  Haselbeck, Robert
;  APPLICANT:  Ohlsen, Kari
;  APPLICANT:  Zyskind, Judith
;  APPLICANT:  Wall, Daniel
;  APPLICANT:  Trawick, John
;  APPLICANT:  Carr, Grant
;  APPLICANT:  Yamamoto, Robert
;  APPLICANT:  Forsyth, R.
;  APPLICANT:  Xu, H.
;  TITLE OF INVENTION: Identification of Essential Genes in Microorganisms
;  FILE REFERENCE: ELITRA.034A
;  CURRENT APPLICATION NUMBER: US/10/282,122A
;  CURRENT FILING DATE:  2003-02-20
;  PRIOR APPLICATION NUMBER: 60/191,078
;  PRIOR FILING DATE: 2000-03-21
;  PRIOR APPLICATION NUMBER: 60/206,848
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 60/207,727
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: 60/230,335
;  PRIOR FILING DATE: 2000-09-06
;  PRIOR APPLICATION NUMBER: 60/230,347
;  PRIOR FILING DATE: 2000-09-09
;  PRIOR APPLICATION NUMBER: 60/242,578
;  PRIOR FILING DATE: 2000-10-23
;  PRIOR APPLICATION NUMBER: 60/253,625
;  PRIOR FILING DATE: 2000-11-27
;  PRIOR APPLICATION NUMBER: 60/257,931
;  PRIOR FILING DATE: 2000-12-22
;  PRIOR APPLICATION NUMBER: 60/267,636
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/269,308
;  PRIOR FILING DATE: 2001-02-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 78614
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 71852
;   LENGTH: 40
;   TYPE: PRT
;   ORGANISM: Staphylococcus haemolyticus
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (31)..(31)
;   OTHER INFORMATION: X=any amino acid
US-10-282-122A-71852

  Query Match             31.4%;  Score 30.5;  DB 15;  Length 40;
  Best Local Similarity   37.5%;  Pred. No. 9.9e+02;
  Matches    6;  Conservative    6;  Mismatches    3;  Indels    1;  Gaps    1;

Qy          1 EPNHLNSKIAFKIVSQ 16
              :| | |||:  |::::
Db         15 DPIH-NSKLVTKLINK 29


RESULT 48
US-10-424-599-144936
; Sequence 144936, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 144936
;   LENGTH: 40
;   TYPE: PRT
;   ORGANISM: Glycine max
```

```
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_101896C.1.pep
US-10-424-599-144936

  Query Match             31.4%;  Score 30.5;  DB 15;  Length 40;
  Best Local Similarity   35.3%;  Pred. No. 9.9e+02;
  Matches    6;  Conservative    5;  Mismatches    5;  Indels    1;  Gaps    1;

Qy          2 PNHLNSKIAFKIVSQEP 18
              |:|  :|:: ||:  |
Db         25 PDH-GTKVSAKILQHNP 40


RESULT 49
US-10-139-794-103
; Sequence 103, Application US/10139794
; Publication No. US20030232421A1
; GENERAL INFORMATION:
;  APPLICANT: HYBRIGENICS, LYNX THERAPEUTICS INC.
;  APPLICANT:  Pierre Legrain, Simon Whiteside, Jen-I Mao, Irina Khrebtukova, Shujun Luo
;  TITLE OF INVENTION: Protein-Protein Interactions In Adipocyte Cells (3)
;  FILE REFERENCE: B4883A
;  CURRENT APPLICATION NUMBER: US/10/139,794
;  CURRENT FILING DATE:  2002-05-06
;  PRIOR APPLICATION NUMBER: US 60/288,885
;  PRIOR FILING DATE: 2001-05-04
;  NUMBER OF SEQ ID NOS: 2930
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 103
;   LENGTH: 25
;   TYPE: PRT
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   OTHER INFORMATION: Translation of SEQ ID NO:102
US-10-139-794-103

  Query Match             30.9%;  Score 30;  DB 14;  Length 25;
  Best Local Similarity   56.2%;  Pred. No. 7.1e+02;
  Matches    9;  Conservative    1;  Mismatches    4;  Indels    2;  Gaps    1;

Qy          1 EPNHL--NSKIAFKIV 14
              || ||   : || |||
Db          3 EPKHLLEGTIIASKIV 18


RESULT 50
US-09-864-761-48976
; Sequence 48976, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 48976
;   LENGTH: 26
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC011402.1
;   OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.9
US-09-864-761-48976

  Query Match             30.9%;  Score 30;  DB 9;  Length 26;
  Best Local Similarity   46.2%;  Pred. No. 7.4e+02;
  Matches    6;  Conservative    2;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKI 13
              | :||:  | | |
Db          1 EKHHLDQMIKFSI 13


RESULT 51
US-09-933-767-898
; Sequence 898, Application US/09933767
; Publication No. US20030181692A1
; GENERAL INFORMATION:
;  APPLICANT: Ni et al.
;  TITLE OF INVENTION: 207 Human Secreted Proteins
;  FILE REFERENCE: PZ007P2
;  CURRENT APPLICATION NUMBER: US/09/933,767
;  CURRENT FILING DATE:  2001-08-22
;  PRIOR APPLICATION NUMBER: PCT/US01/05614
;  PRIOR FILING DATE: 2001-02-21
;  PRIOR APPLICATION NUMBER: 60/184,836
;  PRIOR FILING DATE: 2000-02-24
;  PRIOR APPLICATION NUMBER: 60/193,170
;  PRIOR FILING DATE: 2000-03-29
;  PRIOR APPLICATION NUMBER: 09/205,258
;  PRIOR FILING DATE: 1998-12-04
;  PRIOR APPLICATION NUMBER: PCT/US98/11422
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/048,885
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,375
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,881
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,880
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,896
;  PRIOR FILING DATE: 1997-06-06
```

; PRIOR APPLICATION NUMBER: 60/049,020
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,876
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,895
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,884
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,894
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,971
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,964
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,882
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,899
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,893
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,900
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,901
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,892
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,915
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/049,019
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,970
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,972
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,916
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/049,373
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,875
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/049,374
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,917
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,949
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,974
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,883
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,897
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,898
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,962
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,963
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,877
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,878
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/068,054
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,064
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/068,053
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/070,923
; PRIOR FILING DATE: 1997-12-18
; PRIOR APPLICATION NUMBER: 60/073,160
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 60/073,159
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 60/073,165
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 60/073,164
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 60/085,925
; PRIOR FILING DATE: 1998-05-18
; PRIOR APPLICATION NUMBER: 60/085,921
; PRIOR FILING DATE: 1998-05-18
; PRIOR APPLICATION NUMBER: 60/085,923
; PRIOR FILING DATE: 1998-05-18
; PRIOR APPLICATION NUMBER: 60/085,922
; PRIOR FILING DATE: 1998-05-18
; PRIOR APPLICATION NUMBER: 60/092,921
; PRIOR FILING DATE: 1998-07-15
; PRIOR APPLICATION NUMBER: 60/094,657
; PRIOR FILING DATE: 1998-07-30
; NUMBER OF SEQ ID NOS: 1245
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 898
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-933-767-898

Query Match 30.9%; Score 30; DB 10; Length 27;
Best Local Similarity 37.5%; Pred. No. 7.7e+02;
Matches 6; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

Qy 2 PNHLNSKIAFKIVSQE 17
Db 6 PSANNQRFAFSPLSEE 21

RESULT 52
US-09-933-767-899
; Sequence 899, Application US/09933767
; Publication No. US20030181692A1
; GENERAL INFORMATION:
; APPLICANT: Ni et al.
; TITLE OF INVENTION: 207 Human Secreted Proteins
; FILE REFERENCE: PZ007P2
; CURRENT APPLICATION NUMBER: US/09/933,767
; CURRENT FILING DATE: 2001-08-22
; PRIOR APPLICATION NUMBER: PCT/US01/05614
; PRIOR FILING DATE: 2001-02-21
; PRIOR APPLICATION NUMBER: 60/184,836
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: 60/193,170
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: 09/205,258
; PRIOR FILING DATE: 1998-12-04
; PRIOR APPLICATION NUMBER: PCT/US98/11422
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/048,885
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/049,375
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,881
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,880
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,896
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/049,020
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,876
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,895
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,884
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/048,894

```
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,971
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,964
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,882
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,899
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,893
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,900
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,901
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,892
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,915
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,019
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,970
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,972
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,916
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,373
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,875
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,374
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,917
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,949
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,974
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,883
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,897
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,898
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,962
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,963
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,877
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,878
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/068,054
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,064
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,053
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/070,923
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/073,160
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 60/073,159
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 60/073,165
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 60/073,164
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 60/085,925
;  PRIOR FILING DATE: 1998-05-18
;  PRIOR APPLICATION NUMBER: 60/085,921
;  PRIOR FILING DATE: 1998-05-18
;  PRIOR APPLICATION NUMBER: 60/085,923
;  PRIOR FILING DATE: 1998-05-18
;  PRIOR APPLICATION NUMBER: 60/085,922
;  PRIOR FILING DATE: 1998-05-18
;  PRIOR APPLICATION NUMBER: 60/092,921
;  PRIOR FILING DATE: 1998-07-15
;  PRIOR APPLICATION NUMBER: 60/094,657
;  PRIOR FILING DATE: 1998-07-30
;  NUMBER OF SEQ ID NOS: 1245
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 899
;   LENGTH: 27
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-933-767-899

  Query Match           30.9%;  Score 30;  DB 10;  Length 27;
  Best Local Similarity  37.5%;  Pred. No. 7.7e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 53
US-10-004-860-898
; Sequence 898, Application US/10004860
; Publication No. US20030065160A1
; GENERAL INFORMATION:
;  APPLICANT: Young et al.
;  TITLE OF INVENTION: 207 Human Secreted Proteins
;  FILE REFERENCE: PZ007P1
;  CURRENT APPLICATION NUMBER: US/10/004,860
;  CURRENT FILING DATE:  2001-12-07
;  Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 1227
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 898
;   LENGTH: 27
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-004-860-898

  Query Match           30.9%;  Score 30;  DB 14;  Length 27;
  Best Local Similarity  37.5%;  Pred. No. 7.7e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 54
US-10-004-860-899
; Sequence 899, Application US/10004860
; Publication No. US20030065160A1
; GENERAL INFORMATION:
;  APPLICANT: Young et al.
;  TITLE OF INVENTION: 207 Human Secreted Proteins
;  FILE REFERENCE: PZ007P1
;  CURRENT APPLICATION NUMBER: US/10/004,860
;  CURRENT FILING DATE:  2001-12-07
;  Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 1227
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 899
;   LENGTH: 27
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-004-860-899

  Query Match           30.9%;  Score 30;  DB 14;  Length 27;
```

```
  Best Local Similarity   37.5%;  Pred. No. 7.7e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 55
US-10-023-282-898
; Sequence 898, Application US/10023282
; Publication No. US20030092893A1
; GENERAL INFORMATION:
;  APPLICANT: Young et al.
;  TITLE OF INVENTION: 207 Human Secreted Proteins
;  FILE REFERENCE: PZ007P1
;  CURRENT APPLICATION NUMBER: US/10/023,282
;  CURRENT FILING DATE: 2001-12-20
;  EARLIER APPLICATION NUMBER: 09/205,258
;  EARLIER FILING DATE: 1998-12-04
;  EARLIER APPLICATION NUMBER: PCT/US98/11422
;  EARLIER FILING DATE: 1998-06-04
;  EARLIER APPLICATION NUMBER: 60/048,885
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,375
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,881
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,880
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,896
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,020
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,876
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,895
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,884
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,894
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,971
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,964
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,882
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,899
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,893
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,900
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,901
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,892
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,915
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,019
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,970
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,972
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,916
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,373
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,875
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,374
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,917
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,949
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,974
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,883
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,897
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,898
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,962
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,963
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,877
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,878
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/070,923
;  EARLIER FILING DATE: 1997-12-18
;  EARLIER APPLICATION NUMBER: 60/092,921
;  EARLIER FILING DATE: 1998-07-15
;  EARLIER APPLICATION NUMBER: 60/094,657
;  EARLIER FILING DATE: 1998-07-30
;  NUMBER OF SEQ ID NOS: 1227
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 898
;   LENGTH: 27
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-023-282-898

  Query Match           30.9%;  Score 30;  DB 14;  Length 27;
  Best Local Similarity   37.5%;  Pred. No. 7.7e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 56
US-10-023-282-899
; Sequence 899, Application US/10023282
; Publication No. US20030092893A1
; GENERAL INFORMATION:
;  APPLICANT: Young et al.
;  TITLE OF INVENTION: 207 Human Secreted Proteins
;  FILE REFERENCE: PZ007P1
;  CURRENT APPLICATION NUMBER: US/10/023,282
;  CURRENT FILING DATE: 2001-12-20
;  EARLIER APPLICATION NUMBER: 09/205,258
;  EARLIER FILING DATE: 1998-12-04
;  EARLIER APPLICATION NUMBER: PCT/US98/11422
;  EARLIER FILING DATE: 1998-06-04
;  EARLIER APPLICATION NUMBER: 60/048,885
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,375
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,881
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,880
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,896
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,020
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,876
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,895
```

```
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,884
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,894
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,971
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,964
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,882
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,899
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,893
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,900
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,901
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,892
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,915
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,019
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,970
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,972
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,916
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,373
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,875
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,374
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,917
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,949
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,974
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,883
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,897
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,898
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,962
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,963
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,877
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,878
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/070,923
;  EARLIER FILING DATE: 1997-12-18
;  EARLIER APPLICATION NUMBER: 60/092,921
;  EARLIER FILING DATE: 1998-07-15
;  EARLIER APPLICATION NUMBER: 60/094,657
;  EARLIER FILING DATE: 1998-07-30
;  NUMBER OF SEQ ID NOS: 1227
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 899
;   LENGTH: 27
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-023-282-899

  Query Match             30.9%;  Score 30;  DB 14;  Length 27;
  Best Local Similarity   37.5%;  Pred. No. 7.7e+02;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQE 17
              |:  | : ||  :|:|
Db          6 PSANNQRFAFSPLSEE 21


RESULT 57
US-09-995-494-87
; Sequence 87, Application US/09995494
; Patent No. US20020127578A1
; GENERAL INFORMATION:
;  APPLICANT: Salceda, Susana
;  APPLICANT:  Macina, Roberto
;  APPLICANT:  Recipon, Herve
;  APPLICANT:  Cafferkey, Robert
;  APPLICANT:  Ali, Shujath
;  APPLICANT:  Sun, Yongming
;  APPLICANT:  Liu, Chenghua
;  APPLICANT:  Chen, Sei-Yu
;  TITLE OF INVENTION: Compositions and Methods Relating to Prostate Specific Genes and
;  FILE REFERENCE: DEX-0293
;  CURRENT APPLICATION NUMBER: US/09/995,494
;  CURRENT FILING DATE:  2001-11-27
;  PRIOR APPLICATION NUMBER: 60/253,176
;  PRIOR FILING DATE: 2000-11-27
;  NUMBER OF SEQ ID NOS: 115
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 87
;   LENGTH: 30
;   TYPE: PRT
;   ORGANISM: Homo sapien
US-09-995-494-87

  Query Match             30.9%;  Score 30;  DB 9;  Length 30;
  Best Local Similarity   45.5%;  Pred. No. 8.7e+02;
  Matches    5;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          7 SKIAFKIVSQE 17
              ||| |:::|:
Db         10 SKIVFQLLNQK 20


RESULT 58
US-10-011-585A-181
; Sequence 181, Application US/10011585A
; Publication No. US20030039986A1
; GENERAL INFORMATION:
;  APPLICANT: Sun, Yongming
;  APPLICANT:  Recipon, Herve
;  APPLICANT:  Chen, Sei-Yu
;  APPLICANT:  Liu, Chenghua
;  TITLE OF INVENTION: Compositions and Methods Relating to Prostate Specific
;  TITLE OF INVENTION:  Genes and Proteins
;  FILE REFERENCE: DEX-0261
;  CURRENT APPLICATION NUMBER: US/10/011,585A
;  CURRENT FILING DATE:  2002-03-14
;  PRIOR APPLICATION NUMBER: 60/245,740
;  PRIOR FILING DATE: 2000-11-03
;  NUMBER OF SEQ ID NOS: 245
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 181
;   LENGTH: 30
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-011-585A-181

  Query Match             30.9%;  Score 30;  DB 14;  Length 30;
  Best Local Similarity   46.2%;  Pred. No. 8.7e+02;
  Matches    6;  Conservative    1;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIVSQ 16
              |||    ||:  |
```

```
Db         13 HLNINFIFKLDQQ 25


RESULT 59
US-10-424-599-207820
; Sequence 207820, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 207820
;   LENGTH: 30
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_29688C.1.pep
US-10-424-599-207820

  Query Match             30.9%;  Score 30;  DB 15;  Length 30;
  Best Local Similarity   33.3%;  Pred. No. 8.7e+02;
  Matches    5;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQ 16
              | |:  |:  |:  |
Db          4 PTHIKVKVLVKVHPQ 18


RESULT 60
US-10-296-734-654
; Sequence 654, Application US/10296734
; Publication No. US20040054137A1
; GENERAL INFORMATION:
;  APPLICANT: Thompson, Scott A
;  APPLICANT:  Ramshaw, Ian A
;  TITLE OF INVENTION: Synthetic molecules and uses therefor
;  FILE REFERENCE: Savine
;  CURRENT APPLICATION NUMBER: US/10/296,734
;  CURRENT FILING DATE:  2003-08-04
;  PRIOR APPLICATION NUMBER: AU PQ7761/00
;  PRIOR FILING DATE: 2000-05-26
;  NUMBER OF SEQ ID NOS: 1507
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 654
;   LENGTH: 30
;   TYPE: PRT
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: HepC 1a segment 124
US-10-296-734-654

  Query Match             30.9%;  Score 30;  DB 15;  Length 30;
  Best Local Similarity   66.7%;  Pred. No. 8.7e+02;
  Matches    6;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          9 IAFKIVSQE 17
              :||||:| |
Db         21 VAFKIMSGE 29


RESULT 61
US-10-296-734-656
; Sequence 656, Application US/10296734
; Publication No. US20040054137A1
; GENERAL INFORMATION:
;  APPLICANT: Thompson, Scott A
;  APPLICANT:  Ramshaw, Ian A
;  TITLE OF INVENTION: Synthetic molecules and uses therefor
;  FILE REFERENCE: Savine
;  CURRENT APPLICATION NUMBER: US/10/296,734
;  CURRENT FILING DATE:  2003-08-04
;  PRIOR APPLICATION NUMBER: AU PQ7761/00
;  PRIOR FILING DATE: 2000-05-26
;  NUMBER OF SEQ ID NOS: 1507
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 656
;   LENGTH: 30
;   TYPE: PRT
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: HepC 1a segment 125
US-10-296-734-656

  Query Match             30.9%;  Score 30;  DB 15;  Length 30;
  Best Local Similarity   66.7%;  Pred. No. 8.7e+02;
  Matches    6;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          9 IAFKIVSQE 17
              :||||:| |
Db          6 VAFKIMSGE 14


RESULT 62
US-10-050-704-215
; Sequence 215, Application US/10050704
; Publication No. US20030050442A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: 62 Human Secreted Proteins
;  FILE REFERENCE: PZ039P1
;  CURRENT APPLICATION NUMBER: US/10/050,704
;  CURRENT FILING DATE:  2002-01-18
;  PRIOR APPLICATION NUMBER: 09/684,524
;  PRIOR FILING DATE: 2000-10-10
;  PRIOR APPLICATION NUMBER: PCT/US00/08979
;  PRIOR FILING DATE: 2000-04-06
;  PRIOR APPLICATION NUMBER: 60/128,693
;  PRIOR FILING DATE: 1999-04-09
;  PRIOR APPLICATION NUMBER: 60/130,991
;  PRIOR FILING DATE: 1999-04-26
;  NUMBER OF SEQ ID NOS: 344
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 215
;   LENGTH: 31
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-050-704-215

  Query Match             30.9%;  Score 30;  DB 14;  Length 31;
  Best Local Similarity   33.3%;  Pred. No. 9e+02;
  Matches    5;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQ 16
              ||::  |    :| |
Db          5 PNNIRHKFGSNVVDQ 19


RESULT 63
US-10-798-512-215
; Sequence 215, Application US/10798512
; Publication No. US20040152164A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: 62 Human Secreted Proteins
;  FILE REFERENCE: PZ039P1
;  CURRENT APPLICATION NUMBER: US/10/798,512
;  CURRENT FILING DATE:  2004-03-12
;  PRIOR APPLICATION NUMBER: US/09/684,524
;  PRIOR FILING DATE: 2000-10-10
```

```
;  PRIOR APPLICATION NUMBER: PCT/US00/08979
;  PRIOR FILING DATE: 2000-04-06
;  PRIOR APPLICATION NUMBER: 60/128,693
;  PRIOR FILING DATE: 1999-04-09
;  PRIOR APPLICATION NUMBER: 60/130,991
;  PRIOR FILING DATE: 1999-04-26
;  NUMBER OF SEQ ID NOS: 344
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 215
;   LENGTH: 31
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-798-512-215

  Query Match             30.9%;  Score 30;  DB 16;  Length 31;
  Best Local Similarity   33.3%;  Pred. No. 9e+02;
  Matches    5;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIVSQ 16
              ||::  |    :| |
Db          5 PNNIRHKFGSNVVDQ 19


RESULT 64
US-10-106-698-5968
; Sequence 5968, Application US/10106698
; Publication No. US20030109690A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: Colon and Colon Cancer Associated Polynucleotides and Polypeptide
;  FILE REFERENCE: PA005P1
;  CURRENT APPLICATION NUMBER: US/10/106,698
;  CURRENT FILING DATE:  2002-03-27
;  PRIOR APPLICATION NUMBER: PCT/US00/26524
;  PRIOR FILING DATE: 2000-09-28
;  PRIOR APPLICATION NUMBER: US 60/157,137
;  PRIOR FILING DATE: 1999-09-29
;  PRIOR APPLICATION NUMBER: US 60/163,280
;  PRIOR FILING DATE: 1999-11-03
;  NUMBER OF SEQ ID NOS: 8564
;  SOFTWARE: PatentIn Ver. 3.0
; SEQ ID NO 5968
;   LENGTH: 32
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: MISC_FEATURE
;   LOCATION: (20)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-10-106-698-5968

  Query Match             30.9%;  Score 30;  DB 14;  Length 32;
  Best Local Similarity   77.8%;  Pred. No. 9.3e+02;
  Matches    7;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          8 KIAFKIVSQ 16
              |||:||| |
Db          5 KIAWKIVIQ 13


RESULT 65
US-10-300-083-13
; Sequence 13, Application US/10300083
; Publication No. US20030153502A1
;   GENERAL INFORMATION:
;        APPLICANT: REGENTS OF THE UNIVERSITY OF MINNESOTA
;        TITLE OF INVENTION: SYNTHETIC APPROACH TO DESIGNED CHEMICAL
;                            STRUCTURES
;        NUMBER OF SEQUENCES: 38
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: MUETING, RAASCH, GEBHARDT & SCHWAPPACH, P.A.
;             STREET: 119 No. US20030153502A1th Fourth Street, Suite 203
;             CITY: Minneapolis
;             STATE: Minnesota
;             COUNTRY: U.S.A.
;             ZIP: 55401
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/300,083
;             FILING DATE: 20-No. US20030153502A1-2002
;             CLASSIFICATION: <Unknown
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/194,296
;             FILING DATE: 15-Oct-1999
;             APPLICATION NUMBER: US 08/653,632
;             FILING DATE: 24-MAY-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: MCCORMACK, MYRA M.
;             REGISTRATION NUMBER: 36,602
;             REFERENCE/DOCKET NUMBER: 110.00330220
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 612-305-1225
;             TELEFAX: 612-305-1228
;   INFORMATION FOR SEQ ID NO: 13:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 33 amino acids
;             TYPE: amino acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-10-300-083-13

  Query Match             30.9%;  Score 30;  DB 14;  Length 33;
  Best Local Similarity   60.0%;  Pred. No. 9.7e+02;
  Matches    6;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKI 13
              ||  || ||:
Db         15 HLKWKIIFKL 24


RESULT 66
US-10-424-599-154283
; Sequence 154283, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 154283
;   LENGTH: 34
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_110339C.1.pep
US-10-424-599-154283

  Query Match             30.9%;  Score 30;  DB 15;  Length 34;
  Best Local Similarity   45.5%;  Pred. No. 1e+03;
  Matches    5;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKI 13
              |:|:|  : ||:
Db         13 NYLDSTMTFKL 23
```

```
RESULT 67
US-10-437-963-139274
; Sequence 139274, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 139274
;   LENGTH: 36
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_40582C.1.pep
US-10-437-963-139274

  Query Match             30.9%;  Score 30;  DB 16;  Length 36;
  Best Local Similarity   42.9%;  Pred. No. 1.1e+03;
  Matches    6;  Conservative    2;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIVSQE 17
              ||    | ||::  |
Db          3 HLPQYILFKLMQDE 16


RESULT 68
US-10-437-963-176739
; Sequence 176739, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 176739
;   LENGTH: 36
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_7445C.1.pep
US-10-437-963-176739

  Query Match             30.9%;  Score 30;  DB 16;  Length 36;
  Best Local Similarity   35.7%;  Pred. No. 1.1e+03;
  Matches    5;  Conservative    5;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQ 16
              :| :|::||   |:
Db         13 DHRSSQVAFSTYSE 26


RESULT 69
US-09-809-391-545
; Sequence 545, Application US/09809391
; Publication No. US20030049618A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: 186 Human Secreted proteins
;  FILE REFERENCE: PZ002P2
;  CURRENT APPLICATION NUMBER: US/09/809,391
;  CURRENT FILING DATE:  2001-03-16
;  Prior application data removed - consult PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 761
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 545
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-809-391-545

  Query Match             30.9%;  Score 30;  DB 10;  Length 39;
  Best Local Similarity   58.3%;  Pred. No. 1.2e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38


RESULT 70
US-09-882-171-545
; Sequence 545, Application US/09882171
; Publication No. US20030175858A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: 186 Human Secreted proteins
;  FILE REFERENCE: PZ002P2
;  CURRENT APPLICATION NUMBER: US/09/882,171
;  CURRENT FILING DATE:  2001-06-18
;  PRIOR APPLICATION NUMBER: 09/809,391
;  PRIOR FILING DATE: 2001-03-16
;  PRIOR APPLICATION NUMBER: 09/149,476
;  PRIOR FILING DATE: 1998-09-08
;  PRIOR APPLICATION NUMBER: PCT/US98/04493
;  PRIOR FILING DATE: 1998-03-06
;  PRIOR APPLICATION NUMBER: 60/040,162
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,333
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/038,621
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,626
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,334
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,336
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,163
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/047,600
;  PRIOR FILING DATE: 1997-05-23
;  PRIOR APPLICATION NUMBER: 60/047,615
;  PRIOR FILING DATE: 1997-05-23
;  PRIOR APPLICATION NUMBER: 60/047,597
;  PRIOR FILING DATE: 1997-05-23
;  PRIOR APPLICATION NUMBER: 60/047,502
;  PRIOR FILING DATE: 1997-05-23
;  PRIOR APPLICATION NUMBER: 60/047,633
;  PRIOR FILING DATE: 1997-05-23
;  PRIOR APPLICATION NUMBER: 60/047,583
;  PRIOR FILING DATE: 1997-05-23
;  PRIOR APPLICATION NUMBER: 60/047,617
;  PRIOR FILING DATE: 1997-05-23
```

; PRIOR APPLICATION NUMBER: 60/047,618
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,503
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,592
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,581
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,584
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,500
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,587
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,492
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,598
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,613
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,582
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,596
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,612
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,632
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,601
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,580
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,568
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,314
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,569
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,311
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,671
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,674
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,669
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,312
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,313
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,672
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,315
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/048,974
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/056,886
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,877
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,889
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,893
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,630
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,878
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,662
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,872
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,882
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,637
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,903
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,888
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,879
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,880
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,894
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,911
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,636
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,874
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,910
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,864
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,631
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,845
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,892
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/057,761
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/047,595
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,599
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,588
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,585
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,586
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,590
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,594
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,589
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,593
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,614
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,578
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,576
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/047,501
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,670
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/056,632
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,664
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,876
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,881
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,909
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,875
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,862
; PRIOR FILING DATE: 1997-08-22

```
;  PRIOR APPLICATION NUMBER: 60/056,887
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,908
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/048,964
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/057,650
;  PRIOR FILING DATE: 1997-09-05
;  PRIOR APPLICATION NUMBER: 60/056,884
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/057,669
;  PRIOR FILING DATE: 1997-09-05

  Query Match             30.9%;  Score 30;  DB 10;  Length 39;
  Best Local Similarity   58.3%;  Pred. No. 1.2e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILPFIV 38


RESULT 71
US-09-962-756-202
; Sequence 202, Application US/09962756
; Publication No. US20030195147A1
; GENERAL INFORMATION:
;  APPLICANT: PILLUTLA, RENUKA
;  APPLICANT:  BRISSETTE, RENEE
;  APPLICANT:  BLUME, ARTHUR J.
;  APPLICANT:  SCHAFFER, LAUGE
;  APPLICANT:  BRANDT, JAKOB
;  APPLICANT:  GOLDSTEIN, NEIL I.
;  APPLICANT:  SPETZLER, JANE
;  APPLICANT:  OSTERGAARD, SOREN
;  APPLICANT:  HANSEN, PER HERTZ
;  TITLE OF INVENTION: INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS
;  FILE REFERENCE: 1878-4051US1
;  CURRENT APPLICATION NUMBER: US/09/962,756
;  CURRENT FILING DATE:  2001-09-24
;  PRIOR APPLICATION NUMBER: 09/538,038
;  PRIOR FILING DATE: 2000-03-29
;  PRIOR APPLICATION NUMBER: 09/146,127
;  PRIOR FILING DATE: 1998-09-02
;  NUMBER OF SEQ ID NOS: 2227
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 202
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-09-962-756-202

  Query Match             30.9%;  Score 30;  DB 10;  Length 39;
  Best Local Similarity   60.0%;  Pred. No. 1.2e+03;
  Matches    6;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         10 AFKIVSQEPA 19
              | |:||: ||
Db         14 ASKVVSEPPA 23


RESULT 72
US-10-132-585-4
; Sequence 4, Application US/10132585
; Publication No. US20030055234A1
; GENERAL INFORMATION:
;  APPLICANT: Kapeller-Libermann, Rosanna
;  TITLE OF INVENTION: 26030, A HUMAN RHO-GAP FAMILY MEMBER AND
;  TITLE OF INVENTION:  USES THEREFOR
;  FILE REFERENCE: MPI01-101P1RM
;  CURRENT APPLICATION NUMBER: US/10/132,585
;  CURRENT FILING DATE:  2002-04-25
;  PRIOR APPLICATION NUMBER: 60/286,581
;  PRIOR FILING DATE: 2001-04-25
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: unknown
;   FEATURE:
;   OTHER INFORMATION: PFAM consensus rhoGAP domain
US-10-132-585-4

  Query Match             30.9%;  Score 30;  DB 14;  Length 39;
  Best Local Similarity   50.0%;  Pred. No. 1.2e+03;
  Matches    5;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKI 13
              |||  :|| :
Db         30 HLNMNLAFPL 39


RESULT 73
US-10-106-698-5006
; Sequence 5006, Application US/10106698
; Publication No. US20030109690A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: Colon and Colon Cancer Associated Polynucleotides and Polypeptid
;  FILE REFERENCE: PA005P1
;  CURRENT APPLICATION NUMBER: US/10/106,698
;  CURRENT FILING DATE:  2002-03-27
;  PRIOR APPLICATION NUMBER: PCT/US00/26524
;  PRIOR FILING DATE: 2000-09-28
;  PRIOR APPLICATION NUMBER: US 60/157,137
;  PRIOR FILING DATE: 1999-09-29
;  PRIOR APPLICATION NUMBER: US 60/163,280
;  PRIOR FILING DATE: 1999-11-03
;  NUMBER OF SEQ ID NOS: 8564
;  SOFTWARE: PatentIn Ver. 3.0
; SEQ ID NO 5006
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-106-698-5006

  Query Match             30.9%;  Score 30;  DB 14;  Length 39;
  Best Local Similarity   42.9%;  Pred. No. 1.2e+03;
  Matches    6;  Conservative    4;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKIV 14
              :|::|| |:   ||
Db         19 KPHYLNIKLPNNIV 32


RESULT 74
US-10-164-861-545
; Sequence 545, Application US/10164861
; Publication No. US20030225248A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: 186 Human Secreted proteins
;  FILE REFERENCE: PZ002P1
;  CURRENT APPLICATION NUMBER: US/10/164,861
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: US/09/149,476
;  PRIOR FILING DATE: 1998-09-08
;  PRIOR APPLICATION NUMBER: PCT/US98/04493
;  PRIOR FILING DATE: 1998-03-06
;  NUMBER OF SEQ ID NOS: 757
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 545
```

```
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-164-861-545

  Query Match             30.9%;  Score 30;  DB 14;  Length 39;
  Best Local Similarity   58.3%;  Pred. No. 1.2e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38


RESULT 75
US-10-253-471-202
; Sequence 202, Application US/10253471
; Publication No. US20030236190A1
; GENERAL INFORMATION:
;  APPLICANT: PILLUTLA, RENUKA et al.
;  TITLE OF INVENTION: INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS
;  FILE REFERENCE: 1878-4057
;  CURRENT APPLICATION NUMBER: US/10/253,471
;  CURRENT FILING DATE:  2002-09-24
;  PRIOR APPLICATION NUMBER: 09/962,756
;  PRIOR FILING DATE: 2001-09-24
;  PRIOR APPLICATION NUMBER: 09/538,038
;  PRIOR FILING DATE: 2000-03-29
;  PRIOR APPLICATION NUMBER: 09/146,127
;  PRIOR FILING DATE: 1998-09-02
;  NUMBER OF SEQ ID NOS: 2227
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 202
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-253-471-202

  Query Match             30.9%;  Score 30;  DB 14;  Length 39;
  Best Local Similarity   60.0%;  Pred. No. 1.2e+03;
  Matches    6;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         10 AFKIVSQEPA 19
              | |:||: ||
Db         14 ASKVVSEPPA 23


RESULT 76
US-10-253-493-202
; Sequence 202, Application US/10253493
; Publication No. US20040023887A1
; GENERAL INFORMATION:
;  APPLICANT: PILLUTLA, RENUKA et al.
;  TITLE OF INVENTION: INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS
;  FILE REFERENCE: 1878-4056
;  CURRENT APPLICATION NUMBER: US/10/253,493
;  CURRENT FILING DATE:  2002-09-24
;  PRIOR APPLICATION NUMBER: 09/962,756
;  PRIOR FILING DATE: 2001-09-24
;  PRIOR APPLICATION NUMBER: 09/538,038
;  PRIOR FILING DATE: 2000-03-29
;  PRIOR APPLICATION NUMBER: 09/146,127
;  PRIOR FILING DATE: 1998-09-02
;  NUMBER OF SEQ ID NOS: 2227
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 202
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: peptide
US-10-253-493-202

  Query Match             30.9%;  Score 30;  DB 15;  Length 39;
  Best Local Similarity   60.0%;  Pred. No. 1.2e+03;
  Matches    6;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy         10 AFKIVSQEPA 19
              | |:||: ||
Db         14 ASKVVSEPPA 23


RESULT 77
US-09-809-391-381
; Sequence 381, Application US/09809391
; Publication No. US20030049618A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: 186 Human Secreted proteins
;  FILE REFERENCE: PZ002P2
;  CURRENT APPLICATION NUMBER: US/09/809,391
;  CURRENT FILING DATE:  2001-03-16
;  Prior application data removed - consult PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 761
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 381
;   LENGTH: 40
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (40)
;   OTHER INFORMATION: Xaa equals stop translation
US-09-809-391-381

  Query Match             30.9%;  Score 30;  DB 10;  Length 40;
  Best Local Similarity   58.3%;  Pred. No. 1.2e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38


RESULT 78
US-09-882-171-381
; Sequence 381, Application US/09882171
; Publication No. US20030175858A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: 186 Human Secreted proteins
;  FILE REFERENCE: PZ002P2
;  CURRENT APPLICATION NUMBER: US/09/882,171
;  CURRENT FILING DATE:  2001-06-18
;  PRIOR APPLICATION NUMBER: 09/809,391
;  PRIOR FILING DATE: 2001-03-16
;  PRIOR APPLICATION NUMBER: 09/149,476
;  PRIOR FILING DATE: 1998-09-08
;  PRIOR APPLICATION NUMBER: PCT/US98/04493
;  PRIOR FILING DATE: 1998-03-06
;  PRIOR APPLICATION NUMBER: 60/040,162
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,333
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/038,621
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,626
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,334
;  PRIOR FILING DATE: 1997-03-07
;  PRIOR APPLICATION NUMBER: 60/040,336
;  PRIOR FILING DATE: 1997-03-07
```

; PRIOR APPLICATION NUMBER: 60/040,163
; PRIOR FILING DATE: 1997-03-07
; PRIOR APPLICATION NUMBER: 60/047,600
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,615
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,597
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,502
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,633
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,583
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,617
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,618
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,503
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,592
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,581
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,584
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,500
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,587
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,492
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,598
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,613
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,582
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,596
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,612
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,632
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,601
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,580
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,568
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,314
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,569
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,311
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,671
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,674
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,669
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,312
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,313
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,672
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,315
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/048,974
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/056,886
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,877
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,889
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,893
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,630
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,878
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,662
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,872
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,882
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,637
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,903
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,888
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,879
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,880
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,894
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,911
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,636
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,874
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,910
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,864
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,631
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,845
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,892
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/057,761
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/047,595
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,599
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,588
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,585
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,586
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,590
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,594
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,589
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,593
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,614
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,578
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,576
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/047,501
; PRIOR FILING DATE: 1997-05-23

```
;  PRIOR APPLICATION NUMBER: 60/043,670
;  PRIOR FILING DATE: 1997-04-11
;  PRIOR APPLICATION NUMBER: 60/056,632
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,664
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,876
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,881
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,909
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,875
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,862
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,887
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/056,908
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/048,964
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/057,650
;  PRIOR FILING DATE: 1997-09-05
;  PRIOR APPLICATION NUMBER: 60/056,884
;  PRIOR FILING DATE: 1997-08-22
;  PRIOR APPLICATION NUMBER: 60/057,669
;  PRIOR FILING DATE: 1997-09-05

  Query Match             30.9%;  Score 30;  DB 10;  Length 40;
  Best Local Similarity   58.3%;  Pred. No. 1.2e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38


RESULT 79
US-10-144-259-29
; Sequence 29, Application US/10144259
; Publication No. US20030109691A1
; GENERAL INFORMATION:
;  APPLICANT: Arnaout, M. Amin
;  APPLICANT:  Li, Rui
;  APPLICANT:  Xiong, Jian-Ping
;  TITLE OF INVENTION: VARIANT INTEGRIN POLYPEPTIDES AND USES THEREOF
;  FILE REFERENCE: 00786-548001
;  CURRENT APPLICATION NUMBER: US/10/144,259
;  CURRENT FILING DATE:  2002-09-04
;  PRIOR APPLICATION NUMBER: US 09/758,493
;  PRIOR FILING DATE: 2001-01-11
;  PRIOR APPLICATION NUMBER: US 60/221,950
;  PRIOR FILING DATE: 2000-07-31
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29
;   LENGTH: 40
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-144-259-29

  Query Match             30.9%;  Score 30;  DB 14;  Length 40;
  Best Local Similarity   46.2%;  Pred. No. 1.2e+03;
  Matches    6;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQE 17
              | ||: : |:| |
Db          7 LLSKLRYNIISME 19


RESULT 80
US-10-164-861-381
; Sequence 381, Application US/10164861
; Publication No. US20030225248A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: 186 Human Secreted proteins
;  FILE REFERENCE: PZ002P1
;  CURRENT APPLICATION NUMBER: US/10/164,861
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: US/09/149,476
;  PRIOR FILING DATE: 1998-09-08
;  PRIOR APPLICATION NUMBER: PCT/US98/04493
;  PRIOR FILING DATE: 1998-03-06
;  NUMBER OF SEQ ID NOS: 757
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 381
;   LENGTH: 40
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (40)
;   OTHER INFORMATION: Xaa equals stop translation
US-10-164-861-381

  Query Match             30.9%;  Score 30;  DB 14;  Length 40;
  Best Local Similarity   58.3%;  Pred. No. 1.2e+03;
  Matches    7;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |||  :| | ||
Db         27 NHLAFRILFFIV 38


RESULT 81
US-10-424-599-267336
; Sequence 267336, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 267336
;   LENGTH: 40
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_83426C.1.pep
US-10-424-599-267336

  Query Match             30.9%;  Score 30;  DB 15;  Length 40;
  Best Local Similarity   85.7%;  Pred. No. 1.2e+03;
  Matches    6;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          9 IAFKIVS 15
              :||||||
Db          9 VAFKIVS 15


RESULT 82
US-10-424-599-278809
; Sequence 278809, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
```

```
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 278809
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_93788C.1.pep
US-10-424-599-278809

  Query Match             30.9%;  Score 30;  DB 15;  Length 44;
  Best Local Similarity   50.0%;  Pred. No. 1.3e+03;
  Matches    6;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              ||| ||   ::|
Db         10 NHLWSKSTMRVV 21


RESULT 83
US-10-437-963-154105
; Sequence 154105, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 154105
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_53998C.1.pep
US-10-437-963-154105

  Query Match             30.9%;  Score 30;  DB 16;  Length 44;
  Best Local Similarity   45.5%;  Pred. No. 1.3e+03;
  Matches    5;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFK 12
              ||| : |  :|
Db          2 PNHFSVKTYYK 12


RESULT 84
US-10-424-599-228808
; Sequence 228808, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 228808
;   LENGTH: 45
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(45)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_48640C.1.pep
US-10-424-599-228808

  Query Match             30.9%;  Score 30;  DB 15;  Length 45;
  Best Local Similarity   58.3%;  Pred. No. 1.4e+03;
  Matches    7;  Conservative    2;  Mismatches    1;  Indels    2;  Gaps    1;

Qy          3 NHLNSKIAFKIV 14
              ||  :|: ||||
Db          7 NH--TKLTFKIV 16


RESULT 85
US-09-764-877-1428
; Sequence 1428, Application US/09764877
; Patent No. US20020147140A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC005
;  CURRENT APPLICATION NUMBER: US/09/764,877
;  CURRENT FILING DATE:  2001-01-17
;  Prior application data removed - refer to PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 4031
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1428
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-764-877-1428

  Query Match             30.9%;  Score 30;  DB 9;  Length 46;
  Best Local Similarity   41.7%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              |: ::|||: :|
Db         28 LSQEVAFKLSTQ 39


RESULT 86
US-10-242-515-1428
; Sequence 1428, Application US/10242515
; Publication No. US20040009488A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC005C1
;  CURRENT APPLICATION NUMBER: US/10/242,515
;  CURRENT FILING DATE:  2002-09-13
;  PRIOR APPLICATION NUMBER: 09/764,877
;  PRIOR FILING DATE: 2001-01-17
;  PRIOR APPLICATION NUMBER: 60/179,065
;  PRIOR FILING DATE: 2000-01-31
;  PRIOR APPLICATION NUMBER: 60/180,628
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: 60/214,886
;  PRIOR FILING DATE: 2000-06-28
;  PRIOR APPLICATION NUMBER: 60/217,487
;  PRIOR FILING DATE: 2000-07-11
;  PRIOR APPLICATION NUMBER: 60/225,758
;  PRIOR FILING DATE: 2000-08-14
```

```
;  PRIOR APPLICATION NUMBER: 60/220,963
;  PRIOR FILING DATE: 2000-07-26
;  PRIOR APPLICATION NUMBER: 60/217,496
;  PRIOR FILING DATE: 2000-07-11
;  PRIOR APPLICATION NUMBER: 60/225,447
;  PRIOR FILING DATE: 2000-08-14
;  PRIOR APPLICATION NUMBER: 60/218,290
;  PRIOR FILING DATE: 2000-07-14
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 4031
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1428
;    LENGTH: 46
;    TYPE: PRT
;    ORGANISM: Homo sapiens
US-10-242-515-1428

  Query Match             30.9%;  Score 30;  DB 15;  Length 46;
  Best Local Similarity   41.7%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQ 16
              |: ::|||: :|
Db         28 LSQEVAFKLSTQ 39


RESULT 87
US-10-424-599-264089
; Sequence 264089, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 264089
;    LENGTH: 47
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT3847_80493C.1.pep
US-10-424-599-264089

  Query Match             30.9%;  Score 30;  DB 15;  Length 47;
  Best Local Similarity   54.5%;  Pred. No. 1.4e+03;
  Matches    6;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKI 13
              | |  || ||:
Db          7 NKLEGKIHFKV 17


RESULT 88
US-10-424-599-208160
; Sequence 208160, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 208160
;    LENGTH: 48
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT3847_29995C.1.pep
US-10-424-599-208160

  Query Match             30.9%;  Score 30;  DB 15;  Length 48;
  Best Local Similarity   42.9%;  Pred. No. 1.5e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQ 16
              || |||  | : ::
Db         33 NHPNSKNKFLVQNE 46


RESULT 89
US-10-424-599-264585
; Sequence 264585, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 264585
;    LENGTH: 48
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT3847_80940C.1.pep
US-10-424-599-264585

  Query Match             30.9%;  Score 30;  DB 15;  Length 48;
  Best Local Similarity   54.5%;  Pred. No. 1.5e+03;
  Matches    6;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIV 14
              |: |||  |:|
Db         26 HVISKIKLKVV 36


RESULT 90
US-10-424-599-231764
; Sequence 231764, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 231764
;    LENGTH: 49
;    TYPE: PRT
;    ORGANISM: Glycine max
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT3847_51305C.1.pep
US-10-424-599-231764

  Query Match             30.9%;  Score 30;  DB 15;  Length 49;
```

```
  Best Local Similarity   38.9%;  Pred. No. 1.5e+03;
  Matches    7;  Conservative    3;  Mismatches    6;  Indels    2;  Gaps    1;

Qy          3 NH--LNSKIAFKIVSQEP 18
              ||  ||:   ||::   |
Db         16 NHPFLNTNSNFKVILLHP 33


RESULT 91
US-10-424-599-239689
; Sequence 239689, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 239689
;   LENGTH: 49
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_58464C.1.pep
US-10-424-599-239689

  Query Match             30.9%;  Score 30;  DB 15;  Length 49;
  Best Local Similarity   83.3%;  Pred. No. 1.5e+03;
  Matches    5;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 NHLNSK 8
              ||||:|
Db         30 NHLNTK 35


RESULT 92
US-10-424-599-244508
; Sequence 244508, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 244508
;   LENGTH: 49
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_62818C.1.pep
US-10-424-599-244508

  Query Match             30.9%;  Score 30;  DB 15;  Length 49;
  Best Local Similarity   46.7%;  Pred. No. 1.5e+03;
  Matches    7;  Conservative    2;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              ||      |||::||
Db         22 NHEYKAPFFKILTQE 36


RESULT 93
US-10-437-963-134140
; Sequence 134140, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 134140
;   LENGTH: 49
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_35942C.1.pep
US-10-437-963-134140

  Query Match             30.9%;  Score 30;  DB 16;  Length 49;
  Best Local Similarity   50.0%;  Pred. No. 1.5e+03;
  Matches    8;  Conservative    1;  Mismatches    3;  Indels    4;  Gaps    1;

Qy          2 PNHLNSK----IAFKI 13
              ||||  |      |||:
Db         33 PNHLIKKKRLSRAFKV 48


RESULT 94
US-09-864-408A-4082
; Sequence 4082, Application US/09864408A
; Publication No. US20040009474A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Shimkets, Richard A.
;  TITLE OF INVENTION: No. US20040009474A1el Human Polynucleotides and Polypeptides Enc
;  FILE REFERENCE: 21402-012
;  CURRENT APPLICATION NUMBER: US/09/864,408A
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: 60/206,690
;  PRIOR FILING DATE: 2000-05-24
;  NUMBER OF SEQ ID NOS: 9068
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4082
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (16)..(16)
;   OTHER INFORMATION: Wherein Xaa may be any naturally occuring amino acid
US-09-864-408A-4082

  Query Match             30.9%;  Score 30;  DB 11;  Length 50;
  Best Local Similarity   37.5%;  Pred. No. 1.5e+03;
  Matches    6;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKIVSQ 16
              |  |:|  ||  : |:
Db         33 EEGHMNGLIAVTLCSR 48


RESULT 95
US-10-437-963-125237
; Sequence 125237, Application US/10437963
; Publication No. US20040123343A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 125237
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_27900C.1.pep
US-10-437-963-125237

  Query Match             30.9%;  Score 30;  DB 16;  Length 50;
  Best Local Similarity   21.4%;  Pred. No. 1.5e+03;
  Matches    3;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQ 16
              :|||:::: : :::
Db         20 SHLNTRLSIQTIAK 33


RESULT 96
US-10-164-359-12
; Sequence 12, Application US/10164359
; Publication No. US20030012776A1
; GENERAL INFORMATION:
;  APPLICANT: Chin, Khew-Voon
;  TITLE OF INVENTION: Nucleic Acid and Protein Expressed Thereby and Their Involvement
;  TITLE OF INVENTION:  Stress
;  FILE REFERENCE: 601-1-108US
;  CURRENT APPLICATION NUMBER: US/10/164,359
;  CURRENT FILING DATE:  2002-08-06
;  PRIOR APPLICATION NUMBER: PCT/US00/33438
;  PRIOR FILING DATE: 2000-12-07
;  PRIOR APPLICATION NUMBER: 60/169,418
;  PRIOR FILING DATE: 1999-12-07
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 24
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-164-359-12

  Query Match             29.9%;  Score 29;  DB 14;  Length 24;
  Best Local Similarity   62.5%;  Pred. No. 9.9e+02;
  Matches    5;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKI 9
              |:|||  |
Db         11 PDHLNGHI 18


RESULT 97
US-10-413-785-6
; Sequence 6, Application US/10413785
; Publication No. US20030229906A1
; GENERAL INFORMATION:
;  APPLICANT: Gelman et al.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF HIV
;  TITLE OF INVENTION:  INFECTION
;  FILE REFERENCE: 29636/38269A
;  CURRENT APPLICATION NUMBER: US/10/413,785
;  CURRENT FILING DATE:  2003-04-14
;  PRIOR APPLICATION NUMBER: US 60/372,557
;  PRIOR FILING DATE: 2002-04-15
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
;   LENGTH: 24
;   TYPE: PRT
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic peptide
US-10-413-785-6

  Query Match             29.9%;  Score 29;  DB 14;  Length 24;
  Best Local Similarity   41.7%;  Pred. No. 9.9e+02;
  Matches    5;  Conservative    2;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          8 KIAFKIVSQEPA 19
              |: | :  | ||
Db          8 KVGFPVTPQVPA 19


RESULT 98
US-10-437-963-177203
; Sequence 177203, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 177203
;   LENGTH: 26
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_74879C.1.pep
US-10-437-963-177203

  Query Match             29.9%;  Score 29;  DB 16;  Length 26;
  Best Local Similarity   64.3%;  Pred. No. 1.1e+03;
  Matches    9;  Conservative    0;  Mismatches    3;  Indels    2;  Gaps    1;

Qy          4 HLNSKIAFKIVSQE 17
              || |  |||| | |
Db          6 HLES--AFKIFSIE 17


RESULT 99
US-09-864-761-40576
; Sequence 40576, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
```

```
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 40576
;   LENGTH: 28
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AL109824.21
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL =   1
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.1
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.1
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.83
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 0.96
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.4
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL =   1
US-09-864-761-40576

  Query Match             29.9%;  Score 29;  DB 9;  Length 28;
  Best Local Similarity   42.9%;  Pred. No. 1.2e+03;
  Matches    6;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          5 LNSKIAFKIVSQEP 18
              | ||  :| | : :|
Db          5 LKSKASFSIYAFDP 18


RESULT 100
US-09-982-172-128
; Sequence 128, Application US/09982172
; Patent No. US20020137119A1
; GENERAL INFORMATION:
;  APPLICANT: Emil Israel Katz
;  TITLE OF INVENTION: PEPTIDES REPRESENTATIVE OF POLYPEPTIDES OF INTEREST AND ANTIBODIE
;  TITLE OF INVENTION:  DIRECTED THEREAGAINST, AND METHODS, SYSTEMS AND KITS FOR GENERAT
;  TITLE OF INVENTION:  UTILIZING EACH
;  FILE REFERENCE: 01/22283
;  CURRENT APPLICATION NUMBER: US/09/982,172
;  CURRENT FILING DATE:  2001-10-19
;  NUMBER OF SEQ ID NOS: 253
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 128
;   LENGTH: 28
;   TYPE: PRT
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Computer generated synthetic peptide
US-09-982-172-128

  Query Match             29.9%;  Score 29;  DB 9;  Length 28;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+03;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 IVSQEP 18
              ||||||
Db          5 IVSQEP 10


RESULT 101
US-10-029-386-29166
; Sequence 29166, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 29166
;   LENGTH: 32
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO CHR7.1
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.4
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.1
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.1
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.4
US-10-029-386-29166

  Query Match             29.9%;  Score 29;  DB 14;  Length 32;
  Best Local Similarity   71.4%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         12 KIVSQEP 18
              |:||:||
Db         17 KVVSREP 23


RESULT 102
US-09-764-891-4901
; Sequence 4901, Application US/09764891
; Publication No. US20030077808A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC006
;  CURRENT APPLICATION NUMBER: US/09/764,891
;  CURRENT FILING DATE:  2001-01-17
;  Prior application data removed - consult PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 10231
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4901
;   LENGTH: 33
```

```
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (29)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-891-4901

  Query Match             29.9%;  Score 29;  DB 10;  Length 33;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              ||| | |:: |
Db         14 PNKLTSQLTF 23


RESULT 103
US-10-091-414-161
; Sequence 161, Application US/10091414
; Publication No. US20030224461A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PA116C1
;  CURRENT APPLICATION NUMBER: US/10/091,414
;  CURRENT FILING DATE:  2002-03-07
;  Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 392
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 161
;   LENGTH: 33
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (29)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-10-091-414-161

  Query Match             29.9%;  Score 29;  DB 14;  Length 33;
  Best Local Similarity   50.0%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAF 11
              ||| | |:: |
Db         14 PNKLTSQLTF 23


RESULT 104
US-10-413-785-4
; Sequence 4, Application US/10413785
; Publication No. US20030229906A1
; GENERAL INFORMATION:
;  APPLICANT: Gelman et al.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF HIV
;  TITLE OF INVENTION:  INFECTION
;  FILE REFERENCE: 29636/38269A
;  CURRENT APPLICATION NUMBER: US/10/413,785
;  CURRENT FILING DATE:  2003-04-14
;  PRIOR APPLICATION NUMBER: US 60/372,557
;  PRIOR FILING DATE: 2002-04-15
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 33
;   TYPE: PRT
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic peptide
US-10-413-785-4

  Query Match             29.9%;  Score 29;  DB 14;  Length 33;
  Best Local Similarity   41.7%;  Pred. No. 1.4e+03;
  Matches    5;  Conservative    2;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          8 KIAFKIVSQEPA 19
              |: | :  | ||
Db         17 KVGFPVTPQVPA 28


RESULT 105
US-10-351-641-1670
; Sequence 1670, Application US/10351641
; Publication No. US20030186874A1
; GENERAL INFORMATION:
;  APPLICANT: Barney, S.
;  APPLICANT:  Guthrie, K.
;  APPLICANT:  Merutka, G.
;  APPLICANT:  Anwer, M.
;  APPLICANT:  Lambert, D.
;  TITLE OF INVENTION: HYBRID POLYPEPTIDES WITH ENHANCED PHARMACOKINETIC
;  TITLE OF INVENTION:  PROPERTIES
;  FILE REFERENCE: 7872-100
;  CURRENT APPLICATION NUMBER: US/10/351,641
;  CURRENT FILING DATE:  2003-01-24
;  PRIOR APPLICATION NUMBER: 09/350,641
;  PRIOR FILING DATE: 1999-07-09
;  PRIOR APPLICATION NUMBER: 09/315,304
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: 09/082,279
;  PRIOR FILING DATE: 1998-05-20
;  NUMBER OF SEQ ID NOS: 1757
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1670
;   LENGTH: 34
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Core polypeptide
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: 17
;   OTHER INFORMATION: Xaa = U (Aminobutyric Acid)
US-10-351-641-1670

  Query Match             29.9%;  Score 29;  DB 14;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.5e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |    | |:: ||
Db         15 NKXNGTDAVKLIKQE 29


RESULT 106
US-10-351-641-1671
; Sequence 1671, Application US/10351641
; Publication No. US20030186874A1
; GENERAL INFORMATION:
;  APPLICANT: Barney, S.
;  APPLICANT:  Guthrie, K.
;  APPLICANT:  Merutka, G.
;  APPLICANT:  Anwer, M.
;  APPLICANT:  Lambert, D.
;  TITLE OF INVENTION: HYBRID POLYPEPTIDES WITH ENHANCED PHARMACOKINETIC
;  TITLE OF INVENTION:  PROPERTIES
;  FILE REFERENCE: 7872-100
;  CURRENT APPLICATION NUMBER: US/10/351,641
;  CURRENT FILING DATE:  2003-01-24
;  PRIOR APPLICATION NUMBER: 09/350,641
;  PRIOR FILING DATE: 1999-07-09
;  PRIOR APPLICATION NUMBER: 09/315,304
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: 09/082,279
;  PRIOR FILING DATE: 1998-05-20
```

```
;  NUMBER OF SEQ ID NOS: 1757
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1671
;    LENGTH: 34
;    TYPE: PRT
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Core polypeptide
;    FEATURE:
;    NAME/KEY: SITE
;    LOCATION: 16
;    OTHER INFORMATION: Xaa = U (Aminobutyric Acid)
US-10-351-641-1671

  Query Match             29.9%;  Score 29;  DB 14;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.5e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |    | |:: ||
Db         14 NKXNGTDAVKLIKQE 28


RESULT 107
US-10-351-641-1672
; Sequence 1672, Application US/10351641
; Publication No. US20030186874A1
; GENERAL INFORMATION:
;  APPLICANT: Barney, S.
;  APPLICANT:  Guthrie, K.
;  APPLICANT:  Merutka, G.
;  APPLICANT:  Anwer, M.
;  APPLICANT:  Lambert, D.
;  TITLE OF INVENTION: HYBRID POLYPEPTIDES WITH ENHANCED PHARMACOKINETIC
;  TITLE OF INVENTION:  PROPERTIES
;  FILE REFERENCE: 7872-100
;  CURRENT APPLICATION NUMBER: US/10/351,641
;  CURRENT FILING DATE:  2003-01-24
;  PRIOR APPLICATION NUMBER: 09/350,641
;  PRIOR FILING DATE: 1999-07-09
;  PRIOR APPLICATION NUMBER: 09/315,304
;  PRIOR FILING DATE: 1999-05-20
;  PRIOR APPLICATION NUMBER: 09/082,279
;  PRIOR FILING DATE: 1998-05-20
;  NUMBER OF SEQ ID NOS: 1757
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1672
;    LENGTH: 34
;    TYPE: PRT
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Core polypeptide
;    FEATURE:
;    NAME/KEY: SITE
;    LOCATION: 15
;    OTHER INFORMATION: Xaa = U (Aminobutyric Acid)
US-10-351-641-1672

  Query Match             29.9%;  Score 29;  DB 14;  Length 34;
  Best Local Similarity   40.0%;  Pred. No. 1.5e+03;
  Matches    6;  Conservative    2;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQE 17
              |  |    | |:: ||
Db         13 NKXNGTDAVKLIKQE 27


RESULT 108
US-10-437-963-179203
; Sequence 179203, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 179203
;    LENGTH: 34
;    TYPE: PRT
;    ORGANISM: Oryza sativa
;    FEATURE:
;    NAME/KEY: unsure
;    LOCATION: (1)..(34)
;    OTHER INFORMATION: unsure at all Xaa locations
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT4530_7668C.1.pep
US-10-437-963-179203

  Query Match             29.9%;  Score 29;  DB 16;  Length 34;
  Best Local Similarity   45.5%;  Pred. No. 1.5e+03;
  Matches    5;  Conservative    2;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKIV 14
              |: | | | |:
Db         24 HITSXITFPII 34


RESULT 109
US-09-820-649-195
; Sequence 195, Application US/09820649
; Publication No. US20030199683A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: 83 Human Secreted Proteins
;  FILE REFERENCE: PZ012P1
;  CURRENT APPLICATION NUMBER: US/09/820,649
;  CURRENT FILING DATE:  2001-03-30
;  PRIOR APPLICATION NUMBER: US/09/236,557
;  PRIOR FILING DATE: 1999-01-26
;  PRIOR APPLICATION NUMBER: PCT/US98/15949
;  PRIOR FILING DATE: 1998-07-29
;  PRIOR APPLICATION NUMBER: 60/054,212
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,209
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,234
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,218
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,214
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,236
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,215
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,211
;  PRIOR FILING DATE: 1997-07-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 353
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 195
;    LENGTH: 37
;    TYPE: PRT
;    ORGANISM: Homo sapiens
US-09-820-649-195
```

```
  Query Match             29.9%;  Score 29;  DB 10;  Length 37;
  Best Local Similarity   54.5%;  Pred. No. 1.6e+03;
  Matches    6;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKI 13
              :|| ||   ||
Db         11 HHLKSKFHLKI 21


RESULT 110
US-10-160-162-195
; Sequence 195, Application US/10160162
; Publication No. US20030166541A1
; GENERAL INFORMATION:
;  APPLICANT: Ruben et al.
;  TITLE OF INVENTION: 83 Human Secreted Proteins
;  FILE REFERENCE: PZ012P2
;  CURRENT APPLICATION NUMBER: US/10/160,162
;  CURRENT FILING DATE:  2002-06-04
;  PRIOR APPLICATION NUMBER: 60/295,558
;  PRIOR FILING DATE: 2001-06-05
;  PRIOR APPLICATION NUMBER: 09/236,557
;  PRIOR FILING DATE: 1999-01-26
;  PRIOR APPLICATION NUMBER: PCT/US98/15949
;  PRIOR FILING DATE: 1998-07-29
;  PRIOR APPLICATION NUMBER: 60/054,212
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,209
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,234
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,218
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,214
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,236
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,215
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,211
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,217
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/054,213
;  PRIOR FILING DATE: 1997-07-30
;  PRIOR APPLICATION NUMBER: 60/055,968
;  PRIOR FILING DATE: 1997-08-18
;  PRIOR APPLICATION NUMBER: 60/055,969
;  PRIOR FILING DATE: 1997-08-18
;  PRIOR APPLICATION NUMBER: 60/055,972
;  PRIOR FILING DATE: 1997-08-18
;  PRIOR APPLICATION NUMBER: 60/056,561
;  PRIOR FILING DATE: 1997-08-19
;  PRIOR APPLICATION NUMBER: 60/056,534
;  PRIOR FILING DATE: 1997-08-19
;  PRIOR APPLICATION NUMBER: 60/056,729
;  PRIOR FILING DATE: 1997-08-19
;  PRIOR APPLICATION NUMBER: 60/056,543
;  PRIOR FILING DATE: 1997-08-19
;  PRIOR APPLICATION NUMBER: 60/056,727
;  PRIOR FILING DATE: 1997-08-19
;  PRIOR APPLICATION NUMBER: 60/056,554
;  PRIOR FILING DATE: 1997-08-19
;  PRIOR APPLICATION NUMBER: 60/056,730
;  PRIOR FILING DATE: 1997-08-19
;  NUMBER OF SEQ ID NOS: 353
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 195
;   LENGTH: 37
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-160-162-195

  Query Match             29.9%;  Score 29;  DB 14;  Length 37;
  Best Local Similarity   54.5%;  Pred. No. 1.6e+03;
  Matches    6;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKI 13
              :|| ||   ||
Db         11 HHLKSKFHLKI 21


RESULT 111
US-10-437-963-107393
; Sequence 107393, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 107393
;   LENGTH: 37
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_1174C.1.pep
US-10-437-963-107393

  Query Match             29.9%;  Score 29;  DB 16;  Length 37;
  Best Local Similarity   80.0%;  Pred. No. 1.6e+03;
  Matches    4;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 PNHLN 6
              |||:|
Db         25 PNHIN 29


RESULT 112
US-09-250-883-21
; Sequence 21, Application US/09250883
; Patent No. US20020042049A1
;  GENERAL INFORMATION:
;    APPLICANT:  Russell, John
;    APPLICANT:  Colpitts, Tracey
;    TITLE OF INVENTION:  REAGENTS AND METHODS USEFUL
;    TITLE OF INVENTION:  FOR DETECTING DISEASE OF THE BREAST
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Abbott Laboratories
;      STREET:  100 Abbott Park Road
;      CITY:  Abbott Park
;      STATE:  IL
;      COUNTRY:  USA
;      ZIP:  60064-3500
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/250,883
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/889,316
```

```
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Becker, Cheryl L
;       REGISTRATION NUMBER:  35,441
;       REFERENCE/DOCKET NUMBER:  6131.US.01
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  847/935-1729
;       TELEFAX:  847/938-2623
;       TELEX:
;   INFORMATION FOR SEQ ID NO:  21:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  38 amino acids
;       TYPE:  amino acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  No. US20020042049A1e
US-09-250-883-21

  Query Match             29.9%;  Score 29;  DB 9;  Length 38;
  Best Local Similarity   83.3%;  Pred. No. 1.7e+03;
  Matches    5;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          4 HLNSKI 9
              |||||:
Db         18 HLNSKL 23


RESULT 113
US-09-925-299-1490
; Sequence 1490, Application US/09925299
; Patent No. US20020055627A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
;  FILE REFERENCE: PA102
;  CURRENT APPLICATION NUMBER: US/09/925,299
;  CURRENT FILING DATE:  2001-08-10
;  PRIOR APPLICATION NUMBER: PCT/US00/05883
;  PRIOR FILING DATE: 2000-03-08
;  PRIOR APPLICATION NUMBER: 60/124,270
;  PRIOR FILING DATE: 1999-03-12
;  NUMBER OF SEQ ID NOS: 1556
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1490
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (5)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (8)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (12)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (28)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (35)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (37)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-925-299-1490

  Query Match             29.9%;  Score 29;  DB 9;  Length 39;
  Best Local Similarity   37.5%;  Pred. No. 1.7e+03;
  Matches    6;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
                | :  : :||  || |
Db         14 NLMTGRHSFKTYSQXP 29


RESULT 114
US-09-071-838-175
; Sequence 175, Application US/09071838
; Patent No. US20020152501A1
; GENERAL INFORMATION:
;   APPLICANT:  Fischer, Robert L.
;   APPLICANT:  Chad, Nir
;   APPLICANT:  Kiyosue, Tomohiro
;   APPLICANT:  Yadegari, Ramin
;   APPLICANT:  Margossian, Linda
;   APPLICANT:  Harada, John
;   APPLICANT:  Goldberg, Robert B.
;   TITLE OF INVENTION:  Nucleic Acids That Control Seed and
;   TITLE OF INVENTION:  Fruit Development in Plants
;   NUMBER OF SEQUENCES:  324
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Townsend and Townsend and Crew LLP
;     STREET:  Two Embarcadero Center, Eighth Floor
;     CITY:  San Francisco
;     STATE:  California
;     COUNTRY:  USA
;     ZIP:  94111-3834
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:  IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:  PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/09/071,838
;     FILING DATE:  01-MAY-1998
;     CLASSIFICATION:  800
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Bastian, Kevin L.
;     REGISTRATION NUMBER:  34,774
;     REFERENCE/DOCKET NUMBER:  023070-086100US
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  (415) 576-0200
;     TELEFAX:  (415) 576-0300
;  INFORMATION FOR SEQ ID NO:  175:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  39 amino acids
;     TYPE:  amino acid
;     TOPOLOGY:  linear
;   MOLECULE TYPE:  peptide
US-09-071-838-175

  Query Match             29.9%;  Score 29;  DB 9;  Length 39;
  Best Local Similarity   33.3%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              ||:| :|:  ::
Db         19 NHVNIRISLIVI 30


RESULT 115
US-09-925-299-1490
; Sequence 1490, Application US/09925299
; Publication No. US20030040617A9
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
;  FILE REFERENCE: PA102
;  CURRENT APPLICATION NUMBER: US/09/925,299
;  CURRENT FILING DATE:  2001-08-10
;  PRIOR APPLICATION NUMBER: PCT/US00/05883
;  PRIOR FILING DATE: 2000-03-08
;  PRIOR APPLICATION NUMBER: 60/124,270
;  PRIOR FILING DATE: 1999-03-12
```

```
;  NUMBER OF SEQ ID NOS: 1556
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1490
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (5)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (8)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (12)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (28)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (35)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
;   NAME/KEY: SITE
;   LOCATION: (37)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-925-299-1490

  Query Match             29.9%;  Score 29;  DB 10;  Length 39;
  Best Local Similarity   37.5%;  Pred. No. 1.7e+03;
  Matches    6;  Conservative    3;  Mismatches    7;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |  :   : :||  || |
Db         14 NLMTGRHSFKTYSQXP 29


RESULT 116
US-10-213-512-175
; Sequence 175, Application US/10213512
; Publication No. US20030110536A1
; GENERAL INFORMATION:
;  APPLICANT: Fischer, Robert L.
;  APPLICANT:  Ohad, Nir
;  APPLICANT:  Kiyosue, Tomohiro
;  APPLICANT:  Yadegari, Ramin
;  APPLICANT:  Margossian, Linda
;  APPLICANT:  Harada, John
;  APPLICANT:  Goldberg, Robert B.
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION: Combinations of Nucleic Acids That Control Seed and
;  TITLE OF INVENTION:  Fruit Development in Plants
;  FILE REFERENCE: 02307O-086110US
;  CURRENT APPLICATION NUMBER: US/10/213,512
;  CURRENT FILING DATE:  2002-08-06
;  PRIOR APPLICATION NUMBER: US/09/177,206
;  PRIOR FILING DATE: 1998-10-22
;  PRIOR APPLICATION NUMBER: US 09/071,838
;  PRIOR FILING DATE: 1998-05-01
;  NUMBER OF SEQ ID NOS: 324
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 175
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Arabidopsis sp.
US-10-213-512-175

  Query Match             29.9%;  Score 29;  DB 14;  Length 39;
  Best Local Similarity   33.3%;  Pred. No. 1.7e+03;
  Matches    4;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              ||:|  :|:  ::
Db         19 NHVNIRISLIVI 30


RESULT 117
US-10-424-599-282214
; Sequence 282214, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 282214
;   LENGTH: 39
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_96862C.1.pep
US-10-424-599-282214

  Query Match             29.9%;  Score 29;  DB 15;  Length 39;
  Best Local Similarity   50.0%;  Pred. No. 1.7e+03;
  Matches    6;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIV 14
              |:|  ||: ||:
Db         28 NNLRFKISIKIL 39


RESULT 118
US-10-029-386-29136
; Sequence 29136, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 29136
;   LENGTH: 40
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO CHR6.1
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 3.1
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 4.7
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 5.9
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 4.1
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 3.5
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 3.8
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 4.2
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 2.6
US-10-029-386-29136

  Query Match             29.9%;  Score 29;  DB 14;  Length 40;
  Best Local Similarity   54.5%;  Pred. No. 1.8e+03;
  Matches    6;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKI 13
              ||||: |   |
Db         27 NHLNNTIVSHI 37
```

```
RESULT 119
US-10-029-386-33231
; Sequence 33231, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 33231
;   LENGTH: 41
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC022127.3
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 3.6
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 3.5
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 4.7
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 4.1
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 3.5
US-10-029-386-33231

  Query Match             29.9%;  Score 29;  DB 14;  Length 41;
  Best Local Similarity   83.3%;  Pred. No. 1.8e+03;
  Matches    5;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          4 HLNSKI 9
              |||||:
Db         35 HLNSKL 40


RESULT 120
US-10-437-963-140191
; Sequence 140191, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 140191
;   LENGTH: 41
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_41412C.1.pep
US-10-437-963-140191

  Query Match             29.9%;  Score 29;  DB 16;  Length 41;
  Best Local Similarity   31.2%;  Pred. No. 1.8e+03;
  Matches    5;  Conservative    5;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKIVSQ 16
              |   :| |  :|:|::
Db         13 EKKKINKKEIYKLVNE 28
```

```
RESULT 121
US-10-424-599-238139
; Sequence 238139, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 238139
;   LENGTH: 42
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_57065C.1.pep
US-10-424-599-238139

  Query Match             29.9%;  Score 29;  DB 15;  Length 42;
  Best Local Similarity   20.0%;  Pred. No. 1.9e+03;
  Matches    3;  Conservative    7;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSKIAFKIVS 15
              :| :|| :: ::  :
Db         17 DPRNLNQRLTYQFAT 31


RESULT 122
US-10-424-599-271865
; Sequence 271865, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 271865
;   LENGTH: 42
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_87512C.1.pep
US-10-424-599-271865

  Query Match             29.9%;  Score 29;  DB 15;  Length 42;
  Best Local Similarity   33.3%;  Pred. No. 1.9e+03;
  Matches    7;  Conservative    4;  Mismatches    6;  Indels    4;  Gaps    1;

Qy          2 PNH----LNSKIAFKIVSQEP 18
              |:|    :  |:| ||   :|
Db          1 PSHKTFRIKKKLAKKIKQNKP 21


RESULT 123
US-10-437-963-151559
; Sequence 151559, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
```

```
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 151559
;   LENGTH: 43
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_51691C.1.pep
US-10-437-963-151559

  Query Match             29.9%;  Score 29;  DB 16;  Length 43;
  Best Local Similarity   62.5%;  Pred. No. 1.9e+03;
  Matches    5;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKI 9
              |::|| ||
Db         29 PSYLNGKI 36


RESULT 124
US-09-989-919-94
; Sequence 94, Application US/09989919
; Patent No. US20020164344A1
; GENERAL INFORMATION:
;  APPLICANT: Macina, Roberto
;  APPLICANT:  Recipon, Herve
;  APPLICANT:  Pluta, Jason
;  APPLICANT:  Ghosh, Malavika
;  APPLICANT:  Sun, Yongming
;  APPLICANT:  Liu, Chenghua
;  TITLE OF INVENTION: Compositions and Methods Relating to Colon Specific Genes and Pro
;  FILE REFERENCE: DEX-0289
;  CURRENT APPLICATION NUMBER: US/09/989,919
;  CURRENT FILING DATE:  2001-11-21
;  PRIOR APPLICATION NUMBER: 60/252,505
;  PRIOR FILING DATE: 2000-11-22
;  NUMBER OF SEQ ID NOS: 124
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 94
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Homo sapien
US-09-989-919-94

  Query Match             29.9%;  Score 29;  DB 9;  Length 44;
  Best Local Similarity   38.5%;  Pred. No. 2e+03;
  Matches    5;  Conservative    4;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVS 15
              | | :|| : ::|
Db         18 NTLTTKIKYSLIS 30


RESULT 125
US-10-424-599-221932
; Sequence 221932, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 221932
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_42434C.1.pep
US-10-424-599-221932

  Query Match             29.9%;  Score 29;  DB 15;  Length 44;
  Best Local Similarity   62.5%;  Pred. No. 2e+03;
  Matches    5;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 EPNHLNSK 8
              || ||:|:
Db         37 EPPHLHSR 44


RESULT 126
US-10-437-963-124421
; Sequence 124421, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 124421
;   LENGTH: 45
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_27161C.1.pep
US-10-437-963-124421

  Query Match             29.9%;  Score 29;  DB 16;  Length 45;
  Best Local Similarity   62.5%;  Pred. No. 2e+03;
  Matches    5;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIA 10
              || ::|||
Db         37 NHFSTKIA 44


RESULT 127
US-09-933-767-340
; Sequence 340, Application US/09933767
; Publication No. US20030181692A1
; GENERAL INFORMATION:
;  APPLICANT: Ni et al.
;  TITLE OF INVENTION: 207 Human Secreted Proteins
;  FILE REFERENCE: PZ007P2
;  CURRENT APPLICATION NUMBER: US/09/933,767
;  CURRENT FILING DATE:  2001-08-22
;  PRIOR APPLICATION NUMBER: PCT/US01/05614
;  PRIOR FILING DATE: 2001-02-21
;  PRIOR APPLICATION NUMBER: 60/184,836
;  PRIOR FILING DATE: 2000-02-24
;  PRIOR APPLICATION NUMBER: 60/193,170
;  PRIOR FILING DATE: 2000-03-29
```

```
;  PRIOR APPLICATION NUMBER: 09/205,258
;  PRIOR FILING DATE: 1998-12-04
;  PRIOR APPLICATION NUMBER: PCT/US98/11422
;  PRIOR FILING DATE: 1998-06-04
;  PRIOR APPLICATION NUMBER: 60/048,885
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,375
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,881
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,880
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,896
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,020
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,876
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,895
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,884
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,894
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,971
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,964
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,882
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,899
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,893
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,900
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,901
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,892
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,915
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,019
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,970
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,972
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,916
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,373
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,875
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/049,374
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,917
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,949
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,974
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,883
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,897
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,898
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,962
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,963
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,877
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/048,878
;  PRIOR FILING DATE: 1997-06-06
;  PRIOR APPLICATION NUMBER: 60/068,054
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,064
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/068,053
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/070,923
;  PRIOR FILING DATE: 1997-12-18
;  PRIOR APPLICATION NUMBER: 60/073,160
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 60/073,159
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 60/073,165
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 60/073,164
;  PRIOR FILING DATE: 1998-01-30
;  PRIOR APPLICATION NUMBER: 60/085,925
;  PRIOR FILING DATE: 1998-05-18
;  PRIOR APPLICATION NUMBER: 60/085,921
;  PRIOR FILING DATE: 1998-05-18
;  PRIOR APPLICATION NUMBER: 60/085,923
;  PRIOR FILING DATE: 1998-05-18
;  PRIOR APPLICATION NUMBER: 60/085,922
;  PRIOR FILING DATE: 1998-05-18
;  PRIOR APPLICATION NUMBER: 60/092,921
;  PRIOR FILING DATE: 1998-07-15
;  PRIOR APPLICATION NUMBER: 60/094,657
;  PRIOR FILING DATE: 1998-07-30
;  NUMBER OF SEQ ID NOS: 1245
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 340
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-933-767-340

  Query Match             29.9%;  Score 29;  DB 10;  Length 46;
  Best Local Similarity   37.5%;  Pred. No. 2.1e+03;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |   |:  :|| |::|
Db         26 NLFTSQKIYKIYSEKP 41


RESULT 128
US-10-004-860-340
; Sequence 340, Application US/10004860
; Publication No. US20030065160A1
; GENERAL INFORMATION:
;  APPLICANT: Young et al.
;  TITLE OF INVENTION: 207 Human Secreted Proteins
;  FILE REFERENCE: PZ007P1
;  CURRENT APPLICATION NUMBER: US/10/004,860
;  CURRENT FILING DATE:  2001-12-07
;  Prior Application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 1227
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 340
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-004-860-340

  Query Match             29.9%;  Score 29;  DB 14;  Length 46;
  Best Local Similarity   37.5%;  Pred. No. 2.1e+03;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |   |:  :|| |::|
```

```
Db         26 NLFTSQKIYKIYSEKP 41


RESULT 129
US-10-023-282-340
; Sequence 340, Application US/10023282
; Publication No. US20030092893A1
; GENERAL INFORMATION:
;  APPLICANT: Young et al.
;  TITLE OF INVENTION: 207 Human Secreted Proteins
;  FILE REFERENCE: PZ007P1
;  CURRENT APPLICATION NUMBER: US/10/023,282
;  CURRENT FILING DATE: 2001-12-20
;  EARLIER APPLICATION NUMBER: 09/205,258
;  EARLIER FILING DATE: 1998-12-04
;  EARLIER APPLICATION NUMBER: PCT/US98/11422
;  EARLIER FILING DATE: 1998-06-04
;  EARLIER APPLICATION NUMBER: 60/048,885
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,375
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,881
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,880
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,896
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,020
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,876
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,895
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,884
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,894
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,971
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,964
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,882
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,899
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,893
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,900
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,901
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,892
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,915
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,019
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,970
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,972
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,916
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,373
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,875
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/049,374
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,917
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,949
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,974
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,883
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,897
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,898
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,962
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,963
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,877
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/048,878
;  EARLIER FILING DATE: 1997-06-06
;  EARLIER APPLICATION NUMBER: 60/070,923
;  EARLIER FILING DATE: 1997-12-18
;  EARLIER APPLICATION NUMBER: 60/092,921
;  EARLIER FILING DATE: 1998-07-15
;  EARLIER APPLICATION NUMBER: 60/094,657
;  EARLIER FILING DATE: 1998-07-30
;  NUMBER OF SEQ ID NOS: 1227
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 340
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-023-282-340

  Query Match           29.9%;  Score 29;  DB 14;  Length 46;
  Best Local Similarity  37.5%;  Pred. No. 2.1e+03;
  Matches    6;  Conservative    4;  Mismatches    6;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVSQEP 18
              |   |:  :|| |::|
Db         26 NLFTSQKIYKIYSEKP 41


RESULT 130
US-10-424-599-143969
; Sequence 143969, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 143969
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_101016C.1.pep
US-10-424-599-143969

  Query Match           29.9%;  Score 29;  DB 15;  Length 46;
  Best Local Similarity  50.0%;  Pred. No. 2.1e+03;
  Matches    5;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          4 HLNSKIAFKI 13
              |||: : | |
Db         33 HLNTSLNFSI 42


RESULT 131
US-10-424-599-194850
```

```
; Sequence 194850, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 194850
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_17978C.1.pep
US-10-424-599-194850

  Query Match             29.9%;  Score 29;  DB 15;  Length 46;
  Best Local Similarity   38.5%;  Pred. No. 2.1e+03;
  Matches    5;  Conservative    3;  Mismatches    5;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIAFKIV 14
              | || ::   ||:
Db         10 PYHLQTQFHLKII 22


RESULT 132
US-10-424-599-196352
; Sequence 196352, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 196352
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_19332C.1.pep
US-10-424-599-196352

  Query Match             29.9%;  Score 29;  DB 15;  Length 46;
  Best Local Similarity   71.4%;  Pred. No. 2.1e+03;
  Matches    5;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 PNHLNSK 8
              |:|| ||
Db         35 PSHLTSK 41


RESULT 133
US-10-029-386-28419
; Sequence 28419, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
;  TITLE OF INVENTION:  EXPRESSION ANALYSIS TWO
;  FILE REFERENCE: AEOMICA-X-2
;  CURRENT APPLICATION NUMBER: US/10/029,386
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 34288
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 28419
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO CHR5.1
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.3
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.6
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.9
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.8
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 2.8
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.4
;   OTHER INFORMATION: SWISSPROT HIT: O27179, EVALUE 8.30e+00
US-10-029-386-28419

  Query Match             29.9%;  Score 29;  DB 14;  Length 47;
  Best Local Similarity   44.4%;  Pred. No. 2.1e+03;
  Matches    4;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          2 PNHLNSKIA 10
              |:|| |:::
Db         38 PSHLKSEVS 46


RESULT 134
US-10-424-599-162168
; Sequence 162168, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 162168
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_117455C.1.pep
US-10-424-599-162168

  Query Match             29.9%;  Score 29;  DB 15;  Length 47;
  Best Local Similarity   38.5%;  Pred. No. 2.1e+03;
  Matches    5;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          3 NHLNSKIAFKIVS 15
              | | ::| ||:::
Db         30 NILKNQIIFKLIN 42


RESULT 135
US-10-424-599-166629
; Sequence 166629, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
```